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ABSTRACT 
Aging is one of the most important risk factors for cardiovascular (CVD) and 
neurodegenerative diseases (ND), which are the main cause of hospitalization, permanent disability, 
and death for Europeans over 65 years. These diseases are due to various causes such as physical 
inactivity, obesity, diabetes, hypertension and unbalanced diets. Several epidemiological studies 
clearly show that proper diets are associated with lower incidence of cardiometabolic disorders, 
cancer, and ND. Therefore, maintaining adequate nutrition or incorporating nutritional supplements 
could be important to prevent CVD and the early onset of ND. Some diets are healthier, e.g. the 
Mediterranean and Japanese ones, than others and certain typical micronutrients consumed in these 
regimens were studied here, namely soy isoflavones (SI), hydroxytyrosol (HT), and polar lipids 
(PLs) of marine and dairy origins enriched in phospholipids (PHLs). The ultimate goal was to find 
solid scientific, i.e. molecular, genomic, and proteomic, as well as human evidence to back up dietary 
advice and the formulation of nutraceuticals and functional foods. 
Soy consumption has been suggested to afford protection against CVD. We investigated the 
nutrigenomic actions of SI, namely a genistein/daidzein mix (in nutritionally relevant amounts) in 
young mice with a specific focus on the adipose tissue, due to its pivotal role in cardiometabolism. 
These compounds have contradictory nutrigenomic effects and differentially expressed genes have 
diverse effects in these tissues. Moreover, we report increased leptin and total cholesterol, and 
decreased triglyceride (TG) plasma concentrations. 
There are several studies demonstrating that HT has numerous potentially beneficial effects 
in the cardiovascular system, in addition to antimicrobial, anticancer, anti-inflammatory, and 
neuroprotective properties. In our human studies, twenty-one volunteers were randomly assigned to 
one of three groups: placebo, 5 or 25 mg of HT per day. We were unable to record significant effects 
on a variety of surrogate markers of CVD and oxidation. We wanted to analyze if the body processes 
these polyphenols as xenobiotics via the Keap1/Nrf2/ARE signaling axis (which is currently the most 
prevalent theory to explain the benefits attributed to polyphenols), leading to the induction of Phase 
II enzymes. We saw that gene expression of Phase II enzymes is not significantly modified in 
peripheral blood mononuclear cells. We also evaluated HT bioavailability following ingestion and 
found that it is bioavailable and is recovered in the urine chiefly as sulphate-3′. In young mice studies 
supplemented with nutritionally relevant amounts of HT, for eight weeks, we investigated CVD 
markers and ran a proteomic analysis, in addition to studying whether HT could modulate the 
expression of microRNAs (miRNAs) in the intestine.  We reported that HT increased TG levels. 
Numerous miRNAs were modulated in the intestine and the analysis of other tissues revealed 
consistent HT-induced modulation of only few miRNAs. Acute treatment of mice with HT and 
experiments in different intestinal cells lines provided mechanistic insights of this induction. HT-
induced expression of one miRNAs was also confirmed in healthy volunteers supplemented with this 
compound. Finally, proteomic analysis of metabolically active tissues (adipose and liver), using the 
super-SILAC method, showed that some oxidative stress-related proteins were modulated in both 
tissues. Peroxiredoxin 1 is among the main ones, presenting a consistent repression and, in some 
cases, a tissue-dependent modulation. To research the effect of this compound on ND, we 
hypothesized that HT could exert beneficial effects on insulin resistance (IR) associated with 
Alzheimer’s disease (AD). An astrocytic cell line was exposed to amyloid beta peptide (Aβ) (25-35) 
and co-incubated with HT for different periods. Viability was significantly decreased by Aβ, but both 
pre- and post-treatment with HT prevented this effect and improved insulin sensitivity, restoring 
insulin-signaling. 
Low consumption of omega 3 fatty acids and PHLs is associated with altered cognitive 
function at aging. Dietary supplementation with bioactive PLs concentrates of marine (KOC) and 
dairy (BMFC) origins could be an effective strategy for preventing ND. During three months, aged 
Wistar rats were supplemented with KOC, BMFC, or the combination of both. We analyzed 
mitochondrial activity and insulin and synaptic signaling in brain. Dietary supplementation with 
KOC and/or BMFC improves peripheral and central IR and increases brain-derived neutrophic factor 
(BDNF) levels, favoring an improvement in the energy state within neurons and facilitating both 
mitochondrial and protein synthesis, which are necessary for synaptic plasticity. Finally, we wanted 
to see whether PLs could influence the expression of genes or miRNAs related to synaptic activity 
and/or neurodegeneration. BMFC differentially modulated the expression of 23 miRNAs, and both 
supplements combined modulated the hippocampal expression of 119 miRNAs. 38, 58, and 72 genes 
were found to be differentially expressed in the groups supplemented with KOC, BMFC and BMFC 
+ KOC, respectively. Functional analysis of differentially expressed genes showed these were mainly 
involved in neuroactive processes in the KOC and BMFC groups, and associated with lysosomes and 
mRNA surveillance pathways in the BMFC + KOC group. Thus, provision of certain PLs could 
favor neuronal health and delay cognitive decline associated to age. 
In conclusion, the results of this doctoral work add to the body of evidence that shows how 
the intake of certain micronutrients can lessen the burden of degenerative diseases (either 
vascular/cardiac or cerebral) and suggest the potential use of supplements in addition to proper 
lifestyle, diet, and medicine. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESUMEN 
El envejecimiento es uno de los factores de riesgo más importantes para las enfermedades 
cardiovasculares (CVD) y neurodegenerativas (ND), las cuales son, en conjunto, la principal causa 
de hospitalización, discapacidad y muerte para los europeos mayores de 65 años. Las causas de estas 
enfermedades se deben a varios factores como, por ejemplo, inactividad física, obesidad, diabetes, 
hipertensión y dietas desequilibradas. Varios estudios epidemiológicos muestran que seguir una 
adecuada alimentación está asociado con una menor incidencia de trastornos cardiometabólicos, 
cáncer y ND.  Por lo tanto, mantener una nutrición adecuada o incorporar suplementos nutricionales 
puede ser importante para prevenir CVD y la aparición temprana de ND. Las dietas mediterránea y 
japonesa se describen como saludables. Por estas razones, nos planteamos estudiar ciertos 
micronutrientes presentes en estas dietas: las isoflavonas de soja (SI), el hidroxitirosol (HT) y los 
lípidos polares (PLs) de orígenes lácteo y marino, enriquecidos en fosfolípidos (PHLs), para 
investigar sus posibles efectos beneficiosos frente a estas enfermedades. 
Se ha sugerido que el consumo de soja proporciona protección contra las CVD. En este 
estudio se investigaron las acciones nutrigenómicas de las SI, genisteína/daidzeína (en cantidades 
nutricionalmente relevantes) en ratones jóvenes, con un enfoque específico en el tejido adiposo 
debido a su papel en el cardiometabolismo. Este compuesto presentó efectos nutrigenomicos 
contradictorios, con una expresión diferencial de genes asociados con efectos diversos en estos 
tejidos. Además, se observó un aumento de colesterol total y de leptina y una disminución en los 
niveles de triglicéridos (TG) plasmáticos. 
Existen numerosos estudios que han demostrado que el HT posee numerosos efectos 
potencialmente beneficiosos sobre el sistema cardiovascular, además de propiedades 
antimicrobianas, anticancerígenas, antiinflamatorias y neuroprotectoras. En un estudio realizado 
durante esta tesis, se reclutaron 21 voluntarios, que se asignaron aleatoriamente al grupo placebo, 5 ó 
25 mg de HT por día. No se registraron efectos estadísticamente significativos en una variedad de 
marcadores de CVD y oxidación. Analizamos si el HT es procesado por el cuerpo como xenobiótico 
a través de la inducción de enzimas de Fase II en las células mononucleares de sangre periférica, 
pero no se encontraron diferencias significativas. Se evaluó también la biodisponibilidad del HT 
después de la ingestión, comprobándose que este es biodisponible y se recupera en la orina 
principalmente como sulfato-3'. En estudios con ratones suplementados con HT, durante 8 semanas, 
se analizaron marcadores de CVD, se realizó un análisis proteómico y se investigó si el HT podría 
modular la expresión de los microARNs (miRNAs). Se observó un aumento en los niveles de TG en 
plasma. También se vio una modulación de numerosos miRNAs en el intestino, así como en otros 
tejidos. La expresión inducida de uno de estos miRNAs se confirmó también en el estudio en 
humanos. El tratamiento agudo con HT en ratones, y experimentos en diferentes líneas celulares 
intestinales, proporcionaron conocimientos mecánicos acerca de esta inducción. Finalmente, el 
análisis proteómico en tejidos metabólicamente activos (tejido adiposo e hígado), mediante la técnica 
super-SILAC, reveló que algunas proteínas relacionadas con el estrés oxidativo fueron moduladas en 
ambos tejidos (ej. peroxiredoxina 1, cuya expresión se encontró consistentemente reprimida) y en 
algunos casos la modulación fue dependiente de tejido (ej. proteínas de síntesis de ácidos grasos). 
Para investigar el efecto de este compuesto en ND, planteamos la hipótesis de que el HT podría 
ejercer efectos beneficiosos sobre la resistencia a la insulina (IR) asociada a la enfermedad de 
Alzheimer (AD). Una línea celular astrocítica se expuso al péptido beta amiloide (Aβ) (25-35) y se 
co-incubó con HT durante diferentes tiempos. La viabilidad se redujo con Aβ, pero tanto el pre- 
como el pos-tratamiento con HT evitaron este efecto y mejoraron la sensibilidad a la insulina. 
El bajo consumo de ácidos grasos omega 3 y PHLs se asocia con la una función cognitiva 
alterada en el envejecimiento. La suplementación dietética de PLs de origen marino (KOC) y lácteo 
(BMFC) podría ser una estrategia efectiva para prevenir las ND. Durante tres meses, ratas viejas 
fueron suplementadas con KOC, BMFC o la combinación de ambas. Analizamos la actividad 
mitocondrial, la señalización de la vía de la insulina y la vía sináptica en el cerebro. La 
suplementación dietética con KOC y/o BMFC mejora la IR central y periférica y aumenta los niveles 
del factor neurotrófico derivado del cerebro (BDNF), favoreciendo una mejora en el estado de 
energía neuronal y facilitando la síntesis mitocondrial y de proteínas, que son necesarias para la 
plasticidad sináptica. Analizamos, en hipocampo, la expresión de genes o miRNAs relacionados con 
la actividad sináptica. La suplementación con BMFC moduló la expresión de 23 miRNAs, y la 
suplementación con ambos concentrados resultó en la modulación de 119 miRNAs. Se encontró que 
38, 58 y 72 genes se expresaron diferencialmente en los grupos suplementados con KOC, BMFC y 
BMFC + KOC, respectivamente. Según el análisis funcional los genes expresados diferencialmente 
en los grupos KOC y BMFC participan en procesos neuroactivos y aquellos encontrados en el grupo 
BMFC + KOC se asocian con lisosomas. Por lo tanto, estas suplementaciones dietéticas podrían 
favorecer la salud neuronal y retrasar el deterioro cognitivo asociado a la edad. 
En conclusión, los resultados de éste trabajo doctoral se suman al conjunto de evidencias que 
avalan efectos positivos frente a las enfermedades degenerativas (ya sean vasculares/cardíacas o 
cerebrales) debido a la ingesta de ciertos micronutrientes, y sugieren que el consumo de suplementos 
puede complementar las pautas recomendadas respeto a la adopción de estilos de vida saludables. 
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INTRODUCTION
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This PhD work focused on the pharma-nutritional effects of selected food 
components, with in vitro, in vivo and human investigations, spanning from 
nutrigenomic actions to molecular outcomes with potential influence in cardiovascular 
and neurodegenerative diseases. The results of this work add to and expand the body of 
evidence in support of rational dietary advice.  
1. Studied diseases  
   1.1. Cardiovascular diseases 
Cardiovascular diseases (CVD) are a group of disorders that affect both the 
circulatory system and the heart. Within this group, we find coronary heart disease 
(heart attacks), cerebrovascular disease, increased blood pressure, peripheral 
vasculopathy, rheumatic heart disease, congenital heart disease, heart failure and 
cardiomyopathy. CVD take the lives of 17.7 million people every year, i.e. 31% of 
all global deaths, primarily manifesting as heart attacks and stroke (1). These 
numbers will increase to 23.3 million in 2030 and the incidence of CVD is expected 
to remain the leading cause of death (2).  
Cardiovascular risk factors are those associated with a higher probability of 
suffering from cardiovascular disease. This concept was introduced in the 
Framingham study (3), more than 50 years ago. Since then, other epidemiological 
studies have been conducted in populations to identify different risk factors. The 
most commonly used tables to calculate the overall cardiovascular risk of an 
individual are those from the Framingham study and the ones derived from the 
Systemic Coronary Risk Estimation (SCORE) project. These tables are a scoring 
system which calculates a 10 year-risk of fatal CVD. Their use is recommended for 
6 
 
risk assessment and can help make logical decisions and avoid both excess and lack 
of treatment. 
 Risk factors are conveniently divided in two main types: 1) non-modifiable 
factors, such as genetic inheritance, sex, age, race, and 2) modifiable factors, such as 
hyperlipidemia, diabetes, hypertension, smoking, alcohol, stress, obesity and heart 
rate (4, 5).  
Many CVD, as angina pectoris, myocardial infarction and peripheral vascular 
disease are caused by atherosclerosis, which is a chronic inflammatory process that 
occurs in the wall of the large arteries in response to an “attack” to the endothelium. 
Atherosclerosis can affect any artery in the body, including those of the heart, brain, 
arms, legs, pelvis, and kidneys. Atherosclerosis is characterized by the presence of 
fibro-fatty plaques that begin to develop in the arterial intima layer. The 
atheromatous plaque mainly develops in aorta, coronary arteries and cerebral 
arteries, but can invade the arterial lumen and cause blockage of blood flow, making 
it difficult for blood to irrigate tissues and causing ischemia. Low-density 
lipoproteins (LDL), the major carriers of cholesterol, are deposited within the 
atheroma plaques. Elevated fasting glucose and lipids levels, postprandial 
hyperglycemia and hypertriglyceridemia are considered as cardiovascular risk 
factors (6). The accumulation of these particles stimulates the endothelium to 
produce pro-inflammatory molecules, including adhesion molecules (VCAM-1, 
PCAM-1, ICAM-1, P-Selectin, E-Selectin), chemotactic proteins, for example 
monocyte chemoattractant protein 1 (MCP-1) and growth factors, macrophage 
colony-stimulating factor (M-CSF). Together, this process is known as endothelial 
activation and is mediated largely by the nuclear factor NF-κB (7). In response to 
these chemotactic factors, immune cells (mainly circulating monocytes) penetrate the 
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wall of the artery and differentiate into macrophages, which have surface scavenger 
receptors, such as SR-A and CD-36 that recognize and capture modified lipoproteins 
(8). Macrophages begin to phagocyte and accumulate lipids and end up becoming 
foam cells. The uptake of LDL particles by the scavenger receptors requires their 
prior modification possibly by oxidation due to free oxygen radicals produced in the 
endothelium or extracellular matrix and by macrophages. 
The atheroma plaque may be fragile and rupture, thereby secreting 
extracellular matrix into the bloodstream and forming a thrombus (embolism), thus 
occluding the circulation in that area. Alternatively, the arteriosclerotic plaque may 
increase its size (but not break) by decreasing the diameter or arterial lumen and 
occluding the artery and cutting the circulation in that area. In both cases, if this 
happens in the heart or brain, it could lead to death. Platelet activation is also critical 
for the development of thrombotic vascular occlusion, which is the most important 
pathophysiological mechanism leading to myocardial infarction or ischemic stroke 
(2). In addition to its important role in hemostasis, platelets also participate in 
inflammatory processes, angiogenesis and tumor progression (9) and they have been 
shown to play an important role in the progression of Alzheimer’s disease (AD) (10, 
11), which will be addressed in section 1.2. 
CVD prevention strategies can be employed before a cardiovascular event 
occurs (primary prevention) or before further episodes take place (secondary 
prevention). Currently, in clinical practice, there are several drugs that act on 
different CVD manifestations (e.g. statins to lower cholesterol), but the search for 
new complementary pharmacological and/or dietary alternatives is still a priority. 
      1.1.1. Changes in eating habits to prevent CVD 
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The prevention of most CVD is performed by addressing behavioural risk 
factors such as tobacco use, poor diet, obesity, physical inactivity and abuse of alcohol, 
using population-wide strategies. Prevention, treatment, and control of these risk factors 
before clinical manifestation are, therefore, primary targets of public health 
interventions to reduce CVD (12).  
An unhealthy diet constitutes a key factor in the initiation and progression of 
these diseases. Therefore, addressing suboptimal nutrition is of key prognostic 
relevance in primary and secondary prevention. Processed foods, high in sodium and 
hydrogenated fats, and low in fiber, are being often consumed in excess. These 
contemporary dietary changes have adversely affected global dietary parameters known 
to be related to health, resulting in an increase in obesity and chronic disease. 
Since 1957, evidence that diet is important in the development of CVD is 
emerging. Those observations were pivotal in the development of the cholesterol 
hypothesis: dietary saturated fat increases serum cholesterol, which in turn leads to 
coronary atherosclerosis. In 1972, a joint statement from the National Academy of 
Sciences-National Research Council and the Council on Foods and Nutrition of the 
American Medical Association reported that the risk of coronary heart disease was 
linked to the blood cholesterol level (13).  
There are several feeding studies regarding the effects of different dietary fatty 
acids on serum cholesterol levels, with predictive equations being developed (14). 
Several studies have suggested that different dietary patterns, like the Mediterranean 
diet, predict CVD or mortality (15). For example, diets rich in fruit, vegetables and low-
fat dairy foods were reported to reduce blood pressure (BP) (16). In addition, increased 
consumption of omega-3 (n-3) fatty acids from fish oil or plant sources improve 
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endothelial dysfunction (17). In summary, it seems clear that changing to specific eating 
habits can confer great benefits regarding CVD prevention. 
      1.1.2. Biomarkers of CVD 
 ‘Biomarker’ or ‘biological marker’ was first used in 1989, as a Medical 
Subject Heading (MeSH) term. This is defined as “measurable and quantifiable 
biological parameters which serve as indices for health and physiology” (18). It 
provides an avenue for research. The term “biomarkers” refers to a broad 
subcategory of medical signs, objective indications of medical state observed from in 
the patient, which can be measured accurately and reproducibly. They are 
measurement tools to determine disease progression and the effects of interventions 
and allow understanding the differences in clinical response that may be influenced 
by various variables (drugs, surgery, functional foods, etc.) (19). In terms of 
nutritional effects of selected food components, investigators are using a wide array 
of analytical tools to assess their actions on biological parameters related to CVD 
risk factors, such as hypertension, obesity, diabetes, and hypercholesterolemia. 
1.1.2.1. Lipidic profile 
In humans, an increase in total blood cholesterol and triglycerides (TG) levels is 
considered a key factor in the development of CVD. Hyperlipidemia or 
hypercholesterolemia are defined as elevations of fasting total cholesterol 
concentrations, which may or may not be associated with elevated TG concentrations. 
TG are not directly atherogenic, but represent an important biomarker of CVD because 
they are associated with atherogenic particles. Lipids are not soluble in plasma, but are 
instead transported in particles known as lipoproteins. High plasma LDL implies more 
substrate to be oxidized (ox-LDL) and form atheroma plaques (6). High-density 
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lipoproteins (HDL), instead, might be protective and are associated with decreased 
coronary heart risk, at least when they are effective on reverse cholesterol transfer (20).  
Laboratory analysis of the lipid profile measures: 
 Total cholesterol, which is the sum of different types of cholesterol. 
 HDL cholesterol, which is usually called the "good" cholesterol by the lay 
public. High-density lipoproteins transport cholesterol back to the liver for 
elimination in a process called reverse cholesterol transport. 
 LDL cholesterol, generally known by the lay public as the "bad" cholesterol. 
LDL lipoproteins that accumulate in the bloodstream can clog blood vessels (see 
the above-mentioned atherosclerosis) and increase the risk of heart disease. 
 TG, which store energy until the body needs it. If the body accumulates too 
many triglycerides, the blood vessels can clog and cause health problems. 
In Table 1, we can see the optimal, medium and high values, in human samples, 
of all the parameters mentioned above. 
Table 1. Lipid profile measures (adapted from (21)). 
LDL Cholesterol 
<100 Optimal 
100-189 Normal 
≥ 190 High 
Total Cholesterol 
<200 Optimal 
200 – 239 Normal 
≥ 240 High 
HDL Cholesterol 
≥ 60 Optimal 
60-40 Normal 
< 40 High 
TG 
<150 Optimal 
150 – 199 Normal 
200-≥ 500 High 
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1.1.2.2. Markers of inflammation, oxidation, and endothelial function 
Several inflammatory mediators, including adhesive and signaling mechanisms, 
are involved in early atherosclerotic lesion formation. Inflammatory processes involving 
activation of cytokines, enzymes, and growth factors continue to play a role in the 
plaques (22). Several circulating inflammatory mediators can be measured in plasma or 
urine samples. For example, high-sensitivity C-reactive protein (hsCRP) is a type of 
innate immune response protein. It is a non-specific inflammatory marker that has been 
studied in CVD and mediates atherosclerosis (23). hsCRP levels < 1 mg/L are desirable 
and reflect a lower atherosclerotic risk and a low systemic inflammatory status: levels 
between 1 and 3 mg/L indicate moderate vascular risk, and levels > 3 mg/L indicate 
higher vascular risk. Thromboxane B2 (TXB2) is an eicosanoid derived from 
cyclooxygenase-2 (COX-2), which can induce vasoconstriction and promote 
aggregations. There exists a strong relationship between elevated TXB2 levels and risk 
of stroke, myocardial infarction and death. Tumor necrosis factor-alpha (TNFα) is 
synthesized by different cell types in response to physiological and pathophysiological 
stimuli such as inflammation (24), and plays an important role in CVD. Cytokines 
(different interleukins) are also good biomarkers of CVD, because they are highly 
expressed in the process of atheroma formation. Such cytokines are significantly 
associated with CVD risk, independently of obesity and conventional risk factors, in a 
log-linear manner (25). The chemokine MCP-1 plays a key role in a variety of 
pathophysiological processes in cardiovascular biology (26), being able to directly act 
on endothelial cells and to induce angiogenesis through the induction of vascular 
endothelial growth factor (VEGF). There are other markers that reflect lipid oxidation 
and participate in CVD progression, e.g ox-LDL and isoprostranes. Isoprostanes 
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(prostaglandins isomers) are a bioactive product of arachidonic acid metabolism and 
elevated levels of these molecules have been associated with several cardiovascular risk 
factors (27). The adipose tissue also plays an important role in CVD because it produces 
several proteins (adipocytokines) such as leptin, adiponectin, resistin, TNFα, and IL-6, 
that modulate insulin sensitivity (28). All these markers can be measured in plasma 
samples. 
1.1.2.3. Glycemic profile 
Levels of postprandial glucose and acute glucose levels may be good predictors 
of CVD. Control of glucose in diabetes patients was first proposed by Koenig and 
collaborators in 1976 (29). The metabolic abnormalities caused by diabetes mellitus 
induce vascular dysfunction and increase the risk of myocardial infarction, stroke, 
amputation, and death (30). Type 1 diabetes is due to insulin deficiency and type 2 
diabetes is due to insulin resistance (IR).  IR, or reduced insulin sensitivity, is a key 
pathophysiologic defect appearing too in CVD (31). The most commonly marker used 
to measure insulin resistance is the homeostatic model assessment (HOMA), which is 
derived from a mathematical calculation of the balance between hepatic glucose output 
and insulin secretion from fasting levels of glucose and insulin (32). HOMA is, among 
other risk factors, a reliable tool for predicting the risk of coronary events. 
1.1.2.4. Anthropometric variables and vital signs 
Anthropometric variables may be the best tools to screen and predict obesity and 
overweight, which are increasing in many countries. Abdominal adiposity has been 
considered one of the best predictors for CVD (33), and waist circumference (WC) and 
waist-to-hip ratio (WHR) have been widely used in epidemiological studies. Body 
weight (BW) is a quick and useful tool that is employed in nutritional studies. Body 
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mass index (BMI) is often used to reflect total body fat, and as surrogates for central 
body fat we often use the WC, WHR and waist to height ratio (WHtR) (34).  
As for vital signs, observational studies have demonstrated associations between 
higher systolic blood pressure (SBP) and diastolic blood pressure (DBP), and increased 
CVD risk; the different reference values can be seen in Table 2. Moreover, high BP (or 
hypertension) directly increases the risk of coronary heart disease and stroke. High BP 
is a symptom that the arteries may have an increased resistance against the flow of 
blood, causing the heart to pump harder. 
Table 2. Categories of BP in adults (adapted from (35)). 
BP Category  SBP  DBP 
Normal  <120 mm Hg   <80 mm Hg 
Elevated  
<120–129 mm 
Hg  
<80 mm Hg 
Hypertension 
Stage 1  
130–139 mm 
Hg  
80–89 mm Hg 
Stage 2  ≥140 mm Hg   ≥90 mm Hg 
  
  1.2. Neurodegenerative diseases 
In addition to CVD, one of the great challenges of our society - due to the 
aging of the population - are neurodegenerative diseases (ND). It is evident that age 
itself causes physiological changes that occur during normal brain aging and that can 
be exacerbated in vulnerable populations of neurons, initiating pathological 
processes that eventually lead to ND, especially AD. Neurodegeneration is defined 
as a progressive loss of structure, function and even death of neurons, affecting many 
of body's activities, such as balance, movement, talking, breathing, and heart 
function. 
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Depending on the type, ND can be serious or even life-threatening. Most of 
them have no cure and treatments may only help improve symptoms, relieve pain, 
and increase mobility. Many of these diseases have genetic origins, but sometimes 
the cause is unknown. According to the most recent Global Burden of Disease Study 
2015, the burden of neurological disorders has increased substantially over the past 
25 years because of expanding population numbers and aging (36). ND include: 
dementias, AD, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's 
disease (HD), Lewy body disease, Parkinson's disease (PD) and spinal muscular 
atrophy. In this thesis, the focus was set on dementia, specifically in mild cognitive 
impairment (MCI) and AD. 
The shortage of molecular data on aging is due to the difficulty of separating 
the effects of "age" from those of age-related diseases (atherosclerosis, diabetes, 
hypertension and dementia) in vascular function and cognition. Life expectancy 
increases significantly in developed countries and the prevalence of MCI, AD and 
other dementias increases with age (37, 38).   
Age is the major risk factor for developing dementia, which is not an 
inevitable consequence of aging. Dementia not only affects the elderly: early onset 
dementia (defined as the onset of symptoms before age 65) represents up to 9% of 
cases. Some research has shown a relationship between the development of cognitive 
impairment and life-style related risk factors that are shared with other 
noncommunicable diseases. 
Risk factors for the development of such diseases include physical inactivity, 
obesity, unbalanced diets, tobacco and harmful alcohol use, diabetes and 
hypertension in middle age, as well as depression, low educational attainment, social 
isolation and cognitive inactivity. 
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      1.2.1. Mild cognitive impairment 
The concept of mild cognitive impairment emerged at the end of the nineties as 
proposed by Ronald C. Petersen and is defined as an intermediate stage between normal 
cognitive aging and very early dementia (39). MCI patients mainly report memory 
impairment, especially episodic memory, disorders of language, attention and visual-
spatial skills (40). 
The prevalence of MCI is in the 14 to 18% range for individuals aged 70 years 
or older (41). The rate of conversion of MCI to AD is 10% to 15% per year and other 
types of dementia have been estimated at 5 to 16% for the elderly adult population (42, 
43). 
The causes of MCI are not yet completely understood; risk factors include aging, 
genetic (heredity) cause of AD or other dementia, and risk of CVD. Some of these risks 
factors cannot be altered, but others are modifiable such as cardiovascular factors, 
physical fitness and diet (44).  
MCI exceeds what is normally expected for age, but does not meet the dementia 
criteria because functionality is preserved. There are no fixed events that determine the 
transition point between the asymptomatic and symptomatic phases of pre-dementia, or 
of the symptomatic pre-dementia phase at the beginning of dementia (45). 
MCI can then be classificated in three subtypes (46):  
 Amnestic: significant impairment of memory that does not meet criteria for 
dementia. 
 Multidomain: mild deficiencies in multiple cognitive and behavioral domains. 
 Non-amnesic monodomain: isolated impairment of some cognitive domain other 
than memory. 
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Despite efforts in the area of research to define the borderline between the 
normal and the pathological, it is known that, during aging, in the absence of 
neurological disease, there is a small decrease in the cognitive area, with visual 
impairment deteriorating first, while verbal skills and general knowledge are better 
preserved (47).  
In structural neuroimaging studies, AD patients have a global cerebral volume 
loss, increased ventricular volumes, and atrophy in the hippocampal and the entorhinal 
cortex. Topographic gray matter loss correlates with very mild AD patients. MCI 
usually presents structural changes intermediate to those observed in AD, usually 
displaying mild, but significant, volume loss in specific brain regions, notably the 
hippocampal structures, and decreased cortical thickness (48). Both are important brain 
regions, which play complementary roles in learning and memory, and are clinically 
important in cognitive disorders (49).  
Several studies have been oriented to the prediction of MCI conversion to 
dementia and an association between said conversion and high levels of microtubule-
associated protein tau (TAU protein) has been suggested (see below) (50). 
There are no effective pharmacological treatments available to treat MCI, 
although multidisciplinary strategies related to the prevention of chronic diseases 
associated with aging are being promoted. Both the Spanish and H2020 research 
programs include multidisciplinary lines with the aim of improving the understanding, 
prevention, early diagnosis and treatment of mental conditions and disorders of the 
elderly (Establishment of preventative strategies favouring the mental dimension of 
healthy ageing. Advancing active and healthy ageing: PHC-20-2014-solutions for 
independent living with cognitive impairment; PHC-21-2015-Early risk detection and 
intervention, etc.). 
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      1.2.2. Alzheimer’s disease  
AD is the most common form of dementia and possibly contributes to 6070% 
of all cases and affects 26 million people worldwide with an upward trend (51, 52). 
Each year, 4.6 million new cases are predicted, with numbers of affected nearly 
doubling every 20 years to reach 81.1 million by 2040 (53). 
 AD is a neurodegenerative disorder characterized by amyloid β-peptide (Aβ) 
deposits followed by neuron loss and decreased cognitive and memory habilities. 
Although it was characterized more than 100 years ago, little progress has been made 
towards an effective cure. AD starts slowly; first, it affects the parts of the brain that 
control thought, memory and language. People with AD may have difficulty 
remembering things that happened recently or the names of people they know. Over 
time, AD symptoms worsen: people may not recognize their relatives and may have 
difficulty speaking, reading or writing. They may forget how to brush their teeth or 
comb their hair. Later, they may become anxious or aggressive. 
The etiology of AD is unclear. Largely, its pathophysiology is related to the 
death of neurons, initiating in the hippocampus, a crucial brain region involved in 
memory and learning; then, atrophy affects the entire brain. Indeed, AD is a polygenic 
and heterogeneous disorder with multiple patterns of expression. The late-onset 
sporadic form is the most prevalent, with the early-onset familial type being responsible 
for only about 1% of the cases. Within the risk factors we find nonmodifiable ones, like 
age and genetic factors, and modifiable factors such as life style (physical activity, diet, 
education), metabolic syndrome (diabetes, hypertension, obesity), and possibly 
depression (54). 
The World Health Organization (WHO) states that AD develops in three stages: 
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 Early stage: the early stage of dementia is often overlooked, because the onset is 
gradual. 
 Middle stage: as dementia progresses to the middle stage, the signs and 
symptoms become clearer and more restricting.  
 Late stage: the late stage of dementia is one of near total dependence and 
inactivity. Memory disturbances are serious, and the physical signs and 
symptoms become more obvious. 
Pathologically, AD is characterized by the presence of senile plaques that 
contain Aβ and neurofibrils of hyperphosphorylated TAU protein. This protein induces 
changes to the cellular architecture as well as to the localization and organization of 
subcellular organelles, in turn inducing synaptic interruption and apoptotic neuronal 
death (55).  
The multifactorial etiology of AD makes the development of viable therapies 
difficult; current approved medications attenuate symptoms, but do not cure the disease. 
AD research has also had several failures in terms of developing disease-modifying 
therapies. Because this pathology begins many years before the symptoms appear, new 
scientific approaches now focus on the early stages of the disease, such as MCI. 
      1.2.3. Changes in eating habits to prevent ND 
In recent years, growing evidence emerged from epidemiological studies 
indicates that certain nutritional deficiencies, especially in the elderly, significantly 
affect the processes of cognitive deterioration associated with aging (56).  
Specific dietary patterns have been associated with increased risk of developing 
AD, whereas others are linked to protection. Other prospective studies showed that the 
Mediterranean diet, characterized by high consumption of cereals, fruit, vegetables, 
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legumes, and olive oil, is associated with lower incidence of AD and can improve 
cognition (57). The intake of unsaturated fatty acids (FAs) (both monounsaturated 
(MUFAs) and polyunsaturated fatty acids (PUFAs)) has been associated with improved 
cognitive performance and a decreased risk of age-related cognitive decline in long-
term observational studies (58). The low intake of n-3 and phospholipids (PHLs), which 
are essential for the activity, functioning, and maintenance of the nervous system, is 
related to a greater risk of ND (59). Also, B-vitamins are important for neuronal 
functioning and cognition (60). n-3, mainly those of marine origin of long chain and 
high degree of unsaturation, such as eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), are involved in the prevention of CVD, improving cerebral vascularization 
in some neuro-psychiatric disorders, particularly in depression and in AD associated 
with aging (61). 
For these reasons, specific dietary interventions or patterns might play 
preventive actions on dementia and its manifestations. Therefore, it is important to fully 
elucidate the role that dietary components (micro- and macronutrients) play at the 
molecular level, which enable to provide sound scientific advice to public health 
authorities. 
      1.2.4. Biomarkers of ND 
Biomarkers are important to monitor the development of disease or for 
implementing evidence-based prevention. Mapstone et al. (62) reported for the first time 
that ten blood metabolites (consisting mainly of PHLs) could be used to predict future 
cognitive impairment in asymptomatic older adults. There is growing evidence from in 
vitro experiments, animal models, and observations in patients that links abnormal 
insulin signaling with AD. The underlying mechanisms include interference with the 
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metabolism of Aβ and TAU protein (63). Studies on brain pathogenesis propose 
Aβ, neuritic plaque (NP), and neurofibrillary tangle (NFT) aggregation. However, 
autopsies of brains of aged people who were not diagnosed with a neurological disease, 
also revealed Aβ, NFT, Lewy bodies, inclusions, synaptic dystrophy, and loss of 
neurons and brain volume. In short, other processes can contribute to ND (64). 
These data highlight the enormous potential that biomarkers have to predict the 
shift of cognitive deterioration, in a preclinical phase, to AD.   
1.2.4.1. Glycemic profile 
Epidemiological evidence indicates that diabetes is a risk factor for AD onset 
and development (65, 66). Longitudinal epidemiologic studies show that diabetes 
increases AD risk by 50–100%; this includes type 2 diabetes, which accounts for 90% 
of all cases (67). Lower glucose metabolism has also been observed in MCI (68). In 
1979, the glucose tolerance test was introduced, as an intermediate state in the transition 
in glucose homeostasis from normal to diabetes state (69). IR-associated risk factors 
such as obesity, poor diet, physical inactivity, aging, and genetic predispositions are 
correlated with cognitive dysfunction. Overall, the analysis of plasma biochemical 
biomarkers related to diabetes provides relevant information in ND studies.  
1.2.4.2. Mitochondrial biogenesis 
Growing evidence suggests that mitochondrial dysfunction plays an important 
role in the aging of the brain and in the pathogenesis of ND (70). This loss of cognition 
associated with age is seen in both animal and human models. The underlying 
mechanisms that lead to endothelial dysfunction and dementia are poorly understood. 
However, as mentioned, all these damaging changes are probably linked to 
mitochondrial dysfunction and, in particular, to mitochondrial oxidative decay, which is 
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an important contributor to aging. Although the loss of mitochondrial function 
associated with age is undoubtedly multifactorial, several lines of evidence indicate that 
certain molecular and cellular alterations are significantly involved in the progression of 
the changes that ultimately lead to an altered mitochondrial energy metabolism (71).  
It has been hypothesized that the characteristics of mitochondrial deterioration 
are symptomatic of a vicious circle where the defective electron transport chain (ETC) 
complexes contribute to a greater generation of reactive oxygen species (ROS) by the 
mitochondria, which in turn increases the damage and mutations of the mitochondrial 
DNA (mtDNA), and finally affects reciprocally the structure of ETC components (72). 
Damages and deletions in mtDNA that correlate with lower age-related oxidative 
respiratory activity have been reported in the liver and heart muscle of rats, the liver and 
skeletal muscle of primates, and in the skeletal and cardiac muscle of human beings 
(73). Ultimately, higher rates of ROS production increase the oxidative modification of 
membrane lipids and proteins, to the point where the accumulation of molecular defects 
exceeds the capacity to maintain mitochondrial homeostasis through autophagy (74). 
Mutations in genes that encode mitochondrial proteins could compromise the 
mitochondria by altering the components of ETC, resulting in an inefficient transport of 
electrons, decrese adenosine triphosphate (ATP) and an increase in the production of 
superoxide. The oxidative damage resulting from the mitochondria can compromise its 
ability to satisfy the demands of the brain's equilibrium energy. The accumulation of 
oxidative damage to mitochondria, proteins and nucleic acid in the brain can lead to 
neuronal and cognitive dysfunction (75).   
Because mitochondrial dysfunction plays an important role in ND, obtaining 
information on the mitochondrial energetic state is obviously pertinent. 
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1.2.4.3. Signaling related to ND 
Insulin signaling 
A relationship between the appearance of cognitive disorders and IR has been 
observed, and the latter has been identified as a major risk factor for the onset of AD 
(76). Research shows that cerebral glucose metabolism impairment, in diferents brain 
regions, precedes the onset of dementia and can predict decline from normal cognition 
to MCI and AD. Hippocampus and temporal cortex show the highest levels of insulin 
receptor expression, indicating the important role of insulin in learning and memory 
(77). At the cellular level, it has been seen that astrocytes are responsible for converting 
glucose into lactate and transfer it to neurons, which is an important neuronal energy 
reservoir during periods of high activity, like learning and memory (78).  
Insulin is a polypeptide hormone produced and secreted by the beta cells of the 
islets of Langerhans, reaching the brain through the cerebrospinal fluid and crossing the 
blood-brain barrier. Once insulin reaches the cells it binds to its receptor, which induces 
transphosphorylation, giving rise to an activation loop, activating the insulin receptor 
substrate (IRS) and, in turn, the signaling pathway of the phospho-inositol-3-kinase 
(PI3K) and/or the pathway of the mitogen-activated protein kinases (MAPK). The 
insulin-signaling pathway (Figure 1) is interrupted in IR because regulatory 
mechanisms are altered. In AD, the IRS-1 is hyperphosphorylated (79). Given all the 
above, exploring the levels of relevant actors involved in these pathways provides 
important information when conducting ND-related studies. 
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Figure 1. Insulin signaling. Image taken from https://www.cellsignal.com 
Neurotransmission 
Impulse transmission from one neuron to another depends on the action of 
neurotransmitters through synapses. Synaptic transmission is the biological process by 
which a neuron communicates with a target cell through a synapse. There are two types 
of synaptic transmission, chemical and electrical. Their chemistry involves the release 
of a neurotransmitter from the pre-synaptic neuron and its consequent binding to 
specific post-synaptic receptors. The electrical synapse involves the transfer of electrical 
signals through gap junctions (80). During neurodegeneration, a progressive loss of 
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structure or function of neurons occurs, which can end with their death (81). Synaptic 
dysfunction is an early change in both cognitive decline and AD (82).  
Studying genes that code for pre- and post-synaptic proteins and their proteins, 
in key tissues, provides information on how nerve cells function and the possible 
evolution that they can have towards ND. This information is more robustly correlated 
with cognitive decline than neuropathological hallmarks of AD (83). For example, α-
synuclein and other synaptic proteins have been shown to be differentially expressed in 
various ND (84).  
 
2. Functional foods and micronutrients 
Many studies have investigated the health benefits of various functional food 
ingredients, including n-3 FAs, polyphenols, fiber, and plant sterols, among others. 
These bioactive compounds may help to prevent and reduce the incidence of chronic 
diseases. Several epidemiological studies clearly show that proper diets are associated 
with lower incidence of degenerative diseases, namely cardiometabolic disorders 
(CMD) and cancer (85). Neurodegeneration also appears to be partially preventable by 
following specific dietary regimens. The general consensus is that plant foods should 
provide the major portion of caloric intake, as this reduces the development of certain 
diseases, in particular cancer and CVD. In the past few years, there has been a steadily 
growing interest in the role that oligonutrients (aka micronutrients), commonly found in 
plant foods, might play in the maintenance of human health. Although “plant 
oligonutrient” deficiencies in diets are yet to be described, the recent discovery that 
several phenolic molecules, namely catechols, exert interesting biological activities led 
to a re-evaluation of the contribution of these compounds to human health (86). This is 
also leading to increasing marketing of “functional foods” or “nutraceuticals”, i.e. 
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fortified or enriched foodstuffs that are attributed health-promoting effects. The 
rationale on which the hypothesis that certain phytochemicals might contribute to 
lowering CVD and ND is based on the notion that oxidative and inflammatory 
processes play a role in the onset and development of these pathologies (87, 88). 
Several phytochemicals (notably catechols) are endowed with enzyme-modulating 
activities, hence expressing the potential to lower cardiovascular risk. It is noteworthy 
that a diet that derives a large proportion of its calories from plant foods allows having a 
significant daily intake of these phytochemicals. Although the absorption, metabolism, 
and excretion of most of these compounds is being slowly elucidated, such high intake 
makes this group of molecules particularly interesting from a preventive medicine point 
of view, and the study of their bioavailability is very important (89).  Also, it is 
important to note that, apart from phytochemicals, the human body cannot synthesize 
lipid- and water-soluble vitamins that, therefore, must also be taken up from the diet or 
provided through functional foods or “pharmaceutical” preparations. 
Epidemiologically, the best diets (in terms of cardio- and chemoprevention) are 
the Mediterranean and the Japanese ones (90). Of note, there is growing evidence that 
classic risk factors for CMD such as high serum cholesterol and blood pressure are not 
much different in the populations of Southern Europe and Japan, as compared to other 
Western countries. This suggests that other unexplored risk factors (for which, however, 
biochemical evidence is accumulating), in addition to the classic ones, may be favorably 
affected by these diets (91). Food composition studies have shown that both diets are 
rich in minor components derived from fruits, vegetables, tea, red wine, olive oil, and n-
3, derived from fish, nuts, certain seed oils, and vegetables. The typical Mediterranean 
and Japanese diets also provide adequate intakes of fiber and folic acid. Fiber intake 
(both of cereal and of fruit/vegetable origin) has been shown to reduce the incidence of 
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all the clinical events related to atherosclerotic disease. Adequate intakes of folic acid, 
on the other hand, are associated with reduced blood levels of homocysteine, an amino 
acid that damages the inner arterial lining (endothelium) and whose high blood 
concentrations have been associated with elevated cardiovascular risk. Finally, 
consumption of complex carbohydrates, as bread, pasta, and rice (largely represented in 
the Mediterranean and Japanese diets) is also associated with favorable health effects.  
For instance, they induce a limited post-prandial rise of plasma glucose and 
consequently a limited insulin response, thus reducing the risk of developing 
overweight and diabetes (two important risk factors of CVD and ND). 
Though the healthful properties of the Mediterranean diet as a whole have 
gained recognition, basic researchers are nowadays concentrating their efforts on 
individual food items (e.g. cereals, fruits, vegetable, olive oil) and their components 
(e.g. fibers, vitamins, polyphenols). Why so? There are several reasons to investigate 
the molecular effects of single food components. Observational claims resulting from 
epidemiological studies often fail when tested in randomized trials. Epidemiology and 
observational associations are prone to fallacies because they most often rely on food 
frequency questionnaires. In this sense, a recent analysis showed that, in the National 
Health and Nutrition Examination Survey, the energy intake measures inferred from the 
questionnaires of two thirds of the participants are incompatible with life (92).   
The best way to obtain reliable data for diets and their components would be to 
carry out randomized controlled trials (RCTs), as is customary in pharmacological 
research. With the notable exception of the PREDIMED (93), this proves to be nearly 
impossible because the effects of diets are – by definition – modest and difficult to 
gauge clinically and because the optimal setting is that of a metabolic ward where 
participants are required to stay for prolonged periods of time. In the absence of 
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controlled conditions such as those of metabolic wards, it becomes very difficult to 
assess compliance. Indeed, the field of metabolomics is addressing precisely this, i.e. 
finding circulating or urinary metabolites indicative of selected foods. Budgetary and 
technical issues currently prevent the extensive application of metabolomics to human 
studies (94).  
One alternative way to provide supportive evidence in favor or against dietary 
profiles is to build enough in vitro and animal data to back claims and strengthen dietary 
guidelines. By targeting relevant enzymatic systems and cellular pathways, researchers 
can shed light on the effects of food components and, in turn, substantiate claims. Of 
course, this approach requires rigorous scientific behavior and the use of relevant 
concentrations or doses, appropriate biomarkers, and adequate exposures. Interestingly, 
human trials with selected, isolated food components (or mixtures of them) can be 
carried out to test the effects of biochemical and physiological responses (95). 
In summary, by singling out the contribution of micronutrients to the protective 
activities, one can better focus dietary guidelines and, when possible, formulate 
appropriate functional foods or nutraceuticals. 
Indeed, an emerging area of research situates itself at the interface of 
pharmacology and nutrition. This field is currently experiencing renewed impetus as 
several food components are being employed as medicines, either directly or as pro-
drugs. As a matter of fact, there are areas in which the border between food and 
“pharma” is not well-defined, as the former often contains several bioactive compounds 
including secondary plant molecules (polyphenols), fibers, friendly bacteria, essential 
FAs, probiotics, and other contributions. Furthermore, several current drugs are derived 
from natural products including those to which humans have been exposed via diet. 
Indeed, it is sometimes difficult to distinguish between bioactive molecules termed 
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“drugs” and other substances classified as “nutrients”. Optimal health and prevention of 
chronic diseases can be attained (to a certain extent) by modulating the intake of macro- 
and micro-nutrients, often in pharmacological doses as in the case of supplements, 
nutraceuticals, and functional foods. Classic pharmacotherapy can also be accompanied 
by adjunct treatments with nutrition-derived remedies that are often able to decrease the 
doses of medicines and/or lessen their side effects. In summary, the border between 
pharma and food is becoming less distinct (96). 
A healthy lifestyle, with exercise and a varied and balanced diet can prevent and 
even reduce the risk of developing certain types of diseases such as CVD and ND.  
3. Nutrigenomics tools 
It should be noted that in the last decade, omics tools have allowed deepening 
the knowledge of the metabolism of some diseases where genetic techniques are not 
enough. These techniques allow determining possible biomarkers that have become 
increasingly important in the understanding of many diseases such as CVD and ND.   
Nutrigenomics attempts to study the genome-wide influences of nutrition. It 
investigates the impact of dietary components on the genome, the proteome and the 
metabolome (the sum of all genes, proteins, and metabolites), studies the effect of 
different diets or foods in specific cells, tissues and organisms, and how nutrition 
influences homeostasis (97). Furthermore, nutrigenomics aims to identify the genes that 
influence the risk of diet-related diseases on a genome-wide scale, and to understand the 
mechanisms that underlie these genetic predispositions.  
Dietary intervention studies have successfully used transcriptomics and 
proteomics to show how diet induces alterations in gene and protein expression for three 
different purposes: 1) provide information about the mechanism underlying the effect of 
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a certain nutrient, 2) determine possible biomarkers, and 3) identify pathways regulated 
by micronutrients. 
Thanks to all these techniques, we can better understand how the diet or 
different foods influence CVD and ND.  
The main nutrigenomics tools used during this PhD work mainly concerned 
transcriptomics and proteomics: 
1) Transcriptomics 
Microarrays  
This omics tool, important in transcriptomics, quantitatively measures levels of 
gene expression. It consists of different nucleic acid known probes that are chemically 
hybridized to a substrate, which can be a microchip or a glass slide. The analysis of 
samples from nutritionally relevant studies in animal and cell models have led to the 
identification of genes regulated at the messenger RNA (mRNA) level by exposure to 
different dietary components in different tissues (98). The adipose tissue, for example, 
is important to study lipid metabolism, because it plays an important role in obesity and 
CVD (99). Likewise, the intestine, which is crucial in regulating cholesterol and lipid 
homeostasis in the body, is the limiting tissue of lipid absorption and it participates in 
the elimination of cholesterol through faeces in the process called trans-intestinal 
cholesterol excretion (TICE) (100). 
With regards to ND, many learning and memory processes are influenced by 
gene transcriptional changes and are affected by nutrition (101). In this sense, the 
studying of brain tissues such as the hippocampus and temporal cortex are of special 
relevance, due to their involvement in memory formation and because they suffer great 
damage and morphological changes during neurodegeneration (102).  
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RT-qPCR 
This technique is used to amplify and quantify gene expression. From a sample 
of ribonucleic acid (RNA), retrotranscription (RT) is carried out, using the reverse 
retrotranscriptase enzyme, to convert the RNA into DNA complementary (cDNA), then 
real-time polymerase chain reaction (PCR) is performed in the same way as 
conventional PCR, a deoxyribonucleic acid (DNA) template, dNTPs (deoxynucleotide 
triphosphates), at least a pair of specific primers, and a thermostable DNA polymerase; 
a fluorophore is added to the mixture and the emitted fluorescence is measured in the 
thermocycler. The PCR process usually consists of a series of temperature changes that 
are repeated 25-40 times, called cycles.  This reaction is usually divided in three stages: 
the first, at high temperatures to activate the enzyme and to dehybridize both cDNA 
chains; the second, at a temperature around 50-60 °C, allows the hybridation between 
the primers and the template DNA; and the third, at 68-72 °C, facilitates the 
polymerization by the DNA polymerase. 
RT-qPCR is commonly applied after microarrays analysis, in order to confirm 
and validate the results obtained from the latter (103). Besides mRNA quantification, 
other types of non-coding RNA, like microRNA (miRNAs), can also be analyzed with 
this tool (104). Another use of this technique is through the design of specific primers 
for known genes, within the same signaling pathway, or involved in some process of 
interest, for example involved in neurotransmission, to study ND, or involved for 
example in the expression of phase II enzymes, to study antioxidants’ functions or 
detoxifications. 
Next generation sequence (NGS) 
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The first technique used to sequence is Sanger sequencing, based on the chain 
termination method that Frederick Sanger and colleagues developed in 1977 (105). It 
was widely used since it was created until 2007. This method has been replaced by 
NGS, which refers to high-throughput DNA sequencing (seq) technologies. Millions or 
billions of DNA strands can be sequenced in parallel, yielding substantially more 
throughput and minimizing the need for the fragment-cloning methods that are often 
used in Sanger sequencing of genomes (106).  
The applications of this technique are: 
 Sequencing and assembly of de novo genomes 
 Re-sequencing of genomes and analysis of variability Analysis of the 
functional activity of the genome and epigenetics 
-Chromatin analysis: ChIPseq, FAIREseq: regulation of gene expression 
- Epigenetic analysis (Bisulphite seq) DNA methylation 
- Transcriptome gene expression analysis: RNAseq 
 Metagenomics studies 
A large number of NGS platforms exist, including Illumina, the Applied 
Biosystems SOLiD System, 454 Life Sciences (Roche), Helicos HeliScope, Complete 
Genomics, Pacific Biosciences PacBio and Life Technologies Ion Torrent (107).  
Understanding the transcriptome throught RNA Seq is essential for the 
interpretation of the functional elements of the genome and for understanding the 
molecular constituents of cells and tissue.  
Recent advances in the RNA-Seq workflow, from sample preparation to library 
construction to data analysis, have enabled researchers to further elucidate the 
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functional complexity of the transcription(108). The main advantage of RNA-seq with 
the previous methods is the high performance, the sensitivity and the ability to discover 
new transcripts, gene models and non-coding RNA, such as miRNAs. This technique 
enables a deep profiling of the transcriptome and, in the case of this thesis, the 
opportunity to elucidate transcryptional responses to different diet components. 
2) Proteomics  
Proteomics is the large-scale study of different proteins in a sample, cell line, 
tissue, or organism. This term was first coined in 1995 (109). The proteome is not 
constant, it differs from cell to cell and changes over time. To some degree, the 
proteome reflects the underlying transcriptome. However, protein activity (often 
assessed by the reaction rate of the processes in which the protein is involved) is also 
modulated by many factors in addition to the expression level of the relevant gene. In 
dietary context, proteomics is the study of proteins and their functions and how they are 
modulated in response to different foods. Proteomics can provide significant biological 
information such as: 
 Which proteins interact with a particular protein of interest  
 Which proteins are localized to a subcellular compartment (e.g. the effect of 
food in different organs). 
 Which proteins are involved in a biological process 
Mass-spectrometry (MS)-based Super-SILAC 
Mass-spectrometry (MS) based quantitative proteomics are the most commonly 
applied techniques besides Tandem-MS and gel-based techniques such as differential 
in-gel electrophoresis (DIGE). These high-throughput technologies generate huge 
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amounts of data. Databases are critical for recording and carefully storing the data. MS 
is a powerful method that allows identifying the compilation of proteins expressed in 
biological systems, in addition to their interactions and modifications. Stable isotope 
labeling with amino acids in cell culture (SILAC) has risen as a powerful quantification 
technique in MS. Specifically, the super-SILAC technique uses a mixture of SILAC-
labeled cells on study as a spike-in standard for accurate quantification of unlabeled 
samples, for the quantification of human or animal tissue samples (110). 
Western Blot 
Western blotting is an important technique used in cell and molecular biology. 
By using a western blot, researchers are able to identify specific proteins from a 
complex mixture of proteins extracted from cells or tissues. After protein extraction and 
quantification, the same concentration for each sample is loaded onto polyacrylamide 
gels and submitted to Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis 
(SDS-PAGE). In SDS-PAGE, proteins are separated based on their molecular weight. 
Proteins are then transferred to a solid support (i.e. membrane) and, finally, the proteins 
of interest are visualized by marking with proper primary and secondary antibodies 
(111). This technique is commonly used to study proteins known to be involved in 
signaling pathways of interest or for the validation of results found in the mass 
spectrometry. 
4. miRNAs as biomarkers 
miRNAs are short (-22 nucleotides) noncoding RNA molecules acting as post-
transcriptional regulators, mainly as gene expression repressors, but also as activators 
(112). Generally, under physiological conditions they work as "buffers" of gene 
expression by regulating different genes at the same time. Thus, a single miRNA can act 
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on hundreds of mRNAs, modulating the regulation of specific biological processes 
acting in a coordinated manner in pathways of functionally related genes (113).  
miRNAs biogenesis begins with a large RNA precursor, pri-miRNA, which is 
transcribed and matured in the nucleus by the RNA polymerase II. RNase III and 
protein partner Drosha subsequently cleave it near the hairpin stem base. The pre-
miRNA precursor has a hairpin of 60 to 70 nucleotides and is released in the cytoplasm 
by exportin-5. Through DICER protein, it is divided, resulting in a double stranded 
miRNA/miRNA with 21–25 base pairs, which is unwound by RNA induced silencing 
complex (RISC). RISC will then carry the mature miRNA to target messenger RNAs 
resulting in gene silencing. Its function is to regulate a series of cellular processes, such 
as apoptosis, differentiation, cell cycle, and immune functions (114). However, under 
stress conditions, its function is enhanced, revealing its importance in health and illness, 
and it can be altered by a wide range of environmental factors such as smoking, alcohol, 
sleep, exercise, stress, radiation and nutrition.    
Numerous pathways affected by miRNA regulation, such as lipid metabolism, 
glucose homeostasis, vascular integrity and endothelial cell function, are involved in 
CVD (115). The role of some miRNAs in lipid metabolism, in tissues other than the 
intestine has been described, but it is still unknown whether miRNAs may be actively 
participating in the regulation of lipid metabolism in the gut. There is scientific 
evidence indicating that some components of our diet can have beneficial effects 
through the modulation of the expression of miRNAs (116). However, very few studies 
have evaluated such effects in depth. 
miRNAs are present, stable, and detectable in the circulation. Several cardiac 
miRNAs are detectable in blood and might be employed to improve CVD diagnosis 
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(117).  Dimmeler et al., in a pioneering work, observed changes in miRNA levels in the 
serum of patients with coronary artery disease compared to controls (118). After this 
study, numerous miRNAs have been reported to be involved in CVD. Examples include 
miRNAs implicated in cardiovascular death (miRNA-132, 140 and 210), in acute heart 
failure (miRNA-423), or in cardiac autophagy (miRNA-22) (119-121).  
To determine whether some diet components modulate the expression of 
important miRNAs involved in disease, it is important to search for their modulation 
or/and to demonstrate whether the therapeutic inhibition of those miRNAs could have 
benefits in vivo (using animal models). As proof of concept, the therapeutic inhibition of 
miRNA-122, using antisense oligonucleotides, has been shown in clinical trials (122).  
Current approaches for ND identification and progression include the analysis of 
proteins in cerebrospinal fluid (CSF), biomarkers in blood samples, and various imaging 
techniques. Minimally-invasive specific biomarkers of ND would facilitate patient 
selection and disease progression and some groups have proposed the use of circulating 
miRNAs for disease detection (123, 124). For example, the expression of miRNA-9 was 
reported to be downregulated in the blood serum of AD patients compared with age-
matched controls (125).  Other miRNAs reported to be dysregulated in AD are miR-
125b and miR-138, showing increased levels in the hippocampal CA1 region (126). 
Moreover, miRNAs play essential roles in synaptic plasticity by regulating the 
expression synthesis of relevant proteins to the synapse (127).  
5. Micronutrients studied 
      5.1. Soy Isoflavones 
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Soy provides various nutrients, such as proteins, FAs and isoflavones. Soy 
consumption might be beneficial in terms of reducing the concentration of sugars in the 
blood (important against diabetes) (128), prevent osteoporosis by reducing female 
estrogens, and protect against CVD (129). Soy isoflavones (SI) have estrogenic activity, 
due to their structural similarity with 17-β-estradiol. SI are different from human 
endogenous steroids, yet have the ability to bind to estrogen receptors (130). The major 
isoflavones in soybean are genistein and daidzein.  
Isoflavones are used as supplements. It is suggested that daily consumption of 
≥25 g of soy protein, with its associated intact phytochemicals, can improve lipid 
profiles in humans with hypercholesterolemia. The European Food Safety Authority 
(EFSA) has conducted a risk assessment of SI supplements, with intakes up to 150 
mg/day by post-menopausal women, and no adverse effects were found (131). Indeed, 
the supposed cardioprotective effects of soy have been attributed mainly to its protein 
components (132), but also notable examples include genistein, daidzein, and glycitein 
(133, 134). Numerous clinical studies claim benefits of genistein and daidzein in the 
chemoprevention of breast cancer and prostate cancer, cardiovascular disease, and 
osteoporosis (135). For example, the intake of soy isoflavones from one month up to 
one year could significantly improve serum lipid profiles in both healthy and 
hypercholesterolemic individuals (136). It has also been reported to improve vascular 
function and lower blood pressure (137).  
However, the belief that soy foods and their supplements are beneficial in human 
health is increasingly controversial due, precisely, to the estrogenic activities of this 
micronutrient, which could negatively affect the risk of breast cancer, in particularly 
among ER-positive breast cancer survivors (135). Moreover, a meta-analysis of 10 
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randomized placebo-controlled trials, where plasma lipoproteins concentrations had 
been determined, revealed no significant effect of soy isoflavones treatments (138).  
In summary, the effects of SI on CVD and its associated risk factors have not 
been fully clarified and further investigation is needed. 
      5.2. Hydroxytyrosol 
Hydroxytyrosol (HT) is a compound almost exclusively found in olives and in 
extra virgin olive oil. It is generated by the hydrolysis of oleuropein (OE), which occurs 
during the maturation of the fruit and during the process of producing table olives, 
giving rise to OE aglycone, hydroxytyrosol, and elenoic acid. 
HT - which can currently be synthesized (unlike OE) - has properties that have 
aroused great interest for its use as a potential nutritional supplement and as a 
preservative in cosmetics as well as in the nutraceutical and food industry. Its short-term 
exploitation at the industrial level is envisioned. 
There are numerous studies that have shown that HT has numerous antioxidant 
properties, beneficial effects on the cardiovascular system, as well as antimicrobial, 
anticarcinogenic, anti-inflammatory and neuroprotective properties (139). 
Regarding the safety of hydroxytyrosol, the first acute toxicity test with HT in 
experimental animals was carried out in 2001. Results showed that a single dose of 2 
g/kg of body weight did not produce any adverse effect, other than for piloerection 
(disappeared after 48 hours), or macroscopic alteration of internal organs (140). 
Subsequent studies evaluating acute toxicity in rats, such as the 90-day chronic toxicity 
test, confirmed the absence of toxic effects at doses of 2000 mg/kg/day, as well as the 
absence of teratogenic and mutagenic effects (141).  Moreover, in 2013, a study 
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proposed a No Observed Adverse Effect Level (NOAEL) of 500 mg/kg BW/day for 
HT, which would represent for humans (considering a safety factor of 100) 5 mg/kg 
BW/ day of HT or 300 mg/day of HT for a person of 60 kg (142).  Finally, HT has been 
recently approved by the EFSA as a novel food (143). 
At the molecular level, HT is able to modulate several enzymatic activities 
related to CVD, including the inhibition of platelet aggregation (144) and pro-
inflammatory enzymes, such as the enzyme 5-lipoxygenase (145, 146), and the 
stimulation of the inducible form of nitric oxide synthase (147). The effects of olive leaf 
extracts at the vascular level have been demonstrated in a rabbit model (148), but the 
relevance of these studies in humans is not known. While most data have been obtained 
in vitro, several experimental evidence has been confirmed in vivo. Regarding human 
studies, more than 15 experiments have been conducted with healthy volunteers or 
patients and the vast majority confirm that olive oil rich in phenols positively modifies 
indirect markers of cardiovascular disease; other studies compared the effect of olive oil 
with those of extra virgin olive oil. Of note, extra virgin olive oil contains phenols other 
than HT (149). Therefore, conducting studies in humans with this compound, as the 
only phenolic source, is vital in order to determine the role it plays in CVD and 
neurodegenerative disorders. HT and other related olive phenols have been indeed 
tested as supplements in humans, and to date there have been only two studies with HT, 
as the only source of polyphenols (150, 151). The most notable results are the inhibition 
of the generation of thromboxane B2 in whole blood, suggesting an antithrombotic 
activity in vivo (152, 153). Regarding neurodegeneration, epidemiological studies report 
a better cognitive function in people (mostly elderly) whose diet includes a large part of 
olive oil. Studies showed that the Mediterranean diet is associated with lower incidence 
of AD and improved cognition (57, 154). HT is being explored in neurodegeneration 
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and ameliorates AD-involved neuronal impairment via modulating mitochondrial 
oxidative stress, neuronal inflammation, and apoptosis (155, 156). 
      5.3. Bioactive polar lipids  
Lipids are a group of organic molecules that fulfill numerous biological 
functions in the body such as energy reservation (TG), structural PHLs, sphingolipids 
(SLs), cholesterol), regulation (steroid hormones), and transport (bile acids) (157). 
Within lipids, polar lipids (PLs) are characterized by being amphipathic molecules in 
which an apolar region and a polar region are identifiable. Among the PLs, we find the 
PHLs and the SLs. 
PHLs are compounds with potent biological activities and are the main lipid 
constituents of all biomembranes and especially those of the nervous system. In addition 
to their structural action, they also regulate biological processes such as intracellular 
signaling processes, many of which are altered in various metabolic and neurological 
diseases (158). PHLs, depending on their vegetable or animal origin, predominantly 
contain an unsaturated FAs in position sn-2, such as oleic, linoleic, arachidonic or EPA 
or DHA (of marine origin), while the sn-1 position predominantly carries a saturated 
FAs, such as stearic or palmitic. The phosphate group, bound by a phosphodiester bond, 
gives the name to PHLs, depending if it is choline (phosphatidylcholine, (PC)), 
ethanolamine (phosphatidylethanolamine, (PE)), inositol (phosphatidylinositol, (PI)) or 
serine (phosphatidylserine, (PS)). In the case of SLs, the alcohol sphingosine binds to a 
FA resulting in sphingomyelin (SM).  
The absorption of diet FAs is much higher when they are part of PLs, since in 
the intestine the latter are absorbed almost completely (> 90%). It has been documented 
that almost 20% of PLs are absorbed in the intestine passively, without hydrolyzation, 
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and that they are preferably incorporated into HDL, from which they are transferred to 
plasma and reach the membranes as such or as their corresponding isoforms, thus 
contributing to the renewal of the PHLs of cell membranes. These mechanisms are 
highly complex and have not been fully elucidated (159).  
An important source of polar lipids of dairy origin is the milk fat globule 
membrane (MFGM), mainly composed of triacylglycerides and different concentrations 
of other compounds such as diacylglycerides, monoacylglycerides and cholesterol. 
MFGM also contains different phospho- and sphingolipids. Buttermilk (BM), a by-
product obtained from butter manufacturing, contains high proportions of PS and SM. 
PS and SM acquire special importance due to their activities in the organism. PS plays 
an important role in cellular functions including the integrity of the mitochondrial 
membrane, release of presynaptic neurotransmitters, activity of postsynaptic receptors 
and activation of the protein Kinase C in the formation of memory (160). The decrease 
in SM-containing myelin content in the brain has been related to the slowing down of 
the cognitive process associated with aging (161). Another important source of polar 
lipids from marine origin is krill oil (KO). Krill (Euphausia superba) is a small marine 
crustacean mainly found in the Antarctic Ocean. It is rich in long chain polyunsaturated 
n-3 as well as in PHLs. KO is a unique source of EPA and DHA, mostly incorporated in 
PC. Numerous studies in animals have shown the importance of PC in the diet of 
pregnant mothers because of its impact on brain development and function (162). 
The EFSA recently concluded that n-3 effectively reduce TG levels when 
consumed at intakes of 2 to 4 g/day. Food and Agriculture Organization (FAO) and 
WHO recommend a daily intake of 500 mg of EPA + DHA (163). 
Both BM and KO, because of their composition, could be helpful against ND. 
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Cardiovascular and neurodegenerative diseases are the leading cause of 
mortality and morbidity worldwide. Environmental factors such as stage of 
development, nutrition, physical exercise, environmental pollution, among others, might 
modulate (in either direction) the onset and development of degenerative diseases. 
Despite progress in the prevention and treatment of both maladies, there is a clear need 
to identify novel biomarkers and pharma-nutritional interventions to further ameliorate 
prognosis. In other words, the search for new pharmacological or dietary therapeutic 
alternatives for CVD and ND prevention or treatment must, and does so, continue. 
 
 The hypothesis of this doctoral thesis is that selected micronutrients can 
partially protect against neurodegenerative and/or cardiovascular diseases. 
Further, we investigated the specific molecular mechanisms of action of these 
selected molecules. 
 
The main objective of this doctoral thesis is that, by studying the biological 
effects of certain micronutrients, we can contribute in the laying of scientific basis for 
their potential use to prevent, treat, or at least mitigate the consequences of these 
pathologies. In this sense, we aimed to study the nutrigenomic and epigenetic effects of 
certain micronutrients on the expression of key genes and proteins included in pathways 
relevant to cardiovascular and/or neurodegenerative diseases, through in vitro and in 
vivo (experimental animals and human clinical trials) approaches. In addition, we aimed 
at investigating the beneficial actions of these compounds, to identify novel biomarkers 
of their effects, and to look for new molecular targets, in order to provide strong 
scientific evidence to their potential incorporation into nutraceuticals or functional 
foods.  
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The specific aims are listed below and sub-divided into three chapters, based on 
the micronutrients under study.  
 
Chapter 1: Soy isoflavones (Objectives 1) 
 
 To investigate the nutrigenomic actions of soy isoflavones (in nutritionally 
relevant amounts) in mice, with a specific focus on adipose tissue, due to their 
fundamental role in cardiovascular metabolism. 
 
Chapter 2: Hydroxytyrosol (Objective 2) 
 
 Determine the effect of hydroxytyrosol supplementation in healthy volunteers, 
investigating its bioavailibility, as well as its potential effect on the modulation 
of Phase II enzymes and certain microRNAs in PBMCs. In order to achieve this, 
a pilot randomized, crossover, placebo-controlled trial was conducted.  
 Determine the molecular mechanisms by which hydroxytyrosol exerts its 
possible beneficial effects against cardiovascular diseases and to search for 
potential new therapeutic targets of this micronutrient, using in vitro and in vivo 
(rodents) models.  
 Analyze the beneficial effects of hydroxytyrosol in an in vitro model of 
Alzheimer's disease. 
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Chapter 3: Bioactive phospholipids (Objective 3) 
 
 To investigate the potential beneficial effects of bioactive phospholipids on 
glucose metabolism and mitochondrial dysfunction, in aged rats. 
 To study the effects of bioactive phospholipids on cognitive functions and to 
look for cerebral microRNAs as potential markers in the treatment of mild 
cognitive impairment, in aged rats.  
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To carry out the work performed, during this PhD thesis, three different 
compounds were used: 
SOY ISOFLAVONES  
To perform the work reported in Chapter 1 we used a mixture of glycosylated 
soy isoflavones, with genistein and daidzein as the main ingredients (14.7%; 
Soyselect
®
), kindly donated by Indena (Milan, Italy). Soyselect
®
 is a standardized 
extract obtained from soy with a double standardization procedure and which contains 
13%–17% of isoflavone glycosides genistein and daidzein and ~ 18% of B-group 
saponins, as quantified by HPLC. The product is prepared by extracting ripe whole 
soybeans or oil-free soy flour with aliphatic alcohols through a patented process of 
industrial manufacture (US Pat. Nos. 6,280,777 and 6,617,757). One gram of extract 
also contains 0.058 g of protein, 0.035 g of fat and 0.023 g of ash. The batch (nr. 
30432/M1) used in this study for the preparation of the feed, contained specifically 
14.7% isoflavone glycosides and 21.2% B-group saponins.   
The feed was prepared by the company Research Diets (New Jersey, USA), that 
developed the control diet and the one supplemented with soy isoflavones. The amounts 
used in the diet correspond to a supplementation of 0.45 g% of the extract that is a final 
quantity of isoflavones mix in the diet corresponding to ~0.661 mg/g of solid diet 
(0.0661%). Both the supplemented and the control diet provided equal amounts of 24.0 
Kcal % from proteins, 15.0 Kcal % from fats, and 61.0 Kcal % from carbohydrates. 
To fulfil Objective 1, the following working scheme was followed (Figure 2). 
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Figure 2. Workplan to investigate the nutrigenomic actions of soy isoflavones. 
 
HYDROXYTYROSOL 
To perform the work described in Chapter 2, hydroxytyrosol was supplied as 
described below. 
Hydroxytyrosol used in the human clinical trial 
For the double-blind, randomized, placebo-controlled trial, we gave subjects 
encapsulated Hytolive
®
 with different doses of hydroxytyrosol. These were kindly 
donated by Genosa I+D (Madrid, Spain). Hytolive
®
 is an aqueous extract of olive mill 
wastewater produced as a standardized syrup or dry powder. Both the syrup and the 
powder have the characteristic odor of processed olives. The biologically important 
constituent of this extract is hydroxytyrosol. The constituents of Hytolive
®
 are also 
found in olive oil, as well as in table olives and are, therefore, commonly consumed by 
humans. In the process of obtaining this product, no solvents or other chemicals are 
used.  
The Hytolive
®
 we used in the human study contains 10-15% of HT and has been 
officially recognized by the American FDA (Food and Drug Administration) as safe for 
its food use in humans, acquiring the GRAS status (generally regarded as safe). 
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The doses used in this study were 5 or 25 mg per day, against placebo. The 
clinical trial work outline and the different doses used are represented in Figure 3. 
 
Figure 3. Work scheme of the pilot study to determine different effects of 
supplementation with hydroxytyrosol in healthy volunteers. 
 
Hydroxytyrosol used in studies with laboratory mice 
In the investigations with mice, pure hydroxytyrosol, kindly donated by Seprox 
Biotech (Madrid, Spain), was used. Two experimental designs were realized. In the 
long-term feeding study, hydroxytyrosol was incorporated in the chow provided by 
Research Diets (New Jersey, USA). As in the research with soy isoflavones, the 
company provided both the control diet and the diet supplemented with 0.03 g% HT. 
This dose closely approximates human intake and is a very low one once body surface 
area is taken into account. Each diet provided 24.0%, 15.0% and 61.0% kcal from 
protein, fat and carbohydrates, respectively. For the acute ingestion studies, mice were 
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given, by gavage, 15 mg of HT dissolved in water. The scheme of the working plan is 
detailed in figure 4. 
 
Figure 4. Workplan of the in vivo studies with hydroxytyrosol described in objective 2. 
 
Hydroxytyrosol in cell culture studies  
For in vitro studies, pure hydroxytyrosol (99.5%, tested by HPLC; batch E012 
0814172327, donated by Seprox Biotech (Madrid, Spain)) was used. 
First, 1 g of the compound was resuspended in 6.48 ml of absolute ethanol to 
achieve a stock concentration of 1 M. This was done in a glass tube, to prevent the 
compound from adhering to plastic. Compound manipulation was always done in 
darkness to avoid hydroxytyrosol oxidation. 
This stock solution was used at different concentrations depending on the 
experimental design carried out and taking into account the physiological concentrations 
required in each experiment. 
The working scheme and the different concentrations used in the in vitro studies 
is described in Figure 5. 
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Figure 5. Workplan of the in vitro investigations with hydroxytyrosol described in 
objective 2. 
 
POLAR LIPIDS FROM MILK (BM) & MARINE ORIGINS (KO) 
BM powder and Antarctic KO from Euphausia superba were used to elaborate 
the compounds used in the experiments described in Chapter 3, regarding the potential 
beneficial effects of PLs against MCI. Both were kindly donated by Reny Picot 
(Oviedo, Spain) and AKO3™ (Aker Biomarine Antarctic AS, Oslo, Norway), 
respectively. 
The elaboration of the compounds used was carried out by Dr. Javier Fontecha 
and his team members, Pilar Castro Gomez and Alba García Serrano, at the Research 
Institute of Food Science (CIAL) in Madrid, Spain. BM fat was extracted by pressurized 
liquid extraction (PLE) method using an accelerated solid extraction ASE-200 extractor 
(Dionex Corp. Sunnyvale, CA) starting from 15g of the product that was mixed with sea 
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sand (1:1) and loaded into a stainless steel extraction cell. To obtain the maximum BM 
fat yield, the extraction was based in the optimized PLE method by Castro-Gómez et al 
(164).  
In brief, the concentration of the PLs of both compounds was increased as 
follows. BM was dissolved with acetone in a ratio of 1:5 (v/v). The mixture was kept on 
a stirrer or and subsequently centrifuged. The precipitate obtained was subjected to the 
same process by incorporating more acetone in a 1: 2 (v/v) ratio. Finally, the latter 
precipitate, namely butter milk fat concentrate (BMFC), was evaporated and stored at -
35 °C for further use in the preparation of rats' feed.  
KO was dissolved in 96% (v/v) ethanol in a 1:8 ratio and kept for 24 h at 
different temperatures. Then, it was evaporated and the final precipitate, krill oil 
concentrate (KOC), was used for the elaboration of animal feed. 
The animals were fed a standard feed from LabDiet (EURodent diet 22%) along 
with a daily single-dose supplementation of the study concentrates in the form of 
strawberry jellies. The monodosis was prepared for 4 groups: refined olive oil as the 
control, BMFC, KOC, and BMFC+KOC mixture. Concentrations and experimental 
design are described in Figure 6. 
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Figure 6. Work scheme of the research involving polar phospholipids supplementation 
described in objective 3. 
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Abstract: Soy consumption has been suggested to afford protection from cardiovascular 
disease (CVD). Indeed, accumulated albeit controversial evidence suggests that daily 
consumption of ≥25 g of soy protein with its associated phytochemicals intact can improve 
lipid profiles in hypercholesterolemic humans. However, the belief that soy foods and 
supplements positively impact human health has become increasingly controversial among 
the general public because of the reported estrogenic activities of soy isoflavones. In this 
study, we investigated the nutrigenomic actions of soy isoflavones (in nutritionally-relevant 
amounts) with a specific focus on the adipose tissue, due to its pivotal role in 
cardiometabolism. Young C57BL/6 mice were maintained for eight weeks under two 
different diet regimes: (1) purified control diet; or (2) purified control diet supplemented 
with 0.45 g% soybean dry purified extract (a genistein/daidzein mix). Soy isoflavones 
increased plasma total cholesterol concentrations and decreased triglyceride ones. 
Circulating leptin levels was also increased by soy consumption. Differentially expressed 
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genes in adipose tissue were classified according to their role(s) in cellular or metabolic 
pathways. Our data show that soy isoflavones, administered in nutritionally-relevant 
amounts, have diverse nutrigenomic effects on adipose tissue. Taking into account the 
moderate average exposure to such molecules, their impact on cardiovascular health needs 
to be further investigated to resolve the issue of whether soy consumption does indeed 
increase or decrease cardiovascular risk. 
Keywords: soy; isoflavones; leptin; genistein; daidzein 
 
1. Introduction 
Soy consumption has been suggested to afford protection from cardiovascular disease (CVD) [1]. 
This notion largely stems from observation that CVD mortality rates are lower in Asian countries,  
where soy is an important part of the diet. Indeed, accumulated evidence suggests that daily 
consumption of ≥25 g of soy protein with its associated phytochemicals intact can improve lipid 
profiles in hypercholesterolemic humans, even though this has not been confirmed yet [2,3]. 
The purported cardioprotective effects of soy have been mostly attributed to its proteic  
constituents [4], yet soy also contains isoflavones, i.e., phytoestrogens with potent estrogenic activity; 
notable examples include genistein, daidzein, and glycitein [5,6]. Numerous clinical studies claim 
benefits of genistein and daidzein in chemoprevention of breast and prostate cancer, cardiovascular 
disease, and osteoporosis as well as in relieving postmenopausal symptoms [7]. However, the belief 
that soy foods and supplements positively impact human health is becoming increasingly controversial 
among the lay public. This is due precisely to the estrogenic activities of soy isoflavones, which might 
negatively impact breast cancer risk, in particular among ER-positive breast cancer survivors [7]. 
In short, the effects of soy and its component on CVD and associated risk factors have not been  
fully elucidated. In this study, we investigated the nutrigenomic actions of soy isoflavones (in 
nutritionally-relevant amounts) with specific focus on the adipose tissue, due to its pivotal role  
in cardiometabolism. 
2. Results and Discussion 
2.1. Body Weight, Food Intake and Lipid Profiles 
To investigate whether chronic feeding of soybean extract had an effect on body parameters, we 
measured body intake and food intake of C57BL/6 male mice maintained for eight weeks on either a 
purified control diet or control diet supplemented with 0.45% soybean extract, which is equivalent to 
0.0661% of isoflavone mixture pure aglycones. No changes in such parameters were observed  
(Table 1A), but soy isoflavone supplementation induced a significant increase in plasma cholesterol 
concentrations (Table 1B) as compared with control diet. Conversely, triacylglycerol concentrations 
were significantly reduced. 
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Table 1. Body weight and food intake (A) and cholesterol and triglyceride circulating 
concentrations (B) in controls and in mice fed a 0.45% Soyselect® diet. 
(A) 
    
 
Body Weight Food Intake 
 
g g/day 
 
Control diet 29.1 ± 2.1 Control diet 3.0 ± 0.1 
 
0.45% Soyselect® 27.7 ± 3.5 0.45% Soyselect® 2.7 ± 0.1 
(B)     
 
Cholesterol Triglycerides 
 
mg/dL plasma mg/dL plasma 
 
Control diet 117.5 ± 9.3 Control diet 67.6 ± 16.1 
 
0.45% Soyselect® 132.5 ± 2.9 * 0.45% Soyselect® 53.7 ± 8.14 * 
Notes: Values are means ± SD; n = 7. Body weight, cholesterol, and triglyceride data are those obtained at 
the end of the study. Food intake data are those measured at the beginning and at the end of the study.  
* p < 0.05 as compared with controls. 
2.2. Leptin Concentrations 
Feeding 0.45% Soyselect® led to a significant increase in circulating leptin concentrations which 
rose from 1.49 ± 0.27 to 3.85 ± 1.16 ng/mL (Figure 1). 
 
Figure 1. Leptin circulating concentrations in mice receiving either chow diet (control) or 
0.45% Soyselect® during eight weeks (n = 7 per group). * p < 0.05 as compared with controls. 
2.3. Peritoneal Fat Genome Expression Profiles 
Whole-transcriptome microarray analysis was carried out on perigonadal adipose tissue samples 
isolated from mice fed either purified control diet or 0.45% soybean extract diet. A total of 983 genes 
(437 downregulated and 546 upregulated) were differentially expressed at (a 2-fold cutoff with a q 
value of less than 5%). Complete lists of upregulated and downregulated genes are shown in 
Supplementary Tables S2 and S3, respectively. 
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GENECODIS3 was used to perform biological pathway enrichment analyses of all downregulated 
genes in the interaction network (Table 2). The results show that a wide range of genes involved in 
many different biological pathways are modulated by Soyselect®. We selected three significantly 
enriched molecular functions, which include MAPK signaling, chemokine signaling, and TGFβ 
signaling, because they play pivotal roles in several cellular processes such as adipocyte differentiation 
and proliferation [8]. Specifically, a Venn diagram was constructed to evaluate the number of shared 
genes these three pathways: MAPK signaling [six genes], chemokine signaling [four genes], and TGFβ 
signaling [two genes] (Figure 2). The diagram shows that three genes, i.e., MAPK1  
(mitogen—activated protein kinase 1), PRKCB (protein kinase c, beta), and HRAS1 (Harvey rat 
sarcoma virus oncogene) are shared by the MAPK and chemokine groups; one gene, i.e., MAPK1 is 
shared by all three groups and one gene, i.e., ROCK1 (Rho-associated, coiled-coil containing protein 
kinase 1) is shared by chemokine and TGFβ signaling groups. 
Table 2. Gene co-occurence annotations found by GeneCodis (molecular function) for 
genes downregulated by Soyselect® in perigonadal white adipose tissue. 
Genes NGR TNGR NG TNG Hyp Hyp * Annotations 
53 genes 1999 37681 53 365 3.21184 × 10−11 4.5287 × 10−9 GO:0000166: nucleotide binding (MF) 
42 genes 1501 37681 42 365 9.08868 × 10−10 6.40752 × 10−8 GO:0016787: hydrolase activity (MF) 
38 genes 1314 37681 38 365 2.51857 × 10−9 1.18373 × 10−7 
GO:0005524: ATP binding (MF)  
GO:0000166: nucleotide binding (MF) 
39 genes 1421 37681 39 365 6.44848 × 10−9 2.27309 × 10−7 GO:0005524: ATP binding (MF) 
61 genes 2999 37681 61 365 2.77158 × 10−8 7.81585 × 10−7 GO:0005515: protein binding (MF) 
p-values have been obtained through hypergeometric analysis (Hyp) corrected by FDR method (Hyp *) 
NGR, number of annotated genes in the reference list; NG, number of annotated genes in the input list. 
 
Figure 2. Venn diagram of selected pathway analyses. Pathway analyses of  
Soyselect®-modulated genes were performed and MAPK, TGFβ, and chemokine signaling 
were included as examples. 
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2.4. Gene Expression Validation by qRT-PCR 
MAPK, TGFβ and chemokine signaling selected genes were analyzed by qRT-PCR (Figure 3) for 
validation. We also report other known genes related to lipid metabolism in adipose tissue and other 
highly modulated genes that came out from microarrays analysis, using a customized RT2 profiler PCR 
array (Supplementary Table S4). 
 
Figure 3. RT-qPCR validation of selected genes related to MAPK, TGFβ, chemokine 
signaling, and others related to lipid metabolism. Mice received either chow diet (ctrl) or 
0.45% Soyselect® during eight weeks. mRNA is given as relative expression (n = 6 per 
group). * p < 0.05 as compared with controls. 
Only Mknk1, Mapk1, and Prkcb1 were found to be modulated by the genistein/daidzein mix, while 
the other genes were not confirmed by qRT-PCR, suggesting either a modest effect of Soyselect® on 
adipose tissue gene expression or lack of sensitivity of microarray experiments, which highlight the 
need for validation using qRT-PCR. However, other genes related to adipose biology and lipid 
metabolism were found to be modulated by Soyselect®, including the fatty acid binding protein 9 
(Fabp9), neuropeptide Y (Npy), and sphingosine kinase 1 (Sphk1). In most cases, validated genes 
exhibited a more modest effect in their expression when evaluated by qRT-PCR than by microarrays. 
2.5. Discussion 
We have performed the first nutrigenomic study of soy isoflavones in adipose tissue. Our data show 
that these molecules, administered in nutritionally-relevant amounts [6,7,9], have diverse albeit modest 
effects on adipose tissue, which is an organ prominently involved in cardiometabolism [4]. As 
mentioned, the low cardiovascular mortality of some Asian countries, particularly Japan, has often 
been attributed to the high consumption of soy products, e.g., miso, natto, shoyu, soy beans, etc. [3,5]. 
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Inadequate epidemiological research prevents from drawing firm conclusions [10] and it is noteworthy that, 
while most of the cardioprotective effects of soy have been ascribed to its proteic fraction [4,11,12], these 
products only contribute small amounts of protein to the whole diet. Therefore, the real contribution of 
soy protein to cardioprotection has been questioned [2]. In addition to putatively healthful proteins, soy 
is rich in isoflavones such as genistein and daidzein. These compounds are the subject of active 
research and current recommendations on their consumption are under intense scrutiny. In fact, 
isoflavones resemble 17-β-estradiol in structure, and as such are able to bind the estrogen receptor 
(ER) in vitro, behaving much as a natural selective estrogen receptor modulator (SERM) [13]. 
Therefore, soy isoflavones might act as tumor-promoting or tumor-inhibiting agents, likely depending 
on cell type, dose, and genetic predisposition. As far as the cardiovascular system is concerned, the 
current consensus appears to be that estrogens exert complicated and poorly understood effects on 
cardiovascular health [14,15]. When the effects of estrogens are analyzed for men and women 
separately, they clearly exert a protective effect on cardiovascular function during a woman’s 
childbearing years [14]. The challenge is now to convey these beneficial effects without unwanted 
steroid side effects on other organs and tissues, e.g., the breast [14]. Finally, genistein and daidzein 
have also been suggested to be neuroprotective and myorelaxant, namely in the detrusor muscle [16]. 
In adipose tissue, genistein and daidzein upregulate genes related to MAPK (Figures 2 and 3) and 
downregulate chemokine signaling gene Prkcb1 (Figure 3). The MAPK family is attracting 
considerable attention because of its vast implications in signaling and crosstalk with other signaling 
networks [17]. Indeed, some authors are suggesting considering the possibility of targeting  
MAPK-mitochondria interactions in the prevention and treatment of heart disease [17]. Some 
polyphenols for which cardioprotective properties have been suggested—such as epigallocatechin 
gallate—do increase MAPK [18]. Yet, as recently reviewed by Hopkins [19], MAPK generally have 
strong prosurvival effects on macrophages and can have varied effects on scavenger receptor 
expression and foam cell formation. The resulting effects on atherosclerosis can be nuanced and 
difficult to predict [19]. Chemokines are expressed vessel wall cells and emigrated leukocytes. These 
molecules play important roles in atherosclerotic vascular disease, where they exert various functions 
including cell recruitment [20]. The actions of chemokines in vascular inflammation are stimulating 
research for therapeutic agents aimed at these molecules. In addition to the vascular district, 
chemokines play important roles in the infarcted heart, where unrestrained inflammation induces 
matrix degradation and cardiomyocyte apoptosis [21]. Consequently, inhibition of pro-inflammatory 
signals may be effective in patients with defective resolution of postinfarction inflammation. Of note, a 
recent publication reported that isoflavone supplementation induced anti-inflammatory gene 
expression in equol postmenopausal producers [22]. 
We also measured some circulating surrogate markers of cardiovascular disease. Notably, we 
recorded significantly increase circulating leptin concentrations in mice fed with soy isoflavones, 
namely Soyselect® as compared with controls (Table 2). Even though the extent and precise nature of 
leptin’s contribution to cardiovascular disease is still unclear [23], accumulated evidence points to its 
negative role in vascular impairment and hypertension. It is worth noting that leptin can promote 
angiogenesis and induce neovascularization. In addition, high blood concentrations of leptin associated 
with obesity can lead to arterial endothelial dysfunctions, impaired arterial distensibility, and 
proliferation and migration of vascular smooth muscle cells. In humans, greater soy consumption 
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appears to be associated with a lower presence of elevated total cholesterol, dyslipidemia, 
hyperuricemia and fewer cardiometabolic disturbances components [24]. No significant effect of soy 
isoflavones on blood pressure and endothelial molecules has been recorded [9,25]. A meta-analysis 
also reported that soy isoflavones have an effect of lowering blood pressure in hypertensive subjects, 
but not in normotensive subjects [26]. In short, the effects of soy isoflavones on the vasculature and 
blood pressure appear to be minimal in humans. 
Soy isoflavones also increased total cholesterol while lowering triacylglycerol concentrations.  
The true human relevance of these findings is equivocal because, even though hypercholesterolemia is 
a known risk factor for CVD, lower triacylglycerols’ concentrations are also associated with better  
CV prognosis. It is noteworthy that cholesterol circulates in mice almost exclusively as high-density 
(HDL)-c [27]. As soy consumption brings about hypolipidemic effects [27], the true significance of the 
observed cholesterol increase is equivocal and deserves further investigation. We found that Fabp9, 
Npy, and Sphk1 were upregulated by Soyselect® (Figure 3). Fabp9, Npy and Sphk1 are genes that 
regulate different aspects of lipid metabolism [28], adiposity [29], or adipocyte lipolysis [30]. Whether 
these and other Soyselect®-regulated genes are responsible for the observed effects on plasma 
cholesterol and triglycerides levels is not known and needs to be further investigated. 
In conclusion, we add further evidence to the notion that soy isoflavones have assorted effects (both 
positive and negative) on cardiometabolic risk factors [31–33]. Keeping into account the moderate 
average exposure to such molecules, their impact on cardiovascular health need to be further 
investigated to solve the issue of whether soy consumption does indeed increase or decrease 
cardiovascular risk. 
3. Experimental Section 
3.1. Materials 
A soybean purified extract containing isoflavones glycosides genistein and daidzein (14.7%; 
Soyselect®), was kindly donated by Indena (Milan, Italy). Soyselect® is a standardized extract obtained 
from soy with a double standardization procedure and which contains 13%–17% of isoflavone 
glycosides genistein and daidzein and <18% of B-group saponins, as quantified by HPLC [34,35]. The 
product is prepared by extracting ripe whole soy beans or oil-free soy flour with aliphatic alcohols 
through an industrial manufacturing proprietary process [36,37]. One gram of extract also contains 
0.058 g of protein, 0.035 g of fat, and 0.023 g of ash, with the remaining matter undefined 
(Supplementary Table S1). The batch (nr. 30432/M1) used in this study contained 14.7% isoflavone 
glycosides and 21.2% B-group saponins. Of note, saponins increase isoflavone’s bioavailability 
(unpublished data). SuperScript III First-Strand Synthesis System for RT-PCR was from Invitrogen 
(Madrid, Spain). Qiazol was from Qiagen (Izasa, Barcelona, Spain). 
3.2. Animals and Diets 
This investigation conforms to the Guide for the Care and Use of Laboratory Animals, published by 
the US National Research Council [38] and was approved by the Animal Experimentation Committee of 
the Universidad Complutense de Madrid. 
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Young C57BL/6 mice (2 months old, n = 14, i.e., seven mice for each diet) were acclimatized in the 
animal facility on a 12:12 light/dark cycle, with the period of darkness between 7:00 a.m. and  
7:00 p.m., for at least one week before experimentation. During this time, animals were fed a standard 
chow diet; food and water were given ad libitum. Then, mice were maintained for eight weeks under 
two different diet regimens (Research Diets, Inc. New Brunswick, NJ, USA): (1) purified control diet 
or (2) purified control diet supplemented with 0.45 g% soybean dry purified extract (genistein/daidzein 
mix). The final quantities of isoflavones mix in the diet correspond to ~0.661 mg/g of solid diet 
(0.0661%). Each diet provided 24.0%, 15.0%, and 61.0% kcalories from protein, fat, and 
carbohydrates, respectively. Their detailed composition is given in Table 3. To reduce diurnal 
variations, animals were sacrificed between 10:00 and 11:00 a.m., after an overnight fast. Mice were 
anesthetized with isoflurane and a midline incision was cut in the abdomen. Blood samples were 
collected from the vena cava. Heparin (0.4 mg/mL) was injected by means of the iliac vein and Hank’s 
balanced salt solution (HBSS; pH 7.4) was perfused through the portal vein for 2 min to remove blood. 
Tissues were quickly removed, washed twice in ice-cold HBSS, and snap-frozen and stored at −80 °C. 
In order to verify the dietary effects of soybean extract, body weight and food intake have been evaluated. 
Table 3. Composition of the experimental diets. 
 
Control Soyselect® 
 
g% Kcal% g% Kcal% 
Protein 23 24 23 24 
Carbohydrate 60 61 60 61 
Fat 6 15 6 15 
Ingredient g/kg diet 
Casein 244 244 
L-Cystein 3 3 
Corn Starch 318 318 
Maltodextrin 10 45 45 
Dextrose 250 250 
Cellulose 75 75 
Inulin 25 25 
Sunflower Oil 29.5 29.5 
Olive Oil 18.6 18.6 
Lard 18.5 18.5 
Mineral Mix S10026 10 10 
Dicalcium Phosphate 13 13 
Calcium Carbonate 5.5 16.5 
Potassium Citrate 5.5 16.5 
Vitamin Mix V10001 10 10 
Retinyl Acetate, 500,000 IU/g 0.048 0.048 
Choline Bitartrate 2 2 
Genistein/Daidzein mix 0 4.5 
Cholesterol 0.146 0.146 
Total 1083.84 1088.34 
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3.3. Determination of Circulating Leptin Concentrations 
Plasma concentrations of leptin were determined by ELISA kit, according to the manufacturer’s 
instructions (Mouse Leptin, 96-well plate assay, Millipore, Madrid, Spain). 
3.4. Determination of Plasma Lipid Concentrations 
Plasma cholesterol concentrations were determined by the Amplex Red cholesterol assay kit 
(Invitrogen, Madrid, Spain) following the manufacturer’s instructions. Plasma triglycerides were 
determined using an L-type triglyceride M test kit, according to the manufacturer’s instruction (Wako 
Chemicals, Neuss, Germany). 
3.5. RNA Isolation and Analysis 
Total RNA from perigonadal adipose tissue (100 mg) was isolated using Qiazol Lysis Reagent 
(Qiagen, Isaza, Barcelona, Spain) and QIAGEN RNeasy Mini kit columns (Qiagen). RNA was 
quantified using a NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific Inc., Madrid, Spain) 
and purity was assessed by measuring the ratio of absorbance at 260 nm and 280 nm. The quality of 
the RNA was tested in 1% formaldehyde-agarose gel stained with ethidium bromide (EtBr). 
3.6. Microarray Hybridization 
Gene expression profiles were assessed using Gene Expression Service with the Illumina  
MouseRef-8 v2 Expression BeadChip® with Ambion Labelling. This BeadChip targets approximately 
25,600 well-annotated RefSeq transcripts, over 19,100 unique genes. 
Data were analyzed by using the GenomeStudioTM Software (Illumina, San Diego, CA, USA) 
following the manufacturer’s instruction. Significant modulated genes were defined as those with an 
absolute fold change of >2.0 and an adjusted p value of <0.05. 
Differentially expressed genes were classified according to their role(s) in cellular or metabolic 
pathways using the online GeneCodis analysis software for modular and singular enrichment  
analysis [39]. Gene Ontology (GO) analysis was also performed to describe the associated biological 
process of the differentially expressed genes overall [40]. 
3.7. Quantitative Real-Time PCR (qRT-PCR) 
qRT-PCR of selected genes was performed to validate microarray results of adipose samples by 
using RT2 profiler PCR array (SABiosciences, Qiagen). The array was customized in 384 wells plates 
to contain a panel of genes specifically relevant to MAPK pathway, five different housekeeping genes 
and controls for genomic DNA contamination, reverse transcription and positive PCR controls. 
Dissociation curves were assessed to ensure the presence of a single amplicon. Reactions were 
performed with 50-fold diluted cDNA (1 ng/µL), 5 μL of USB VeryQuest SYBR Green qPCR Master 
Mix (2X) (Affymetrix, Madrid, Spain) and RNAse-free water being added to a final volume of 10 μL. 
Real-Time RT-PCR reactions were performed in 384-well plates and gene expression was determined 
using the 7900HT Real-Time PCR System (Life Technologies, Alcobendas, Spain). Cycling conditions 
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were initial activation step at 95 °C for 15 min; 3-steps cycling for 40 cycle including denaturation at 
94 °C for 15 s, annealing at 58 °C for 30 s and extension at 70 °C for 30 s; dissociation curve at 95 °C 
for 15 s, 60 °C for 15 s, 95 °C for 15 s. Gene expression was quantified using the ΔΔCt method and 
fold-change values were reported as 2−(∆∆Ct). 
3.8. Statistical Analysis 
Statistical analyses were carried out using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Apart from 
gene expression, data independent samples t-test was used when the corresponding assumptions were 
met; otherwise the non-parametrical Wilcoxon Mann-Whitney test was employed. p < 0.05 was 
considered significant. Results are presented as means ± SD. 
Supplementary Materials 
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/02/2310/s1. 
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Supplementary Materials 
Table S1. Chemical composition of the Soyselect batch used in this study. 
 
Energy Value 58 (247) kcal/100 g (kJ/100 g) 
Proteins (as sum of aminoacids after hydrolysis) 1.93 g/100 g 
Total Fat 1.4 g/100 g 
 Saturated Fatty Acids 0.14 g/100 g 
 Monounsaturated Fatty Acids <0.05 g/100 g 
 Polyunsaturated Fatty Acids 0.21 g/100 g 
 trans-Fatty Acids <0.05 g/100 g 
Total Dietary Fiber <0.5 g/100 g 
Sugars Composition   
Fructose, anhydrous 2.10 g/100 g 
Glucose, anhydrous 0.73 g/100 g 
Lactose, anhydrous <0.10 g/100 g 
Saccharose (Sucrose), anhydrous 6.70 g/100 g 
Maltose, anhydrous <0.10 g/100 g 
Total Sugars 9.53 g/100 g 
Moisture 3.9 g/100 g 
Ash 2.54 g/100 g 
Sodium 37.0 mg/100 g 
Calcium 2.82 mg/100 g 
Iron 0.32 mg/100 g 
Cholesterol <0.10 mg/100 g 
Vitamin A (retinol) <0.01 mg/100 g 
Β-Carotene <0.02 mg/100 g 
Vitamin C (Ascorbic Acid, HPLC) <2.5 mg/100 g 
 
 
 
Table S2. Soy isoflavones mix induced genes. 
 
DEFB37 
DEFB38 
DEFB21 
HEXB 
EIF3K 
PRPS1L1 
PAPOLB 
ADAM5 
C730025P13RIK 
STK22B 
BEX4 
RASL2-9 
PRM1 4921520G13RIK ST6GALNAC2 1700021C14RIK 2700055A20RIK LOC100044177 
SPINT4 OTTMUSG00000016790 OXCT2B LCN13 SQRDL CYP4A12A 
OTTMUSG00000016293 BHLHB2 BCAS2 MRPS18C KPNB1 1190002A17RIK 
DEFB23 NLRP14 GM128 KRT14 D430015B01RIK 1700093K21RIK 
DEFB39 COX6C SMARCD3 SEC61G 4921507P07RIK SLC2A3 
OAZ3 NTSR2 DEFB29 ODF4 CLK1 SLC30A6 
SMCP TCP11 D19ERTD721E MAP1LC3B TAX1BP1 BCKDHB 
4931407G18RIK HOXD4 1700025K23RIK ODF3 CAGE1 CCNL1 
NPY COX8C A330021E22RIK SOCS7 HGFAC IRGM 
FABP9 ARL8A 1700010M22RIK WDR20B NPAL2 TWISTNB 
9230002F21RIK CRISP4 ACRV1 LOC100047749 1700010A17RIK SLTM 
SPAG11 CLDN11 AKTIP GM1679 XLR4A RAB5C 
OTTMUSG00000015852 DDX25 STARD10 CCNO BC048546 RNF133 
SPINK2 DYNLT3 CCDC113 RASSF3 MRPL20 YWHAB 
SPINK8 C130090K23RIK ENPP2 CDH1 RPO1-1 1700067P10RIK 
AY761185 CAMK2B CCT6B PRF1 1300007L22RIK WBP4 
TNP1 MYCBPAP ZMAT1 1700026L06RIK FRK ZFP654 
CUZD1 2410116G06RIK PICALM GRHL2 AGPAT3 ZBBX 
SPINK11 SETX COQ2 4921517D21RIK RRN3 PABPC2 
DEFB2 LOC100042777 GAPDHS A530050D06RIK CIZ1 PLP1 
TSSK6 DDC8 KIF2B ANKRD46 LOC100047200 RAD52 
INDO LOC677317 MNS1 SLC1A1 LOC100048020 EG385328 
RPL3L KCNC4 GSTT3 UBQLNL 4933402J07RIK PLA2G4F 
ADAM32 TCOF1 CPEB2 SPZ1 LIP1 DAPL1 
WFDC15B SLFNL1 LCN8 1700054O13RIK HSP90B1 CFB 
ODF1 KLHL10 1700020D05RIK VDAC2 4922505E12RIK 1700001C02RIK 
DEFB11 CCDC92 1700065I17RIK 4833420G17RIK ERGIC2 TLE2 
 Table S2. Cont. 
 
 
WFDC10 PRM3 SERF1 FYCO1 ELAVL1 2610101N10RIK 
DEFB19 LRRC50 1700011H14RIK ATP6V1A UHRF1BP1L 1700019H03RIK 
ALDH6A1 GRB7 4732415M23RIK 4933422H20RIK RASGRF1 THAP4 
SPINLW1 PTGDS MOD1 EMG1 DYNLRB2 DEFB12 
RSPH1 1810015C04RIK CTNNB1 LLGL2 NDUFB9 IQCF4 
BC051142 LOC100039532 1700029H14RIK TMEM51 CGGBP1 TCTEX1D2 
TCFAP2B GSTT4 NOTCH1 ACTL7B TRIM36 NIT1 
LCN12 MFAP3L 4930412F15RIK MED28 ARRDC2 1110002B05RIK 
TULP2 LOC100048622 NT5C1B TMCO5 ARHGEF4 1700026D08RIK 
LDHC HCFC1 CHCHD7 COL16A1 TNP2 HOXD3 
BC030476 PTPRB IDH2 CYB561 ADAM28 SETD1B 
BC048679 GLDC NXF1 HIST2H2BE H3F3B ISYNA1 
PGK2 TUBA3B BC038286 1700012L04RIK KRT8 CC2D2A 
LOC435023 SYTL4 CUL1 USP20 1700007K09RIK M6PR 
SPATA19 LYPD4 HADHB SMAD1 ATP5A1 DEFB10 
GSG1 SLC7A4 TMC5 4930526D03RIK MBOAT1 ZPBP 
PGAM2 DDIT4L HILS1 PTGES3 ZDHHC4 OTUD5 
ZNRF4 ATP13A4 1700094C09RIK HSD17B10 HNRPAB ZC3H15 
UBQLN3 DEFB42 AQP9 1700057K13RIK TBC1D8 2400003C14RIK 
GYKL1 SPATA6 1700049L16RIK TEKT1 BC020002 SPO11 
SVS4 ACTL6A PRDX6-RS1 CCT8 ATF4 CLIC3 
SERPINA1F LRRC57 BC049635 SMEK2 1110017D15RIK SLC38A5 
HDAC6 TDRD6 EG432867 4931406C07RIK MAPBPIP EG654465 
CLGN CST9 ENOPH1 EXOSC8 LRRC34 IL10RB 
KCNK1 YBX2 ACTL7A SKP1A HUWE1 LOC100045098 
TSGA8 BGLAP-RS1 BZW1 MDH1B 4930404H21RIK 5133400G04RIK 
CLDN3 PFN3 EG433365 CUGBP2 GM614 SGPP1 
LY6F SMC5L1 CLCNKB REC8 PAIP2 CAPZA3 
 Table S2. Cont. 
 
 
DBIL5 P2RX2 NOL14 SATB1 HSD3B2 CYB5R1 
SVS5 1700034E13RIK ARID2 HOOK2 PURB AKAP3 
4922502D21RIK AI314180 CLDN4 WDR23 CSTL1 MTMR12 
EIF2S3Y NUP210 LOC100048480 KCTD2 LRRC46 5830403L16RIK 
TESK1 MLF1 ADCY8 OTTMUSG00000015859 GNPDA2 CRYBA4 
PLS3 DEFB40 ZFP263 SNX1 NDFIP2 PRPS2 
PDZK1 SPINK10 H2-AA RPRM GLB1 LAMA1 
HOXB4 ESPN TCTE3 STAG3 1700123L14RIK PQLC1 
LOC669168 CDH16 ODF2 DPEP3 TAF13 COX7A2 
AP3B2 KRT18 C4BP TRIP12 MGL1 DRBP1 
RNASE9 SUSD4 LOC217341 GM1698 R3HDM2 4933405O20RIK 
AKR1C19 SPACA3 SRP14 LYZL4 PBP2 PGM2 
HBB-B1 ALDH1A1 EG665378 RGMA CDC42EP3 TMEM176B 
WFDC6B GKAP1 1600016N20RIK LOC100044779 1700018C11RIK SLC44A4 
ADAM3 ACTG2 DDX21 DDX3X PRSS21 PTPRE 
PACRG DEFB30 1700080E11RIK ACTR3 1700019D03RIK SNF8 
CYP17A1 ACSBG2 ISG20 ST13 ARL1 ANKRD10 
SEC11C HRASLS5 PGRMC1 HMGB4 4930451I11RIK ZC3H6 
NPC2 D11WSU47E FHL5 AHCTF1 SPAG6 PIWIL1 
DNAJC5B TCP10A CYP1B1 NDUFB10 ECSIT CSPP1 
DAZAP2 EMB HSDL1 SPERT PTPN1 IZUMO1 
ACADSB SELK H1FNT LYZL1 TTC29 D030013I16RIK 
DEFB15 TESP1 QRICH2 PLAA SERINC2 MGC107098 
MRPL52 SVS7 TMED9 DCUN1D5 TECTA RPS3A 
RHBDL2 LTF CRISP1 MARCH10 CCDC54 HSPA2 
4930563D23RIK HSPA1L DNALI1 PRPS1 GALNTL5 AKAP4 
WFDC13 S100A10 SPATA20 RAG1AP1 CATSPER3 1700030J22RIK 
 Table S2. Cont. 
 
 
RBM35A LOC100048703 OXCT2A GOT2 DEFB25 AARD 
LOC100047619 DEFB43 LCN5 ARMCX1 TXNDC8 HOXD8 
POLR2G ACTRT2 DEFB20 1700029J07RIK TXNDC12 DEFB18 
ZXDA RNASE12 PROM2 TXNDC2 SLCO4A1 2900010M23RIK 
YWHAZ 9230104L09RIK LYZL6 PABPC1 TJP2 TRIM39 
TUBA3A DNAJC10 TEDDM1 4930503B20RIK UPK1B BC089491 
ADAM7 LYAR ENPP1 KCNH3 TPP2 SPHK1 
 
Table S3. Soy isoflavones mix repressed genes. 
 
LYZ2 C1QB TMEM9 2410166I05RIK THRSP TAP1 
NNAT LAMC1 IGFBP6 AGTR1A GTRGEO22 CRY2 
GSN ARSB NID2 LOX IL1RL1L 2010316F05RIK 
APCDD1 ADRB3 DGAT2 HIST1H2BH APOC3 ORC6L 
SERPINA3C 2210021J22RIK 2010311D03RIK REEP5 RGS16 HEPH 
VIM MFAP5 LOC100046393 LOC100044204 GEMIN7 C1QBP 
TMEM45B TMEM131 2310058J06RIK DYNC1LI2 LEPREL2 EPB4.9 
SSPN GPX7 TMEM159 MRPL11 MAPK3 SH3KBP1 
SVEP1 CIDEA YIF1A LOC654426 2600010E01RIK ME2 
AGPAT2 UGT1A10 MC2R MCOLN1 NUMA1 BC031181 
LUM PTRF CD248 CHCHD4 MRPS16 MCTS1 
MAPK1 PI16 SLC19A1 MRPL3 LOC100045697 HLCS 
HSPA8 PLEKHB2 HTATIP2 FRMD6 TSPAN7 PLD2 
ATP5F1 LOC641240 CHPT1 SRPX COL14A1 4631427C17RIK 
GPR81 MKNK1 ZFP207 TNFRSF1A PGAM1 MS4A6D 
AKR1B7 APOA2 ACSM3 STX18 2610204L23RIK MYCL1 
G0S2 EMP3 GSTT1 IER3IP1 EG630499 MAEA 
 Table S3. Cont. 
 
 
PXMP2 SPR PPP2R1A GBP2 VTN RPS27A 
CRTAP TGFBR3 COX7A2L GPX1 PCX 2510010F15RIK 
H2-AB1 LPIN1 EMD ATP6V0E2 TMEM100 ARHGDIB 
HTRA1 MRPL9 H2-M3 MRPL53 CMTM7 MAPK1 
GPR109A SLC1A5 NAP1L1 PEG3 HTRA3 9030624J02RIK 
FSTL1 ADH1 EAR4 MPP1 TCEAL8 LOC100048613 
RARRES2 EMILIN2 LOC100047937 OSTF1 TGFBI CHST12 
COL15A1 ADFP PRKCDBP IFI35 CCDC80 TM6SF1 
RNF4 GALM BLCAP CD83 RPL18 AU019823 
CD14 MSN IFITM2 GSTO1 RBPMS2 H3F3A 
RNASET2 LOC100046650 LOC381629 HCLS1 1500032L24RIK ZCCHC14 
FFAR2 PSME2 GSTP2 OSTM1 SNRPB CDKN2C 
EG433923 NAPEPLD GNB1 FKBP9 TRAPPC4 9330186A19RIK 
SPARC SNF1LK2 D430028G21RIK FOXO1 JAZF1 MRPL4 
ORM1 HP LOC100048413 SRD5A3 PDDC1 A730042J05RIK 
C1QC GNG10 2010004A03RIK SCP2 CRYAB VKORC1 
CXX1C GFPT2 OXCT1 P2RX4 ANXA6 YKT6 
H2AFZ DHRS1 TMED10 G6PDX ENTPD2 AMOTL2 
ARL6IP5 FADS3 HNRPF LOC100047012 LRG1 CPNE8 
CYP4B1 LGALS3BP PRKCB1 CSPG4 UQCRH 2700038C09RIK 
SORBS1 MXRA8 ABCD2 SEPP1 SCOTIN D830050J10RIK 
TRF HSD11B1 RAP2A NID1 PRTN3 EMILIN1 
NTRK2 ITGA7 FOLR2 COPS6 HIST1H2BF 1110031B06RIK 
SAA3 IAH1 MOBK1B GSTP1 CLPTM1 NOL5A 
ACTN4 PHKG1 DOCK1 DPEP1 HRAS1 PER3 
SYNGR2 NPR3 COQ9 1110002N22RIK CD68 LDHA 
 Table S3. Cont. 
 
 
S100A1 SLC2A4 TSC22D1 SDF2 NDUFB6 BC038156 
SUCNR1 SUMO3 CAPNS1 MPDU1 CLTA APOE 
HEBP1 MYADM B4GALT1 1190002H23RIK GMPR GRB10 
LGMN ATP5L DAD1 CHIC2 PPP1R8 TINAGL 
LY6C1 TPPP3 UBE2E3 PDK4 RAC2 BCKDK 
CXCL1 EPS8 CXX1A AHNAK PLTP 2700078K21RIK 
TIMP4 SOD3 RPS2 CXCL9 KCNJ8 CDK2AP2 
LOC100045567 IDH1 CAR3 IARS2 LOC100047653 ACSF3 
CEBPA ITGA1 BMP3 WWTR1 MED11 PPAPDC1 
PLA1A CYC1 GPD1 RPS7 EG622320 SPCS1 
CISH PHGDH NDUFS2 MTPN FCGRT A730008L03RIK 
COL4A2 EMP1 THBS2 PODN AP2A2 SNTG2 
SERPING1 S100A8 MRAP CYBA PPAP2C MTAP 
TSPO DARC SCARA5 CHURC1 TMEM41A ORAI3 
PHLDA3 1190005I06RIK PCBP1 RTN2 KDELR2 D930001I22RIK 
RPS6 PRDX3 2310044H10RIK PPCS LRRC8 RPS4X 
MMP2 MNAT1 OTTMUSG00000000971 OLFM1 AW146242 CCM2 
PRKCB1 NDUFC2 TMEM9B MGL2 DHRS7 CASP6 
CTSF 2310008M10RIK MRVI1 TMEM43 NFKB1 MAPK14 
SLIT3 TSPAN3 NOMO1 CALU HFE IL2RG 
H2-EB1 COL6A2 MRC1 EPB4.1L1 EPDR1 TBC1D9B 
ENC1 PLIN TGFBR2 FGFRL1 EAR2 TMEM16K 
CD74 5730437N04RIK LOC100047353 CIITA VPS35 TPST1 
EG667977 ALOX5AP RAB18 PEPD ITIH5 CAML 
LEP LOC100043257 SGTA BC051227 IL1B CTSH 
EHD2 POLD4 RBCK1 L7RN6 TIMP1 ROCK1 
 Table S3. Cont. 
 
 
EEF2 BC004044 SLC11A2 MGC41689 COPZ1 PPP5C 
SORL1 VNN3 ERRFI1 THRA PTGES SCAMP3 
TRP53INP2 C1QA BC013712 MAN2A1 MGST1 HRAS1 
4833421E05RIK 9030224M15RIK TNNC2 ACAA2 MRPL34  
 
Table S4. Validated genes by qRT-PCR. 
  Upregulated Genes Downregulated Genes  
 
DEFB37 CLDN3 VIM 
DEFB38 PDZK1 LUM 
PRM1 ADAM3 MAPK1 
SPINT4 SEC11C ATP5F1 
DEFB39 DEFB15 FSTL1 
OAZ3 MRPL52 RARRES2 
SMCP POLR2G CD14 
NPY YWHAZ PRKCB1 
FABP9 DEFB21 GPX7 
SPINK2 COX6C MKNK1 
SPINK8 TCP11 HSD11B1 
TNP1 COX8C SOD3 
CUZD1 CRISP4 PRKCB1 
SPINK11 CLDN11 LOX 
DEFB2 SLFNL1 TNFRSF1A 
TSSK6 LRRC50 FOXO1 
RPL3L GRB7 CYBA 
WFDC15B PTGDS TGFBI 
DEFB11 ATP13A4 HRAS1 
WFDC10 DEFB40 NFKB1 
SPINLW1 SPINK10 MAPK1 
 Table S4. Cont. 
 
 
  
  Upregulated Genes Downregulated Genes  
LDHC CDH16 MAPK14 
PGK2 KRT18 ROCK1 
SPATA19 DEFB30 PPP5C 
GSG1 HRASLS5 HRAS1 
ZNRF4 LTF  
SERPINA1F EIF3K  
CLGN CYP1B1  
KCNK1 PTPN1  
TSGA8 SPHK1  
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The  notion  that  (poly)phenols  act as  direct  free  radical  scavengers  is  being  challenged  by  mere  chemical
and  biochemical  considerations  such  as  bioavailability  and  intracellular  concentrations.  An alternative
hypothesis  that  is  gaining  considerable  traction  is  that (poly)phenols  are  processed  by  the  body  as  xenobi-
otics  via  the  Keap1/Nrf2/ARE  signaling  axis, leading  to the  induction  of Phase  II enzymes.  However,  there
are  no solid  human  data  to conﬁrm  this  interesting  supposition.  In this  study,  we tested  the activities  of
hydroxytyrosol  (HT)  on  Phase  II enzymes’  expression  in a double-blind,  randomized,  placebo-controlled
study.  We  tested  two HT  doses,  i.e. 5 and  25 mg/d,  vs. placebo  following  a Latin  square  design.  We  report
that  HT  is well  tolerated  but  does  not  signiﬁcantly  modify  Phase  II enzyme  expression  in peripheral
blood  mononuclear  cells.  Moreover,  we were  unable  to record  signiﬁcant  effects  on  a variety  of  surrogate
markers  of  cardiovascular  disease  such  as lipid  proﬁle  and  inﬂammation  and  oxidation  markers.  Available
evidence  indicates  that  the “hormesis  hypothesis”  that  (poly)phenols  activate  Phase  II enzymes  requires
solid  human  conﬁrmation  that  might  be provided  by  future  trials.
This study  is registered  at ClinicalTrials.gov  (identiﬁer:  NCT02273622).
© 2015  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
(Poly)phenols are the products of plants’ secondary metabolism
and are endowed with several botanical activities [1]. Notable
examples include roles in pollination, color, insect repelling,
and cellular signal transduction. In addition, since the Zutphen
Study [2] (poly)phenol consumption by humans is being con-
sistently associated with better cardiovascular prognosis and
chemoprevention. Pharma-nutritionists are trying to explain the
molecular mechanisms responsible for the purported healthful
activities of (poly)phenols; major emphasis is being placed on their
antioxidant actions, which would counteract the noxious effects of
reactive oxygen species and free radicals. However, the widespread
notion that (poly)phenols act as direct free radical scavengers
is challenged by mere chemical and biochemical considerations
∗ Corresponding author at: IMDEA-Food, CEI UAM+CSIC, Carretera de Cantoblanco
8,  28049 Madrid, Spain. Tel.: +34 912796986; fax: +39 02700426106.
E-mail address: francesco.visioli@imdea.org (F. Visioli).
such as bioavailability and intracellular concentrations (namely,
as compared with endogenous antioxidants), reaction kinetics, etc.
[3].
An alternative hypothesis that is gaining considerable traction
is that (poly)phenols are processed by the body as xenobi-
otics [3,4]. Therefore, they stimulate stress-related cell signaling
pathways that result in increased expression of genes encod-
ing cytoprotective genes. In particular, Nrf2 (NF-E2-related factor
2) is a transcription factor which binds to the Antioxidant
Response Element (ARE) in cells and thus regulates enzymes
involved in antioxidant functions or detoxiﬁcation such as thiore-
doxin reductase-1 and glutathione peroxidases [3]. According
to the hormesis theory, (poly)phenols paradoxically act on the
Keap1/Nrf2/ARE signaling axis to produce additive increases in
electrophilic signaling that results in the induction of Phase
II enzymes and increased nucleophilic substrates, such as glu-
tathione, thioredoxin, and NADPH. In brief, (poly)phenols likely
exert indirect rather than direct antioxidant actions. However,
there are no solid human data to conﬁrm this interesting suppo-
sition.
http://dx.doi.org/10.1016/j.phrs.2015.03.018
1043-6618/© 2015 Elsevier Ltd. All rights reserved.
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Fig. 1. Study ﬂowchart.
In this study, we tested the activities of hydroxytyrosol (HT)
on Phase II enzymes’ expression in a double-blind, randomized,
placebo-controlled study.
2. Materials and methods
2.1. Subjects and study design
The study protocol was approved by the local Ethics commit-
tee and was fully explained to the participants. Written informed
consent was obtained by all subjects prior to starting the trial. This
work has been carried out in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki) and is
registered at ClinicalTrials.gov (identiﬁer: NCT02273622).
This was a double-blind, randomized, placebo-controlled study.
We tested two HT doses, i.e. 5 and 25 mg/d provided via adminis-
tration of Hytolive® (Genosa, Madrid, Spain), an olive mill waste
water (OMWW)  extract selectively enriched in HT, i.e. devoid of
oleuropein or other HT-containing secoiridoids as assessed by HPLC
[5], via anion-exchange chromatography. Twenty-two apparently
healthy volunteers were recruited from within the IMDEA-Food
Genyal platform database. Inclusion criteria were: age between 20
and 40 years; adequate understanding of the study; willingness to
complete the entire treatment. Exclusion criteria were: body mass
index <19 or >26; diagnosis of diabetes mellitus, hypertension,
dyslipidemia or other cardiometabolic disorders; impaired cogni-
tive function; diagnosed hepatic, renal, or cardiovascular disease;
allergy to olives and their derivatives; pharmacological therapies;
and habitual smoking. To our knowledge, there are no previous
studies testing the activities of HT on Phase II enzymes’ expression
in humans. Therefore, we  designed a pilot study and we could not
calculate power. However, the use of repeated measures increases
the power to detect treatment differences in mean levels of the
outcome measure over time.
We followed a Latin square design: after one-week washout,
i.e. olive-free diet, subjects were randomly assigned to either the
placebo (maltodextrin), 5 mg/d HT, or 25 mg/d HT group (Fig. 1).
The complete capsule composition is described in Supplementary
Table 1. Administration of each treatment was  carried out for one
week, followed by a one-week washout after which treatments
were switched. Volunteers were instructed not to consume any
olive-based products or medication throughout the study and were
instructed to write down any occurrences (consumption of prohib-
ited foods, medication intake, etc.) and intolerance issues (diarrhea,
acidity, nausea, abdominal distension, or halitosis) in question-
naires. Capsules were provided in bottles labeled A, B, or C and
their contents were unknown to both the volunteers and the nurse
who administered the bottles. Compliance was assessed by capsule
count.
Blood samples were drawn and anthropometric data (height,
weight, body mass index (BMI), bioelectric impedance analysis
(BIA)) and vital constants (systolic (SBP) and diastolic blood pres-
sure (DBP), and heart rate) were monitored at each visit. Morning
urine was  also collected at each time point.
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2.2. Biochemical analyses
Triacylglycerol (TG), total (TC), low-density (LDL-c), and high-
density (HDL-c) cholesterol concentrations were measured by
routine laboratory (Laboratorio CQS, Madrid, Spain, which follows
the UNE-ISO 15189:2007 directives) methods. Urea, creati-
nine, hepatic enzymes: glutamyl oxaloacetic transaminase (GOT),
glutamic-pyruvatetransaminase (GPT) and gamma  glutamyltrans-
ferase (GGT), bilirubin, and alkaline phosphatase (AP) were
also measured by routine laboratory methods. The concentra-
tion of oxidized LDL was measured by sandwich enzyme-linked
immunosorbent assay (ELISA) by using the monoclonal antibody
mAb-4E6 (Mercodia AB, Sweden).
Urinary thromboxane B2 and total isoprostanes were quanti-
ﬁed by competitive ELISA (Enzo Biochem, Inc., NY, USA and Oxford
Biomedical Research, MI,  USA, respectively).
2.3. Multiplex bead immunoassay
In a subset of samples, plasma concentrations of Interleukin
(IL)-6, IL-8, IL-10, IL-17, monocyte chemoattractant protein 1 (MCP-
1); Tumor necrosis factor alpha (TNF), and vascular endothelial
growth factor (VEGF) were measured using a magnetic bead-based
immunoassay (MAGPIX-Luminex) kit from Millipore, following the
manufacturer’s instructions. A minimum of 50 beads per parameter
were analyzed by the MAGPIX-Luminex system. Raw data (median
ﬂuorescence intensity, MFI) were analyzed with the xPONENT soft-
ware 4.1.
2.4. Isolation of peripheral blood mononuclear cells (PBMCs)
Subjects were instructed to fast overnight before each blood
collection. Blood samples were collected between 8 and 10 AM
to minimize circadian variations. Blood samples were collected
in heparinized tubes (BD Vacutainer, Franklin Lakes, NJ, USA) at
each visit, processed within 2 h after extraction and used to PBMCs.
Isolation was carried out under sterile conditions to avoid mono-
cytes activation. Whole blood was diluted (1:1) with phosphate
buffer solution (PBS) and centrifuged by density gradient with
Histopaque-1077 (Sigma–Aldrich, Madrid, Spain) according to the
manufacturer’s instructions. After collection, PBMCs were washed
twice with PBS, homogenized in Qiazol (Qiagen, Madrid, Spain) and
stored at −80 ◦C prior to RNA extraction.
2.5. RNA extraction and microarray samples preparation
Total RNA was  extracted and puriﬁed from homogenized PBMCs
with miRNeasy minikit (Qiagen, Valencia, CA, USA) following
the manufacturer’s protocol. Recovered RNA’s concentration and
integrity were veriﬁed using a Nanodrop ND-1000 spectropho-
tometer (Nanodrop TechnologyR, Cambridge, UK) and an Agilent
2100 Bioanalyzer (Agilent, Madrid, Spain).
2.6. Gene expression analysis
After DNAse I treatment (Invitrogen, Madrid, Spain), reverse
transcription was performed with miScript® II Reverse Transcrip-
tion kit (Qiagen, Germantown, MD)  according to the manufacturer’s
guidelines. RT-qPCR reactions were performed in 384-well plates
and gene expression was  determined using the 7900HT Real-Time
PCR System (Life Technologies, Spain). Reactions were performed
with 5 L of miScript SYBR® Green qPCR Master Mix (Qiagen,
Madrid, Spain). Cycling conditions were 15 min at 95 ◦C for one
cycle, then 40 cycles at 94 ◦C for 15 s, 58 ◦C for 30 s, 70 ◦C for 30 s,
for each gene. The dissociation stage was  analyzed at 95 ◦C for 15 s,
followed by one cycle at 60 ◦C for 15 s, and 95 ◦C for 15 s. Gene
expression analysis was carried out for twenty Phase II enzymes
(primers can be found in Supplementary Table 2). Three potential
reference genes–GAPDH, HPLPO, and ACTB–were tested in order
to select the most stable to be used in target gene’s normaliza-
tion, which according to Normﬁnder was  the latter. Reactions were
run in triplicate and relative expression of Phase II enzymes was
calculated by the comparative Ct method and presented as 2−Ct.
2.7. Statistical analyses
Continuous descriptive variables were expressed as
mean ± SEM. Two-way repeated measures ANOVA was used
to evaluate the effects of time (t1 and t2), treatment (A, B, C)
and the time × treatment interaction. A Bonferroni correction for
multiple analyses was  applied and models were adjusted for age
and sequence (ABC/CAB/BCA) as covariates. All statistical analyses
were considered as bilateral and signiﬁcance was set at p < 0.05.
Data were analyzed with R Statistical Software version 3.1.1
(www.r-project.org).
3. Results
One volunteer was  excluded from the study because he exhib-
ited abnormal basal bilirubin concentrations (Fig. 1); attrition rate
was, therefore, zero. Both 5 and 25 mg  HT doses were well-tolerated
and no adverse effect was  reported.
No differences in anthropometric variables, such as weight or
body mass index, were recorded and no signiﬁcant variations in
vital signs such as blood pressure were noted either (Table 1).
Table 1
Anthropometric parameters and vital signs.
Measured parameters A B C Effect (p)*
Initial Final Initial Final Initial Final Time Treatment Time × treatment
Weight (kg) 73.31 (1.58) 73.1 (1.61) 73.1 (1.58) 72.85 (1.57) 73.07 (1.62) 72.73 (1.64) 0.002* 0.989 0.833
B.M.I  (kg/m2) 23.69 (0.41) 23.62 (0.42) 23.62 (0.43) 23.55 (0.43) 23.61 (0.44) 23.49 (0.45) 0.002* 0.984 0.721
FM  (%) 19.99 (1.16) 20.01 (1.23) 20.1 (1.23) 20.02 (1.24) 19.87 (1.3) 19.82 (1.25) 0.787 0.991 0.944
MM  (%) 39.81 (0.71) 39.72 (0.77) 39.69 (0.77) 39.67 (0.77) 39.78 (0.81) 39.82 (0.78) 0.805 0.993 0.821
AVF  5.9 (0.42) 5.95 (0.43) 5.86 (0.44) 5.76 (0.44) 5.86 (0.44) 5.76 (0.45) 0.263 0.973 0.287
SBP  (mmHg) 130 (2.35) 131.1 (1.98) 129.62 (2.84) 131.19 (2.18) 130.14 (2.47) 128.71 (2.17) 0.681 0.920 0.424
DBP  (mmHg) 70.1 (1.51) 72.48 (1.48) 71.57 (1.61) 71.71 (1.46) 70.29 (1.21) 71.24 (1.76) 0.1622 0.878 0.531
HR  (Beat/min) 60.19 (3.96) 69 (2.91) 64.05 (2.15) 67.76 (2.5) 63.38 (2.01) 66.1 (2.75) 0.0013* 0.893 0.214
A: 250 mg  Hytolive (25 mg  hydroxytyrosol); B: 50 mg  Hytolive (5 mg  hydroxytyrosol); C: Placebo. B.M.I, body mass index; FM,  Fat mass; MM:  Muscle mass measured by BIA:
bioelectrical impedance analysis; AVF, abdominal visceral fat (measured by BIA); SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, Heart Rate. Effect (p); Time:
indicates the evolution in the same group from the beginning to the end of the intervention. Treatment: indicates differences between treatments (A, B, C) independently of
time.  Time × treatment: indicates the differences in evolution between groups as a result of treatment received (A, B, C). The p value for interaction was  adjusted for age and
sequence of consumption as covariates. Data are means (SEM).
* p < 0.05.
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Table  2
Biochemical parameters evaluated in each of the visits.
Measured parameters A B C Effect (p)*
Initial Final Initial Final Initial Final Time Treatment Time × treatment
TC (mg/dl) 169.3 (6.54) 169.7 (6.51) 168.6 (6.39) 173.9 (6.8) 170.8 (6.77) 169.4 (5.97) 0.388 0.975 0.258
HDL  (mg/dl) 52.83 (2.57) 51.04 (2.06) 52.17 (2.66) 52.14 (2.44) 51.84 (2.26) 50.87 (2.48) 0.229 0.960 0.644
LDL  (mg/dl) 99.47 (5.47) 103.0 (5.41) 101.3 (5.47) 106.2 (5.7) 102.5 (5.78) 103.7 (5.17) 0.031* 0.923 0.559
TG  (mg/dl) 85.1 (7.26) 78.24 (6.15) 75.81 (4.2) 77.6 (6.57) 82 (8.05) 74.6 (4.96) 0.163 0.793 0.371
hs-CRP (mg/dl) 0.07 (0.02) 0.16 (0.06) 0.09 (0.02) 0.05 (0.01) 0.09 (0.02) 0.05 (0.01) 0.47 0.117 0.049*
TXB2 (ng/ml) 1.55 (0.2) 1.71 (0.14) 1.97 (0.26) 1.72 (0.16) 2.17 (0.18) 1.83 (0.3) 0.253 0.316 0.222
TXB2/Creat (g/g) 0.87 (0.06) 0.86 (0.05) 1.03 (0.10) 0.9 (0.06) 1.01 (0.06) 0.94 (0.08) 0.097 0.373 0.502
LDL-ox (U/l) 42.6 (2.32) 41.34 (2.04) 42.19 (2.31) 43.95 (2.56) 41.28 (2.84) 41.34 (2.31) 0.849 0.814 0.445
Isop  (ng/ml) 2.99 (0.34) 3.59 (0.41) 3.71 (0.41) 3.78 (0.42) 4.78 (0.63) 3.38 (0.56) 0.477 0.298 0.052*
Isop/Creat (g/g) 1.64 (0.08) 1.75 (0.1) 1.92 (0.13) 2.05 (0.17) 2.42 (0.33) 1.74 (0.14) 0.257 0.128 0.020*
GOT/AAT (UI/l) 19.71 (1.26) 19.95 (1.18) 18.05 (0.79) 18.9 (0.96) 19.52 (0.77) 19.33 (1.09) 0.525 0.520 0.662
GPT/AT (UI/l) 19.33 (1.9) 19.67 (1.79) 18.38 (1.49) 18.24 (1.38) 20.0 (1.6) 18.62 (1.17) 0.458 0.744 0.403
GGT  (UI/l) 21.07 (1.99) 21.48 (2.44) 22.38 (2.27) 21.89 (2.0) 21.69 (2.07) 20.66 (1.78) 0.260 0.909 0.196
TB  (mg/dl) 1.1 (0.08) 1.16 (0.1) 1.16 (0.11) 1.12 (0.09) 1.06 (0.08) 1.21 (0.1) 0.148 0.994 0.143
AP  (UI/l) 55.95 (2.92) 64.33 (3.89) 58.86 (3.31) 62.86 (3.23) 57.76 (3.6) 61.76 (3.3) 0.001* 0.967 0.204
Urine  creatinin (mg/dl) 177.5 (16.9) 202.2 (15.9) 190.2 (14.5) 193.6 (14.0) 215.7 (14.8) 184.8 (14.1) 0.910 0.814 0.024*
A: 250 mg  Hytolive (25 mg hydroxytyrosol); B: 50 mg  Hytolive (5 mg  hydroxytyrosol); C: Placebo. TC: total cholesterol; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; TG:Triglycerides; hs-CRP: high-sensitive C-reactive protein; TXB2: Thromboxane B2; TXB2/Creat: TXB2 ratio and creatinine in urine; LDL-ox: Oxidized Low
Density Lipoprotein; Isop: Isoprostanes, Isop/Creat: Isoprostanes ratio and creatinine in urine; GOT: glutamyl oxaloacetic transaminase; GPT: glutamic-pyruvatetransaminase;
GGT: Gamma  Glutamyltransferase; TB: total bilirubin; AP: alkaline phosphatase. Time: indicates the evolution in each group from beginning to end of the intervention.
Treatment: differences between treatments (A, B, C) independently of time. Time × treatment: differences in evolution between groups as a result of treatment received (A,
B,  C). Age and sequence of consumption were used as covariates. Data are means (SEM).
* p < 0.05.
Table 3
Cytokine levels after the consumption of the study products (A and C).
Measured parameters A C Effect (p)*
Initial Final Initial Final Time Treatment Time × treatment
IL-10 (pg/ml) 2.22 (0.97) 1.36 (0.41) 0.79 (0.16) 1.71 (0.97) 0.96 0.46 0.17
IL-17  (pg/ml) 30.7 (10.2) 29.2 (8.18) 14.3 (2.61) 15.3 (3.98) 0.91 0.12 0.58
IL-6  (pg/ml) 10.6 (4.99) 11.5 (5.73) 6.20 (2.80) 5.20 (1.51) 0.96 0.18 0.45
IL-8  (pg/ml) 30.4 (9.57) 28.1 (8.56) 14.3 (4.43) 21.4 (9.92) 0.50 0.31 0.20
MCP-1  (pg/ml) 486 (54.0) 472 (54.1) 412 (37.0) 446 (43.5) 0.52 0.36 0.14
TNF-  (pg/ml) 8.99 (1.02) 8.31 (0.88) 7.37 (0.64) 6.74 (0.54) 0.04* 0.12 0.92
VEGF  (pg/ml) 605 (164) 682 (182) 577 (110) 497 (98.2) 0.98 0.53 0.10
A: 250 mg  Hytolive (25 mg  hydroxytyrosol); C: Placebo. n = 10 in both groups, randomly selected. IL-10: Interleukin 10; IL-17: Interleukin 17; IL-6: Interleukin 6; IL-8:
Interleukin 8; MCP-1: Monocyte chemoattractant protein 1; TNF-: Tumor necrosis factor alpha; VEGF: Vascular endothelial growth factor. Data are means (SEM).
* p < 0.05.
Table 2 reports the plasma concentrations of selected surrogate
markers of cardiovascular disease and hepatic enzymes. We  only
recorded signiﬁcant time × treatment interactions for isoprostanes
(markers of oxidation) and hs-CRP (marker of inﬂammation). Of
note, hepatic function enzymes, which are – alas – rarely measured
in nutraceutical studies, were not modiﬁed by either treatment.
In a subset of samples, namely those who received the highest
HT dose vs. controls, we also quantiﬁed an array of plasma cytokines
(Table 3) and did not ﬁnd any signiﬁcant variation induced by HT.
Phase II enzyme expression in PBMCs is reported in Table 4. We
only documented a time effect on GSTO1 and GSTP1 levels, whereas
all other genes were unaffected by the provision of HT.
4. Discussion
The notion that (poly)phenols trigger stress signaling mediated
by Nrf-2 and Phase II enzymes is, nowadays, predominant over that
of their plain antioxidant actions [3,6]. However, this hypothesis
has never been conﬁrmed in humans (to the best of our knowledge),
with the exception of Hofmann et al. [7], who reported modest yet
signiﬁcant increases of glutathione S-transferase P1 (hGSTP1) pro-
tein expression in leukocytes of healthy volunteers given fruit juice.
In brief, while biochemical veriﬁcation of Nrf-2 mediated hormesis
is strong, human evidence is scant or non-existent.
In this paper we report that HT, administered at two different
doses in a Latin-square design study was well tolerated (as shown
by the unaltered levels of hepatic enzymes, Table 2), but does not
signiﬁcantly modify Phase II enzyme expression in PBMCs. More-
over, we were unable to record signiﬁcant effects on a variety of
surrogate markers of cardiovascular disease such as lipid proﬁle
and inﬂammation and oxidation markers. Actually, we  computed
a non-signiﬁcant increase in plasma hs-CRP and in urinary iso-
prostanes concentrations. The latter ﬁnding is in agreement with
that of Leger el al. [8] and in disagreement with Visioli at al [9],
who, however, administered extra virgin olive oils rather than HT.
Because these differences were non-signiﬁcant it is difﬁcult to
comment on their true physiological relevance; however, these
data reiterate the concept that (poly)phenols and other minor
food components exert biological effects whose nature and extent
depend on the matrix, i.e. as part of food or provided as pharma-
nutritional formulations.
We chose hydroxytyrosol (the foremost component of extra
virgin olive oil [10]) as paradigmatic example of (poly)phenols
because (1) it is the only phenolic molecule that received a Euro-
pean Food Safety Authority (EFSA) health claim [11]; (2) it has been
shown to increase Nrf-2 expression in vitro [12,13] albeit at non-
physiological doses [14]; (3) a “xeno-hormesis” postulation has also
been proposed to explain the salubrious actions of extra virgin
olive oil phenolics [15]; and (4) a previous human study with an
olive mill waste water (OMWW)  preparation reported increased
glutathione levels short-term in human volunteers [16]. A glu-
tathione effect was also recorded in rats [17] and a short-term
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Table 4
Gene expression of Phase II enzymes after the consumption of the study products (A, B and C).
Phase II enzymes Initial Final Effect (p)*
A B C Time Treatment Time × treatment
NQO1 1 1.11 (0.11) 0.81 (0.07) 1.50 (0.61) 0.79 0.58 0.35
NQO2  1 1.79 (0.87) 1.04 (0.08) 1.05 (0.09) 0.74 0.66 0.95
GSTA1  1 1.28 (0.32) 1.32 (0.24) 1.01 (0.17) 0.38 0.93 0.45
GSTA4  1 1.01 (0.10) 1.11 (0.09) 1.10 (0.13) 0.73 0.79 0.58
GSTK1  1 1.27 (0.35) 0.99 (0.07) 1.03 (0.12) 0.87 0.42 0.96
GSTM1 1 1.22 (0.13) 0.89 (0.06) 1.19 (0.24) 0.40 0.89 0.16
GSTM2 1 1.73 (0.37) 1.20 (0.15) 1.54 (0.44) 0.12 0.92 0.97
GSTM3 1 1.16 (0.17) 1.15 (0.12) 1.06 (0.15) 0.96 0.92 0.46
GSTM4 1 1.22 (0.17) 0.97 (0.07) 1.19 (0.29) 0.63 0.89 0.29
GSTM5 1 1.39 (0.39) 1.07 (0.15) 1.18 (0.24) 0.36 0.88 0.95
GSTO1  1 0.90 (0.09) 1.18 (0.15) 0.90 (0.08) 0.03* 0.65 0.25
GSTO2  1 0.97 (0.08) 0.93 (0.08) 1.11 (0.11) 0.30 0.82 0.69
GSTP1  1 1.24 (0.09) 1.28 (0.16) 1.46 (0.25) 0.02* 0.85 0.99
GSTT1  1 0.94 (0.07) 1.06 (0.09) 1.22 (0.21) 0.73 0.84 0.56
GSTT2  1 1.58 (0.26) 1.22 (0.15) 1.08 (0.14) 0.50 0.59 0.29
HNMT  1 0.97 (0.08) 1.02 (0.10) 1.02 (0.08) 0.56 0.94 0.63
INMT  1 1.00 (0.13) 1.13 (0.15) 1.03 (0.15) 0.09 0.54 0.52
MGST1 1 1.06 (0.13) 1.19 (0.13) 1.05 (0.10) 0.98 0.70 0.22
MGST2 1 1.01 (0.07) 1.02 (0.08) 1.06 (0.13) 0.31 0.89 0.55
MGST3 1 0.90 (0.08) 1.13 (0.08) 1.05 (0.11) 0.16 0.92 0.17
A: 250 mg  Hytolive (25 mg hydroxytyrosol); B: 50 mg  Hytolive (5 mg hydroxytyrosol); C: Placebo. NQO1: NADPH dehydrogenase, quinone 1; NQO2: NADPH dehydrogenase,
quinone 2; GSTA1: Glutathione S-transferase alpha 1; GSTA4: Glutathione S-transferase alpha 4; GSTK1: Glutathione S-transferase kappa 1; GSTM1: Glutathione S-transferase
mu  1; GSTM2: Glutathione S-transferase mu 2; GSTM3: Glutathione S-transferase mu 3; GSTM4: Glutathione S-transferase mu 4; GSTM5: Glutathione S-transferase mu
5;  GSTO1: Glutathione S-transferase omega 1; GSTO2: Glutathione S-transferase omega 2; GSTP1: Glutathione S-transferase pi 1; GSTT1: Glutathione S-transferase theta
1;  GSTT2: Glutathione S-transferase theta 2; HNMT: Histamine N-methyltransferase; INMT: Indolethylamine N-methyltransferase; MGST1: Microsomal glutathione S-
transferase 1; MGST2: Microsomal glutathione S-transferase 2; MGST3: Microsomal glutathione S-transferase 3. Data are fold change means (SEM).
* p < 0.05.
increase in skeletal muscle glutathione concentrations after exer-
cise was reported by Bast and Haenen, who administered an
HT-rich olive extract (providing 200 mg  of HT) to human volunteers
[18]. Finally, a nutrigenomic study carried out in mice reported that
HT – in nutritionally relevant amounts – is able to positively mod-
ulate the glutathione-driven antioxidant enzymatic machinery in
adipose tissue [19].
Of note, Visioli et al. [16] previously suggested that part of
the purported healthful activities of HT might be governed by the
antioxidant response element (ARE)-mediated increase in Phase
II enzyme expression. Therefore, we undertook the current study
to verify this premise in a controlled setting. Indeed, we  also
wanted to verify in humans the now popular notion that describes
(poly)phenols as activators of the stress response pathways. We
used PMBCs because they are easily accessible, express many genes
previously believed to be restricted to non-blood tissues respon-
ding to macro- or micro-environment alterations in organs, and
have been shown to be suitable for nutritional studies, reﬂecting
speciﬁc effects of diets or nutrients [20–22].
To date, there are two human studies that have been performed
with OMWW and one where the authors administered pure HT
[8,23,24]. The former reported anti-thrombogenicity [8,23], while
the latter only addressed absorption and disposition and did not
inform on biochemical data [24].
Several hypotheses can be formulated to explain the dis-
crepancy between our current results and those obtained with
high-polyphenol extra virgin olive oil or those of Visioli et al. [16],
namely in terms of oxLDL [25] and platelet aggregation [8,23] or
oxidation and inﬂammatory markers [9]. First and foremost, we
administered two doses of HT, i.e. 5 and 25 mg/d for one week.
Higher doses might produce the hypothesized effects and are
supposed to be safe. However, it is noteworthy that the EFSA health-
claim [11] relates to 5 mg/d of HT and HT-containing phenols as
protectors of LDL from oxidation. From a practical viewpoint this
implies that formulations that provide HT amounts higher than
this dose might have to deal with some regulatory issues, even
though the safety proﬁle of HT is excellent [26–28] as conﬁrmed
by the current study (Table 2). As a matter of fact, Visioli and
Galli administered 50 mg  of HT and recorded effects on TXB2 pro-
duction by serum short term, i.e. 1 h after intake [23]. These data
were conﬁrmed by Leger et al. [8], who  provided ﬁve type I dia-
betic patients with 25 mg  of HT the ﬁrst day and 12.5 mg/day the
following 3 days. A 46% decrease in the serum TXB2 production
after blood clotting at T (4d) was recorded [8]. Whether high doses
of (poly)phenols trigger other short-term effects such as Phase II
enzyme expression remains to be veriﬁed in humans. Also, the acti-
vation of Phase II enzymes might be organ-speciﬁc [29]; whether
sustained hepatic Phase II enzymes activation occurs in humans
would be very difﬁcult to ascertain for obvious ethical and practical
reasons.
Another important issue that the nutraceutical world is trying to
address is that of healthy volunteers vs. patients [30]. Clinical trials
of nutraceuticals, supplements, or functional foods in patients clash
with obvious ethical guidelines; as a result, these preparations are
often added to established, top-quality therapy, therefore making
it difﬁcult to ascertain their real contribution. One notable exam-
ple is that of omega 3 fatty acids [31,32]. Our cohort of healthy
volunteers exhibited normal-range concentrations of surrogate
markers of cardiovascular disease at baseline: further reduction
of such concentrations might be difﬁcult to achieve. Conversely,
HT might speculatively be beneﬁcially used as medical food [33],
i.e. as adjunct therapy of cardiovascular and other inﬂammation-
based diseases [34] or to metabolic syndrome patients, pending
conﬁrmation by appropriate clinical trials [35].
Finally, it is worth reiterating that nutraceuticals and functional
foods must exert modest (and often undetectable based on current
methodologies) physiological effects which, however, could pro-
duce remarkable health activities if taking place long-term [36].
Indeed, epidemiological evidence of healthful activities is strong
and corroborates the “sub-clinical, lifetime exposure” proposition.
In conclusion, the physiological activities of HT are – as of today –
limited to inhibition of TXB2 production by serum, leading to a pos-
sible prevention of thrombotic and micro-thrombotic processes.
Most important, the “hormesis hypothesis” that (poly)phenols
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activate Phase II enzymes requires solid human conﬁrmation that
might be provided by future trials.
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 Supplementary Table 1. Composition of the capsules used in the study. 
Ingredient 
A B C 
Weight (mg) 
OMWW extract >10% hydroxytyrosol 250 50 - 
Maltodextrin (maltosweet 180) - - 253,44 
Microcrystalline cellulose  type 101-CG 3,44 203,44 - 
Precipitated silica, IBERSIL® d250 
(46,7%si)-CG 
2,64 2,64 2,64 
Magnesium stearate-CG 7,92 7,92 7,92 
Caps"1"bl 76 76 76 
Total weight 340 340 340 
OMWW, olive mill waste water. 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 2. Primer sequences used and expected amplicon sizes. 
Gene 
symbol 
Gene name Primer sequence (5´-3´) 
Amplicon 
size (bp) 
NQO1 NAD(P)H dehydrogenase, quinone 1 Fw:GAAGAGCACTGATCGTACTGGC 196 
Rev:GGATACTGAAAGTTCGCAGGG 
NQO2 NAD(P)H dehydrogenase, quinone 2 Fw:CCACGAAGCCTACAAGCAAAG 103 
Rev:CCAGTACAGCGGGAACTGAAATA 
GSTA1 Glutathione S-transferase alpha 1 Fw:CTGCCCGTATGTCCACCTG 185 
Rev:AGCTCCTCGACGTAGTAGAGA 
GSTA4 Glutathione S-transferase alpha 4 Fw:CCGGATGGAGTCCGTGAGAT 127 
Rev: GGGCACTTGTTGGAACAGC 
GSTK1 Glutathione S-transferase kappa 1 Fw:TCTGGAAAAGATCGCAACGC 83 
Rev:GCCCAAAGGCTCCGTATCTG 
GSTM1 Glutathione S-transferase mu 1 Fw:TCTGCCCTACTTGATTGATGGG 117 
Rev:TCCACACGAATCTTCTCCTCT 
GSTM2 Glutathione S-transferase mu 2 Fw:TGTGCGGGGAATCAGAAAAGG 99 
Rev:CTGGGTCATAGCAGAGTTTGG 
GSTM3 Glutathione S-transferase mu 3 Fw:TCGTGCGAGTCGTCTATGGT
  
100 
Rev:TCTCCTCATAAGAGGTATCCGTG 
GSTM4 Glutathione S-transferase mu 4 Fw:TCTGCCCTACTTGATTGATGGG 117 
Rev:TCCACACGAATCTTCTCCTCT
  GSTM5 Glutathione S-transferase mu 5 
Fw:CCATCCTGCGCTACATTGC 111 
Rev:CCAGCTCCATGTGGTTATCCAT 
GSTO1 Glutathione S-transferase omega 1 Fw:GAACGGCTGGAAGCAATGAAG 69 
Rev:TGCCATCCACAGTTTCAGTTT
  GSTO2 Glutathione S-transferase omega 2 
Fw:TGCCCCTATTCTCACAGGACC
  
188 
Rev:TCCAGGTACTCACAAGCAATAAC 
GSTP1 Glutathione S-transferase pi 1 Fw:CCCTACACCGTGGTCTATTTCC 137 
Rev:CAGGAGGCTTTGAGTGAGC
  GSTT1 Glutathione S-transferase theta 1 
Fw:TCTACCTGACGCGCAAATATAAG 112 
Rev:CTTCTCCGCAGAGTCGTGT
  GSTT2 Glutathione S-transferase theta 2 
Fw:GACGCTCAAGGATGGTGATTT
  
104 
Rev:GCAGGTCAGATGGATACCAGT 
HNMT Histamine N-methyltransferase Fw:GTGGAAAAAGTACGGATCACGC 211 
Rev:GTGGAAAAAGTACGGATCACGC 
INMT Indolethylamine N-methyltransferase Fw:AAGGGGACACGCTGATTGAC
  
93 
Rev:AGTCGGAGAGAGTGATGTCTTG 
MGST1 Microsomal glutathione S-transferase 1 Fw:ATGACAGAGTAGAACGTGTACGC 82 
Rev:TACAGGAGGCCAATTCCAAGA 
MGST2 Microsomal glutathione S-transferase 2 Fw:TCGGCCTGTCAGCAAAGTTAT
  
119 
Rev:TGTTGTGCCCGAAATACTCTCT 
MGST3 Microsomal glutathione S-transferase 3 Fw:GGCCCACCTAGCCATCAATG
  
111 
Rev:CGCTGAATGCAGTTGAAGATGT 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  Fw:AGCCACATCGCTCAGACA 69 
Rev:GCCCAATACGACCAAATCC 
RPLPO Ribosomal protein, large, P0 Fw:CCTCATATCCGGGGGAATGTG 95 
Rev:GCAGCAGCTGGCACCTTATTG 
ACTB Actin, beta Fw:CCAACCGCGAGAAGATGA 97 
Rev:CCAGAGGCGTACAGGGATAG 
The complete sequence description of the target gene was obtained from the nucleotide sequence 
database (Primerbank) 
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A B S T R A C T
Among the various (poly)phenols that are being sold as such or as part of a more complex
mixture, hydroxytyrosol (HT) is the only one that bears a European Food Safety Authority
health claim. Therefore, several HT-based products are being developed and sold and it
becomes necessary to evaluate its accessibility following ingestion. Twenty-one volunteers
were recruited for a randomized, crossover, placebo-controlled, and double-blind interven-
tion study.We performed a Latin square design: after one-week washout, i.e. olive-free diet,
subjects were randomly assigned to the placebo (maltodextrin), 5, or 25 mg/day HT group.
Twenty-four hour urine samples were collected after the intervention week, and baseline
urines were collected the week before the study and during periods of washout. The results
show that HT given as the foremost component of a nutraceutical preparation is bioavailable
and is recovered in the urine chiefly as sulphate-3′.
© 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
The nutraceutical and functional food market is rapidly ex-
panding and several new products enter the market on a daily
basis (Mahabir, 2014; Tome-Carneiro & Visioli, 2015). Of note,
such products are rarely tested in controlled human trial set-
tings and the efficacy of individual molecules or raw extracts
is often questionable. In addition, the bioavailability of indi-
vidual molecules or active principle(s) is seldom assessed, in
part because of technical limitations and lack of proper
equipment.
Among the various (poly)phenols that are being sold as such
or as part of a more complex mixture, hydroxytyrosol (HT) is
the only one that bears a European Food Safety Authority health
claim (EFSA Panel on Dietetic Products, 2011).Therefore, several
HT-based products are being developed and sold (Visioli &
Bernardini, 2011) and it becomes necessary to evaluate acces-
sibility of HT following ingestion. It is noteworthy that HT
bioavailability has been reported after extra virgin olive oil
* Corresponding author. Department of Molecular Medicine, University of Padova,Viale G. Colombo 3, 35121 Padova, Italy.Tel.: +390498276107;
fax: +3902700426106.
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administration (Caruso, Visioli, Patelli, Galli, & Galli, 2001;
Miro-Casas et al., 2003), yet never after the intake of HT-
containing supplements, with the exception of one study with
pure HT (Gonzalez-Santiago, Fonolla, & Lopez-Huertas, 2010).
In this study, we report the urinary excretion of HT (as such
and as its metabolites) after its administration to healthy
volunteers.
2. Materials and methods
2.1. Standards and chemicals
Hydroxytyrosol (HT, 98% purity) standard was purchased from
Extrasynthese (France). HT 3′-O- and 4′-O- glucuronides (HT-
G-3′ and HT-G-4′, 86% and 97% purity, respectively) were
synthesized as previously described (Giordano, Dangles,
Rakotomanomana, Baracchini, & Visioli, 2015). HT 3′-O-
sulphate (HT-S-3′, 98% purity) standard was bought from
Toronto Research Chemicals Inc. (Toronto, ON, Canada).
Hydroxyphenylpropanol (HOPhPr, 99% purity), used as the in-
ternal standard (ISTD), was purchased from Sigma-Aldrich (St.
Louis, MO, USA).
LC-grade solvents methanol and ACN were purchased from
Scharlau Chemie, S.A. (Sentmenat, Spain). Ammonium acetate
and glacial acetic acid were purchased from Panreac Química,
S.A.U. (Castellar del Vallés, Spain). Ultrapure water (Milli-Q) was
obtained from Millipore (Bedford, MA, USA).
The capsules that we administered were elaborated from
an olive mill waste water extract preparation called Hytolive®,
supplied by the company Genosa ID, S.L. (Madrid, Spain).
2.2. Subjects and study design
The study protocol was approved by the local ethics commit-
tee andwritten informed consent was obtained from all subjects
prior to starting the trial. This work was carried out in accor-
dance withThe Code of Ethics of theWorld Medical Association
(Declaration of Helsinki) and is registered at ClinicalTrials.gov
(identifier: NCT02273622).
Samples of this research were obtained from a previous in-
tervention study, whose objective was to evaluate the effect
of HT on the gene expression of Phase II enzymes (Crespo et al.,
2015). Briefly, twenty-one volunteers were recruited for a ran-
domized, crossover, placebo-controlled, and double-blind
intervention study.The design of this study is shown in Fig. 1.
We performed a Latin square design: after one-week washout,
i.e. olive-free diet, subjects were randomly assigned to the
placebo (maltodextrin) group, 5 mg/day HT group, or 25 mg/
day HT (Hytolive®) group. Baseline characteristics of participants
and inclusion and exclusion criteria are given in detail in
Supplementary Information 1 (S.I.1 in Appendix S1). Volun-
teers were given dietary guidelines (Supplementary Information
2, S.I.2 in Appendix S1) that included abstention from olive prod-
ucts and limitation of high-polyphenol foods and alcohol
(Crespo et al., 2015).Twenty-four hour urine samples were col-
lected after the intervention week, and baseline urines were
collected the week before the study and during periods of
washout, and immediately stored at −80 °C.
2.3. Pretreatment and processing of the urine samples
A total of 63 24-hour (from 21 volunteers, collected in the three
experimental phases, after administration of the supple-
ment) and 42 basal urine samples (collected during the final
days of the second and third washout periods) were analysed.
All urine samples were thawed, vortexed, and centrifuged
at 9000 × g for 5 min at 4 °C.The supernatant (20 µL) from each
urine sample was diluted with 0.1% acetic acid by a factor of
10 (1:10 vol:vol) for detection of HT and its glucuronidate me-
tabolites and by a factor of 50 (1:50 vol:vol) for its sulphates
(HT-S-3′and HT-S-4′). Calibration standards of 5-10-25-50-100-
250-500-1000 ng/mL for HT and 20-40-100-200-400-1000-2000-
4000 ng/mL for HT-G-3′, HT-G-4′ and HT-S-3′ in blank human
urine were processed like the 10-fold diluted samples. An in-
ternal standard (HOPhPr) was used at the final concentration
of 500 ng/mL in all cases. Samples and calibration curves were
distributed in 96-well plates and 2 µL of each were injected in
randomized order.
2.4. Sample analysis
LC–MS/MS analysis of diluted samples was performed on the
Agilent (Santa Clara, CA, USA) 1290 Infinity Binary LC system
coupled to an AB SCIEX QTRAP® 6500 spectrophotometer.
Acquity UPLC BEH C18 1.7 µm, 2.1 × 5 mm analytical column
(Waters) at 40 °C and 1 mM ammonium acetate at pH 5.0 and
100% ACN as aqueous (A) and organic (B) mobile phases, re-
spectively, were used for separation (Khymenets et al., 2011;
Kotronoulas et al., 2013). Next, gradient elution (B% (v/v), t (min))
at flow of 0.4 mL/min was applied: (1%, 0–3); (1–20%, 3–3.2); (20%,
3.2–4.5); (20–95%, 4.5–4.8); (95%, 4.8–5.3); (95–1%, 5.3–5.5); (1%,
5.5–6.5). Common MS parameters were as follows: ion spray
voltage (IS) −4500.00, source temperature (TEM) 600 °C, curtain
Fig. 1 – Study design.
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gas (CUR) 20.00 psi, ion source gas 1 (GS1) and gas 2 (GS2) 50.00
psi each, collision-activated dissociation (CAD) 3.00 psi, en-
trance potential (EP) −10.00 and cell exit potential (CXP) 13.00.
The data were collected under negative ionization in mul-
tiple reaction monitoring mode (MRM) with following settings
for compound fragmentations (declustering potential, DP: V;
collision energy, CE: eV): HT 153− → 123− (DP: −55; CE: −20); HT-
G-3′ and HT-G-4′ 329− → 153− (DP: −60; CE: −30); HT-S-3′ and HT-
S-4′ 233− → 153− (DP: −60; CE: −25) and HOPhPr 151− → 121− (DP:
−65; CE: −22). HT, HT-G-3′, HT-G-4′ and HT-S-3′ were quanti-
fied using calibration curves constructed with corresponding
standards. HT-S-4′ has been identified only in samples with high
concentration of HT-S-3′; its concentration was estimated using
slope of HT-S-3′ calibration curve. The method based on LC–
MS/MS analysis for HT and its glucuronidated and sulphated
metabolites in diluted urine samples was successfully vali-
dated, showing good linearity (r2 ≥ 0.99 in all cases) and following
sensitivity (LOQs): 5 and 20 ng/mL urine for HT and its me-
tabolites (glucuronides and sulphate), respectively. Intra- and
inter-day precision and accuracy results were according to the
standard requirements (U.S. Department of Health and Human
Services, 2001) for method validation criteria: RSD% and ERR%
were <20% (except HT-S-3′, where they were ≤28%, due to the
impact of ever existing endogenous metabolite) for low and
<15% (all compounds) for medium and high concentrations of
tested standards.
The results were processed using Analyst 1.6.2 Software (AB
SCIEX) and then statistically analysed. The final results, ex-
pressed as concentrations (ng/mL urine) of HT, HT-G-3′, HT-
G-4′, HT-S-3′ and HT-S-4′, are shown in Supplementary Table 1
(S.T.1 in Appendix S1).
2.5. Statistical analysis
Data were analysed with R Statistical Software version
3.1.1. Continuous descriptive variables were expressed as
means ± SEM. Two-way repeated measures ANOVA was used
to evaluate the effects of time (basal and 24-hour urine), treat-
ment (A, B, C) and the time × treatment interaction.A Bonferroni
correction for multiple analyses was applied and models were
adjusted for age and sequence (ABC/CAB/BCA) as covariates.
All statistical analyses were considered as bilateral and sig-
nificance was set at p < 0.05.
3. Results
The administration of a standardized, 10%-HT nutraceutical
resulted in a dose-dependent urinary excretion of HT and its
metabolites (Table 1). These changes were statistically signifi-
cant and were more pronounced for HT-S-3′. Of note, this
molecule was also detected in urines from placebo-treated sub-
jects, possibly as a consequence of endogenous HT production
and excretion (Perez-Mana et al., 2015a,b). Inter-individual vari-
ability varied, but was – on average – ~10%.
Quantitatively, the total amount of HT and its metabolites
recovered in the urine accounted for 21% (for the 25 mg dose)
to 28% (for the 5 mg dose) of the administered dose (Table 2).
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Again, the major metabolite we detected was HT-S-3′, which
accounted for 23.6% (for the 5 mg dose) to 16.6% (for the 25 mg
dose) of the administered HT.
Quantitatively, as we represent in Table 2, the total amount
of HT recovered in the urine was minimal and accounted for
0.02% (only for the 25 mg dose). For others metabolites, we ob-
served a dose-dependent increase in their excretion.Again, the
major metabolite we detected was HT-S-3′, which accounted
for 23.1% (for the 5 mg dose) and 16.6% (for the 25 mg dose)
of the administered HT, followed by HT-G-3′ with 2.78% (for the
5 mg dose) and 2.87% (for the 25 mg dose).
When results were expressed as micromole% (in order to
compare the different excreted compounds; Table 3), the total
per cent excretion of all components dropped to 12.4% (for the
5 mg dose) and 10.2% (for the 25 mg dose). The per cent ex-
cretion of HT-S-3′ dropped to 10.7% (for the 5 mg dose) and
8.33% (for the 25 mg dose) of the initial dose, but this metabo-
lite remained the most abundant one we recovered.
4. Discussion
One important – yet often overlooked issue – in the
nutraceutical field is that of absorption and/or bioavailability
of the active principle(s). This applies to omega 3 fatty acids,
vitamins, and (poly)phenols. We here report that HT (one of
the most popular and biologically active phenol) is absorbed
and excreted when given as an olive mill waste water extract
preparation. In particular, we recovered ~8 to 10% (as mole%)
of the administered HT in the urine and confirmed that most
of it undergoes sulphation at the 3′ position.To date, only one
study has been published with pure HT (Gonzalez-Santiago
et al., 2010), whereas many other ones report excretion of this
phenol when given as component of extra virgin olive oil to
rats or humans. Indeed, there is ample evidence of the ab-
sorption and excretion of HT via extra virgin olive oil use, even
though a comprehensive profile of its metabolites is being slowly
developed. In the first report, Visioli et al. (2000) described how
30–60% of the administered HT was recovered in the urine,
mostly as glucuronide conjugate. These data were subse-
quently confirmed by Vissers, Zock, Roodenburg, Leenen, and
Katan (2002). Afterwards, more complete investigations
(Miro-Casas et al., 2003) contributed to the near-complete elu-
cidation of HT’s metabolism in humans. More recently, HT
sulphate has been proposed as a suitable biomarker for moni-
toring compliance with olive oil intake as its values in plasma
or/and 24-h urine were significantly higher after extra virgin
olive oil administration compared to baseline pre-intervention
concentrations (Rubió et al., 2014). The data we present here
reinforce this notion: HT-S-3′ should be quantified in studies
of HT as nutraceutical, to monitor compliance.
One unresolved issue is whether the extensive first-pass me-
tabolism affects the manifold in vitro activities reported for HT
and (poly)phenols in general. Indeed, this is an often over-
looked aspect of (poly)phenol research and calls for more
metabolite-based biochemical and molecular studies (Giordano
et al., 2015), even though organ-specific deconjugation might,
theoretically, yield pure HT and contribute to its biological ac-
tivities (Giordano et al., 2015).
In conclusion, we prove that HT given as the foremost com-
ponent of a nutraceutical preparation is bioavailable and is
recovered in the urine chiefly as sulphate-3′, which can be
adopted as biomarker of extra virgin olive oil consumption.This
is important in light of future HT-based nutraceutical formu-
lations and epidemiological studies.
Table 2 – Twenty-four hour urine excretion of hydroxytyrosol and its main metabolites (as milligrams).
Dose
(mg)
HT
(mg)
HT
(%)
HT-G-4
(mg)
HT-G-4
(%)
HT-G-3-
(mg)
HT-G-3
(%)
HT-S-3
(mg)
HT-S-3
(%)
HT-S-4
(mg)
HT-S-4
(%)
0 0.00 0.00 0.03 0.00 0.02 0.00 0.14 0.00 0.00 0.00
5 0.00 0.00 0.11 2.23 0.14 2.78 1.18 23.1 0.01 0.26
25 0.00 0.02 0.46 1.83 0.72 2.87 4.15 16.6 0.07 0.28
0: Placebo; 5: 5 mg hydroxytyrosol; 25: 25 mg hydroxytyrosol.
HT: free hydroxytyrosol; HT-G-4: hydroxytyrosol-O-glucuronide 4; HT-G-3: hydroxytyrosol-O-glucuronide 3; HT-S-3: hydroxytyrosol-sulphate-
3; HT-S-4: hydroxytyrosol-sulphate-4.
Table 3 – Twenty-four hour urine excretion of hydroxytyrosol and its main metabolites (as micromoles).
Dose
(µM)
HT
(µM)
HT
(%)
HT-G-4
(µM)
HT-G-4
(%)
HT-G-3-
(µM)
HT-G-3
(%)
HT-S-3
(µM)
HT-S-3
(%)
HT-S-4
(µM)
HT-S-4
(%)
Total
(µM)
Total excreted%
0 0.00 0.00 0.02 0.00 −0.01 0.00 −0.26 0.00 0.00 0.00 −0.05 0.00
32.4 0.00 0.00 0.22 0.67 0.27 0.84 3.47 10.7 0.04 0.14 0.80 12.4
162 0.02 0.01 1.10 0.68 1.72 1.06 13.5 8.33 0.22 0.13 3.32 10.2
0: Placebo; 3.2 E-5 µM: 5 mg hydroxytyrosol; 16 E-5 µM: 25 mg hydroxytyrosol.
HT: free hydroxytyrosol; HT-G-4: hydroxytyrosol-O-glucuronide 4; HT-G-3: hydroxytyrosol-O-glucuronide 3; HT-S-3: Hydroxytyrosol-sulphate-
3; HT-S-4: Hydroxytyrosol-sulphate-4.
µM: micromole; Total
(µM): Total micromole as the sum of compounds found in urine samples; Total excreted
(µM): Total percentage as the sum of compounds recovered in urine.
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 SUPPLEMENTARY INFORMATION 
Supplementary materials and methods 
S.I.1 Inclusion and exclusion criteria 
Volunteers included in this trial were age between 20 and 40 years; adequate 
understanding of the study; willingness to complete the entire treatment. 
Exclusion criteria included body mass index <19 or >26; diagnosis of diabetes 
mellitus, hypertension, dyslipidemia or other cardiometabolic disorders; impaired 
cognitive function; diagnosed hepatic, renal, or cardiovascular disease; allergy to 
olives and their derivatives; pharmacological therapies; and habitual smoking. 
 
S.I.2. Dietary guidelines  
Food Variety Guideline 
Olives Green or black  
They 
should not 
be 
consumed 
along the 
whole 
intervention 
products made from or 
with olives 
Derived from olives, 
pates, 
jams 
vinaigrettes 
Pizza with olives 
Olive bread 
Olive oil   
products made from or 
with olive oil 
Mayonnaise with 
olive oil, biscuits, 
fried 
Cod-liver oil   
Hydroxytyrosol 
supplements 
  
Supplements of 
vitamins, minerals and 
antioxidants 
  
High content in 
polyphenols and 
antioxidants 
Red wine, wine, 
beer, coffee, tea, 
fruit, chocolate, 
fruits, nuts. 
They may 
only be 
consumed 
in 
moderate 
amounts 
 
 S.T.1. Quantitative results of the samples studied. Concentrations of free HT and its principal metabolites. 
Voluntary ID Group Initial HT 
ng/mL 
Final HT 
ng/mL 
Initial HT´-
G-4´ ng/mL 
Final  
HT-G-4´ 
ng/mL 
Initial HT-
G-3´ ng/mL 
Final HT-G-
3´  ng/mL 
Initial HT-
S-3´ ng/mL 
Final HT-S-
3´ ng/mL 
Initial HT-S-
4´ ng/mL* 
Final HT-S-
4´ ng/mL* 
24 h 
Urine 
mL 
Basal 
Urine 
mL 
856 A 0.0 12.0 0.0 482.5 25.3 712.0 28.6 1811.2 0.0 17.1 1250.0 42.5 
857 A NA 0.0 NA 124.3 NA 259.3 NA 2466.9 NA 40.4 1600 NA 
858 A 0.0 5.2 12.9 140.4 20.9 283.8 98.6 4385.9 0.0 94.5 1820.0 42.5 
859 A NA 6.8 NA 840.0 NA 764.6 NA 1670.2 NA 22.6 1100 NA 
860 A 0.0 0.0 0.0 394.9 14.7 557.9 0.0 2830.5 0.0 51.3 1450.0 47.5 
861 A 0.0 5.2 15.8 554.0 36.4 1113.8 42.7 3091.9 0.0 53.4 825.0 50.0 
862 A NA 10.0 NA 552.9 NA 901.8 NA 5449.9 NA 80.5 800 NA 
864 A NA 0.0 NA 218.6 NA 251.8 NA 2960.7 NA 54.3 1920 NA 
865 A 0.0 0.0 0.0 228.2 33.0 377.9 117.4 2185.5 0.0 36.1 1950 51.0 
866 A 0.0 0.0 0.0 320.0 17.8 506.7 431.9 4813.1 0.0 73.1 1200 42.5 
867 A 0.0 5.2 36.7 418.0 101.5 752.7 282.9 4827.7 0.0 36.8 800 45.0 
868 A NA 0.0 NA 251.0 NA 365.0 NA 1650.5 NA 28.9 1850 NA 
869 A NA 0.0 NA 182.4 NA 286.9 NA 2479.0 NA 48.7 1300 NA 
870 A 0.0 6.7 55.3 639.0 70.9 1049.9 695.2 3849.4 0.0 62.1 800 42.5 
871 A NA 0.0 NA 185.2 NA 302.9 NA 1497.8 NA 28.8 3000 NA 
872 A NA 5.9 NA 289.0 NA 483.4 NA 2320.5 NA 53.1 1600 NA 
 873 A 0.0 7.0 0.0 478.5 16.7 717.0 46.3 5214.9 0.0 75.4 750 42.5 
874 A 0.0 0.0 12.3 247.8 15.5 456.5 83.0 1878.0 0.0 54.6 1850 40.0 
875 A 0.0 6.9 0.0 475.6 10.7 689.8 72.4 5693.3 0.0 88.0 1000 55.0 
876 A 0.0 0.0 109.1 384.0 37.9 647.1 492.3 5133.6 0.0 45.1 1350 45.0 
877 A 0.0 5.8 0.0 480.1 0.0 871.0 67.4 2653.4 0.0 53.2 1150.0 47.5 
856 B 0.0 0.0 0.0 103.6 15.8 140.2 0.0 792.9 0.0 10.3 1150.0 52.5 
857 B 0.0 0.0 24.4 43.1 17.1 99.9 22.8 963.1 0.0 16.7 1600.0 45.0 
858 B NA 0.0 NA 82.3 NA 148.0 NA 482.9 NA 12.0 2000 NA 
859 B 0.0 0.0 23.9 208.4 18.5 123.8 150.4 730.4 0.0 10.2 1430.0 50.0 
860 B 0.0 0.0 30.1 185.5 21.8 209.3 226.6 1255.2 0.0 16.9 1100.0 45.0 
861 B NA 0.0 NA 90.3 NA 127.9 NA 1433.9 NA 25.4 950 NA 
862 B 0.0 0.0 0.0 97.2 14.9 211.4 75.2 1178.3 0.0 14.7 600.0 42.5 
864 B 0.0 0.0 10.7 59.0 30.9 54.7 213.0 882.0 0.0 11.5 1900.0 47.0 
865 B 0.0 0.0 35.4 100.3 29.6 102.2 544.2 953.4 0.0 13.7 1350.0 51.0 
866 B 0.0 0.0 15.0 30.1 28.2 49.9 175.4 530.8 0.0 0.0 1750.0 40.0 
867 B NA 0.0 NA 65.5 NA 74.3 NA 1781.0 NA 22.6 1250 NA 
868 B 0.0 0.0 29.5 62.0 31.4 38.1 461.5 451.3 0.0 0.0 2150.0 45 
869 B 0.0 0.0 18.6 20.8 13.8 27.1 179.0 259.7 0.0 0.0 2550.0 48 
870 B 0.0 0.0 19.0 133.1 32.5 155.9 222.5 522.0 0.0 0.0 1100.0 45.0 
871 B 0.0 0.0 0.0 45.3 13.6 62.2 25.3 711.7 0.0 13.2 2100.0 46.0 
872 B 0.0 0.0 11.4 29.9 0.0 44.7 79.4 283.8 0.0 0.0 2430.0 51 
873 B NA 0.0 NA 134.7 NA 119.0 NA 2325.4 NA 22.5 650 NA 
874 B NA 0.0 NA 62.3 NA 100.5 NA 191.8 NA 0.0 2600 NA 
 875 B NA 0.0 NA 72.7 NA 100.9 NA 1472.9 NA 26.0 1000 NA 
876 B NA 0.0 NA 84.1 NA 103.2 NA 1678.0 NA 9.3 1250 NA 
877 B 0.0 0.0 0.0 31.8 14.6 78.1 142.3 699.1 0.0 0.0 1300 42.5 
856 C NA 0.0 NA 98.2 NA 33.5 NA 320.8 NA 0.0 1250 NA 
857 C 0.0 0.0 35.6 0.0 102.4 18.6 1258.0 133.6 0.0 0.0 1450 42.5 
858 C 0.0 0.0 25.6 0.0 26.5 19.5 326.4 734.6 0.0 14.0 1330 47.5 
859 C 0.0 0.0 24.8 44.1 17.6 15.9 202.6 33.4 0.0 0.0 1300 50 
860 C NA 0.0 NA 52.8 NA 17.3 NA 25.6 NA 0.0 1850 NA 
861 C 0.0 0.0 0.0 0.0 20.0 12.5 46.3 0.0 0.0 0.0 1500.0 51.0 
862 C 0.0 0.0 27.9 0.0 28.8 19.8 109.1 170.6 0.0 0.0 850 45 
864 C 0.0 0.0 23.3 45.9 20.5 16.2 106.4 32.8 0.0 0.0 1600 47.5 
865 C NA 0.0 NA 17.3 NA 18.9 NA 49.7 NA 0.0 2150 NA 
866 C NA 0.0 NA 0.0 NA 14.9 NA 49.3 NA 0.0 1650 NA 
867 C 0.0 0.0 12.8 0.0 32.3 14.6 407.8 234.5 0.0 0.0 1100 48 
868 C 0.0 0.0 18.6 0.0 13.6 0.0 26.8 0.0 0.0 0.0 1600.0 47.5 
869 C 0.0 0.0 0.0 0.0 16.4 0.0 160.8 0.0 0.0 0.0 2350.0 52.5 
870 C NA 0.0 NA 14.9 NA 19.9 NA 202.6 NA 0.0 1050 NA 
871 C 0.0 0.0 0.0 0.0 17.7 15.1 275.7 91.2 0.0 0.0 2250 45 
872 C 0.0 0.0 11.8 31.1 11.1 0.0 113.0 14.1 0.0 0.0 1750.0 47.0 
873 C 0.0 0.0 29.2 0.0 20.2 0.0 195.3 0.0 0.0 0.0 1450.0 47.5 
874 C 0.0 0.0 0.0 0.0 18.0 0.0 112.4 63.0 0.0 0.0 1700.0 45 
875 C 0.0 0.0 34.4 0.0 14.1 0.0 246.4 33.5 0.0 0.0 1430.0 40 
876 C 0.0 0.0 0.0 57.9 12.9 19.5 112.3 171.1 0.0 0.0 1365.0 40 
 877 C NA 0.0 NA 26.4 NA  15.4 116.5 116.5 NA 0.0 440 NA 
A: 250 mg Hytolive (25 mg hydroxytyrosol); B: 50 mg Hytolive (5 mg hydroxytyrosol); C: Placebo. HT (free Hydroxytyrosol); HT-G-4´ 
(Hydroxytyrosol 4´-O-glucurodine); H-G-3´ (Hydroxytyrosol 3´-O-glucurodine);  HT-S-3 (Hydroxytyrosol 3´-O-sulphate); HT-S-4´ 
(Hydroxytyrosol 4´-O-sulphate). Initial: result obtained in basal urine samples; Final: Result obtained in 24 h urine samples.  ng/mL: 
nanogram/millilite
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Abstract
Dietary microRNAs (miRNAs) modulation could be important for health and wellbeing. Part of the healthful activities of polyphenols might be due to a
modulation of miRNAs' expression. Among the most biologically active polyphenols, hydroxytyrosol (HT) has never been studied for its actions on miRNAs. We
investigated whether HT could modulate the expression of miRNAs in vivo. We performed an unbiased intestinal miRNA screening in mice supplemented (for 8
weeks) with nutritionally relevant amounts of HT. HT modulated the expression of several miRNAs. Analysis of other tissues revealed consistent HT-induced
modulation of only few miRNAs. Also, HT administration increased triglycerides levels. Acute treatment with HT and in vitro experiments provided mechanistic
insights. The HT-induced expression of one miRNA was confirmed in healthy volunteers supplemented with HT in a randomized, double-blind and placebo-
controlled trial. HT consumption affects specific miRNAs' expression in rodents and humans. Our findings suggest that the modulation of miRNAs' action through
HT consumption might partially explain its healthful activities and might be pharmanutritionally exploited in current therapies targeting endogenous miRNAs.
However, the effects of HT on triglycerides warrant further investigations.
© 2016 Elsevier Inc. All rights reserved.
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1. Introduction
MicroRNAs (miRNAs) exert important regulatory actions on gene
expression not only under physiological circumstances but also in
disease [1]. Indeed, miRNAs often target multiple functionally related
genes and extensively interfere with biological processes, rendering
them good candidates for therapeutic and/or nutraceutical interven-
tions [2]. Two divergent approaches are currently being studied: (1)
miRNAs inhibition via pharmaceutical formulations and (2) the use of
miRNAs mimics in therapy.
To therapeutically constraint miRNAs, small-molecule inhibitors or
activators aimed at miRNAs' expression regulation are being actively
studied. Within this context, the potential role of plant-derived phenolic
molecules (e.g. polyphenols) inmiRNAsmodulation is being very actively
investigated [3–6]. As of now, however, there is no clear published
evidence of a deﬁnite direct effect of a polyphenol on a speciﬁc miRNA.
Therefore, phenolicmodulation ofmiRNAs becomes an attractive strategy
to target several biological processes and, in turn, ameliorateprognosis [7].
Olive phenolics exhibit cardioprotective activities such as their ability
to protect low-density lipoproteins fromoxidation (European FoodSafety
Authority scientiﬁc opinion). In particular, hydroxytyrosol (HT), the
foremost phenolic component of extra virgin olive oil, has been
hypothesized to possess antiinﬂammatory, antiaggregant and anticancer
properties, among others [8]. Nevertheless, the exact molecular mecha-
nisms underlying many of these actions are yet to be fully clariﬁed [9].
Regarding miRNAs, previous in vitro studies suggest that Olea europaea
leaf extracts alter some cancer-related miRNAs in glioblastoma cells [10].
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In addition, the Mediterranean diet (of which extra virgin olive oil is an
important component) has been reported to modify inﬂammation-
related miRNAs [11].
In this study, we aimed to explore the effects of nutritionally
relevant amounts of HT on miRNAs' modulation in vivo.
2. Materials and methods
2.1. Materials
HTwas kindly donated by Seprox Biotech (Madrid, Spain); miScript II RT for RT-qPCR
and Qiazol were purchased fromQiagen (Izasa, Barcelona, Spain). The primers used in the
validation of our experiments were purchased from ISOGEN (Life Science, Belgium).
2.2. Animals and diets
This investigation conforms to the Guide for the Care and Use of Laboratory
Animals, published by the US National Research Council (Eight Edition, 2010) and was
approved by the Animal Experimentation Committee of the Universidad Complutense
de Madrid (CEA-UCM 93/2012), Universidad de Oviedo and Hospital Universitario
Ramón y Cajal (CEBA-HRC 23/2011). For the long-term feeding studies, young C57BL/6
mice from two different cohorts (2 months old, n=14: ﬁrst cohort and n=20: second
cohort) were acclimatized and kept on a 12:12 light/dark cycle, with the period of
darkness between 7:00 p.m. and 7:00 a.m., for at least 1 week before the beginning of
the experimentation. During this period, mice were fed a standard chow diet; food and
water were given ad libitum. Thereafter, mice were maintained for 8 weeks under two
different diet regimens (Research Diets, Inc., New Brunswick, NJ): (1) puriﬁed control
diet (n=17) or (2) puriﬁed control diet added with 0.03 g% HT (n=17). This dose
closely approximates human intake [8] and is a very low one once body surface area is
taken into account [12]. Each diet provided 24.0%, 15.0% and 61.0% kcal from protein, fat
and carbohydrates, respectively [13]. To reduce diurnal variations, animals were
sacriﬁced between 10:00 and 11:00 a.m. Mice were anesthetized with ketamine (0.4
mg/ml) and dissected through a midline incision in the abdomen. Blood samples were
collected through cardiac puncture. Phosphate-buffered saline (PBS; pH 7.4) was
perfused through the portal vein for 1 min to remove blood. All tissues were extracted
quickly, washed in PBS, frozen with liquid nitrogen and stored at−80°C.
For the acute ingestion studies,weused36youngmale C57BL/6mice of 10weeks of age.
Animalsweremaintained under the same conditions of acclimatization described above and
with a standarddiet until the timeof the experiment. Animalswere separated into four study
groups (n=9 per group). The day of experiment, after 6 h fasting, mice were provided, by
gavage, with 15mg of HT dissolved in water and then sacriﬁced at different time points: 0 h
(control), 1 h, 2 h and 4 h, using the same methodology as for long-term feeding. Blood
sampleswere collected through cardiac puncture, centrifuged at 1500g for 15min for plasma
collection, snap-frozen and stored at−80°C. In addition, after perfusion, liver and intestines
samples were extracted, washed with PBS, snap-frozen and kept at−80°C.
2.3. Lipid analysis
Total plasma cholesterol, triglyceride and phospholipid concentrations were
analyzed with a microtiter assay using commercially available kits (Bradford
Diagnostics, Kemia Cientíﬁca S.A., Spain). For plasma lipoprotein proﬁles, 200 μl of
pooled plasmas from each dietary group was subjected to fast protein liquid
chromatography (FPLC) gel ﬁltration using a Superose 6 HR 10/30 column (Pharmacia).
Samples were eluted with 150 mM NaCl, 10 mM Tris–HCl, 2 mM Na2-EDTA and 0.02%
NaN3, pH 7.4, at a ﬂow rate of 0.3 ml/min to collect 0.4-ml fractions. In individual
fractions, cholesterol and triglyceride concentrations were determined using commer-
cially available kits. For the analysis of lipids in tissues, the former were extracted with
chloroform-methanol [14] and analyzed enzymatically using commercial kits from
Spinreact (Sant Esteve de Bas, Spain) after being solubilized in water by the addition of
Triton X-100 as described [15].
2.4. RNA extraction and microarray sample preparation
Total RNA from all tissues was isolated using Qiazol Lysis Reagent and miRNeasy
Mini kit columns (Qiagen, Madrid, Spain). RNA was quantiﬁed using a NanoDrop-1000
Spectrophotometer (Thermo Fisher Scientiﬁc Inc., Spain) and purity was assessed by
measuring the 260/280 nm and 260/230 nm ratios. RNA integrity was assessed using
Agilent's 2100 Bioanalyzer. Samples with RIN N8 were selected for analyses.
2.5. miRNA screening
For the unbiased whole genome miRNA screening, cDNA was synthesized from
total RNA (40 ng) using Universal cDNA synthesis kit II (Exiqon). miRNA quantiﬁcation
was performed by real-time PCR (RT-qPCR) using the ExiLENT SYBR green master mix
kit (Exiqon) on a 7900HT fast real-time PCR system (Applied Byosystems) using a 384-
well plate format. Five samples per conditionwere analyzed using themousemiRNome
panels (752 mice mature miRNAs) Version 3 (Exiqon). miRNA relative expression
analysis was performed using the GenEx software (MultiD Analyses AB, Sweden).
2.6. Microarray analysis
RNA ampliﬁcation and labeling was carried out by using the Low RNA Input Linear
Ampliﬁcation Kit, PLUS, Two-Color (Agilent Technologies, Palo Alto, CA). Brieﬂy, for
each sample, 2 μg of total RNA input was ampliﬁed in two rounds of ampliﬁcation by
following manufacturer's instructions. The ﬁrst strand cDNA syntheses and ampliﬁca-
tion reactions were carried out by using random and T7 primers, respectively. During
the 2-h in vitro transcription, Cy3- or Cy5-labeled CTP was incorporated in each
ampliﬁed RNA (cRNA) from reference pooled and tested samples, respectively. Reaction
products were then puriﬁed using RNAeasy mini spin columns (Qiagen, Dusseldorf,
Germany). Hybridization and slide and image processing procedures were all carried
out according to the manufacturer's instructions (Two-Color Microarray-Based Gene
Expression Analysis protocol). cRNA samples were fragmented at 60°C for 30 min and
hybridized at 65°C for 17 h. Slideswere scanned at a 10-μmresolutionwith AgilentG2565BA
Microarray Scanner (Agilent Technologies, Palo Alto, CA). Signal quantiﬁcation was carried
out with Feature Extraction 9.1 software (Agilent Technologies, Palo Alto, CA) using default
analysis parameters for Agilent's 44Kwhole genomemouse gene expression arrays (Feature
Extraction protocol 44K). The reproducibility of the microarray data was assessed by
performingaPearson correlation coefﬁcient analysis of the twobiological replicates using the
statistical computing program R (version 2.10.1; http://www.r-project.org/) between the
absolute signal intensity of the background-corrected Cy5 channel (treated samples) and the
absolute signal intensity of the background-corrected Cy3 channel (pool of control samples)
for all theprobespresenton themicroarray. Thequality andhomogeneityof thebackground-
correctedandVSN-normalizedmicroarraydata for theCy5andCy3channelswasassessedby
the Bioconductor package arrayQualityMetrics version 2.4.3
Data were analyzed by using the GeneSpring Software (Agilent), following the
manufacturer's instructions. Signiﬁcantly modulated genes were deﬁned as those with
an absolute fold change higher than 1.5 in both directions and with an adjusted P value
lower than .05. Differentially expressed genes were classiﬁed according to their
functional role(s) in cellular or metabolic biological processes using the online
GeneCodis analysis software for functional enrichment analysis [16].
Volcano plots represent the relationship between fold change and statistical
signiﬁcance of the differentially expressed genes, using an absolute fold change cutoff of
1.5. log2 fold change and − log10 adjusted P value are shown on the x-axis and y-axis,
respectively. Each probe is represented by a dot. Colored dots represent statistically
signiﬁcant probes (adjusted P value b .05)with a log2 fold change either higher than 1 in
both directions. A total of 342 probes were found to be signiﬁcantly up-regulated, and
332 probes were found to be signiﬁcantly down-regulated. These 674 differentially
modulated genes were used for genetic interaction (GI) analysis (see below).
2.7. GI analysis
For GI analysis, a subset of miRNAs was selected from those that were signiﬁcantly
changed by HT supplementation. Only those miRNAs conserved within humans and
showing a higher differentially expression pattern were included. A total of 21 miRNAs
were selected fromwhich threewere down-regulated and 18were up-regulated. For GI
analysis, miRNA's targets were predicted using the miRanda algorithm [17]. When
available, miRNAs' predicted targets were directly retrieved from the database (http://
www.microrna.org/). For the selected miRNAs that were unavailable in the database
(e.g. mmu-miR-1247-5p) target predictions were generated locally by running the
miRanda algorithm code. Only targets showing a statistically signiﬁcant differential
Fig. 1. HT supplementation modulates miRNAs expression. Volcano plot of hydro-
xytyrosol-modulated miRNAs in mouse small intestinal. miRNA expression was
analyzed by RT-qPCR (n=5 mice per group). Labeled miRNAs are selected miRNAs
for further studies.
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Fig. 2. Effects of HT supplementation on lipid metabolism. Plasma concentrations of cholesterol (A), triglycerides (B) and phospholipids (C) of mice receiving either chow diet (Ctrl) or
HT supplementation during 8 weeks. (D) Plasma lipoprotein proﬁle (FPLC) from mice following the different experimental conditions. Representative pooled plasma samples were
fractionated and cholesterol and triglycerides were analyzed. Intestinal concentrations of triglycerides (E), cholesterol (F) and phospholipids (G). Liver concentrations of triglycerides
(H), cholesterol (I) and phospholipids (J). n=9 in control and n=10 in HT-treated mice. *Pb .05 vs. control without HT.
Fig. 3. miRNA–gene interactions contribute to intestinal HT-modulated genes. (A) Volcano plot of HT-modulated genes in mouse small intestine. Mice received either chow or HT-
supplemented diet (8 weeks) and transcriptomic analysis evaluated. Signiﬁcant modulated genes (Pb .05) are depicted in green. (B) Functional enrichment analysis of biological
processes. (C) Validation of selectedmodulated genes by RT-qPCR. *, signiﬁcantly different from controls at Pb .05. (D)GI analysis betweenmodulatedmiRNAs and their predicted target
genes frommodulated genes. Target dot sizes are directly correlatedwith the number of interactionswith themiRNA's set. (E) Validation of selected GI genes by RT-qPCR. *, signiﬁcantly
different from controls at Pb .05.
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gene expression in microarrays were considered as valid interactions. Target dot sizes
are directly correlated with the number of interactions with the miRNA's set.
2.8. RT-qPCR validation
RT-qPCRs of selected genes to validate microarray results from intestine samples were
performed in 384-well plates and gene expression was determined using the 7900HT Real-
Time PCR System (Life Technologies, Spain). Reactions were performedwith 5 μl of miScript
SYBRGreen qPCRMaster Mix (Qiagen, Madrid, Spain) following these cycling conditions: 15
min at 95°C for one cycle, then 40 cycles at 94°C for 15 s and 58°C for 30 s. The dissociation
stage was analyzed at 95°C for 15 s, followed by one cycle at 60°C for 15 s and 95°C for 15 s.
Gene expression analysiswas carried out for 50 genes. 18S andRPLP0were used as reference
genes for normalization. Reactions were run in triplicate and relative expression of these
selected genes was calculated by the comparative Ct method and presented as 2−ΔΔCt.
2.9. Validation of miRNA expression
RT-qPCRs of selected miRNAs were performed to validate qPCR array results of
intestinal samples and other tissues, by miScript II RT Kit (Qiagen), following the
manufacturer's protocol. Reactions were performed in 384-well plates, using SYBR
green Supermix (Qiagen), and gene expression was determined using the 7900HT Fast
Real-time PCR System (Applied Biosystems). Primers speciﬁc for human or mouse
miRNAs were used and values were normalized using RNU1A1 and RNU6 as
housekeeping small RNAs.
2.10. In vitro studies
For in vitro studies, human colonic adenocarcinoma cell line (Caco-2), human
primary epithelial intestinal cells (InEpCells) and mouse primary organoids were used.
Caco-2 cellswere obtained from the American Type Culture Collection (Manassas, USA).
Cells were maintained at 37°C and 5% CO2 in DMEM medium (Lonza, Switzerland)
containing 10% fetal bovine serum (HyClone, USA) and antibiotic. For differentiation,
Caco-2 cells were split and seeded at a density of 5×105 cells/well on 24-mm-diameter
polycarbonate Transwell ﬁlter inserts of 0.4 μm pore size (Costar, Madrid, Spain).
Monolayers were cultured for 21 days. Differentiated Caco-2 cells were treated with HT
(10 μM) or vehicle for 24 h prior to miRNAs analysis by RT-qPCR.
InEpCellswere purchased fromLonza (Switzerland) and cultured in a coating of rat-
tail type 1 collagen (BD Biosciences). Cells were maintained at 33°C and 5% CO2 in
SmGM-2 smooth muscle growth medium 2 (Lonza) containing SmGM-2 Bullekit
(Lonza) for 7 days before experiment. InEpCellswere treatedwithHT (10 μM)or vehicle
for 24 h prior to miRNAs analysis by RT-qPCR.
For mouse primary intestinal organoids or “miniguts”, mice were sacriﬁced and
their small intestines were harvested. The intestine was ﬂushed with ice-cold PBS and
intestinal crypts isolated using IntestiCult (Stem Cell Technologies, Grenoble, France)
protocol. Brieﬂy, the small intestine was disaggregated by pipetting up and down with
15 ml of ice-cold PBS for 20 times. Tissues were rocked with 25 ml of cell dissociation
reagent (Stem Cell Technologies) for 15 min at room temperature and resuspended in
10ml PBS containing 0.1% BSA. Tissue pieces were ﬁltered through a 70-μmcell strainer
(BD Biosciences) and a crypt suspension was obtained. After centrifugation, crypt
fractionswere resuspended in 10ml of coldDMEM/F12 (Lonza). Cryptswere suspended
in a mixture (50:50) of Matrigel (growth factor reduced phenol-red free Matrigel,
Corning) and complete IntestiCult Organoid Growth Medium (Stem Cell Technologies)
and gently placed in the center of each well of a prewarmed 24-well plate until the
Matrigel solidiﬁed. After solidiﬁcation, IntestiCult Organoid GrowthMediumwas added
and crypts were cultured at 37°C until organoids were fully developed. Seven days after
plating, organoids were treated with HT (10 μM) or vehicle for 24 h prior to miRNAs
analysis by RT-qPCR.
2.11. Human studies
Samples analyzed were obtained from a previous intervention study [9]. This work
is registered at ClinicalTrials.gov (identiﬁer: NCT02273622). In brief, 21 volunteers
were recruited for a randomized, cross-over, placebo-controlled and double-blind
intervention study. After 1-week washout, i.e. olive-free diet, subjects were randomly
assigned to the placebo (maltodextrin) or 25 mg/d HT (which was included in an
encapsulated extract of olive mill wastewater called Hytolive) group. Subjects took the
respective capsules for 1 week, then volunteers crossed over to consume the other type
of capsules for 1 week. Blood samples were collected in heparinized tubes (BD
Vacutainer, Franklin Lakes, NJ) at each visit, processed within 2 h after extraction and
peripheral blood mononuclear cells (PBMCs) were isolated. RNAs were extracted from
PBMCs and our selected miRNAs candidates were analyzed by RT-qPCR.
2.12. Statistical analysis
Normality and equality of variances of variables were tested before statistical tests
were conducted. Parametric tests were applied only when both requirements were
met; otherwise, nonparametric testswere employed (variables in Figs. 2, 3C andE, 4 and
6were compared using unpaired t tests orMann–Whitney tests; variables in Fig. 5were
compared by one-way ANOVA using Dunnett's test for multiple comparisons; variables
in Fig. 7 were compared by two-way ANOVA followed by Sidak's test for multiple
comparisons). Data are reported as mean±SEM. The level of signiﬁcance was set at
Pb .05 for all analyses. Statistical analysis was performed using IBM SPSS (version
19.0) for Windows.
3. Results
3.1. The expression of intestinal miRNAs is modulated by HT
To gain insight into novel targets of dietary polyphenols — as small-
moleculemodulators ofmiRNAs [18]—weperformed anunbiasedwhole
genome screening of miRNAs in the small intestines of mice fed with HT
for a prolonged period [13]. Several intestinal miRNAs were found to be
induced or repressed in response to HT feeding (Fig. 1), supporting an
miRNA modulation action for this low-molecular-weight molecule.
3.2. HT supplementation has varied effects on lipid concentrations
Previous results from other laboratories [19] suggested that
phenolic-enriched products could have adverse effects on lipid
metabolism. In order to corroborate such data and our preliminary
ﬁndings [13], we performed a second experiment with a new cohort
study. For this, animals (n=10 per group) were fed with either chow
diet or HT-enriched diet during 8 weeks. Plasma total cholesterol (Fig.
2A) concentration was not modiﬁed. However, plasma total triacyl-
glycerol (Fig. 2B) concentrations were slightly, but signiﬁcantly,
increased in response to HT supplementation, whereas plasma
phospholipids (Fig. 2C) were not modiﬁed. The distribution of
cholesterol and triacylglycerol among the different plasma lipopro-
teins after supplementation or control corroborated these ﬁndings
(Fig. 2D). To determine whether these changes in the plasma lipid
proﬁle increased the accumulation of lipids in the intestine, we also
evaluated triacylglycerol (Fig. 2E) and cholesterol levels in this tissue
(Fig. 2F). While tissue triacylglycerol levels increased, cholesterol
remained unchanged. Phospholipids levels also remained constant in
the intestine (Fig. 2G). To conﬁrm these ﬁndings in another tissue, we
evaluated lipid concentrations in liver samples. Similar to the
intestine, triacylglycerol (Fig. 2H), but not cholesterol (Fig. 2I) or
phospholipids (Fig. 2J), concentrations were altered by HT. Overall,
these ﬁndings suggest that — at least in rodents — long-term HT
supplementationmight disturb lipidmetabolism, but its physiological
signiﬁcance remains to be clariﬁed.
3.3. HT-modulated intestinal genes are influenced by miRNA–gene
interaction
To search for novel intestinal targets of HT, we performed a whole
transcriptome expression proﬁle (mRNA microarrays) of small
intestines. A total of 674 genes were found to be differentially
modulated by HT supplementation (Fig. 3A), of which 332 genes were
down-regulated and 342 were up-regulated. Compared to previous
adipose tissue analysis, genes including Acox2, Pibf1, Mras Asb11,
Sh3gl2, Slc35f3, Fsd2, Acad10, Cyp4b1, Retsat, Pmm1, Mgst1,
Gramd1a, Cblb, Apom and Vnn3 were found to be modulated, which
conﬁrms previous transcriptomic studies [13]. Functional analysis of
intestinal modulated genes indicated that major biological processes
modulated by HT include oxidative stress, lipid metabolism and other
metabolic processes (Fig. 3B). Some of the HT-modulated miRNAs
target triglyceride metabolic-related genes (Supplementary Table 1)
which might be associated with increased triacylglycerol levels
observed. We next chose some key genes involved in these biological
processes to validate our transcriptomic data by RT-qPCR. We found
that genes including Car2, Crym, Cxcl13, Dusp6, Hsph1 and Il33 were
up-regulated, while Cd36, Cyp4a10, Gsta3, Hsd3b2, Paqr7, Pdk4 and
Slc35e3 were down-regulated in response to HT feeding (Fig. 3C).
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One of themost fascinating features of miRNA function is that they
can target different genes at the same time, generally producing either
target mRNA degradation or translational inhibition [20]. We thus
performed an in silico interaction analysis (detailed above inMaterials
and methods) of genes likely to be modulated by combined miRNAs'
expression. As one gene can be likely modulated by several miRNAs,
we analyzed all putative GIs (number of HT-modulated miRNAs that
can potentially target the 3´-UTR of the protein coding gene showed)
(Fig. 3D). Several down-regulated geneswere predicted to be targeted
bymore than one of these selectedmiRNAs.Me3 (13GI),Mras (12 GI),
Ndrg1 (12 GI), Ccbe1 (11 GI), Fam188b (11 GI), Hsd17b11 (11 GI),
Lpin2 (11 GI), Pibf1 (11 GI), Tia1 (11 GI), C1qtnf7 (10 GI), Fkbp5 (10
GI), Lrrtm4 (10 GI) and Spsb4 (10 GI) are potentially targeted bymore
than 9 miRNAs each. Several other genes have ≤9 GIs. Validation by
RT-qPCR of selected genes (Fig. 3E) conﬁrms these ﬁndings. While we
do not discard other mechanisms of genetic regulation, our ﬁndings
suggest that HT-modulated miRNAs contribute to the regulation of
genes involved in oxidative stress, lipid metabolism and other
metabolic processes.
3.4. miRNAs modulation by HT in different tissues
A solidmiRNA target of a speciﬁcmolecule is likely to bemodulated
in different tissues after supplementation, although some exceptions
may exist. In order to determine the effects of HT on other tissues, we
evaluated, by RT-qPCR, the expression of selected miRNAs candidates
in different tissues from the ﬁrst cohort. To this end, spleen, liver,
heart, white adipose tissue, brown adipose tissue and brain were
evaluated for our 21 selected miRNAs candidates (Fig. 4A). Very few
miRNAswere found to bemodulated in these tissues in response toHT
supplementation, including miR-483-3p and miR-1982-5p in the
liver; miR-135a-1-3p, miR-483-3p and miR-1982-5p in the heart;
miR-1982-5p in white adipose tissue; miR-483-3p and miR-1982-5p
in spleen; miR-135a-1-3p, miR-346-5p and miR-491-3p in brown
adipose tissue; and miR-196b-3p, miR-483-3p, miR-1898 and miR-
1982-5p in brain. To conﬁrm some of these ﬁndings, we evaluated
these same miRNA candidates in liver, spleen and brain tissues in our
second cohort of samples (Fig. 4B). ConsistentmodulationofmiR-483-
3p in liver and miR-1982-5p in spleen was seen in both cohorts after
HT supplementation.
Except for miR-1982, for which a human homolog does not exist,
the other 6 miRNAs candidates of modulation by HT (miR-135a-1-3p,
miR-193a-5p, miR-196b-3p,miR-483-3p, miR-1247-5p andmiR-346-
5p) were selected for further characterization.
3.5. Acute ingestion of HT also modulates miRNAs' expression
To determine whether the observed effect of long-term (8 weeks)
HT supplementation is also observed when it is administered acutely,
we performed an acute time-course response to a single ingestion of
HT. Mice (n=9per group) were intragastrically administeredwith 15
mg of HT dissolved in water and were sacriﬁced at baseline (0 h), 1, 2
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and 4 h after oral gavage. The six selected miRNAs were evaluated by
RT-qPCR (Fig. 5A). Acute administration of HT reduced the expression
of miR-196b-3p and miR-483-3p in the small intestine. To verify
whether this acute administration is sufﬁcient to modulate the
expression of miRNAs in other tissues, we also evaluated the selected
candidates in liver samples by RT-qPCR (Fig. 5B). In contrast to the
intestine, miR-483-3p was induced in the liver. Interestingly, miR-
1247-5p was also consistently induced in all time points evaluated.
Taken together, these data suggest that HT could also acutely
modulate the expression of certain miRNAs, and miR-483-3p, in
particular, is further supported as a consistent target of modulation by
this molecule.
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3.6. In vitro validation of HT-modulated miRNAs
To conﬁrm the modulation of these miRNAs by HT, we also
performed some in vitro experiments. We exposed differentiated
Caco-2 cells to HT (10 μM) and evaluated the expression of the six
miRNAs candidates by RT-qPCR. The 24-h HT treatment repressed the
expression of miR-196b-5p in differentiated Caco-2 cells (Fig. 6A). To
further conﬁrm these ﬁndings, human primary epithelial intestinal
cells were exposed to HT (10 μM) or vehicle for 24 h andmiRNAswere
evaluated by RT-qPCR. miR-1247-5p and miR-483-3p were signiﬁ-
cantly induced by HT treatment (Fig. 6B). Finally, mouse small
intestinal organoids or “miniguts” [21,22] were used to test the
effect of HT on miRNAs' expression. In this case, miR-193a-5p and
miR-1247-5p were consistently induced in miniguts by HT treatment
(Fig. 6C).
3.7. miR-193a-5p is modulated by HT supplementation in healthy
subjects
To evaluate whether the selected HT-modulatedmiRNAs observed
in the animal supplementation studies were also modulated in
humans, we investigated the effects of HT supplementation (25 mg/
day) in a double-blind, randomized, placebo-controlled trial
(NCT02273622) [9]. One-week supplementation with HT resulted in
a within-group increase in the expression of miR-193a-5p in PBMCs
(Fig. 7), suggesting that HT supplementation can also modulate the
expression of miRNAs in humans.
4. Discussion
This study provides the ﬁrst in vivo evidence that HT intake
modulates speciﬁc miRNAs in the small intestine of mice. Some of
these miRNAs are also modulated in other tissues, strengthening the
causality of our ﬁndings. Notably, some of these data were conﬁrmed
in a human setting.
Our transcriptomic analysis conﬁrms previous results from our
group [13] and those of other groups [23–25] pointing towards
physiological effects of HT on oxidation–reduction processes. We now
provide evidence that, in the small intestine, long-term HT supple-
mentation also inﬂuences these pathways. In addition, HT is able to
modify several lipid metabolism-associated pathways. By contrast, in
Caco-2 cells, HT was found to modulate pathways related to apoptosis
[26]. However, in ﬁbroblasts, it was also observed that the age-related
expression of genes associated with oxidative stress was corrected by
the provision of HT [27]. When we merge the results of these studies,
Dusp6 [27] and Cyp1a1 [26] stand out as commonly regulated genes,
conﬁrming that HT regulates the antioxidant network at a transcrip-
tomic level.
miRNAs are “buffers” of gene expression and probably contribute
to the stronger evolutionary constraint of protein expression levels
compared to mRNA levels [28]. Our GI analysis (genes likely
modulated by miRNAs) suggested that certain genes might be highly
inﬂuenced bymiRNAs' expression, as some of them, i.e. Spsb4, Lrrtm4,
Fkbp5, C1qtnf7, Tia1, Pibf1, Lpin2, Hsd17b11, Fam188b, Ccbe1, Ndrg1,
Mras and Me3, might be tagged by more than 9 miRNAs. Biological
process analysis of genes having 5 or more GIs (55 in total) also
suggested that redox (GO:0055114) and transport (GO:0006810)
processes are major biological pathways inﬂuenced by HT. Although
the high redundancy among miRNA targets underscores the role of a
speciﬁc miRNA in gene regulation, we show here that an miRNA-
mediated network inﬂuences intestinal gene expression in response
to HT supplementation. We, thus, suggest that the antioxidant effects
observed after HT supplementation might be — at least in part —
modulated by miRNA GI.
There is still limited information about the effects of HT on plasma
lipids. Previous studies in mice reported contradictory results,
showing both increased [19] and decreased [13] levels of plasma
cholesterol. We now found that cholesterol concentrations were not
modiﬁed byHT supplementation,which is also reﬂected by the plasma
lipoprotein proﬁle. Other studies also found no changes in plasma
cholesterol after HT supplementation [24]. We also evaluated tissue
cholesterol levels in both the intestine and liver and found no
signiﬁcant changes. However, HT supplementation tended to increase
triglycerides' concentration. This was also visually clear when
intestine and liver tissues were removed. No changes in phospholipid
levels in plasma or tissues were observed. Cd36-deﬁcient mice exhibit
increased plasma free fatty acids and triglyceride levels [29].We found
that Cd36 was down-regulated in mice supplemented with HT for 8
weeks, which could be related to the increase in triacylglycerol levels
seen. Moreover, several other intestinal-modulated miRNAs target
other genes related to triacylglycerol metabolism (Supplementary
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Fig. 6. HT modulates miRNAs expression in cell systems. (A) Differentiated Caco-2 cells.
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Table 1). However, we do not discard any other miRNA-related or
unrelated mechanism. It is important to note that lipoprotein
metabolism in rodents does not perfectly match the one of humans
[30] and that more appropriate humanized models for these type of
studies exist [31].
We found that a selection of intestinal HT-modulated miRNAs are
putative targets of modulation by HT when it is long-term supple-
mented (8 weeks). miR-196b-3p, miR-346-5p, miR-483-3p, miR-
1247-5p, miR-135-a-5p, miR-193a-5p and miR-1982-5p were also
found to be modulated in one or more of other tissues analyzed.
Noteworthy consistency was seen in both cohorts in the case of miR-
483-3p in liver and miR-1892-5p in spleen.
Analysis of host genes or sequences (data not shown) of these
miRNAs suggested that their expression might be modulated
independently and deserves further investigation. By analyzing
these miRNAs, i.e. those only conserved in humans, we also found
that an acute ingestion of HT inﬂuenced the expression of some of
them either in the intestine or in the liver, namely miR-483-3p,
reinforcing the notion of a direct effect. In vitro experiments with
Caco-2 cells, human primary intestinal epithelial cells and mouse
small intestine organoids conﬁrmed some of these ﬁndings. Although
the six selected miRNAs did not show the same response in every
system tested, miR-483-3p and also miR-1247 were found to some
extent to be consistently affected by HT exposure. One reasonable
explanation for the absence of absolute consistency is that, contrary to
what occurs in tissues, in the in vitro systems tested, many types of
cells are lacking. Even in the case of mouse intestinal organoids, which
contain almost all types of cells within the intestine, including
absorptive enterocytes, multiple secretory cells (Paneth cells, goblet
cells, enteroendocrine cells and tuft cells) and the M cells of Peyer's
patches [21,32], they still lack smoothmuscle cells, vasculature cells or
other less abundant cell types.
In summary, some interesting notions could be identiﬁed from the
series of in vivo and in vitro studies carried out. Although potential
modulation of selected miRNAs by HT was not fully consistent in all
models studied,miR-483-3p stoodout as a robust candidate.miR-483-
3p has been associated with hypertension [33], apoptosis [34] and
proliferation [35]. miR-483-3p has been also associated with the
capacity of adipocytes to store lipids and dysregulation of its
expression could directly inhibit adipose tissue expandability and
lipid storage, which in turn affect other tissues by stimulating ectopic
triglyceride storage and lipotoxicity [36]. Regarding the othermiRNAs
and their function, miR-196b has been associated with inﬂammatory
bowel disease [37], insulin [38] and cancer [39]; miR-346 has been
implicated in rheumatoid arthritis [40], osteogenic differentiation [41]
and cancer [42]; miR-1247 was implicated in cancer [43,44]; miR-
135a was implicated in proliferation [45], inﬂammation [46] and
calciﬁcation [47]; and miR-193a-5p was associated with cancer
[48,49]. Although their effects in the intestine need to be evaluated,
it is clear that HT could speciﬁcally modulate their expression and
exert biological effects through this mechanism.
Very few studies evaluated the effect of dietary polyphenols on
miRNAs modulation in humans. Resveratrol, ellagic acid or green tea
catechins [3,4,50] have been previously shown to modulate miRNA
expression in certain tissues.Wehereprovide additional evidence that
HT, the foremost polyphenol of extra virgin olive oil and a unique
component of the Mediterranean diet, also modulates the expression
of miRNAs. Among the six selected miRNAs from mice studies, miR-
193a-5p was found to be induced by HT consumption in humans. In
PBMCs, it was showed very recently that up-regulation of miR-193a-
5p could have antiinﬂammatory effects by decreasing the expression
of IL-12 [51].
Pharmacologically, miRNAs can be modulated by miRNA mimics,
inhibitors (antisense oligonucleotides), sponges, miRNA masking or
small-molecule modulators of miRNA function or expression [2]. In
fact, antisense oligonucleotides [52], RG-012 (NCT02136862) or
miRNA mimic (MRX34, NCT01829971) have already entered clinical
trials. The search for small molecules — including those that can be
found in foods — capable of modulating miRNA function and the
elucidation of their mechanisms of action could represent a novel
approach aimed at modulating the expression of certain miRNAs or
developing drugs against speciﬁc miRNAs.
A limitation of this study is that we focused our validation
experiments — both in mice tissues and human PBMCs — only within
a selection of miRNAs (i.e. six miRNAs) that are conserved in humans.
There might be other mouse or humanmiRNAs modulated by HT that
were not evaluated in this study.
In conclusion, our data provide novel evidence to the hypothesis that
dietary polyphenols can modulate miRNAs' expression. Although the
precisemolecularmechanismunderlying the changes inmiRNAexpression
induced by HT remains to be elucidated, our data suggest that the use of
small, low-molecular-weight molecules capable of modulating miRNAs´
functions might be a viable alternative or an adjuvant to the current
pharmacologic arsenal targeting endogenous miRNAs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jnutbio.2016.05.009.
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Supplemental table 1. Hydroxytyrosol-modulated genes related to triglyceride metabolism and target of intestinal miRNAs. 
 
 
Gene 
symbol 
GO ID GO Biological process Fold 
change 
adj pvalue 
(array) 
Target of mmu-miR-: Profile 
Cd36 GO:0034197 triglyceride transport -2,7075 0,00475066 -1931, -871-5p miRNA up, target down 
Pck1 GO:0046327 glycerol biosynthetic 
process from pyruvate 
-2,0325 0,009130449 -431-3p, -1957, -687, -
23a-5p 
miRNA up, target down 
Lpin2 GO:0019432 triglyceride biosynthetic 
process 
-1,46 0,024896731 -1898, -1247-5p, -743b-
5p, -1954, -1957, -483-
5p, -675-3p, -871-5p, -
1894-3p, -1907, 1982-
5p 
miRNA up, target down 
Cyp2e1 GO:0006641 triglyceride metabolic 
process 
-1,3125 0,0308357 -483-5p miRNA up, target down 
Rgn GO:0010867 positive regulation of 
triglyceride biosynthetic 
process 
-1,17 0,037066887 -346-5p, -675-3p, -1954 miRNA up, target down 
Acsl1 GO:0006641 triglyceride metabolic 
process 
-0,845 0,064781237 -431-3p, -1982-5p, -
1907, -23a-5p, -687, -
346-5p, -675-3p, -483-
5p, -1954 
miRNA up, target down 
Hmgcs2 GO:0034014 response to triglyceride -0,8775 0,066440076 -23a-5p, -483-5p, -
743b-5p, -1931, -1894-
3p, -1907, -1954 
miRNA up, target down 
Cat GO:0006641 triglyceride metabolic 
process 
-0,8425 0,066481224 -346-5p, -675-3p, R-
1931, -1982-5p 
miRNA up, target down 
Angptl4 GO:0070328 triglyceride homeostasis -0,77 0,068092023 -491-3p, -1957, -23a-
5p, -871-5p 
miRNA up, target down 
Gpat2 GO:0019432 triglyceride biosynthetic 
process 
-0,845 0,079641444 -743b-5p miRNA up, target down 
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a b s t r a c t
Background and aims: Hydroxytyrosol (HT) is the primary phenolic compound of olives, virgin olive oil,
and their byproducts. Proteomic analysis of metabolically active tissues helps elucidating novel mech-
anisms of action and potential targets in cardiometabolic disease. Thus, we aimed at determining the
impact of long-term HT supplementation on the proteome of adipose and liver tissue, in mice.
Methods: C57BL/6J mice received either a control diet or a diet supplemented with nutritionally relevant
doses of HT for eight weeks.
Results: HT supplementation differentially affects the adipose and liver tissues proteome, as evaluated by
super-SILAC. Some oxidative stress-related proteins were modulated in both tissues, such as the
multifunctional protein peroxiredoxin 1, which was consistently repressed by HT supplementation. In
some cases tissue-dependent modulation was observed, as in the case of FASN.
Conclusions: This study provides interesting information on the connection between changes seen at
tissue proteome level and the metabolic effects of HT. The use of this pertinent proteomics quantiﬁcation
approach may prove quite useful for uncovering novel potential pharmaco-nutritional targets of HT
supplementation.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
The variegated biological activities of olive oil and its phenolic
constituents are being actively investigated worldwide (Bernardini
and Visioli, 2017; Hmimed et al., 2016). Indeed, the European Food
Safety Authority (EFSA) granted a health claim to the car-
dioprotective activities (i.e. they protect low-density lipoproteins
from oxidation (EFSA Panel on Dietetic Products, 2011)) of such
phenolics, of which hydroxytyrosol (HT) is the foremost compo-
nent. However, the precise molecular mechanisms that explain
several of these potentially healthful actions have not been yet fully
clariﬁed (Bernardini and Visioli, 2017).
Mass-spectrometry (MS)ebased quantitative proteomics is a
powerful method that allows identifying the compilation of pro-
teins expressed in biological systems, in addition to their in-
teractions and modiﬁcations (Shenoy and Geiger, 2015). Metabolic
labeling approaches, e.g. stable isotope labeling with amino acids in
cell culture (SILAC), are being acknowledged as a robust tool in
proteomic quantiﬁcation, with several variations of this technique
being developed in recent times (Ong, 2012). In the case of super-
SILAC, unlabeled tissues from a model organism, e.g. Mus muscu-
lus are compared with a representative mixture of heavy-SILAC
Abbreviations: HT, hydroxytyrosol; MS, mass-spectrometry; SILAC, stable isotope labeling with amino acids in cell culture; DEG/P, differentially expressed genes/proteins;
GO, gene ontology; STRING, search tool for the retrieval of interacting genes/proteins; FASN, fatty acid synthase; Car3, carbonic anhydrase 3; Prdx1, peroxiredoxin 1; FABP4,
fatty acid binding protein; PBMC, peripheral blood mononuclear cells.
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labeled cell lines that act as a common internal standard (super-
SILAC mix) (Chen et al., 2015). The plusses of super-SILAC makes it
an ideal tool for basic and clinical research aimed at identifying
protein changes and precisely quantify useful biomarkers (Shenoy
and Geiger, 2015). Accurate quantiﬁcation of such proteins can
contribute to evaluate the biological consequences of dietary
exposure to a nutrient/molecule. In this context, SILAC-MS quan-
titative proteomic strategies have been applied to in vitro studies
involving exposure to (poly)phenols such as quercetin (Zhou et al.,
2009) or resveratrol (Alayev et al., 2014). On the other hand,
quantitative proteomics approximations applied to the impact on
tissue proteome of supplementation with (poly)phenols are scant.
As data on the effects of HT on tissue proteome in vivo are
limited, we employed MS-based quantitative proteomics, namely
super-SILAC, to investigate differences in protein levels in adipose
tissue and the liver, i.e. the most metabolically active tissues (Uhlen
et al., 2015), of mice fed long-term with HT. We also analyzed pe-
ripheral blood mononuclear cells (PBMCs) obtained from healthy
volunteers supplemented with HT for one week.
2. Material and methods
2.1. Materials
Dulbecco's Modiﬁed Eagle Medium (DMEM) R6K6 was pur-
chased from Dundee cell (Dundee, Scotland, UK). Dialyzed fetal
bovine serum (FBS), phosphate buffer saline pH 7.4 (PBS) and
trypsin-EDTA was supplied by Fisher Scientiﬁc (Madrid, Spain).
NaCl, NaF, ethylenediaminetetraacetic acid (EDTA), MgCl2, Triton X-
100, ammonium bicarbonate and formic acid were obtained from
Sigma-Aldrich (Madrid, Spain). Tris and Coomassie brilliant blue
were bought from Bio-Rad (Madrid, Spain). Chloroform, methanol
and ethanol were purchased from Scharlab (Barcelona, Spain).
Trypsin Gold-Mass Spectrometry Grade, 100 mg was purchased
from Promega (Madrid, Spain). LC-MS-grade water and acetonitrile
(ACN) were obtained from Fisher Scientiﬁc (Madrid, Spain).
2.2. Animals and diets
This research followed the Guide for the Care and Use of Labo-
ratory Animals, published by the US National Research Council
(Eight Edition, 2010). Animal experiments were approved by the
Animal Experimentation Committee of the University Complutense
of Madrid (CEA-UCM 93/2012). C57BL/6 male mice (2 months old,
n ¼ 14) were kept on a 12:12 light/dark cycle and acclimatized for
oneweek before experimentation. For the dietary supplementation
study, food and water were given ad libitum. Mice were kept for
eight weeks under either a puriﬁed control diet or a puriﬁed control
diet (Research Diets, Inc. New Brunswick, NJ, USA; n ¼ 7 each
group) with 0.03% hydroxytyrosol incorporated into the pellet
(Seprox Biotech, Madrid, Spain), resulting in approximately 45 mg
HT/kg bw/day (human equivalent dose (HED) of 3.6 mg HT/kg bw/
day). Each diet provided 24.0%, 15.0%, and 61.0% Kcal from protein,
fat and carbohydrates, respectively, and their detailed composition
is described elsewhere (Giordano et al., 2014). After eight weeks of
supplementation, mice were anesthetized with 0.1 mL/20 g mouse
cocktail containing ketamine (100 mg/kg) and xylazine (10 mg/kg)
by intraperitoneal injection, and dissected through a midline inci-
sion in the abdomen. Blood samples were collected through cardiac
puncture. Phosphate-buffered saline (PBS; pH 7.4) was perfused
through the portal vein for 1 min to remove any remaining blood.
Tissues were quickly extracted, washed in PBS, snap-frozen in
liquid nitrogen, and stored at 80 C.
2.3. Generation of the super-SILAC mix
Mouse embryo ﬁbroblast (3T3-L1) and mouse epithelial hepa-
toma cells (Hepa 1e6) were grown in “heavy” DMEM medium
containing 13C6-Lys and 13C6-Arg and supplemented with 10%
dialyzed FBS and 100 units/mL of penicillin/streptomycin. Complete
incorporation of the heavy amino acids after six cell divisions was
veriﬁed by MS of a protein digest (data not shown).
Completely labeled cells were washed twice with cold PBS and
lysed in total lysis buffer containing 1% Triton X-100, 0.5 M NaCl,
20 mM Tris, pH 8, 10 mM EDTA, 50 mM NaF, 5 mM MgCl2 and
protease inhibitors. The super-SILAC mix was generated by
combining equal amounts of heavy lysates from the two cell lines.
2.4. Protein isolation from adipose and liver tissues
Proteins from adipose tissues were extracted as previously
described (Sajic et al., 2011). Brieﬂy, visceral adipose tissues were
homogenized with a micro pestle and sonicated with an ultrasonic
probe using a buffer containing Tris 50 mM, NaCl 150 mM, EDTA
0.2 mM and protease inhibitors. The homogenate was then trans-
ferred into a glass tube and extracted with a 1:2 mixture of
chloroform-methanol followed by addition of a 1:1 mixture of
chloroform-water. After centrifugation at 3700g during 5 min at
4 C, proteins were found in the upper phase and the disk between
phases. Finally, proteins were precipitated with acetone overnight
at20 C and resuspended in theminimum required volume of PBS
depending on the initial amount of tissue.
Ground liver tissues were homogenized in total lysis buffer with
a micro pestle. The homogenate was then sonicated and incubated
at 4 C with rotatory agitation during 15 min. The sample was
cleared by centrifugation at 4 C and 15,800g.
2.5. Protein identiﬁcation and quantitation
Two independent super-SILAC experiments with two replicates
each, were carried out for the identiﬁcation of differentially
expressed proteins (DEP) in the adipose and liver tissues of HT-
supplemented mice in comparison to controls. The super-SILAC
mix was blended with both control and treated tissues lysates
independently in a 1:1 ratio based on protein concentration. 20 mg
total protein extracts were separated by SDS-PAGE on 10% SDS-
polyacrylamide gels. After electrophoresis, proteins were visual-
ized by Coomassie blue staining and in-gel digested as previously
described (Luque-Garcia et al., 2008).
The peptides mixtures from the different in-gel tryptic digestion
fractions were loaded onto a trap column (Reprosil C18, 3 mm
particle size, 0.3  10 mm, 120 Å pore size, SGE) and then eluted
through the analytical column (Acclaim Pep Map 100, C18, 3 mm
particle size, 75 mm 150mm,100 Å pore size, Dionex, LC Packings)
with a linear gradient of 5e95% ACN in 0.1% formic acid. Samples
were delivered over 120 min by a nano-LC ultra 1D plus system
(Eksigent) at a ﬂow-rate of 200 nl/min, through the analytical
column to a stainless steel nano-bore emitter (O.D. 150 mm, I.D. 30
mm Proxeon, Odense, Denmark). The resulting peptides were
scanned and fragmented with an LTQ XL linear ion trap mass
spectrometer (Thermo Scientiﬁc, San Jose, CA, USA) operated in
data-dependent ZoomScan and MS/MS switching mode using the
threemost intense precursors detected in a survey scan from 400 to
1600 u (three mscans). ZoomScan mass window was set to 12 Da
enabling monitoring of the entire 12C/13C isotopic envelope of most
doubly and triply charged peptides. Singly charged ions were
excluded for MS/MS analysis. Normalized collision energy was set
to 35% and dynamic exclusion was applied during 3 min periods to
avoid repetitive fragmentation of ions.
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Generated raw ﬁles were converted to mgf ﬁles (Bioworks 3.3.1)
for submission to the MASCOT database. A database containing the
NCBInr Mus musculus sequences (as of September 2014, 34966
sequences) was searched using the MASCOT protein identiﬁcation
software (v2.3 Matrix Science). Search criteria included trypsin
speciﬁcity with one missed cleavage allowed, and with methionine
oxidation, 13C6-Arg and 13C6 eLys as variable modiﬁcations. Mini-
mum precursor and fragment-ion mass accuracies of 1.2 and 0.3 Da
were used. To precisely identify proteins, at least one unique pep-
tide (bold-red peptides meaning highest scoring peptide matching
to proteinwith highest total score) with a Mascot score higher than
39 (p < 0.05) and a minimum total protein score of 46 (p < 0.01)
were required. The false discovery rate (FDR) was calculated by
searching the same spectra against the NCBInrMus musculus decoy
database. Relative quantiﬁcation ratios of identiﬁed proteins based
on peak area were calculated using Quixot v.1.3.26 open-source
software (https://www.cnic.es/wiki/proteomica/index.php/
QuiXoT). Protein ratios obtained by Quixot were veriﬁed manually
for all peptides. Functional processes and subcellular localization of
the proteins identiﬁed by SILAC were assigned based on the bio-
logical knowledge available in Gene Ontology (GO) annotations.
2.6. Bioinformatic analysis
The Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) (Huang da et al., 2009), a wide-ranging set of
functional annotation tools, was used in order to obtain informa-
tion regarding the biological processes, molecular function and
cellular component associated with the list of DEP found in adipose
tissue or liver, using the adjusted thresholds of P-value <0.05 and
enrichment gene count >2.
To explore the interaction between the differentially expressed
proteins, the Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) database (Franceschini et al., 2013) was used,
setting a score of 0.4 as the reliability threshold. The STRING
database provides both experimental and predicted interaction
information, providing a probabilistic association conﬁdence score.
Ingenuity Pathway Analysis (IPA) was used for predicting down-
stream effects on biological and disease processes.
2.7. mRNA vs protein correlation analysis
We also wanted to explore eventual correlations between
transcriptomic and proteomic results. Spearman correlation co-
efﬁcients were used to assess how mRNA and protein expression
corresponded. Transcriptome data was obtained in both adipose
and liver samples from these mice has described in a previous work
(Giordano et al., 2014). Brieﬂy, Illumina MouseRef-8 v2 Expression
BeadChips® with Ambion Labelling, which target approximately
25,600 well annotated Ref Seq transcripts, were used. Signiﬁcant
modulated genes were deﬁned as those with an absolute fold
change of >2.0 and an adjusted P value of <0.05.
2.8. Western blot
Western blot (WB) was performed using standard methods.
Brieﬂy, cells from adipose and liver tissues were lysed with RIPA
buffer added with complete protease inhibitors (Sigma-Aldrich,
Madrid, Spain) and quantiﬁed using the Pierce BCA Protein Assay kit
(ThermoFisher Scientiﬁc, Madrid, Spain). Protein samples were
loaded on 10% SDS-polyacrylamide gradient gels and transferred to
0.2 mm poreesize nitrocellulose membranes (Bio-Rad, Madrid,
Spain). After blocking with 5% nonfat milk, membranes were
incubated overnight at 4 C with rabbit polyclonal fatty acid syn-
thase (FASN, also known as FAS) antibody (1:1000, Cell Signaling
Technology, Beverly, MA, USA), fatty acid binding protein 4 (FABP4)
antibody (1:1000, Cell Signaling Technology, Beverly, MA, USA),
rabbit Polyclonal carbonic anhydrase 3 (Car3) antibody (1:1000,
ThermoFisher Scientiﬁc, Madrid, Spain), rabbit monoclonal perox-
iredoxin 1 (Prdx1) antibody (1:1000, Cell Signaling Technology,
Beverly, MA, USA) or mouse monoclonal glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (1:5000, Sigma-
Aldrich, Madrid, Spain). After washing with Tris-buffered saline
including Tween-20, membranes were incubated with secondary
antirabbit or antimouse antibodies for 1.5 h at room temperature
and protein detection was carried out using the enhanced chem-
iluminescence system with a Clarity™ Western ECL Substrate kit
(Bio-Rad, Madrid, Spain).
2.9. Human study
Samples for protein analysis by WB were obtained from a pre-
vious intervention (ClinicalTrials.gov identiﬁer: NCT02273622)
study (Crespo et al., 2015). Brief, twenty-one male volunteers were
recruited for a randomized, crossover, placebo-controlled, and
double blind intervention trial. After one-week of an olive-free diet,
subjects were randomly assigned to either placebo (maltodextrin)
or 25 mg/d HT group. Blood samples were collected and PBMCs
were isolated as described previously [15]. Proteins were extracted
from PBMCs and analyzed by WB as described above.
2.10. Statistical analysis
WB data results were tested for normality and equality of vari-
ances before statistical tests were carried out. Since both re-
quirements were met in all cases unpaired t-tests were conducted.
3. Results
3.1. Super-SILAC analysis of differentially expressed proteins (DEP)
We applied super-SILAC in combination with LC-ESIeMS/MS to
detect DEP in the adipose and liver tissues isolated from mice. The
distribution of SILAC ratios (RSILAC, referring to ratios tissue1/tis-
sue2 for all proteins found in adipose and liver tissue) was
concentrated between 1.5 and 1.5 for most proteins identiﬁed, as
expected when closely analyzing related tissues in a 1∶1 protein
mixture. RSILAC distribution is represented as log10 (Fig. 1).
Fig. 1. Logarithm distribution of the SILAC ratio obtained.
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A total of 88 proteins were identiﬁed in adipose tissue
(Supplementary Table 1). Out of the proteins quantiﬁed in adipose
tissue 39 were mutual to both study groups (Supplementary
Table 2). Proteins were quantiﬁed with at least two unique pep-
tides and the mean relative standard deviation (RSD) of the ratios
from different peptides was lower than 20%. The overall FDR was
0.05%, being estimated by the number of hits against the reverse
sequence/total hits (p < 0.01). Using 1.5 as the RSILAC threshold ratio,
21 out of the 39 common quantiﬁed proteins were considered DEP,
12 up-regulated and 9 down-regulated (Table 1).
As regards the liver, a total of 523 proteins were identiﬁed
(Supplementary Table 4). A total of 106 proteins quantiﬁed were
shared by both groups (Supplementary Table 5). The higher the
number of analyzed spectra, the higher is the probability of ﬁnding
false positives. Since FDR is calculated according to the same MS
spectra (against a decoy database with no biological meaning) and
more proteins were found in liver, overall FDR used for this tissue
was 0.2%. Using a threshold RSILAC ratio of 1.5, 16 proteins were
found to be up-regulated and 24 down-regulated out of the 106
common quantiﬁed proteins (Table 2).
3.2. Functional classiﬁcations of differentially expressed proteins
(DEP)
The 21 and 40 DEP between controls and HT supplemented
animals found in adipose tissue and liver, respectively, were sub-
jected to categorical ontological analysis: Biological Process, Mo-
lecular Function and Cellular Component. In terms of biological
processes, DEP found in adipose tissue weremainly associated with
nervous system development, phosphorylation, and cellular pro-
tein metabolic process. Analysis of metabolic functions suggested
some of these proteins are involved in RNA and protein binding.
Concerning cellular component analysis most proteins were linked
to the cytoplasm or with extracellular exosomes (Fig. 2A).
On the other hand, liver HT-modulated proteins, in terms of
biological processes, were mainly involved in oxidative stress and
oxidation-reduction responses, as well as in metabolic processes.
Analysis of metabolic function established that most of these pro-
teins play a role in oxidoreductase and lyase activity. Concerning
cellular component analysis, most proteins were associated with
the cytoplasmic region of the cell and with mitochondria (Fig. 2B).
3.3. Proteineprotein interaction analysis and pathway annotation
A string database was used to explore possible proteineprotein
interactions between the DEP in both adipose tissue and liver
Table 1
Differentially expressed proteins in the adipose tissue of mice fed a diet containing
0.03 gm% of hydroxytyrosol and controls.
Protein
abbreviation
Protein full name Mascot
score
RSILAC RSD
Car3 carbonic anhydrase 3 362 3.92 10.56
Hspd1 60 kDa heat shock protein.
mitochondrial
136 3.53 14.51
Cav1 caveolin-1 isoform 1 66 3.17 8.02
Hbb-b1 hemoglobin subunit beta-1 118 2.79 19.90
Trf serotransferrin precursor 105 2.72 18.16
Fabp4 fatty acid-binding protein.
adipocyte
204 2.58 18.76
Eef1a1 elongation factor 1-alpha 1 46 2.47 14.27
Hsp90ab1 heat shock protein HSP 90-beta 344 2.42 15.89
Alb serum albumin precursor 46 2.33 17.91
Nme2 nucleoside diphosphate kinase B 93 1.83 17.31
Fasn fatty acid synthase 70 1.71 6.97
Uba52 ubiquitin-60S ribosomal
protein L40
327 1.52 17.44
Vim vimentin 281 1.63 18.22
Prdx1 peroxiredoxin-1 356 1.64 18.97
Ptrf polymerase I and transcript
release factor
77 1.75 18.12
Tpi1 triosephosphate isomerase 199 1.89 12.41
Ywhag 14-3-3 protein gamma 80 1.98 15.44
Ppia peptidyl-prolyl cis-trans
isomerase A
676 2.08 17.83
Ywhaz 14-3-3 protein zeta/delta
isoform 1
210 2.08 9.94
Hist2h4 histone H4 181 2.12 16.83
Lgals1 galectin-1 338 3.13 3.22
Table 2
Differentially expressed proteins in the liver of mice fed a diet containing 0.03 gm%
of hydroxytyrosol and controls.
Protein
abbreviation
Protein full name Mascot
core
RSILAC RSD
Rpl23 60S ribosomal protein L23 124 5.38 17.29
Hbb-b1 hemoglobin subunit beta-1 1298 5.24 5.88
Aco1 cytoplasmic aconitate hydratase 438 3.22 16.45
Vcl vinculin 402 2.63 19.75
Hpd 4-hydroxyphenylpyruvate dioxygenase 282 2.59 17.52
Ces3a carboxylesterase 3A isoform 1
precursor
69 2.27 13.49
Hba-a2 hemoglobin alpha 745 2.16 7.13
Aldh7a1 alpha-aminoadipic semialdehyde
dehydrogenase isoform b
273 1.99 14.47
Car3 carbonic anhydrase 3 1699 1.90 14.86
Gsn gelsolin isoform 2 166 1.61 11.47
Pcx pyruvate carboxylase. mitochondrial
isoform 2
1345 1.61 17.92
Prdx2 peroxiredoxin-2 666 1.60 11.63
Cﬂ1 coﬁlin-1 1457 1.58 18.79
Hspa9 stress-70 protein. mitochondrial 647 1.57 17.47
Uba1 ubiquitin-like modiﬁer-activating
enzyme 1 isoform 1
437 1.52 17.86
Actn4 alpha-actinin-4 117 1.52 19.87
Aldh1a1 retinal dehydrogenase 1 644 1.50 7.25
Sord sorbitol dehydrogenase 339 1.53 12.52
Pdia3 protein disulﬁde-isomerase A3
precursor
324 1.56 13.10
Aldob fructose-bisphosphate aldolase B 3196 1.59 14.14
Rrbp1 ribosome-binding protein 1 isoform a 46 1.61 14.89
P4hb protein disulﬁde-isomerase precursor 385 1.71 18.92
Aldh6a1 methylmalonate-semialdehyde
dehydrogenase [acylating],
mitochondrial precursor
305 1.92 17.63
Pygl glycogen phosphorylase. liver form 648 1.93 19.20
Eif4a1 eukaryotic initiation factor 4A-I isoform
1
313 1.95 15.40
Glud1 glutamate dehydrogenase 1,
mitochondrial precursor
231 1.96 12.28
Hadh hydroxyacyl-coenzyme A
dehydrogenase. mitochondrial
precursor
278 2.01 17.07
Prdx1 peroxiredoxin-1 286 2.17 19.79
Aldoa fructose-bisphosphate aldolase A
isoform 2
1658 2.18 9.02
Npm1 nucleophosmin isoform 1 459 2.22 16.91
Got2 aspartate aminotransferase,
mitochondrial
54 2.22 17.19
Hadha trifunctional enzyme subunit alpha,
mitochondrial precursor
659 2.26 17.33
Ftl1 ferritin light chain 1 434 2.44 14.41
Aldh4a1 delta-1-pyrroline-5-carboxylate
dehydrogenase. mitochondrial
precursor
408 3.20 4.38
Cat catalase 251 3.23 19.73
Fasn fatty acid synthase 764 3.69 17.58
Asl argininosuccinate lyase 766 3.71 11.41
Ephx2 bifunctional epoxide hydrolase 2 746 4.31 18.49
Ass1 argininosuccinate synthase 927 4.85 18.94
Dmgdh dimethylglycine dehydrogenase,
mitochondrial precursor
954 5.27 18.64
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(Fig. 3A and B, respectively). In adipose tissue, a group of 15 pro-
teins stands out by forming a network of interactions (Cav1, Fasn,
Fabp4, Eef1a, Hist2h4, Hsp90ab1, Hspd1, Nme2, Ppia, Prdx1, Ptrf,
Tpi1, Uba52, Ywhaz, Ywhag), the function of which is related to
protein synthesis (Mateyak and Kinzy, 2010), folding (Haase and
Fitze, 2016), peroxidase activity (Rhee et al., 2012), glycolysis
(Mota et al., 2009), gene expression (Kar and Chowdhury, 2015), or
lipid metabolism (Capobianco et al., 2012). As for liver, a wide
interaction network was found, connecting proteins related to fatty
acid oxidation (Hadha), metabolism (Aco1, Got2 or Dmgdh),
glycolysis (Aldoa), protein synthesis (Eif4a1), antioxidation (Prdx2)
and aldehyde dehydrogenation (Aldh7a1, Aldh6a1, Aldh4a1 and
Aldh1a1).
Due to the wide diversity of processes related to the DEP found
in both tissues we decided to center our attention in the few DEP
which could be HT targets in both tissues. Carbonic anhydrase 3
(Car3), which is associated with oxyradical scavenging, among
other processes (Kharbanda et al., 2009), was the highest upregu-
lated DEP identiﬁed in adipose tissue and was also upregulated in
liver. Peroxiredoxin-1 (Prdx1), a member of antioxidant enzymes,
which reduces hydrogen peroxide and alkyl hydroperoxides, was
the only downregulated DEP common to both tissues. FASN, a
major metabolic enzyme and a key player in fatty acid synthesis
(Wu et al., 2011), was the only common DEP identiﬁed as being
upregulated in one tissue and downregulated in the other.
Considering the possible effects of HT on lipid metabolism (Tome-
Carneiro et al., 2016), the upregulation of FABP4, which is
involved in the regulation of glucose and lipid metabolism in
relation to inﬂammatory and metabolic processes in adipocytes
(Furuhashi et al., 2014), also seemed interesting.
3.4. WB validation of super-SILAC results regarding selected
hydroxytyrosol-modulated proteins
Following identiﬁcation by MS, presence of proteins should be
validated qualitatively and/or quantitatively by other methods. WB
is frequently used for this purpose, at least for proteins to which
antibodies are available. Bearing this in mind, wewanted to check if
the four above mentioned DEP identiﬁed, Car3, Prdx1, FASN and
FABP4 (only in adipose tissue), could be reproduced by WB in a
second cohort of eight-week HT-supplemented mice (Tome-
Carneiro et al., 2016). Consistent corroboration of super-SILAC re-
sults in both tissues was observed regarding the downregulation of
Prdx1 (Fig. 4A and B). Consistency was also found regarding FASN
upregulation in visceral adipose tissue (Fig. 4A) and down-
regulation in liver (Fig. 4B). Car3 upregulationwas not conﬁrmed by
WB in either tissue and neither was FABP4 upregulation in adipose
tissue (results not shown).
Even though the aforementioned mouse tissues were the aim of
this proteomic study, the consistency found for Prdx1 and FASN led
Fig. 2. Major biological processes, molecular functions, and cellular components related to the altered proteins found in mouse visceral adipose tissue (A) and liver (B).
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us to analyze the expression of these protein in PBMCs samples
isolated from volunteers who participated in a one-week HT-sup-
plementation study (Crespo et al., 2015). Prdx1 expressionwas also
diminished in the PBMCs of HT supplemented individuals
compared to controls (Fig. 4C), whereas no difference was found for
FASN (results not shown).
3.5. Proteins are poorly correlated with transcripts
To determinewhether changes in protein levels resemble that of
Fig. 3. Proteineprotein interaction network of the differentially expressed proteins quantiﬁed in (A) adipose tissue and (B) liver, according to the Database for Annotation,
Visualization and Integrated Discovery (DAVID).
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their transcripts, we next examined transcript-protein relation-
ships. Commonly quantiﬁed proteins in adipose (39) and liver (106)
tissues found in hydroxytyrosol-supplemented mice and their
respective controls were correlated to the correspondingmRNAs by
Spearman correlation coefﬁcients. As showed in Fig. 5A and B,
proteins changes were poorly correlated with transcripts.
4. Discussion
In this study, we show that long-term hydroxytyrosol supple-
mentation has the potential to modulate protein expression in
adipose tissue and the liver. Considering that these two tissues are
seen as the foremost metabolically active ones (Uhlen et al., 2015),
we expose that the potentially HT-modulated proteins detected
here are involved in different metabolic processes including lipid
metabolism and in oxidative stress response. Bearing in mind the
lists of identiﬁed proteins was limited in both tissues, it is inter-
esting that IPA examination predicted the activation of fatty acids’
release and metabolism in adipose tissue, whereas lipid oxidation
and lipid synthesis were predicted to be inhibited in liver. Modiﬁ-
cations in fatty acid trafﬁcking are likely involved in the progress of
insulin resistance, and subsequentmetabolic complications, and HT
has been associated with an amelioration of peripheral insulin
resistance in vitro (Crespo et al., 2017). However, the exact mech-
anisms through which alternate routing of fatty acids contribute to
metabolic disease are yet to be ascertained (Mittendorfer, 2011).
Interpretation of the existing literature regarding the effect of olive
phenolics and, particularly, HT on tissue proteome is not straight-
forward. Treatment, species, proteomic approach, or analyzed tis-
sues differed among investigations impeding direct comparisons.
Super-SILAC in combination with LC-ESIeMS/MS analysis showed
a consistent up- and downregulation for Car3 and Prdx1, respec-
tively, while FASN was downregulated in liver and FABP4 was
upregulated in adipose tissue. Loss of Car3 in preadipocytes has
been shown to enhance adipogenesis (Mitterberger et al., 2012),
while its reduced expression has been associated to hepatocellular
carcinoma growth (Kuo et al., 2003). Hence, its upregulation seen in
the liver of the animals we studied may contribute to counteract
these unfavorable outcomes, although LC-ESIeMS/MS results were
not conﬁrmed by WB. Prdx1 is an antioxidant enzyme, but its
physiological role in oxidizationereduction balance and in human
malignances remains unclear (Jang et al., 2004). While Prdx1
knockout mice exhibited shortened life-span due to hemolytic
anemia and the development of several malignant cancers, studies
in humans conﬁrmed that prdx1 is overexpressed in several types
of cancer. It has also been reported that type 2 diabetes mellitus
(T2DM) patients displayed higher levels of plasma Prdx1 than non-
diabetics (Al-Masri et al., 2014) and that its overexpression may
induce insulin resistance (Tang et al., 2015). We observed a
consistent downregulation of Prdx1 in HT-supplement animals in
Fig. 4. Hydroxytyrosol effects on other physiological conditions. Protein analysis by Western blot of mouse visceral adipose tissue (A) and liver (B) samples of mice supplemented
with a human equivalent dose of 3.6 mg hydroxytyrosol/kg bw/day, during eight weeks. (C) Blots of human PBMCs before and after a 1-week supplementation with 25 mg/d of
hydroxytyrosol. Blots are representative of the whole cohort (n  6). *P < 0.05.
Fig. 5. Transcript-protein correlation of adipose (A) and liver (B) after hydroxytyrosol supplementation.
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both liver and adipose tissue, using super-SILAC and WB, suggest-
ing this protein may be a pharma-nutritional target of HT. Inter-
estingly, Prdx1was also found to be downregulated in the PBMCs of
volunteers who had taken 25 mg/day of HT for one week, which
reinforces the notion that the actions of HT on this protein are
worth ad-hoc investigations, with possible therapeutic re-
percussions (Ding et al., 2017). FABP4 is involved in the regulation
of glucose and lipid metabolism in relation to inﬂammatory and
metabolic processes in target cells, e.g. participates in the transport
of fatty acids and other lipids to various cellular pathways
(Furuhashi et al., 2014; Hotamisligil et al., 1996; Maeda et al., 2005).
Under contemporary lifestyle its overexpression may be rather
disadvantageous for regulating inﬂammatory or metabolic ho-
meostasis, although WB did not corroborate super-SILAC results.
Finally, FASN is a multifunctional protein, which plays a critical role
in a number of metabolic functions by catalyzing the terminal steps
in the synthesis of long-chain saturated fatty acids (Peck and
Schulze, 2016). It has been reported that excessive triacylglycerol
(TG) accumulation in adipose tissue induces insulin resistance and
represses adipose tissue lipogenic enzymes such as FASN
(Katsurada et al., 1990). In contrast, hepatic levels of lipogenic en-
zymes are enhanced by the development of insulin resistance and/
or T2DM (Memon et al., 1994). In this context, the upregulation
found in adipose tissue and the downregulation seen in liver sug-
gest that HT-supplementation might modulate this enzyme in a
healthful way.
While the study of transcripts is helping unveil the possible
biological effects of dietary supplementation with these and other
phytochemicals (Giordano et al., 2014; Pereira-Caro et al., 2013), the
development of large scale proteomic screening (Chick et al., 2016;
Uhlen et al., 2015) is advancing our understanding of the complex
regulatory variations from RNA to protein. The lack of correlation
between transcripts and proteins shown here is not novel, as
studies in model organisms and humans have shown that varia-
tions in mRNA and protein expression levels are often uncorrelated
(Battle et al., 2015; Foss et al., 2007; Greenbaum et al., 2003; Gygi
et al., 1999; Schwanhausser et al., 2011). In this respect, our pre-
vious transcriptomic (Giordano et al., 2014) analysis, and those of
other groups (Granados-Principal et al., 2011; Pereira-Caro et al.,
2013), did not shown any change in Car3, Prdx1, FASN or FABP4 at
transcript levels (results not shown). As RNA-seq technology pro-
vides some advantages compared to microarrays, such as increased
speciﬁcity and sensitivity and easier detection of rare and low-
abundance transcripts (Lowe et al., 2017), gene expression ana-
lyses might be worth redoing in the future.
Yet, we are aware of the limitations regarding the results ob-
tained and the interpretations that can be drawn from them. The
amount of common quantiﬁed proteins identiﬁed in our super-
SILAC proteomic approach was quite low. We are aware that
several hundred or even thousand proteins have been identiﬁed in
somewhat similar LTQ XL Orbitrap-MS studies (Fang et al., 2015;
Meierhofer et al., 2014). The histological complexity of adipose
tissue makes it technically challenging to analyze and could help
explain the low protein/peptide concentration found. Nevertheless,
this type of challenge is not expected for regular liver tissue sam-
ples, even though the large number of tissue-enriched gene
expression found in this tissue (Uhlen et al., 2015) may contribute
to the low number of commonly modulated proteins. Another
contributing account concerns the restrictive criteria set for at least
2 unique peptides per protein for positive identiﬁcations. The aim
of this work was to identify as much differently expressed proteins
upon hydroxytyrosol administration as possible and we believe our
contribution to the current knowledge on this subject, though
limited, is useful. We acknowledge subsequent studies could
beneﬁt from supplementary workﬂow optimization. However,
despite the limited number of common proteins identiﬁed, it needs
to be clear that proteins in cell lines were just used as “internal
standard” and the fact that most “light” peptides (coming from
tissues) were coupled to “heavy” peptides (coming from SILAC-
labeled cell culture lines), meaning most of the proteins found in
the tissues were also in the cell lines used for the super-SILAC mix,
thus conﬁrming the suitability of this approach. In addition, several
proteins reported as being modulated by HT and/or olive phenolics
(Al-Masri et al., 2014; Jang et al., 2004; Kuo et al., 2003;
Mitterberger et al., 2012) coincided to some extent with the ones
found here. These proteins include fatty acid binding protein,
glutamate dehydrogenase, ornithine carbamoyltransferase,
epoxide hydrolase, nucleoside diphosphate kinase, pyruvate
carboxylase mitochondrial, aconitate hydratase, 4-
hydroxyphenylpyruvate dioxygenase, carboxylesterase, catalase,
fructose-biphosphate aldolase, superoxide dismutase [Cu-Zn],
vinculin, myosin-9, coﬁlin-1, vimentin, and hemoglobin subunit
beta-1, among others.
Protein phosphorylation is the most common eukaryotic post-
translational modiﬁcation and can act as either a molecular
switch or a regulator for protein functions (Vlastaridis et al., 2017).
Although we did not perform phosphoproteomic enrichment,
additional proteins were identiﬁed in adipose tissue and liver after
expanding searches to include Y, S and T protein phosphorylation
(Supplementary Tables 3 and 6, respectively).
In conclusion, the proteomic analysis approach used here rep-
resents a promising suitable tool to study the effects of food sup-
plementation on the proteome, contributing to the potential
uncovering of novel mechanisms of action and targets of micro-
nutrients, such as HT. Our study resulted in the identiﬁcation of
several differently expressed proteins and pathways that justify a
follow-up targeting a larger set of proteins in these pathways (for
example with WB or targeted proteomics). An impact on the pro-
teome was seen after supplementation with nutritionally relevant
amounts of HT (Bernardini and Visioli, 2017; Giordano et al., 2014),
especially in the case of Prdx1 and FASN, and deserves further
investigation.
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Supplementary table 1. Proteins identified in adipose tissue. 
GI number Protein name Mascot score 
6671507 actin, aortic smooth muscle  264 
6671509 actin, cytoplasmic 1  60 
6678079 alpha-1-antitrypsin 1-1 isoform 1 
precursor  
79 
6678085 alpha-1-antitrypsin 1-4 precursor  79 
6678189 seminal vesicle secretory protein 5 
precursor  
96 
6678483 ubiquitin-like modifier-activating enzyme 
1 isoform 1  
61 
6678682 galectin-1  338 
6679078 nucleoside diphosphate kinase B  93 
6679108 nucleophosmin isoform 1  59 
6679439 peptidyl-prolyl cis-trans isomerase A  676 
6679567 polymerase I and transcript release factor  77 
6680604 keratin, type I cytoskeletal 16  59 
6680748 ATP synthase subunit alpha, 
mitochondrial precursor  
148 
6680854 caveolin-1 isoform 1  66 
6680924 cofilin-1  246 
6681137 acyl-CoA-binding protein isoform 2  193 
6753036 aldehyde dehydrogenase, mitochondrial 
precursor  
81 
6753060 annexin A5  60 
6754084 glutathione S-transferase Mu 1  61 
6754254 heat shock protein HSP 90-alpha  129 
6754976 peroxiredoxin-1  122 
6755040 profilin-1  248 
6755863 endoplasmin precursor  105 
6755911 thioredoxin  89 
6756041 14-3-3 protein zeta/delta isoform 1  210 
6996913 annexin A2  148 
7106439 tubulin beta-5 chain  253 
9845265 ubiquitin-60S ribosomal protein L40  327 
9910294 keratin, type II cytoskeletal 71  184 
14149635 fatty acid-binding protein, adipocyte  127 
14192922 actin, alpha cardiac muscle 1  60 
20330802 serotransferrin precursor  105 
20799907 histone H2A type 2-A  54 
20911031 keratin, type II cytoskeletal 5  168 
21361209 histone H4  113 
21489935 keratin, type I cytoskeletal 14  65 
22164776 keratin, type II cytoskeletal 79  73 
29244126 histone H2A.J  276 
29789317 keratin, type II cytoskeletal 75  134 
31543974 14-3-3 protein beta/alpha  58 
31543976 14-3-3 protein gamma  80 
31560686 heat shock-related 70 kDa protein 2  116 
31980648 ATP synthase subunit beta, mitochondrial 
precursor  
167 
31980922 elongation factor 1-beta  77 
31981068 microsomal glutathione S-transferase 1  95 
31981562 pyruvate kinase isozymes M1/M2 isoform 
1  
54 
31981690 heat shock cognate 71 kDa protein  309 
31981890 beta-2-microglobulin precursor  91 
31982186 malate dehydrogenase, mitochondrial 
precursor  
212 
31982300 hemoglobin subunit beta-1  118 
31982755 vimentin  377 
31982861 carbonic anhydrase 3  362 
40556608 heat shock protein HSP 90-beta  229 
42415475 protein disulfide-isomerase precursor  73 
45597447 superoxide dismutase [Cu-Zn]  1297 
47059013 keratin, type II cytoskeletal 73  87 
51092293 keratin, type II cytoskeletal 1b  87 
52353955 D-3-phosphoglycerate dehydrogenase  356 
54607171 keratin, type II cytoskeletal 6A  120 
61743961 AHNAK nucleoprotein isoform 1  112 
70794816 uncharacterized protein LOC433182  138 
76881807 alpha-1-antitrypsin 1-2 precursor  79 
84794552 phosphatidylethanolamine-binding protein 
1  
70 
93102409 fatty acid synthase  70 
112293264 protein disulfide-isomerase A3 precursor  59 
112983636 keratin, type I cytoskeletal 10  206 
113195684 keratin, type II cytoskeletal 6B  94 
114145561 keratin, type II cytoskeletal 8  70 
117553604 carboxylesterase 1D precursor  115 
124487419 keratin, type II cytoskeletal 2 epidermal  48 
124517663 annexin A1  75 
125347376 filamin-A  65 
126116585 keratin, type II cytoskeletal 1  127 
145301549 hemoglobin alpha, adult chain 2  64 
145580629 keratin Kb40  66 
160333304 apolipoprotein A-I preproprotein  121 
160358829 hemopexin precursor  46 
161760667 prelamin-A/C isoform C  51 
163310765 serum albumin precursor  123 
164698408 perilipin-1  90 
183396771 60 kDa heat shock protein, mitochondrial  136 
226823220 keratin, type I cytoskeletal 15  61 
226874906 14-3-3 protein epsilon  66 
226958349 triosephosphate isomerase  199 
227116343 platelet glycoprotein 4  94 
251823978 pyruvate carboxylase, mitochondrial 
isoform 2  
67 
254540166 78 kDa glucose-regulated protein 
precursor  
124 
257153450 semenogelin I precursor  314 
 
 
 
Supplementary Table 2. Commonly quantified proteins in the adipose tissue of mice 
fed a diet containing 0.03 gm% of hydroxytyrosol and controls. 
Protein 
abbreviation 
Protein full name Mascot 
score 
RSILAC RSD 
Car3 carbonic anhydrase 3 362 3.92 10.56 
Hspd1 60 kDa heat shock protein. mitochondrial 136 3.53 14.51 
Cav1 caveolin-1 isoform 1   66 3.17 8.02 
Hbb-b1 hemoglobin subunit beta-1 118 2.79 19.90 
Trf serotransferrin precursor 105 2.72 18.16 
Fabp4 fatty acid-binding protein. adipocyte 204 2.58 18.76 
Eef1a1 elongation factor 1-alpha 1 46 2.47 14.27 
Hsp90ab1 heat shock protein HSP 90-beta 344 2.42 15.89 
Alb serum albumin precursor 46 2.33 17.91 
Nme2 nucleoside diphosphate kinase B 93 1.83 17.31 
Fasn fatty acid synthase   70 1.71 6.97 
Uba52 ubiquitin-60S ribosomal protein L40   327 1.52 17.44 
Hba-a2 hemoglobin alpha. adult chain 2   64 1.43 19.52 
Anxa1 annexin A1   67 1.42 6.12 
Atp5b ATP synthase subunit beta. mitochondrial 
precursor   
167 1.35 4.15 
Hspa5 78 kDa glucose-regulated protein 
precursor   
124 1.35 17.75 
Hspa8 heat shock cognate 71 kDa protein   309 1.2 17.61 
Anxa5 annexin A5   60 1.02 11.09 
Pfn1 profilin-1   248 1.01 16.00 
Hist2h2bb histone H2B type 2-B   40 1 7.81 
Eno1b uncharacterized protein LOC433182   138 -1.05 17.1 
Serpina1e alpha-1-antitrypsin 1-5 precursor   229 -1.08 9.70 
Krt10 keratin. type I cytoskeletal 10   294 -1.11 8.62 
Actb actin. cytoplasmic 1   60 -1.14 17.74 
Cfl1 cofilin-1   246 -1.18 17.58 
Anxa2 annexin A2   148 -1.37 17.06 
Sod1 superoxide dismutase [Cu-Zn]   1297 -1.45 15.05 
Mgst1 microsomal glutathione S-transferase 1   95 -1.45 4.08 
Tubb5 tubulin beta-5 chain   253 -1.47 17.80 
Phgdh D-3-phosphoglycerate dehydrogenase   356 -1.47 16.46 
Vim vimentin 281 -1.63 18.22 
Prdx1 peroxiredoxin-1 356 -1.64 18.97 
Ptrf polymerase I and transcript release factor   77 -1.75 18.12 
Tpi1 triosephosphate isomerase 199 -1.89 12.41 
Ywhag 14-3-3 protein gamma 80 -1.98 15.44 
Ppia peptidyl-prolyl cis-trans isomerase A   676 -2.08 17.83 
Ywhaz 14-3-3 protein zeta/delta isoform 1   210 -2.08 9.94 
Hist2h4 histone H4 181 -2.12 16.83 
Lgals1 galectin-1   338 -3.13 3.22 
 
Supplementary table 3. Additional proteins identified in adipose tissue after expanding 
search to Y, S and T phosphorylation.  
GI number Protein name Mascot score 
83921595 acyl-CoA-binding protein isoform 1  62 
30425250 beta-actin-like protein 2  73 
6671664 calnexin precursor  51 
19526922 keratin, type I cytoskeletal 25  57 
85701680 keratin, type II cytoskeletal 2 oral  51 
133778953 keratin, type II cytoskeletal 4  59 
114326546 phosphoglycerate mutase 1  53 
9256624 phosphoglycerate mutase 2  53 
309267203 PREDICTED: keratin, type II cytoskeletal 
78-like, partial  
55 
148747546 serine protease inhibitor A3K precursor  46 
33563240 actin, alpha skeletal muscle  253 
269914154 uncharacterized protein LOC239673  51 
 
Supplementary table 4. Proteins identified in liver. 
GI number Protein name Mascot score 
17975508 1,4-alpha-glucan-branching enzyme  60 
31543974 14-3-3 protein beta/alpha  592 
226874906 14-3-3 protein epsilon  948 
6756037 14-3-3 protein eta  265 
31543976 14-3-3 protein gamma  644 
6756039 14-3-3 protein theta  310 
6756041 14-3-3 protein zeta/delta isoform 1  1270 
254553340 17-beta-hydroxysteroid dehydrogenase 13 
isoform 2 precursor  
76 
13385680 2,4-dienoyl-CoA reductase, mitochondrial 
precursor  
171 
7110703 26S protease regulatory subunit 8  64 
19882201 26S proteasome non-ATPase regulatory 
subunit 2  
46 
6754724 26S proteasome non-ATPase regulatory 
subunit 7  
66 
31560355 2-hydroxyacyl-CoA lyase 1  59 
19527294 3-alpha-hydroxysteroid dehydrogenase  81 
61888838 3-hydroxyacyl-CoA dehydrogenase type-2  719 
17921976 3-hydroxyanthranilate 3,4-dioxygenase  370 
21704140 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial precursor  
293 
22122625 3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial precursor  
161 
18700004 3-ketoacyl-CoA thiolase A, peroxisomal 
precursor  
581 
22122797 3-ketoacyl-CoA thiolase B, peroxisomal 
precursor  
844 
29126205 3-ketoacyl-CoA thiolase, mitochondrial  2262 
13386034 40S ribosomal protein S13  77 
6677799 40S ribosomal protein S15  114 
158966704 40S ribosomal protein S16  163 
6677801 40S ribosomal protein S17  134 
6755368 40S ribosomal protein S18  113 
12963511 40S ribosomal protein S19  107 
46519156 40S ribosomal protein S24 isoform 1  145 
28372479 40S ribosomal protein S25  179 
6755372 40S ribosomal protein S3  124 
254553321 40S ribosomal protein S3a  124 
6677805 40S ribosomal protein S4, X isoform  186 
254675270 40S ribosomal protein S5  110 
6677809 40S ribosomal protein S6  216 
6755376 40S ribosomal protein S7  46 
33504483 40S ribosomal protein S9  120 
224994260 40S ribosomal protein SA  225 
37202121 4-aminobutyrate aminotransferase, 
mitochondrial isoform 1 precursor  
109 
33859486 4-hydroxyphenylpyruvate dioxygenase  282 
115334671 4-trimethylaminobutyraldehyde 
dehydrogenase precursor  
56 
183396771 60 kDa heat shock protein, mitochondrial  2147 
6671569 60S acidic ribosomal protein P0  276 
9256519 60S acidic ribosomal protein P1  150 
255003735 60S ribosomal protein L10a  70 
13385408 60S ribosomal protein L11  250 
160333553 60S ribosomal protein L12  154 
33186863 60S ribosomal protein L13  79 
13385472 60S ribosomal protein L14  59 
83699424 60S ribosomal protein L18  322 
58037465 60S ribosomal protein L18a  59 
226958653 60S ribosomal protein L19 isoform 1  93 
12584986 60S ribosomal protein L23  124 
46430508 60S ribosomal protein L23a  233 
18250296 60S ribosomal protein L24  306 
6677777 60S ribosomal protein L26  93 
255308899 60S ribosomal protein L3  55 
16716589 60S ribosomal protein L31  132 
13385044 60S ribosomal protein L35  61 
30794450 60S ribosomal protein L4  132 
84662736 60S ribosomal protein L6  49 
31981515 60S ribosomal protein L7  93 
7305443 60S ribosomal protein L7a  184 
6755358 60S ribosomal protein L8  153 
124486895 6-phosphogluconate dehydrogenase, 
decarboxylating  
267 
254540166 78 kDa glucose-regulated protein 
precursor  
1887 
171460960 abhydrolase domain-containing protein 
14B  
112 
21450129 acetyl-CoA acetyltransferase, 
mitochondrial precursor  
483 
110625948 acetyl-Coenzyme A acetyltransferase 3  146 
18700032 acidic leucine-rich nuclear phosphoprotein 
32 family member B  
54 
18079339 aconitate hydratase, mitochondrial 
precursor  
525 
6671507 actin, aortic smooth muscle  674 
6671509 actin, cytoplasmic 1  50 
112363072 actin-related protein 2/3 complex subunit 
2  
56 
9790141 actin-related protein 2/3 complex subunit 
3  
48 
74271799 acyl-CoA dehydrogenase family member 
11  
76 
100817933 acyl-CoA dehydrogenase family member 
9, mitochondrial  
47 
24418933 acyl-CoA synthetase family member 2, 
mitochondrial precursor  
75 
6681137 acyl-CoA-binding protein isoform 2  231 
16905127 acyl-coenzyme A synthetase ACSM1, 
mitochondrial  
146 
19527306 adenosine kinase isoform 1  112 
262263372 adenosylhomocysteinase  1393 
34328230 adenylate kinase 2, mitochondrial isoform 
b  
303 
157951604 adenylyl cyclase-associated protein 1  155 
22094075 ADP/ATP translocase 2  206 
6680720 ADP-ribosylation factor 4  183 
240120054 aflatoxin B1 aldehyde reductase member 2  122 
61743961 AHNAK nucleoprotein isoform 1  244 
34610207 alanine--tRNA ligase, cytoplasmic  104 
10946870 alcohol dehydrogenase [NADP(+)]  316 
6724311 alcohol dehydrogenase 1  196 
26080429 aldehyde dehydrogenase family 16 
member A1  
69 
30520135 aldehyde dehydrogenase family 8 member 
A1  
410 
7106242 aldehyde dehydrogenase, cytosolic 1  138 
6753036 aldehyde dehydrogenase, mitochondrial 
precursor  
1630 
171846276 aldo-keto reductase family 1 member C13  94 
85719330 aldo-keto reductase family 1, member C12  70 
160707894 aldose reductase  153 
61097906 alpha-actinin-1  202 
11230802 alpha-actinin-4  117 
188035915 alpha-aminoadipic semialdehyde 
dehydrogenase isoform b  
273 
31980703 alpha-aminoadipic semialdehyde synthase, 
mitochondrial  
449 
46518506 alpha-methylacyl-CoA racemase  87 
257196228 amine oxidase [flavin-containing] B  97 
124517663 annexin A1  711 
6996913 annexin A2  791 
160707925 annexin A3  131 
161016799 annexin A4  432 
6753060 annexin A5  1265 
31981302 annexin A6 isoform a  126 
21313640 AP-2 complex subunit beta isoform b  70 
160333304 apolipoprotein A-I preproprotein  66 
163644329 apolipoprotein E precursor  60 
6755004 apoptosis-inducing factor 1, mitochondrial 
precursor  
99 
7106255 arginase-1  2912 
19526986 argininosuccinate lyase  766 
6996911 argininosuccinate synthase  617 
219275596 asparagine--tRNA ligase, cytoplasmic 
isoform 2  
129 
160298209 aspartate aminotransferase, cytoplasmic  246 
6754036 aspartate aminotransferase, mitochondrial  213 
6680748 ATP synthase subunit alpha, 
mitochondrial precursor  
1753 
31980648 ATP synthase subunit beta, mitochondrial 
precursor  
3397 
21313679 ATP synthase subunit d, mitochondrial  105 
166851828 ATP synthase subunit delta, mitochondrial 
precursor  
94 
83715998 ATP synthase subunit e, mitochondrial  52 
31980744 ATP synthase subunit g, mitochondrial  292 
163838641 ATP synthase subunit gamma, 
mitochondrial isoform a  
275 
20070412 ATP synthase subunit O, mitochondrial 
precursor  
368 
313151222 ATP-citrate synthase isoform 1  80 
19527256 ATP-dependent RNA helicase DDX1  105 
38372907 ATP-dependent RNA helicase DDX39A  49 
6753620 ATP-dependent RNA helicase DDX3X  90 
31981310 B-cell receptor-associated protein 31  76 
7709990 betaine--homocysteine S-
methyltransferase 1  
1110 
21703976 bifunctional ATP-dependent 
dihydroxyacetone kinase/FAD-AMP lyase 
(cyclizing)  
555 
31982393 bifunctional epoxide hydrolase 2  746 
227908823 bifunctional purine biosynthesis protein 
PURH  
76 
261878543 C-1-tetrahydrofolate synthase, 
cytoplasmic  
262 
7657583 calcium-binding mitochondrial carrier 
protein Aralar2 isoform 1  
167 
21704156 caldesmon 1  74 
6671664 calnexin precursor  357 
6680836 calreticulin precursor  195 
124248512 carbamoyl-phosphate synthase 
[ammonia], mitochondrial precursor  
5409 
31982861 carbonic anhydrase 3  1699 
117553604 carboxylesterase 1D precursor  126 
257743052 carboxylesterase 3A isoform 1 precursor  69 
226874914 carboxylesterase 3B isoform 1 precursor  354 
157951741 catalase  786 
6680888 CD63 antigen  50 
15617203 chloride intracellular channel protein 1  82 
13385942 citrate synthase, mitochondrial precursor  90 
6680924 cofilin-1  1457 
6671746 cofilin-2  193 
34328108 collagen alpha-1(I) chain precursor  102 
41152517 core histone macro-H2A.1 isoform 1  80 
189409138 cullin-associated NEDD8-dissociated 
protein 1  
46 
22122387 cystathionine gamma-lyase  126 
148747198 cysteine--tRNA ligase, cytoplasmic 
isoform 1  
65 
13385268 cytochrome b5  173 
46593021 cytochrome b-c1 complex subunit 1, 
mitochondrial precursor  
98 
22267442 cytochrome b-c1 complex subunit 2, 
mitochondrial precursor  
383 
6753498 cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial precursor  
177 
112181182 cytochrome c oxidase subunit 5A, 
mitochondrial precursor  
183 
34538601 cytochrome c oxidase subunit II  270 
13385006 cytochrome c1, heme protein, 
mitochondrial  
133 
19526798 cytochrome P450 2A12 precursor  139 
116268125 cytochrome P450 2C29 precursor  118 
268607560 cytochrome P450 2C50 isoform 1 
precursor  
66 
31981816 cytochrome P450 2D10  239 
13386414 cytochrome P450 2D26  144 
160948612 cytochrome P450 2D9  167 
11276065 cytochrome P450 2E1  152 
124001560 cytochrome P450 2F2 precursor  221 
148747522 cytochrome P450, family 2, subfamily d, 
polypeptide 22  
128 
110347487 cytoplasmic aconitate hydratase  438 
134288917 cytoplasmic dynein 1 heavy chain 1  91 
62526118 cytoskeleton-associated protein 4  56 
255069715 cytosol aminopeptidase  201 
27532959 cytosolic 10-formyltetrahydrofolate 
dehydrogenase  
121 
31981273 cytosolic non-specific dipeptidase  79 
52353955 D-3-phosphoglycerate dehydrogenase  442 
170014720 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor  
214 
6753618 D-dopachrome decarboxylase  395 
7949037 delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial precursor  
139 
225543103 delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial precursor  
408 
34328485 delta-aminolevulinic acid dehydratase  95 
9790219 destrin  53 
7106289 dihydrofolate reductase  74 
31982856 dihydrolipoyl dehydrogenase, 
mitochondrial precursor  
138 
257796245 dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  
143 
21313536 dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial  
114 
21312520 dihydropteridine reductase  559 
21311901 dimethylglycine dehydrogenase, 
mitochondrial precursor  
954 
56699423 E3 ubiquitin-protein ligase NEDD4  76 
31542602 ELAV-like protein 1  46 
227500281 electron transfer flavoprotein subunit 
alpha, mitochondrial  
1467 
38142460 electron transfer flavoprotein subunit beta  264 
126032329 elongation factor 1-alpha 1  273 
31980922 elongation factor 1-beta  329 
110625979 elongation factor 1-gamma  150 
33859482 elongation factor 2  78 
6755863 endoplasmin precursor  187 
31981810 enoyl-CoA delta isomerase 1, 
mitochondrial precursor  
484 
160333193 enoyl-CoA delta isomerase 2, 
mitochondrial isoform a  
99 
29789289 enoyl-CoA hydratase, mitochondrial 
precursor  
238 
12963667 epididymal secretory protein E1 precursor  49 
19526926 ester hydrolase C11orf54 homolog  59 
13487925 estradiol 17 beta-dehydrogenase 5  680 
9789991 estradiol 17-beta-dehydrogenase 12  115 
157951743 estradiol 17-beta-dehydrogenase 8  62 
21450625 eukaryotic initiation factor 4A-I isoform 1  262 
22203755 eukaryotic translation initiation factor 3 
subunit C  
106 
83921618 ezrin  89 
359279938 farnesyl pyrophosphate synthase isoform 
1 precursor  
170 
93102409 fatty acid synthase  764 
14149635 fatty acid-binding protein, adipocyte  244 
8393343 fatty acid-binding protein, liver  2409 
75677435 fatty aldehyde dehydrogenase  140 
6753912 ferritin heavy chain  133 
114326466 ferritin light chain 1  434 
125347376 filamin-A  259 
145966915 filamin-B  81 
124487139 filamin-C  67 
18252784 formimidoyltransferase-cyclodeaminase  367 
9506589 fructose-1,6-bisphosphatase 1  921 
6671539 fructose-bisphosphate aldolase A isoform 
2  
1658 
21450291 fructose-bisphosphate aldolase B  3196 
226823367 fumarate hydratase, mitochondrial 
precursor  
205 
240120112 fumarylacetoacetase  370 
6678682 galectin-1  1701 
329755239 gelsolin isoform 2  166 
254553458 glucose-6-phosphate isomerase  180 
6679465 glucosidase 2 subunit beta precursor  56 
6680027 glutamate dehydrogenase 1, mitochondrial 
precursor  
404 
31982332 glutamine synthetase  95 
390190196 glutaryl-CoA dehydrogenase, 
mitochondrial  
57 
84871986 glutathione peroxidase 1  199 
31981724 glutathione S-transferase A3  492 
21313138 glutathione S-transferase kappa 1  129 
6754084 glutathione S-transferase Mu 1  808 
6680121 glutathione S-transferase Mu 2  435 
6754086 glutathione S-transferase Mu 5  97 
6754090 glutathione S-transferase omega-1  203 
10092608 glutathione S-transferase P 1  93 
6679937 glyceraldehyde-3-phosphate 
dehydrogenase  
1495 
6753966 glycerol-3-phosphate dehydrogenase 
[NAD(+)], cytoplasmic  
234 
22122359 glycine N-acyltransferase  532 
268835741 glycine N-acyltransferase-like protein  97 
6754026 glycine N-methyltransferase  825 
93102417 glycine--tRNA ligase  121 
268836255 glycogen phosphorylase, liver form  648 
17933768 glyoxylate reductase/hydroxypyruvate 
reductase  
91 
13277394 grpE protein homolog 1, mitochondrial 
precursor  
51 
23956104 GTP:AMP phosphotransferase, 
mitochondrial  
119 
6680047 guanine nucleotide-binding protein 
subunit beta-2-like 1  
490 
13386120 H/ACA ribonucleoprotein complex 
subunit 2  
46 
112293266 heat shock 70 kDa protein 4  226 
31981690 heat shock cognate 71 kDa protein  1896 
114145505 heat shock protein 105 kDa  84 
13385998 heat shock protein 75 kDa, mitochondrial 
precursor  
305 
6754254 heat shock protein HSP 90-alpha  1041 
40556608 heat shock protein HSP 90-beta  1507 
145301549 hemoglobin alpha, adult chain 2  745 
31982300 hemoglobin subunit beta-1  1890 
6754222 heterogeneous nuclear ribonucleoprotein 
A/B isoform 2  
78 
226443091 heterogeneous nuclear ribonucleoprotein 
A0  
52 
6754220 heterogeneous nuclear ribonucleoprotein 
A1 isoform a  
85 
157277969 heterogeneous nuclear ribonucleoprotein 
A3 isoform c  
288 
19527048 heterogeneous nuclear ribonucleoprotein F  272 
10946928 heterogeneous nuclear ribonucleoprotein 
H  
114 
13384620 heterogeneous nuclear ribonucleoprotein 
K  
274 
21313308 heterogeneous nuclear ribonucleoprotein 
M isoform a  
94 
160333923 heterogeneous nuclear ribonucleoprotein 
U  
144 
32880197 heterogeneous nuclear ribonucleoproteins 
A2/B1 isoform 2  
172 
8393544 heterogeneous nuclear ribonucleoproteins 
C1/C2 isoform 1  
129 
225735584 hexokinase-1 isoform HK1  59 
6754208 high mobility group protein B1  71 
6754152 histidine ammonia-lyase  64 
33468857 histidine triad nucleotide-binding protein 
1  
78 
31560697 histone H1.0  78 
9845257 histone H1.2  163 
254588110 histone H1.3  123 
13430890 histone H1.4  130 
21426893 histone H1.5  73 
29244126 histone H2A.J  444 
7949045 histone H2A.Z  165 
21361209 histone H4  1121 
111038118 hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial precursor  
278 
227499238 hydroxyacylglutathione hydrolase, 
mitochondrial isoform 1 precursor  
59 
171543858 hydroxymethylglutaryl-CoA lyase, 
mitochondrial precursor  
190 
88014720 importin subunit beta-1  320 
6678281 indolethylamine N-methyltransferase  321 
27754065 inorganic pyrophosphatase  141 
18250284 isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial precursor  
105 
162417975 isocitrate dehydrogenase [NADP] 
cytoplasmic  
429 
225579033 isocitrate dehydrogenase [NADP], 
mitochondrial precursor  
81 
145580629 keratin Kb40  57 
112983636 keratin, type I cytoskeletal 10  73 
254540068 keratin, type I cytoskeletal 18  199 
7106337 keratin, type I cytoskeletal 27  48 
126116585 keratin, type II cytoskeletal 1  59 
51092293 keratin, type II cytoskeletal 1b  60 
85701680 keratin, type II cytoskeletal 2 oral  47 
47059013 keratin, type II cytoskeletal 73  64 
29789317 keratin, type II cytoskeletal 75  88 
22164776 keratin, type II cytoskeletal 79  61 
114145561 keratin, type II cytoskeletal 8  52 
31982229 ketohexokinase  206 
27229113 kynureninase  51 
165932331 lactoylglutathione lyase  143 
188219589 lamin-B1  49 
19527026 leucine-rich repeat-containing protein 59  61 
21450339 liver carboxylesterase B-1 precursor  108 
6754524 L-lactate dehydrogenase A chain isoform 
1  
1053 
31982520 long-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor  
159 
31560705 long-chain-fatty-acid--CoA ligase 1  391 
58218988 long-chain-fatty-acid--CoA ligase 5  129 
113195678 lysosome-associated membrane 
glycoprotein 1 precursor  
51 
169790977 major urinary protein 10 precursor  977 
317008607 major urinary protein 14 precursor  1085 
113930712 major urinary protein 2 precursor  521 
59858561 major urinary protein 20 precursor  70 
88196796 major urinary protein 3 precursor  104 
254540027 malate dehydrogenase, cytoplasmic  430 
31982186 malate dehydrogenase, mitochondrial 
precursor  
1224 
6754092 maleylacetoacetate isomerase isoform 1  340 
31981106 mannosyl-oligosaccharide glucosidase  46 
6680618 medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor  
48 
31980806 membrane-associated progesterone 
receptor component 1  
115 
19527258 methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial 
precursor  
423 
31981068 microsomal glutathione S-transferase 1  192 
254540023 microsomal triglyceride transfer protein 
large subunit isoform 1 precursor  
60 
9790055 mitochondrial carrier homolog 2  54 
254826790 mitochondrial dicarboxylate carrier  76 
70778915 moesin  94 
19526848 MOSC domain-containing protein 2, 
mitochondrial precursor  
61 
31982724 myb-binding protein 1A  165 
33620739 myosin light polypeptide 6  67 
33598964 myosin-10  107 
241982716 myosin-11 isoform 1  312 
114326446 myosin-9 isoform 1  1451 
54292135 N(4)-(beta-N-acetylglucosaminyl)-L-
asparaginase isoform 1 precursor  
48 
13195624 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 10, 
mitochondrial precursor  
77 
58037109 NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 10  
169 
281485615 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 4, mitochondrial  
94 
19745150 NADH-cytochrome b5 reductase 3  530 
229892316 NADH-ubiquinone oxidoreductase 75 
kDa subunit, mitochondrial precursor  
80 
162139827 NADP-dependent malic enzyme isoform 1  239 
163965357 nascent polypeptide-associated complex 
subunit alpha isoform a  
221 
6679891 neutral alpha-glucosidase AB  77 
45476581 non-specific lipid-transfer protein  204 
84875537 nucleolin  53 
6679108 nucleophosmin isoform 1  459 
37700232 nucleoside diphosphate kinase A  303 
7657357 nucleosome assembly protein 1-like 1 
isoform 2  
67 
8393866 ornithine aminotransferase, mitochondrial 
precursor  
96 
6679184 ornithine carbamoyltransferase, 
mitochondrial precursor  
1858 
9910482 PCTP-like protein  62 
6679439 peptidyl-prolyl cis-trans isomerase A  1524 
71774133 peptidyl-prolyl cis-trans isomerase B 
precursor  
259 
6754976 peroxiredoxin-1  286 
148747558 peroxiredoxin-2  666 
6671549 peroxiredoxin-6  1078 
6753622 peroxisomal 2,4-dienoyl-CoA reductase  247 
66793429 peroxisomal acyl-coenzyme A oxidase 1  200 
31541815 peroxisomal bifunctional enzyme  660 
165972342 peroxisomal coenzyme A diphosphatase 
NUDT7 isoform 1  
78 
227908837 peroxisomal trans-2-enoyl-CoA reductase  182 
31560132 phenazine biosynthesis-like domain-
containing protein 1  
185 
13385584 phenazine biosynthesis-like domain-
containing protein 2  
224 
171543886 phenylalanine-4-hydroxylase  114 
84794552 phosphatidylethanolamine-binding protein 
1  
373 
7110683 phosphoenolpyruvate carboxykinase, 
cytosolic [GTP]  
207 
227330633 phosphoglucomutase-2  253 
70778976 phosphoglycerate kinase 1  712 
114326546 phosphoglycerate mutase 1  365 
54292132 phosphoserine aminotransferase isoform 1  75 
6679525 phosphotriesterase-related protein  57 
165932375 plasminogen activator inhibitor 1 RNA-
binding protein isoform 1  
115 
6754994 poly(rC)-binding protein 1  140 
291327528 poly(rC)-binding protein 2 isoform 4  78 
31560656 polyadenylate-binding protein 1  96 
116517301 polypyrimidine tract-binding protein 1 
isoform 1  
91 
94383782 PREDICTED: 40S ribosomal protein S2-
like  
91 
149272413 PREDICTED: 60S ribosomal protein L23-
like  
124 
63572172 PREDICTED: 60S ribosomal protein 
L27a-like  
53 
407262235 PREDICTED: adenosylhomocysteinase-
like  
59 
407262010 PREDICTED: protein AHNAK2-like  112 
162287370 prelamin-A/C isoform A  282 
161760667 prelamin-A/C isoform C  366 
13385656 probable 4-hydroxy-2-oxoglutarate 
aldolase, mitochondrial precursor  
143 
83816893 probable ATP-dependent RNA helicase 
DDX5  
97 
31542409 probable N-acetyltransferase CML2  52 
6755040 profilin-1  215 
6679299 prohibitin  222 
126723336 prohibitin-2  118 
7242171 propionyl-CoA carboxylase alpha chain, 
mitochondrial precursor  
57 
6755100 propionyl-CoA carboxylase beta chain, 
mitochondrial precursor  
50 
33563282 proteasome subunit alpha type-1  58 
134031994 proteasome subunit alpha type-2  80 
261824000 proteasome subunit alpha type-3  63 
7106387 proteasome subunit alpha type-5  110 
6755198 proteasome subunit alpha type-6  117 
7106389 proteasome subunit alpha type-7  80 
6755202 proteasome subunit beta type-3  72 
6755204 proteasome subunit beta type-5  232 
238231384 proteasome subunit beta type-6 precursor  58 
9903607 protein disulfide-isomerase A3 precursor  324 
112293264 protein disulfide-isomerase A4 precursor  109 
58037267 protein disulfide-isomerase A6 precursor  378 
42415475 protein disulfide-isomerase precursor  385 
55741460 protein ETHE1, mitochondrial precursor  63 
12963539 protein FAM49B  66 
22324938 protein kinase C delta-binding protein  64 
7305305 protein NDRG2 isoform 1  53 
6679066 protein NipSnap homolog 1  105 
21886811 protein S100-A11  252 
7305395 purine nucleoside phosphorylase  162 
14861844 putative ATP-dependent RNA helicase 
Pl10  
56 
31560090 pyrroline-5-carboxylate reductase 1, 
mitochondrial  
57 
26006861 pyruvate carboxylase, mitochondrial 
isoform 2  
1345 
6679261 pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, 
mitochondrial precursor  
50 
18152793 pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial precursor  
210 
31981562 pyruvate kinase isozymes M1/M2 isoform 
1  
91 
359807367 pyruvate kinase isozymes M1/M2 isoform 
2  
468 
153792131 pyruvate kinase isozymes R/L isoform 1  83 
33859530 quinone oxidoreductase  261 
116089273 rab GDP dissociation inhibitor beta  292 
157277948 radixin isoform a  120 
153792001 ras GTPase-activating-like protein 
IQGAP1  
115 
7305075 ras-related C3 botulinum toxin substrate 1 
precursor  
55 
30841008 ras-related protein Rab-1A  54 
6679587 ras-related protein Rab-2A  118 
148747526 ras-related protein Rab-7a  248 
6677739 regucalcin  963 
85861182 retinal dehydrogenase 1  644 
6677697 retinol dehydrogenase 16  77 
8567342 retinol dehydrogenase 7 precursor  92 
31982030 rho GDP-dissociation inhibitor 1  191 
40807498 ribonuclease UK114  466 
124486712 ribosome-binding protein 1 isoform a  46 
19526790 S-adenosylmethionine synthase isoform 
type-1  
200 
20149748 sarcosine dehydrogenase, mitochondrial  849 
21362309 SEC14-like protein 2  77 
22164798 selenium-binding protein 1  1208 
9507079 selenium-binding protein 2  1647 
160333789 sepiapterin reductase  154 
6754816 septin-7 isoform 1  63 
28173550 serine hydroxymethyltransferase, 
cytosolic  
51 
6755478 serine/arginine-rich splicing factor 2  71 
8394027 serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha 
isoform  
52 
111038130 serine--pyruvate aminotransferase, 
mitochondrial  
154 
20330802 serotransferrin precursor  61 
161353502 serpin H1 precursor  138 
163310765 serum albumin precursor  319 
31982522 short-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor  
193 
15147224 sideroflexin-1  87 
45544618 S-methyl-5~-thioadenosine phosphorylase  137 
23943838 solute carrier family 25, member 1  46 
22128627 sorbitol dehydrogenase  339 
77404392 staphylococcal nuclease domain-
containing protein 1  
221 
12963591 stress-70 protein, mitochondrial  647 
162461907 stress-induced-phosphoprotein 1  150 
34328286 succinate dehydrogenase [ubiquinone] 
iron-sulfur subunit, mitochondrial 
precursor  
113 
255958286 succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial precursor  
77 
46849708 succinyl-CoA ligase [ADP-forming] 
subunit beta, mitochondrial precursor  
66 
165972309 succinyl-CoA ligase [GDP-forming] 
subunit beta, mitochondrial precursor  
133 
18266680 succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial precursor  
174 
28202011 sulfotransferase-like protein 1  396 
7709986 SUMO-activating enzyme subunit 2  66 
45597447 superoxide dismutase [Cu-Zn]  626 
31980762 superoxide dismutase [Mn], mitochondrial 
precursor  
104 
33859662 synaptic vesicle membrane protein VAT-1 
homolog  
66 
227116327 talin-1  225 
126521835 T-complex protein 1 subunit beta  340 
6753322 T-complex protein 1 subunit delta  155 
6671702 T-complex protein 1 subunit epsilon  51 
238814391 T-complex protein 1 subunit eta  129 
6753320 T-complex protein 1 subunit gamma  149 
126723461 T-complex protein 1 subunit theta  119 
6753324 thioredoxin  321 
6755911 thiosulfate sulfurtransferase  273 
6755763 threonine--tRNA ligase, cytoplasmic  55 
27229277 trans-1,2-dihydrobenzene-1,2-diol 
dehydrogenase  
57 
30519911 transgelin-2  497 
225543319 transitional endoplasmic reticulum 
ATPase  
1080 
6678359 transketolase  359 
6678437 translationally-controlled tumor protein  144 
165377206 translocon-associated protein subunit 
alpha precursor  
56 
21312062 transmembrane emp24 domain-containing 
protein 10 precursor  
168 
33859811 trifunctional enzyme subunit alpha, 
mitochondrial precursor  
904 
21704100 trifunctional enzyme subunit beta, 
mitochondrial precursor  
135 
226958349 triosephosphate isomerase  1217 
256000788 tropomyosin alpha-1 chain isoform 6  66 
47894398 tropomyosin alpha-4 chain  216 
71043961 trypsinogen 7 precursor  73 
6755901 tubulin alpha-1A chain  988 
6678469 tubulin alpha-1C chain  1223 
6678467 tubulin alpha-4A chain  782 
21746161 tubulin beta-2B chain  1317 
22165384 tubulin beta-4B chain  1404 
7106439 tubulin beta-5 chain  1484 
18017605 ubiquitin-conjugating enzyme E2 N  68 
6678483 ubiquitin-like modifier-activating enzyme 
1 isoform 1  
437 
284413688 UDP glucuronosyltransferase 1 family, 
polypeptide A6B precursor  
153 
6678499 UDP-glucose 6-dehydrogenase  161 
145699099 UDP-glucuronosyltransferase 1-1 
precursor  
607 
145864463 UDP-glucuronosyltransferase 1-9 
precursor  
483 
306518591 UDP-glucuronosyltransferase 2B17 
precursor  
323 
22779901 UDP-glucuronosyltransferase 2B4 
precursor  
151 
70794816 uncharacterized protein LOC433182  2095 
6678509 uricase  261 
172072677 urocanate hydratase  47 
21314832 UTP--glucose-1-phosphate 
uridylyltransferase  
151 
9790285 vacuolar protein sorting-associated protein 
29  
89 
21624609 valacyclovir hydrolase precursor  196 
113374154 very long-chain acyl-CoA synthetase  61 
23956084 very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor  
144 
31982755 vimentin  1406 
31543942 vinculin  402 
6755963 voltage-dependent anion-selective channel 
protein 1  
204 
6755965 voltage-dependent anion-selective channel 
protein 2  
107 
45504359 V-type proton ATPase subunit E 1  49 
77682555 xanthine dehydrogenase/oxidase  57 
 
 
Supplementary Table 5. Commonly quantified proteins in the liver of mice fed a diet 
containing 0.03 gm% of hydroxytyrosol and controls. 
Protein 
abbreviation 
Protein full name Mascot 
score 
RSILAC RSD 
Rpl23 60S ribosomal protein L23 124 5.38 17.29 
Hbb-bt hemoglobin subunit beta-1 1298 5.24 5.88 
Aco1 cytoplasmic aconitate hydratase 438 3.22 16.45 
Vcl vinculin 402 2.63 19.75 
Hpd 4-hydroxyphenylpyruvate dioxygenase 282 2.59 17.52 
Ces3a carboxylesterase 3A isoform 1 
precursor 
69 2.27 13.49 
Hba-a2 hemoglobin alpha 745 2.16 7.13 
Aldh7a1 alpha-aminoadipic semialdehyde 
dehydrogenase isoform b 
273 1.99 14.47 
Car3 carbonic anhydrase 3 1699 1.90 14.86 
Gsn gelsolin isoform 2 166 1.61 11.47 
Pcx pyruvate carboxylase, mitochondrial 
isoform 2 
1345 1.61 17.92 
Prdx2 peroxiredoxin-2 666 1.60 11.63 
Cfl1 cofilin-1 1457 1.58 18.79 
Hspa9 stress-70 protein, mitochondrial 647 1.57 17.47 
Uba1 ubiquitin-like modifier-activating 
enzyme 1 isoform 1 
437 1.52 17.86 
Actn4 alpha-actinin-4 117 1.52 19.87 
Anxa1 annexin A1 711 1.49 17.90 
Cps1 carbamoyl-phosphate synthase 
[ammonia] 
47 1.47 18.72 
Sardh sarcosine dehydrogenase, mitochondrial 849 1.45 19.93 
Acta2 actin, aortic smooth muscle 674 1.42 8.45 
Actn1 alpha-actinin-1 202 1.39 19.73 
Aldh2 aldehyde dehydrogenase, mitochondrial 
precursor 
1630 1.36 18.22 
Otc ornithine carbamoyltransferase, 
mitochondrial precursor 
1858 1.34 16.10 
Hsp90b1 endoplasmin precursor 177 1.31 19.77 
Glo1 lactoylglutathione lyase 143 1.27 12.34 
Cs citrate synthase, mitochondrial 
precursor 
90 1.24 15.15 
Flna filamin-A 259 1.22 16.65 
Ppib peptidyl-prolyl cis-trans isomerase B 
precursor 
259 1.22 18.78 
Vim vimentin 1406 1.22 16.88 
Rpl4 60S ribosomal protein L4 132 1.21 8.05 
Hsp90ab1 heat shock protein HSP 90-beta 1507 1.19 18.09 
Tkt transketolase 359 1.18 9.37 
Eef2 elongation factor 2 82 1.16 19.32 
Atp5a1 ATP synthase subunit alpha, 
mitochondrial precursor 
1753 1.15 19.37 
Slc25a5 ADP/ATP translocase 2 135 1.14 19.48 
Vcp transitional endoplasmic reticulum 
ATPase 
1080 1.13 19.30 
Ncl nucleolin 575 1.10 11.61 
Alb serum albumin precursor 37.9 1.10 19.16 
Rps9 40S ribosomal protein S9 120 1.09 8.70 
Hspa5 78 kDa glucose-regulated protein 
precursor 
1187 1.08 19.86 
Pfn1 profilin-1 215 1.07 17.72 
Rps3a1 40S ribosomal protein S3a 63 1.06 14.61 
Phgdh D-3-phosphoglycerate dehydrogenase 442 1.05 12.75 
Hsp90aa1 heat shock protein HSP 90-alpha 1041 1.05 16.61 
Rpl23a 60S ribosomal protein L23a 233 1.05 13.44 
Rpl11 60S ribosomal protein L11 189 1.04 19.62 
Acaa2 3-ketoacyl-CoA thiolase, mitochondrial 1139 1.04 17.42 
Rpl18a 60S ribosomal protein L18a 59 1.04 17.79 
Idh1 isocitrate dehydrogenase [NADP] 
cytoplasmic 
401 1.03 17.71 
Nme2 nucleoside diphosphate kinase B 404 1.03 19.52 
Atp5b ATP synthase subunit beta, 
mitochondrial precursor 
3397 1.01 19.80 
Eef1a1 elongation factor 1-alpha 1 93 1.01 19.26 
Sod1 superoxide dismutase [Cu-Zn] 626 1.00 19.57 
Eno1b uncharacterized protein LOC433182 2095 1.00 18.29 
Bhmt betaine--homocysteine S-
methyltransferase 1 
1110 -1.02 15.64 
Hspa8 heat shock cognate 71 kDa protein 1896 -1.03 19.92 
Anxa5 annexin A5 1265 -1.04 18.71 
Ahcy adenosylhomocysteinase 1393 -1.05 18.32 
Rpl12 60S ribosomal protein L12 154 -1.05 16.88 
Ldha L-lactate dehydrogenase A chain 
isoform 1 
4053 -1.06 19.93 
Acaa1b 3-ketoacyl-CoA thiolase B. peroxisomal 
precursor 
844 -1.11 14.34 
Hadhb trifunctional enzyme subunit beta, 
mitochondrial precursor 
135 -1.12 17.24 
Actb actin. cytoplasmic 1 379 -1.13 19.09 
Hist2h4 histone H4 1121 -1.15 19.97 
Mdh2 malate dehydrogenase, mitochondrial 
precursor 
1170 -1.17 15.22 
Acsl1 long-chain-fatty-acid--CoA ligase 1 391 -1.19 12.45 
Hspd1 60 kDa heat shock protein, 
mitochondrial 
2147 -1.21 19.80 
Canx calnexin precursor 357 -1.22 18.25 
Mdh1 malate dehydrogenase. cytoplasmic 430 -1.27 8.54 
Myh9 myosin-9 isoform 1 1451 -1.30 18.91 
Gapdh glyceraldehyde-3-phosphate 
dehydrogenase 
1495 -1.31 19.42 
Pgk1 phosphoglycerate kinase 1 712 -1.31 19.55 
Ywhaz 14-3-3 protein zeta/delta isoform 1 1270 -1.33 17.46 
Arg1 arginase-1 127 -1.35 16.76 
Uqcrc2 cytochrome b-c1 complex subunit 2, 
mitochondrial precursor 
383 -1.35 16.06 
Rps10 40S ribosomal protein S10 62 -1.37 17.46 
Tubb5 tubulin beta-5 chain 1484 -1.38 19.55 
Rpl10a 60S ribosomal protein L10a 70 -1.40 17.51 
Aco2 aconitate hydratase, mitochondrial 
precursor 
525 -1.42 18.74 
Rpl24 60S ribosomal protein L24 306 -1.45 16.76 
Acads short-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor 
242 -1.46 18.75 
Ppia peptidyl-prolyl cis-trans isomerase A 1524 -1.47 18.28 
Aldh1a1 retinal dehydrogenase 1 644 -1.50 7.25 
Sord sorbitol dehydrogenase 339 -1.53 12.52 
Pdia3 protein disulfide-isomerase A3 
precursor 
324 -1.56 13.10 
Aldob fructose-bisphosphate aldolase B 3196 -1.59 14.14 
Rrbp1 ribosome-binding protein 1 isoform a 46 -1.61 14.89 
P4hb protein disulfide-isomerase precursor 385 -1.71 18.92 
Aldh6a1 methylmalonate-semialdehyde 
dehydrogenase [acylating], 
mitochondrial precursor 
305 -1.92 17.63 
Pygl glycogen phosphorylase. liver form 648 -1.93 19.20 
Eif4a1 eukaryotic initiation factor 4A-I isoform 
1 
313 -1.95 15.40 
Glud1 glutamate dehydrogenase 1, 
mitochondrial precursor 
231 -1.96 12.28 
Hadh hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial precursor 
278 -2.01 17.07 
Prdx1 peroxiredoxin-1 286 -2.17 19.79 
Aldoa fructose-bisphosphate aldolase A 
isoform 2 
1658 -2.18 9.02 
Npm1 nucleophosmin isoform 1 459 -2.22 16.91 
Got2 aspartate aminotransferase, 
mitochondrial 
54 -2.22 17.19 
Hadha trifunctional enzyme subunit alpha, 
mitochondrial precursor 
659 -2.26 17.33 
Ftl1 ferritin light chain 1 434 -2.44 14.41 
Aldh4a1 delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial precursor 
408 -3.20 4.38 
Rpl23 catalase 251 -3.23 19.73 
Hbb-bt fatty acid synthase 764 -3.69 17.58 
Aco1 argininosuccinate lyase 766 -3.71 11.41 
Vcl bifunctional epoxide hydrolase 2 746 -4.31 18.49 
Hpd argininosuccinate synthase 927 -4.85 18.94 
Ces3a dimethylglycine dehydrogenase, 
mitochondrial precursor 
954 -5.27 18.64 
 
 
Supplementary table 6. Additional proteins identified in liver after expanding search 
to include Y, S and T protein phosphorylation.  
GI number Protein name Mascot score 
6677799 40S ribosomal protein S15  114 
219276601 asparagine--tRNA ligase, cytoplasmic 
isoform 1  
116 
82617575 bifunctional glutamate/proline--tRNA 
ligase  
711 
6753284 caspase-3  325 
148747410 coatomer subunit delta  76 
339895744 collagen alpha-3(VI) chain isoform 1 
precursor  
96 
126518317 complement C3 precursor  49 
113680661 corticosteroid 11-beta-dehydrogenase 
isozyme 1  
77 
157154304 cytochrome P450 2D11  184 
6681273 elongation factor 1-alpha 2  78 
54287684 elongation factor 1-delta isoform b  138 
60687506 fructose-bisphosphate aldolase C  103 
32401425 glutathione S-transferase P 2  82 
21450105 glutathione S-transferase P-like  149 
183980004 heterogeneous nuclear ribonucleoprotein 
L  
64 
31560689 hydroxymethylglutaryl-CoA synthase, 
mitochondrial precursor  
628 
9789985 isovaleryl-CoA dehydrogenase, 
mitochondrial precursor  
54 
21489935 keratin, type I cytoskeletal 14  47 
226823220 keratin, type I cytoskeletal 15  47 
6680604 keratin, type I cytoskeletal 16  48 
19526922 keratin, type I cytoskeletal 25  47 
283436218 mitochondrial 10-formyltetrahydrofolate 
dehydrogenase  
74 
124486921 MOSC domain-containing protein 1, 
mitochondrial  
59 
19526852 nicotinate-nucleotide pyrophosphorylase 
[carboxylating]  
59 
6679078 nucleoside diphosphate kinase B  358 
21313144 obg-like ATPase 1 isoform a  62 
7948999 peroxiredoxin-4 precursor  81 
309266416 PREDICTED: 40S ribosomal protein 
S15-like isoform 1  
50 
309266590 PREDICTED: 60S ribosomal protein 
L10-like  
85 
309267049 PREDICTED: 60S ribosomal protein 
L17-like  
81 
149272413 PREDICTED: 60S ribosomal protein 
L23a-like  
166 
51712358 PREDICTED: eukaryotic initiation factor 
4A-III-like  
78 
51765047 PREDICTED: tubulin alpha-1C chain 
isoform 1  
856 
407263446 PREDICTED: uncharacterized protein 
LOC667284  
53 
40068493 probable ATP-dependent RNA helicase 
DDX17 isoform 1  
50 
161484668 serine/threonine-protein phosphatase PP1-
beta catalytic subunit  
56 
117938332 spectrin beta chain, non-erythrocytic 1 
isoform 1  
85 
34740335 tubulin alpha-1B chain  387 
27370342 UDP glucuronosyltransferase 2 family, 
polypeptide B35 precursor  
143 
20911031 keratin, type II cytoskeletal 5  70 
113195684 keratin, type II cytoskeletal 6B  58 
9910294 keratin, type II cytoskeletal 71  64 
283436180 heterogeneous nuclear ribonucleoproteins 
C1/C2 isoform 3  
126 
7305229 L-lactate dehydrogenase C chain  68 
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Abstract
Recent epidemiological evidence demonstrated that diabetes
is a risk factor for AD onset and development. Indeed, meta-
analyses of longitudinal epidemiologic studies show that dia-
betes increases AD risk by 50–100%, being insulin resistance
(IR) the main binding link between diabetes and AD. Astro-
cytes are the foremost cerebral macroglial cells and are
responsible for converting glucose into lactate and transfer it
to neurons that use it as fuel, but Ab(1-42) impairs insulin sig-
naling and glycogen storage. Recent prospective studies
showed that the Mediterranean diet is associated with lower
incidence of AD. We hypothesized that hydroxytyrosol (HT,
the preeminent polyphenol of olives and olive oil) could exert
beneficial effects on IR associated with AD and investigated it
mechanisms of action in an astrocytic model of AD. The astro-
cytic cell line C6 was exposed to Ab(25-35) and co-incubated
with HT for different periods. After treatment with Ab(25-35),
astrocytes’ viability was significantly decreased as compared
with controls; however, both pre- and post-treatment with HT
prevented this effect. Mechanistically, we found that the pre-
ventive role of HT on Ab(25-35)- induced cytotoxicity in astro-
cytes is moderated by an increased HT-induced activation of
Akt, which is mediated by the insulin signaling pathway. In
addition, we report that HT prevented the pronounced activa-
tion of mTOR, thereby restoring proper insulin signaling. In
conclusion, we demonstrate that HT protects Ab(25-35)-treated
astrocytes by improving insulin sensitivity and restoring
proper insulin-signaling. These data provide some mechanistic
insight on the observed inverse association between olive oil
consumption and prevalence of cognitive impairment. VC 2017
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1. Introduction
Alzheimer’s disease (AD) is an irreversible neurodegenerative
disorder, characterized by progressive memory deficit and
neuronal loss, whose prevalence is increasing [1,2]. Neuropa-
thologically, AD is characterized by the presence of extracellu-
lar senile plaques containing amyloid b peptides (Ab) and
intracellular neurofibrillary tangles of hyperphosphorylated
tau protein [3]. Both structures damage distinct nerve cells,
inducing neuronal loss. Hyperphosphorylated tau protein indu-
ces changes to the cellular architecture [4] as well as to the
localization and organization of subcellular organelles, in turn
inducing synaptic interruption and apoptotic neuronal death
[5]. In addition, Ab peptides are one of the principal compo-
nents of senile plaques and are considered the dominant
agents of AD pathogenesis [6]. Ab peptides are generated from
amyloidogenic processing of amyloid precursor protein (APP),
which is expressed in many cellular types and tissues, for
example endothelial cells, glial cells, and neurons. Indeed, APP
participates in intracellular communication and signaling
pathways between membrane and nucleus [7]. APP is cleaved
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within the transmembrane domain by c-secretase to release
Ab peptides, mainly Ab[1–40] and Ab[1–42] which constitute
the senile plaques. Ab(1-42) mostly remains in the plaques,
because it is hydrophobic and has a mayor aggregation poten-
tial. Therefore, this fragment represents the core where
Ab[1–40] is deposited [8]. Moreover, the amino-acid sequence
of Ab can be divided into different functional domains, such as
the C-terminus of Ab(1-42) (which has a fragment of 11
amino-acids) and the (25-35) domain, which is responsible for
cytotoxicity and shares with Ab(1-42) the ability to self-
aggregate [9].
The amyloid hypothesis is being proposed to explain AD
onset, but it should be underscored that AD depends on the
interaction between multiple risk factors, for example age >65
years. Recent epidemiological evidence showed that diabetes is
a risk factor for AD onset and development [10–12]. Accord-
ingly, meta-analyses of longitudinal epidemiologic studies
show that diabetes increases AD risk by 50–100%; this
includes type 2 diabetes, which accounts for 90% of all cases
[13,14]. Both disorders share pathophysiological characteris-
tics such as insulin resistance (IR), altered glucose metabolism,
oxidative stress and neuroinflammation, amyloid aggregation,
neuronal degeneration and cognitive decline, being IR the
main binding link between diabetes and AD [15,16].
The insulin-signaling pathway (IR—IRS1/2—PI3K—Akt) is
interrupted in IR because regulatory mechanisms are altered.
In AD, the insulin receptor substrate-1 (IRS1) is hyperphos-
phorylated at serine 636/639 and 616 in the hippocampus and
cortex of AD patients, which leads to a desensitized insulin sig-
naling pathway because IRS1 changes its conformation and can
no longer interact with PI3K, aborting/impeding the activation
of Akt by phosphorylation, in turn blocking glucose cellular
uptake [17,18]. Therefore, many authors proposed the term
“type III diabetes” for AD, precisely because of cerebral IR
[19,20]. Moreover, several works indicate that IR, triggered by
the inhibitory hyperphosphorylation of IRS1, is positively corre-
lated with Ab accumulation via an APP processing regulation
that favors overproduction, accumulation, and deposition of Ab,
which—in a vicious cycle—further stimulates IR [16,21].
Astrocytes are the foremost cerebral macroglial cells; they
are responsible for converting glucose into lactate and transfer
it to neurons that use it as fuel [22]. In addition, astrocytes can
store glucose as glycogen, which is an important neuronal
energy reservoir during period of high activity, for example
learning and memory [23]. Therefore, neurons energetically
depend on substrates provided by astrocytes and any commu-
nication impediment could bear neuronal consequences. Astro-
gliosis is another hallmark of the AD brain, where reactive
astrocytes are surrounding the core of senile plaque and can
even penetrate into them [24]. Both oligomers and deposits of
Ab, among others, can trigger astrogliosis in the AD brain
[25]. Furthermore, recent studies carried out in human astro-
cytes have shown that Ab(1-42) impairs insulin signaling and
glycogen storage [26,27].
Recent prospective studies showed that the Mediterranean
diet is associated with lower incidence of AD [28] and can
improve cognition [29]. Hydroxytyrosol is the preeminent (pol-
y)phenolic component of extra virgin olive oil and is being
actively studied for it manifold biological properties [30–32]. In
addition to its established activities on the cardiovascular sys-
tem, HT is being explored in neurodegeneration [33]. As an
example, in vitro studies have reported that HT is neuropro-
tective against Ab-induced neurotoxicity in neuroblastoma N2a
cells [34]. Likewise, an in vivo study carried out in the AD
APP/PS1 mice model has demonstrated that HT improves elec-
troencephalographic activity and mildly benefits cognitive
behavior of transgenic mice [35]. However, the effect of HT on
IR has been poorly investigated. Pirozzi et al. reported that HT
improves insulin sensitivity and glucose tolerance in an animal
model of IR and non-alcoholic fatty liver disease [36] and a
clinical trial carried out in middle-aged overweight men has
suggested that (poly)phenols from olive leaves might improve
insulin sensitivity [37].
We hypothesized that HT could exert beneficial effects on
IR associated with AD and investigated it mechanisms of
action in an astrocytic model of AD.
2. Materials and methods
2.1. Materials
Ab(25-35) was purchased from Sigma (St. Louis, MO). Ab(25-
35), was dissolved in 9431 lL of sterile PBS and was aged by
incubating it at 378C for 3 days. The solution was aliquoted
into 1-mL tubes, sealed with Parafilm MVR and stored at
2208C. Hydroxytyrosol was kindly donated by Seprox Biotech
(Madrid, Spain) and was dissolved in absolute ethanol to the
desired concentrations.
2.2. Cell line and culture conditions
The astrocytic cell line C6 (rat glioma cells) was purchased
from American Type Culture Collection in partnership with
LGC Standards (Barcelona, Spain). These cells were originally
obtained from a rat glial tumor induced by N-nitrosomethy-
lurea [38]. Astrocytes were routinely cultured in 100 mm cul-
ture dishes in Dulbecco’s modified Eagle’s medium (DMEM)
with 4.5 g/L D-glucose without phenol red and supplemented
with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin–
streptomycin and glutamine (2 mM). All these reagents were
purchased from Thermo Fisher Scientific (Waltham, MA). Cells
were grown at 378C in an atmosphere containing 5% CO2.
2.3. Cell differentiation and treatment of astrocytes
For all experiments, cells were plated in 60 mm culture dishes
(150,000 cells/cm2) or 96-well plates for 72 h, in DMEM con-
taining 10% (v/v) FBS. Once cells reached 80% confluence,
they were differentiated in DMEM, without FBS, but with
0.1 mM cyclic adenosine monophosphate (cAMP) (Sigma, St.
Louis, MO). Cultures were maintained for 48 h in this FBS-free
differentiation medium, to induce the morphological changes
typical of reactive and mature astrocytes [39]. Subsequently,
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astrocytes were treated with 25 lM of Ab(25-35) for 24 h, and/
or treated with 5 lM of HT for 2 h (pretreatment period) and/
or 24 h (post-treatment period) [40], with different combina-
tions giving rise to six experimental groups as shown in Table
1. Astrocytes from control groups received no treatment and
were recollected 24 or 48 h after the differentiation period
(Table 1). Once cells were differentiated, all subsequent treat-
ments and experiments were carried out in DMEM without
FBS. The dose of Ab(25-35) and treatment times were chosen
considering glial fibrillary acidic protein levels as the indicator
of reactive astrocytes (data not shown). Likewise, we used HT
concentration that should be of physiological relevance [32]
and that did not induce cytotoxicity [41]. Three different
experiments were performed in duplicate for each assay.
2.4. Cell viability measurements
The MTT (3-[4,5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazo-
lium bromide, MTT, Sigma) assay is based on the conversion
of MTT into formazan crystals by living cells, which deter-
mines mitochondrial activity and is widely used as a measure
of cell viability. Astrocytes were seeded at a density of 4,000
cells/cm2 into standard 96-well plates, cultured and treated as
described above. After treatments, cells were incubated with
20 mL of MTT reagent (5 mg/mL) for 3 h at 378C. Afterwards,
the media was discarded and the blue formazan crystals were
dissolved in DMSO (Applichem GmbH, Germany). The optical
density of samples was measured by a microplate reader at
560 nm (Biochrom Asys UVM 340, Cambridge, UK).
2.5. Protein extraction and quantification
Astrocytes were grown and differentiated in 60 mm culture
dishes and were exposed to the treatments previously
described. The media was discarded and cells were recollected
in 200 mL lysis buffer: radioimmunoprecipitation assay buffer
(RIPA) buffer (50 mM NaH2PO4, 100 mM Na2HPO4, 0.1%
sodium dodecyl sulfate, 0.5% NaCl, 1% Triton X-100), with
200 mM sodium orthovanadate, 1 mM Pefabloc SC, and 2 mg/
mL protease inhibitor cocktail (Roche Diagnostics, Indianapo-
lis, IN). Samples were incubated overnight at 2808C and then
centrifuged at 14,000 rpm for 30 min at 48C to remove debris
cellular. The combination of cryogenic conditions with the use
of lysis buffer is an excellent method for total extraction, solu-
bilization, and identification of proteins. Clear supernatants
were transferred to new tubes to determine total protein con-
centration by BCA reagent (Pierce, Thermo Fisher Scientific).
2.6. Immunoprecipitation
The associations among targets were studied by immunopreci-
pitation. After treatments, astrocytes were recollected on ice
in 200 lL of lysis buffer pH 7.6 containing 50 mmol/L HEPES,
10 mM EDTA, 50 mmol/L sodium pyrophosphate, 100 mmol/L
NaF, 10 mmol/L Na3VO4, 1% Triton X-100, 2 mmol/L phenyl-
methylsulfonyl fluoride, 10 lg/mL leupeptin, and 10 lg/mL
aprotinin. Then, 150 lg of protein were immunoprecipitated
overnight at 48C with the corresponding antibody and incu-
bated with protein A-agarose beads (Roche Diagnostics, India-
napolis, IN) for 2 h at 48C. Immunocomplexes were washed
with lysis buffer, extracted for 5 min at 958C in 4X SDS-PAGE
sample buffer (200 mmol/L Tris-HCl, 12% SDS, 4 mmol/L
EDTA, 8% 2-mercaptoethanol, 20% glycerol, pH 7.6), and ana-
lyzed by Western blotting as described below. All chemicals
were purchased from Sigma (St. Louis, MO).
2.7. Western blotting
Western blotting was used to quantify the main components of
the insulin-signaling pathway and the associations among
selected targets in astrocytes. Total proteins (30 lg) were
resolved on a 10% SDS-PAGE and then transferred to nitrocel-
lulose membranes. Membranes were blocked with Tris-
buffered saline containing 0.1% Tween 20 (TTBS) containing
5% BSA for 1 h at room temperature. Then, the membranes
were incubated with corresponding primary antibodies
included phosphorylated (p) anti-p-Thr308-Akt, anti-p-Ser473-
Akt, anti-p-mammalian target of rapamycin (mTOR), and their
respective total form; anti-Akt and anti-mTOR. All of them
were from Cell Signaling Technology (Danvers, MA). Anti-p-
Ser636-IRS1, anti-IRS1, anti-regulatory subunit of PI3K (p85),
and anti-transporter glucose 2 (GLUT2) were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA); and anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was from Sigma (St
Louis, MO). All membranes were incubated with the primary
antibodies (diluted 1:1000) in blocking buffer at 48C overnight.
The membranes were washed three times with TTBS and
incubated with the corresponding secondary antibody
Experimental groups originating from different
treatment combinations with hydroxytyrosol (HT) 5
mM for 2 h (pre-treatment) and/or 24 h (post-
treatment), and treatment for 24 h with amyloid b
peptide (25-35) (Ab25-35) 25 mM
Treatments
HT
pre-
treatment
for 2 h
Ab25-35
treatment
for 24 h
HT
post-
treatment
for 24 h
Experimental groups
Control 24 h
2 h HT X
Ab25-35 X
2 h HT 1Ab25-35 X X
Control 48 h
24 h HT X
Ab25-351 24 h HT X X
2 h HT 1Ab25-351 24 h HT X X X
Control 24 h and control 48 h groups received no treatment.
TABLE 1
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conjugated with horseradish peroxidase (Thermo Fisher Sci-
entific, Inc., Waltham, MA) at a dilution of 1:2,000 or 1:5,000
depending on primary antibody, in nonfat milk during 90
min at 258C. All proteins were detected by chemilumines-
cence using an ECL system (PerkinElmer Life Sciences, Bos-
ton, MA) and quantified by densitometry using Adobe Photo-
shop’s (Adobe systems, Inc., Mountain View, CA). All blots
were reblotted with their corresponding total forms or with
anti-GAPDH to normalize each sample for gel-loading
variability.
2.8. Statistical analysis
We performed one-way ANOVAs, followed by a Bonferroni’s
test. Values were considered significantly different when the P
value was<0.05. Statistical analyses were conducted with the
Prism software GraphPad (version 6.00, San Diego, CA). We
present data as means6SD.
3. Results
3.1. Pre- and post-treatment with HT prevents Ab(25-
35)-induced cytotoxicity in astrocytes
We assessed the effects of Ab(25-35) and HT on astrocyte via-
bility by the MTT assay. After treatment with Ab(25-35), astro-
cytes’ viability was significantly decreased as compared with
controls (Table 2); however, both pre- and post-treatment with
HT prevented this effect. The addition of HT alone had no
effect on cell viability with respect to controls. Cell supplemen-
tation with HT before the addition of Ab(25-35) did not avoid
Ab(25-35)-induced decreased viability, because cell viability
(69.462.5%) was significantly lower than of 24-h controls
(10060.2%) (Table 2).
3.2. HT decreases Ab(25-35)-induced
hyperphosphorylation of IRS1
An insulin receptor substrate 1 (IRS1) phosphorylation at ser-
ine 636 inhibits the insulin-signaling pathway, leading to insu-
lin resistance (IR) [42,43]. Numerous post-mortem studies
have indicated that brains of AD patients exhibit IR, exacer-
bated by Ab-induced hyperphosphorylation of IRS1 at serine
636 [17,18]. However, it is not known whether Ab(25-35) indu-
ces this same serine hyperphosphorylation of IRS1 in
astrocytes. We found increased pSer636 IRS1 levels in Ab(25-
35)-stimulated astrocytes (Fig. 1). This finding shows, in astro-
cytes, that Ab(25-35) is able to mimic the central IR associated
with AD. Also, we evaluated the effect of HT on Ab(25-35)-
induced inhibitory hyperphosphorylation of IRS1 in astrocytes
by Western blotting assay. Treatment with HT decreased
Ab(25-35)-increased p-Ser636 ISR1 protein levels, to a point
below control group levels in the Ab(25-35)-treated astrocytes
supplemented with HT post-treatment group (Fig. 1).
Cell viability (%) of astrocytes treated with 25 mM Ab(25-35) and/or 5 mM hydroxytyrosol (HT)
Experimental
groups
Control
24 h 2 h HT Ab(25-35)
2 h HT1Ab
(25-35)
Control
48 h 24 h HT
Ab
(25-35)1
24h HT
2h HT1
Ab(25-35)1
24 h HT
% Cell viability 10060.2 104.36 0.6 52.76 4.5* 69.46 2.5 1006 0.4 10961 100.96 0.5# 10160.3#
The data are percentage of the control6SEM.
*P<0.001 versus control 24 h group.
#P<0.001 versus Ab(25-35) group.
Densitometry from immunoblots derived from the
Western blot analysis of the relative insulin receptor
substrate 1 phosphorylated on serine 636 (p(Ser636)-
IRS1) protein levels in astrocytes treated with amy-
loid beta peptide (25-35) (Ab(25-35)) 25 mM and/or
hydroxytyrosol (HT) 5 mM for 2 (pre-treatment) or
24 h (post-treatment), as well as different combina-
tions of both. The data are percentage of the respec-
tive control ratio6SD. DU, densitometry units.
**P<0.01 compared with control 24 h group;
*P<0.05, **P<0.01, ***P<0.001 compared with
Ab(25-35) group. Three independent experiments
were performed in duplicate.
TABLE 2
FIG 1
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3.3. HT improves insulin response by increasing the
association between p85 and IRS1 in Ab(25-35)-
treated astrocytes
Under normal conditions, after activation of IRS1 by phospho-
rylation this substrate is bound to the regulatory subunit of
PI3K, p85, previous to Akt activation mediated by p110, the
subunit catalytic of PI3K. Given that Ab(25-35) inhibits the
insulin signaling pathway-mediated over-activation of Ser636
IRS1 and HT prevented this effect, we evaluated whether HT
was able to restore insulin signaling in Ab(25-35)-treated
astrocytes, by immunoprecipitating the association between
p85 and IRS1. Immunoblots show that HT post-treatment
increased the association between p85 and IRS1 in Ab(25-35)-
treated astrocytes, whereas HT pre-treatment did not restore
this association altered by Ab(25-35) (Fig. 2).
3.4. HT restores proper Akt activation
in Ab(25-35)-treated astrocytes
Akt is a main downstream target of insulin signaling. It is
worth noting that Akt phosphorylation at Thr 308 is mediated
by glycaemia, which is governed by insulin signaling [44].
Because we observed that HT exerts beneficial effects on
Ab(25-35)-induced upstream of insulin signaling, we also ana-
lyzed its effect on Akt activation at Thr308 in astrocytes. Blots
indicated that HT increased p-Thr308 Akt protein levels (Fig.
3), which was reduced by Ab[25–36] in astrocytes, as
expected. Treatment with HT alone had no effect on these lev-
els (Fig. 3).
3.5. GLUT2 levels are decreased by Ab(25-35)
in astrocytes, whereas treatment with HT
increased them
Metabolically, the main insulin signaling function is to mediate
glucose uptake by inducing the glucose transporter isoform 2
(GLUT2) internalization from membrane plasmatic to cytosol
[45]. Moreover, GLUT2 is differently expressed in astrocytes
[46]. To clarify whether Ab(25-35) modifies protein expression
of GLUT2, we measured protein levels of this transporter in
Ab(25-35)-treated astrocytes and the effects of HT, by Western
blotting. Ab(25-35) reduced GLUT2 levels in astrocytes and
treatment with HT prevented this effect (Fig. 4). Notably, a HT
pre-treatment appeared to be more effective than post-
treatment, as shown by the significantly (as compared with
controls) increased GLUT2 levels (Fig. 4).
Densitometric analysis from immunoblots of relative
protein levels of the regulatory unit of PI3K (p85)
associated with IRS1 in astrocytes treated with amy-
loid beta peptide (25-35) (Ab(25-35)) 25 mM and/or
hydroxytyrosol (HT) 5 mM for 2 (pre-treatment) or
24 h (post-treatment), as well as different combina-
tions of both. For quantification, p85 associated with
IRS1 was measured by immunoprecipitation (IP) of
150 mg of total protein with IRS1 antibody followed
by Western blot with anti-p85 antibodies and normal-
ized against GAPDH levels in the same samples. DU,
densitometry units. **P<0.01, ***P<0.001 com-
pared with control 24 h group; ***P<0.001 com-
pared with Ab(25-35) group; **P<0.01 compared
with control 48 h group.
Western blot and densitometry from immunoblots
derived from the relative protein levels of Akt phos-
phorylated on Thr 308 in astrocytes treated with
amyloid beta peptide (25-35) (Ab(25-35)) 25 mM and/
or hydroxytyrosol (HT) 5 mM for 2 (pre-treatment) or
24 h (post-treatment), as well as different combina-
tions of both. Data are percentage of the respective
control ratio data6SD of three independent experi-
ments performed in duplicate. DU, densitometry
units. ***P <0.001 compared with control 24 h
group; **P<0.01, ***P<0.001 compared with
Ab(25-35) group; **P<0.01 versus control 48 group.
FIG 2
FIG 3
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3.6. Ab(25-35)-induced insulin resistance is
mediated by the over-activation of mTOR. HT
prevented this effect
The mammalian target of rapamycin (mTOR) is a conserved ser-
ine/threonine kinase that inhibits insulin signaling by phosphoryl-
ating IRS-1 serine residues [47]. Recent studies have shown that
mTOR is aberrantly activated in AD brain, which is linked to the
insulin signaling inhibition [48]. Because Ab(25-35) induces IR in
astrocytes, we wanted to resolve whether Ab(25-35) promoted
this resistance through an over-activation of mTOR. We thus
measured phosphorylated mTOR levels in Ab(25-35)-treated
astrocytes, as well as the effect of HT on them. The observed
increased p-mTOR levels (Fig. 5) corroborated the notion that
Ab(25-35) induces IR through of the over-activation of mTOR in
astrocytes. Likewise, both pre- and post-treatment with HT pre-
vented this activation in Ab(25-35)-treated astrocytes (Fig. 5).
4. Discussion
Our main finding is that HT plays both preventive and correc-
tive roles against cytotoxicity and IR induced by Ab[25] in
astrocytes. These data could explain—at the molecular level—
epidemiological findings associating EVOO consumption with
lower incidence of dementia and AD [49]. To gain insight on
the neuroprotective activities of HT, we induced IR with Ab[25]
and we measured cellular viability and proteins pertaining to
the insulin signaling pathway targets. The (25-35) fragment of
Ab is widely used in cellular cultures to approximate the astro-
cytic damage induced by Ab in the brain of AD patients,
because several studies have demonstrated that Ab is able to
pass the cell membrane and exerts cytotoxic effects both on
astrocytes and neurons [9,50]. Several authors used our astro-
cytic “in vitro” model of AD (astrocytes treated with Ab) to
assess the effects of different molecules on diverse Ab-induced
damages in astrocytes, for example [51,52]. Moreover, intrace-
rebroventricular injections of Ab(25-35) cause learning and
memory impairments similar to those of AD, in mice [53].
Therefore, we believe we used an appropriate astrocytic in
vitro model of AD. It is worth clarifying that we used rat
instead of human astrocytes because this study aims at provid-
ing mechanistic insights into the effect of HT in a murine
model of AD (ongoing). The (25-35) domain of Ab reduced
astrocytes viability by 50%, but treatment (either pre or post)Western blot and densitometry from immunoblots
derived from the protein expression levels of the glu-
cose transporter isoform 2 (GLUT2) in astrocytes
treated with amyloid beta peptide (25-35) (Ab(25-35))
25 mM and/or hydroxytyrosol (HT) 5 mM for 2 (pre-
treatment) or 24 h (post-treatment), as well as differ-
ent combinations of both. Data are percentage of the
respective control ratio6SD of three independent
experiments performed in duplicate expressed. DU,
densitometry units. **P <0.01 compared with control
24 h group; and ***P<0.001 compared with Ab(25-
35) group; ***P<0.001 compared with control 48 h
group.
Immunoblots’ densitometry derived from Western
blot analysis of the phosphorylated mammalian tar-
get of rapamycin (p-mTOR) levels in astrocytes
treated with amyloid beta peptide (25-35) (Ab(25-35))
25 mM and/or hydroxytyrosol (HT) 5 mM for 2 (pre-
treatment), or 24 h (post-treatment), as well as differ-
ent combinations of both. Data are percentage of the
respective control ratio6SD of three independent
experiments performed in duplicate. DU, densitome-
try units. *P<0.05 compared with control 24 h
group; ***P<0.001 compared with 2 h HT group;
*P<0.05, **P<0.01 compared with Ab(25-35) group.
FIG 4
FIG 5
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with HT prevented such cytotoxicity. Neuroprotective effects of
HT have been reported before: examples include studies car-
ried out in dopaminergic neurons [54] and in a hypoxia-
reoxygenation model of rat brain slices [55]. In addition, a
recent study reported that HT improves neuron survival in the
brain of db/db mice [56]. However, this is the first time that
HT is shown to restore survival in an astrocytic model of AD
induced by Ab(25-35).
As regards IR, Ab oligomers do impair insulin signaling in
human astrocytes [26], but whether the neurotoxic fragment
Ab(25-35) exerts the same alterations has not been clarified
yet. In this study, we demonstrated that, indeed, Ab(25-35)
induces IR like the Ab(1-42) oligomers, because it increases
the rate of inhibitory phosphorylation of IRS1, in turn impair-
ing the insulin signaling pathway. In fact, the levels of down-
stream targets of insulin signaling such as the associations
between p85 and IRS1, pAkt, p-mTOR and also GLUT2 are
also reduced by Ab(25-35), which leads to reduced activity of
the whole insulin signaling pathway. Of note, serine hyper-
phosphorylation of IRS1 is a marker of IR both in peripheral
tissues and in the brain [57,58]. Moreover, several studies
unequivocally demonstrated that the IR seen in AD brain is
tightly linked to Ab-induced hyperphosphorylation of IRS1
[17,18]. Nevertheless, treatment with HT significantly reduced
Ab(25-35)-induced hyperphosphorylation of IRS1, suggesting
that HT could protect against the Ab(25-35)-induced IR,
thereby augmenting the insulin pathway. To further investi-
gate the effects of HT and to find whether the insulin signaling
pathway is activated in astrocytes co-treated with Ab(25-35)
and HT we measured the association between p85 and IRS1 as
well as protein levels of down-stream targets of insulin path-
way. Indeed, HT treatment prevented the decreased associa-
tion between p85 and ISR1 in Ab(25-35)-treated astrocytes,
which adds evidence the purported protective activity of HT in
IR. The HT-mediated restored association translated in an
increased activation of Akt in Ab(25-35)- and HT-treated astro-
cytes. Given that the insulin signaling pathway was blocked by
Ab(25-35), Akt activation was also reduced in astrocytes (Figs.
1–3). Along this line, several studies demonstrated that direct
exposure to Ab induced a down-regulation of phospho-Akt at
the Thr308 amino acid, in a rat model of induced cognitive
decline [59]. In humans, the hippocampus of AD patients
shows diminished expression of Akt [27,60].
Several studies also reported increased activation of Akt
induced by HT in peripheral tissues. Thus, Pei et al. (2016)
have showed that the antiapoptotic and cardioprotective
effects of HT on myocardial injury are related to the activation
of the Akt/GSK3b pathway [61]. Such HT-induced activation of
Akt has been observed in hepatocytes and retinal epithelial
cells [62,63]. Hence, various studies support the hypothesis
that the protective role of HT is related to activation of Akt.
Indeed, Akt is an indispensable component of a great number
of cellular signaling pathways involved in cellular survival and
prevents cell damage [64]. Therefore, we suggest that the pre-
ventive role of HT on Ab(25-35)-induced cytotoxicity in
astrocytes is moderated by an increased HT-induced activation
of Akt, which is mediated by the insulin signaling pathway.
The main purpose of insulin signaling in astrocytes is
allowing the uptake of glucose through GLUT2 and, indeed,
altered glucose transportation has been related to IR in AD
patients [65]. In our study, Ab(25-35) blocked insulin signaling
in astrocytes, where we also recorded reduced expression of
GLUT2; however, supplementation with HT prevented this
reduction. The reduced expression of GLUT2 was specifically
induced by Ab(25-35) and not by glucose in DMEM, because its
concentrative was unchanged throughout the whole investiga-
tion. In summary, our results suggest that HT could improve
glucose metabolism in astrocytes injured by Ab(25-35). In a
broader context, it is worth mentioning that HT is able to
lessen some of the consequences of the metabolic syndrome
[66–68], which include glucose signaling’s derangement.
Our findings show that Ab(25-35)-induced astrocytic IR is
provoked by increased inhibitory phosphorylation of IRS1,
which is mediated by the activation of mTOR, among other
serine/threonine kinases [47]. Thus, augmented activation of
mTOR was found in Ab(25-35)-treated astrocytes. These high
mTOR levels were correlated with increased inhibitory phos-
phorylation of IRS1 responsible for blocking insulin-signaling
pathway in astrocytes. Moreover, over-activated levels of
mTOR were reported in Ab(25-35)-treated hippocampal neu-
rons and in aged mice brain [69]. In support of these findings,
other studies have indicated that there is a positive correlation
between Ab levels and mTOR in post-mortem tissues from AD
patients [70] and an excessive mTOR activation impaired insu-
lin signaling in hippocampal tissue of rat with diabetes, exac-
erbating the development of AD [71]. Of note, a recent study
by Han et al. [27] did not report increased mTOR levels in HA-
1800 cells challenged with Ab1-42 oligomers and insulin, leav-
ing room for further investigation. In synthesis, reduced glu-
cose utilization is associated with the buildup of Ab as medi-
ated by over-activated mTOR [48], even though the precise
nature of this relation needs to be clarified. Nevertheless, HT
prevented the pronounced activation of mTOR in Ab(25-35)
astrocytes, which suggests that HT protects the Ab(25-35)-
blocked insulin signaling pathway.
In conclusion, we demonstrate that HT protects Ab(25-35)-
treated astrocytes by improving insulin sensitivity. These data
provide some mechanistic insight on the observed inverse
association between Mediterranean diet score (and olive oil
consumption) and prevalence of cognitive impairment. Future,
ad-hoc human studies will eventually verify whether the use of
HT as nutritional supplement could reduce IR associated with
AD and, in turn, improve AD symptoms and clinical
manifestations.
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13 Abstract
14 Impaired glucose metabolism and mitochondrial decay greatly increase with age, when cognitive decline becomes rampant. No
15 pharmacological or dietary intervention has proven effective, but proper diet and lifestyle do postpone the onset of neurodegener-
16 ation and some nutrients are being investigated. We studied insulin signaling, mitochondrial activity and biogenesis, and synaptic
17 signaling in the hippocampus and cortex following dietary supplementation with bioactive phospholipid concentrates of krill oil
18 (KOC), buttermilk fat globule membranes (BMFC), and a combination of both in aged rats. After 3 months of supplementation,
19 although all groups of animals showed clear signs of peripheral insulin resistance, the combination of KOC and BMFC was able to
20 improve peripheral insulin sensitivity. We also explored brain energy balance. Interestingly, the hippocampus of supplemented
21 rats—mainly when supplemented with BMFC or the combination of KOC and BMFC—showed an increase in intracellular
22 adenosine triphosphate (ATP) levels, whereas no difference was observed in the cerebral cortex. Moreover, we found a significant
23 increase of brain-derived neurotrophic factor (BDNF) in the hippocampus of BMFC+KO animals. In summary, dietary supple-
24 mentation with KOC and/or BMFC improves peripheral and central insulin resistance, suggesting that their administration could
25 delay the onset of these phenomena. Moreover, n-3 fatty acids (FAs) ingested as phospholipids increase BDNF levels favoring an
26 improvement in energy state within neurons and facilitating both mitochondrial and protein synthesis, which are necessary for
27 synaptic plasticity. Thus, dietary supplementation with n-3 FAs could protect local protein synthesis and energy balance within
28 dendrites, favoring neuronal health and delaying cognitive decline associated to age-related disrepair.
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30 Abbreviations
32 AD3 Alzheimer’s disease
34 Akt5 Protein kinase B
36 AMPK7 AMP-activated protein kinase
38 α-Syn9 Chaperone α-synuclein
40 ATP1 Adenosine triphosphate
42 BDNF3 Brain-derived neurotrophic factor
44 BMFC5 Buttermilk fat globule concentrate
46 CD7 Cognitive deficiency
48 DHA9 Docosahexaenoic acid
50 EPA1 Eicosapentaenoic acid
52 FAs3 Fatty acids
54 Glut45 Glucose transporter type 4
56 HOMA-R7 Homeostasis model assessment ratio
58 IRβQ3 9 Insulin receptor-beta subunit
60 IRS1 Insulin receptor substrate
62 KOC3 Krill oil concentrate
64 MFGM5 Milk fat globule membrane
66 mTOR7 Mammalian target of rapamycin
68 PUFA9 Polyunsaturated fatty acid
70 PC1 Phosphatidylcholine
72 PS3 Phosphatidylserine
74 PE5 Phosphatidylethanolamine
76 PI7 Phosphatidylinositol
78 PLE9 Pressurized liquid extraction
80 PI3K1 Phosphatidylinositol-3-kinase
82 PGC-1α3 Proliferator-activated receptor γ coactivator 1-α
84 SM5 Sphingomyelin
86 SIRT17 Sirtuin 1
88 Stx1A9 Syntaxin 1A
90 Syn11 Synapsin I
92 Syt13 Synaptotagmin 1
94 TAG5 Triacylglycerides
96 Vamp27 Synaptobrevin 28
99 Introduction
100 Major pathological features of neurodegeneration include im-
101 paired glucose metabolism and mitochondrial decay [1, 2]. In
102 particular, insulin governs whole-body energy and peripheral
103 glucose homeostasis but also exerts specific actions in the
104 brain [3, 4], and it is noteworthy that there is increased insulin
105 resistance with age [5, 6]. In addition, dysfunctional operation
106 of the electron transport chain constitutes a key mechanism
107 involved in the age-associated loss of mitochondrial energy
108 metabolism [7].
109 Insulin signaling in the brain follows the same steps de-
110 scribed for peripheral tissues, and its receptor is expressed in
111 neurons and glial cells in different brain regions [8]. Among
112 them, hippocampus and temporal cortex show the highest
113 levels of insulin receptor expression, indicating the important
114 role of insulin in learning and memory [5, 9]. Glucose flux
115regulates hippocampal memory processing through increased
116glucose transporter type 4 (Glut4) translocation [10]. Thus,
117cerebral insulin resistance could severely affect normal cogni-
118tive processes. Indeed, risk factors associated with insulin re-
119sistance, such as obesity, poor diet, physical inactivity, aging,
120and genetic predispositions, are correlated with cognitive dys-
121function and dementia [11, 12]. Most of these factors are
122modifiable, pointing to the indispensable roles of prevention.
123The Mediterranean diet has been associated with lower
124incidence of age-related diseases, such as Alzheimer’s disease
125(AD) [13]. For instance, amelioration of insulin signaling was
126seen after treatment with hydroxytyrosol in an astrocytic mod-
127el of AD [14], suggesting that the use of extra virgin olive oil
128might slow down cognitive decline. Moreover, during aging,
129the central nervous system becomes depleted of the polyun-
130saturated fatty acid (PUFA) docosahexaenoic acid (DHA)
131which has been associated with pathologies such as senile
132dementia and AD [15]. Therefore, DHA supplementation to
133individuals at risk of cognitive decline could prevent its onset
134or lessen its consequences.
135Currently, there are no dietary recommendations or
136science-backed health claims concerning cognitive decline
137[16]. FAO and WHO recommend (for adults) a daily intake
138of at least 500 mg of eicosapentaenoic acid (EPA) + DHA
139[17]. However, the current recommendations do not distin-
140guish among fatty fish, functional foods, or supplements/
141nutraceuticals [18]. Yet, n-3 FAs associated to phospholipids
142are more bioavailable to different tissues, such as the brain
143[19]. In this respect, krill oil is an attractive source of n-3
144FAs, because a large proportion of them is incorporated into
145phosphatidylcholine (PC). Beneficial effects of krill oil have
146been described on blood lipids [20], inflammation [21], and
147cognitive function in the elderly [22].
148Another nutritionally relevant source of polar lipids is the
149milk fat globule membrane (MFGM). The milk fat globule
150consists of a core, mainly composed of triacylglycerides
151(TAG; 98–99%), and different concentrations of other com-
152pounds such as diacylglycerides, monoacylglycerides, free
153fatty acids (FFAs), and cholesterol. This core is surrounded
154by the MFGM, which contains different phospho- and
155sphingolipids and that could have potentially positive effects
156on human health, namely in neurological pathologies [23].
157Buttermilk (BM), a by-product obtained from butter
158manufacturing with a high content of MFGM, is particularly
159rich, i.e., up to 20% of total fat, in polar lipids [24] and is
160currently not employed in the supplement arena. This percent-
161age could be further increased by using food-grade solvents to
162obtain BM lipids and their subfractions [24].
163It is noteworthy that BM fractions contain high proportions
164of phosphatidylserine (PS) and sphingomyelin (SM). The for-
165mer plays important cellular roles, e.g., in mitochondrial mem-
166brane integrity, release of presynaptic neurotransmitters, activ-
167ity of postsynaptic receptors, and activation of protein kinase C
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168 in memory formation [25]. A decrease of SM in cerebral my-
169 elin has been related to the slowing in the speed of the cogni-
170 tive process associatedwith aging [26]. For these reasons, there
171 might be an opportunity to incorporate BM fractions in func-
172 tional foods rich in phospho- and sphingolipids from MFGM,
173 along with short- and long-chain n-3 FAs, e.g., from krill oil to
174 counteract the age-related loss of PUFAs.
175 Our goal was to study insulin signaling, mitochondrial ac-
176 tivity and biogenesis, and synaptic signaling in the hippocam-
177 pus and cortex following dietary supplementation with bioac-
178 tive phospholipid concentrates of krill oil (rich in n-3 FAs
179 esterified to PC) and phospho- and sphingolipid concentrates
180 from BM (rich in linolenic acid, PC, phosphatidylethanol-
181 amine (PE), phosphatidylinositol (PI), PS, and SM) and a
182 combination of both in aged rats.
183 Materials and Methods
184 Materials
185 Buttermilk and krill oil concentrates (BMFC and KOC, respec-
186 tively) and the elaboration of daily doses in the form of a jelly
187 lollipop were produced at the Institute of Food Science
188 Research (CIAL,Madrid, Spain). Briefly, BM fat was extracted
189 by pressurized liquid extraction (PLE) using an accelerated sol-
190 id ASE-200 extractor (Dionex Corp. Sunnyvale, CA). Fifteen
191 grams of powdered BM was mixed with sand (1:1, by weight)
192 and loaded into a stainless steel extraction cell. To obtain the
193 maximum BM fat yield, the extraction procedure was based on
194 the optimized PLE method of Castro-Gomez et al. [27]. The
195 lipid extracts were capped under nitrogen and stored at − 35 °C.
196 Animals
197 This research followed the Guide for the Care and Use of
198 Laboratory Animals, published by the US National Research
199 Council (Eight Edition 2010). Animal care was according to
200 the standards proposed by the European Community (86/609/
201 EEC). Animal experiments were approved by the Animal
202 Experimentation Committee of the National University of
203 Distance Education. A total of 41 male Wistar rats (9 months
204 of age) were purchased from Charles River Laboratories
205 (Barcelona, Spain). Rats were randomly distributed in groups
206 of two per cage and maintained in a 12:12 light-dark cycle
207 (8 a.m. to 8 p.m.), with constant temperature and humidity
208 conditions (22 ± 2 °C and 50% RH), during the following
209 9 months. Food and water were given ad libitum.
210 Experimental Design and Diets
211 As 18-month rats are considered old and present a variety of
212 cognitive deficiency (CD) symptoms associated with aging,
213when animals reached this age, they were randomly assigned
214to four experimental groups (Table 1). All groups were given a
215standard EURodent (LabDiet, St. Louis, MO) diet plus a
216group-specific supplement as frozen strawberry-flavored
217jellies: (1) control group—refined olive oil (n = 8), (2)
218BMFC group—concentrate of phospho- and sphingolipids
219ofMFGM from buttermilk (n = 11), (3) KOC group—concen-
220trate of omega-3 fatty acids (EPA and DHA) and phospho-
221lipids from krill oil (KO) (n = 10), and (4) BMFC+KOC
222group—combination, in a single jelly, of the concentrates giv-
223en to groups 2 and 3 (n = 12). The detailed composition of
224different phospho- and sphingolipids is described in Table 2.
225Full intake of jellies was visually verified every day.
226The nutritional composition of the diet of the four experi-
227mental groups is shown in Table 3. Rats were sacrificed by
228decapitation after 3 months of supplementation, following a
22912-h fast. Hippocampus and temporal cortex were quickly
230extracted, washed in PBS, snap-frozen in liquid nitrogen,
231and stored at − 80 °C. Blood samples were collected with
232heparin (100 UI/ml), centrifuged for plasma collection at
2331500×g for 15 min, and stored at − 80 °C.
234Determination of Circulating Biochemical Parameters
235Concentration of plasma glucose was measured with commer-
236cial kits (WAKO, Neuss, Germany), and insulin levels were
237determined by an ELISA kit (Rat Insulin, 96-well plate assay,
238Millipore, Madrid, Spain), according to the manufacturer’s
239instructions. The insulin resistance index, a.k.a. homeostasis
240model assessment ratio (HOMA-R), was calculated using the
241following formula:
HOMA ¼ fasting glucose mmol=lð Þ
 fasting insulin μIU=mlð Þ=22:5:
2423
244
245Measurement of ATP Levels in Tissue Samples
246To evaluate the energy status of the cells in the hippocampus
247and temporal cortex, a bioluminescent assaywas used to assess
248intracellular ATP levels (Sigma-Aldrich, St. Louis, MO, USA).
249The homogenized samples were previously filtered through
2500.22-μm filters (Millipore Corp., Bedford, Mass.). The assay
251was performed according to the manufacturer’s protocol, and
252luminescence was measured at 570 nm using a microplate
253reader (Biochrom Asys UVM 340, Cambridge, UK).
254RNA Isolation and qRT-PCR
255Total RNA extractions from both tissues were performed ac-
256cording to the manufacturer’s instructions of the miRNeasy
257Mini kit (Qiagen, Madrid, Spain), including DNA digestion.
258RNA quantity and purity were analyzed using a NanoDrop
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259 ND-1000 UV-Vis Spectrophotometer (Thermo Fisher
260 Scientific Inc., Spain) and RNA integrity using an Agilent’s
261 2100 bioanalyzer. Total RNA was converted into first-strand
262 cDNA using miScript®II Reverse Transcription kit, Qiagen
263 (Izasa, Barcelona, Spain) according to the manufacturer’s
264 guidelines.
265 Electron Transport Chain Array
266 We used a mitochondrion energy metabolism (SAB Target
267 List) H384 Predesigned 384-well panel (Bio-Rad, Madrid,
268 Spain). Five samples of each experimental group with the
269 highest RNA Integrity Number (RIN) were selected to per-
270 form the assay. The predesigned plates were formed by 87
271 genes, within which 10 were reference genes, 27 genes
272 belonged to complex I, 4 to complex II, 6 to complex III, 15
273 to complex IV, and 18 to complex V, and 7 were non-
274 exclusively associated with the respiratory chain.
275 qRT-PCR reactions were performed with miScript SYBR
276 Green PCR kits from Qiagen (Izasa, Madrid, Spain) using a
277 7900HT Real-Time PCR System (Life Technologies,
278 Alcobendas, Spain). Cycling conditions were a first step of
279 activation at 95 °C for 15 min, 40 cycles of denaturation at
280 94 °C for 15 s, annealing at 58 °C for 30 s, and a final step for
281 dissociation curve. PPA1 was identified by NormFinder as the
282 most stable reference gene among other candidates.
283Gene Expression of Synaptic Proteins
284Expression analyses of genes encoding proteins involved in
285neural synapses were performed by qRT-PCR in 384-well
286plates using the same cycling conditions described above.
287Specific primers for each gene were designed using Primer3
288software (Supplementary Table Q41). Quantification of relative
289gene expression was performed using the comparative delta
290Ct method using glyceraldehyde-3-phosphate dehydrogenase
291(GAPDH) for normalization.
292Western Blot Assays
293Temporal cortex and hippocampus samples were homoge-
294nized with RIPA lysis buffer containing protease and phos-
295phatase inhibitors (Sigma-Aldrich, Madrid, Spain).
296Homogenates were kept at − 80 °C for 24 h and centrifuged
297(4 °C, 12,000×g, 30 min), and supernatants were collected.
298Total protein concentrations were determined using BCA pro-
299tein assay reagent (Thermo Fisher Scientific, Madrid, Spain).
300Equal (30 μg) amounts of protein were loaded on 10% poly-
301acrylamide gels, submitted to sodium dodecyl sulfate-
302polyacrylamide gel electrophoresis (SDS-PAGE), and trans-
303ferred to nitrocellulose membranes (Bio-Rad, Madrid, Spain).
304Membranes were blocked with 5% non-fat milk powder in
305Tris-buffered saline containing 0.1% Tween-20 (TBS-T) for
3062 h at room temperature, then incubated overnight at 4 °Cwith
307various primary antibodies regarding key components of the
308insulin signaling pathway and components of the neurotrans-
309missions and neurodegenerations (Supplementary Table 2),
310and involved in respiratory mitochondrial chain (Abcam
311ab110413). Following incubation with appropriate secondary
312antibodies, protein bands were detected by an enhanced
313chemiluminescence method using the ECL kit (Bio-Rad,
314Madrid, Spain). Normalization of total protein expression
315was carried out using GAPDH or corresponding total form
316in the case of phosphorylated proteins.
317Statistical Analyses
318Statistical analyses were carried out using GraphPad Prism
3197.02 software (GraphPad Software, Inc., La Jolla, CA, USA).
t1:1 Table 1 Daily supplements
assigned to the four experimental
groups
t1:2 Experimental group Control diet Daily supplement (jelly)
t1:3 Control Ad libitum 70 mg refined olive oil
t1:4 BMFC Ad libitum 70 mg of BMFC
t1:5 KOC Ad libitum 70 mg of KOC
t1:6 BMFC+KOC Ad libitum 70 mg of BMFC + 70 mg of KOC
BMFC, concentrate of phospho- and sphingolipids of milk fat globule membrane from buttermilk; KOC, con-
centrate of omega-3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) enriched in
phospholipids from krill oil; BMFC+KOC, combination of both concentrates
t2:1 Table 2 Phospholipid composition of the study supplements
t2:2 Control KOC BMFC BMFC+KOC
t2:3 PE (%) – 0.55 15.66 5.16
t2:4 PI (%) – – 1.92 0.77
t2:5 PS (%) – – 16.92 6.79
t2:6 PC (%) – 99.45 38.74 72.48
t2:7 SM (%) – – 26.76 14.79
BMFC, concentrate of phospho- and sphingolipids of milk fat globule
membrane from buttermilk; KOC, concentrate of omega-3 fatty acids
(eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA))
enriched in phospholipids from krill oil; BMFC+KOC, combination of
both concentrates; PE, phosphatidylethanolamine; PI, phos-
phatidylinositol; PS, phosphatidylserine; PC, phosphatidylcholine; SM,
sphingomyelin. Values are percentage means
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320 For gene expression analysis, data were quantified using the
321 ΔΔCt method and fold-change values were reported as 2
322 − (ΔΔCt). Data from independent samples from all experiments
323 were compared by one-way ANOVA, using the Tuckey test to
324 compare all study groups. Values of p < 0.05 were considered
325 significant. Results are presented as means ± SEM.
326 Results
327 A Combination of BMFC and KOC Improves Peripheral
328 Insulin Sensitivity
329 Aged rats fed isocaloric diets (Table 3) for 3 months did not
330 show significant changes in body weight (data not shown). As
331 insulin resistance is tightly associated with aging and cogni-
332 tive dysfunction [28], we wondered whether different dietary
333 supplements affected glycemic profiles. No significant differ-
334 ences in glucose levels in any of the study groups were ob-
335 served (Fig. 1a). However, glucose levels in all groups (values
336 close to 150 mg/dl) indicated an insulin resistance process,
337 since the normal physiological glucose range of adult (>
338 4 months) rats is around 75.4 ± 5.5 mg/ml [29]. In addition,
339 serum insulin concentrations were higher than customary for
340 adult rats. Compared to the control group, the combination of
341 BMFC with KOC induced lower insulin levels (Fig. 1b). This
342observation was further confirmed by the HOMA ratio
343(Fig. 1c), suggesting that the mixture improves peripheral in-
344sulin sensitivity.
345Hippocampal and Cortical Insulin Signaling Is
346Increased in High Phospholipid Concentrate Diets
347Dysregulation of brain insulin signaling is associated with
348aging and neurodegenerative disorders [3, 4, 11]. To deter-
349mine whether the different supplements influence central in-
350sulin signaling, we evaluated key insulin pathway molecules
351in the hippocampus and cerebral cortex. Protein analysis from
352hippocampal samples showed a significant increase in the
353insulin receptor-beta subunit (IRβ) expression levels both in
354KOC and BMFC+KOC groups (Fig. 2a), whereas the activat-
355ed insulin receptor substrate (IRS) 1 was augmented in those
356groups supplemented with BMFC. This activation mediated
357by the insulin receptor was not observed in the IRS2 protein.
358Since cytoplasmic insulin signaling is mediated through
359phosphatidylinositol-3-kinase (PI3K), we also explored the
360expression levels of the regulatory subunit p85 from this ki-
361nase. As seen for IRS1, BMFC supplementation increased
362PI3K expression levels. As the last step of the insulin pathway,
363i.e., protein kinase B (Akt) activation, was detected in hippo-
364campal samples of the three experimental groups, it is con-
365ceivable that a high-phospholipid diet improves hippocampal
t3:1 Table 3 Nutritional composition
of the diets fed to the four
experimental groups
t3:2 Lipids (g) Carbohydrates (g) Fiber (g) Proteins (g) Energy (Kcal)
t3:3 Control 1.82 32.10 2.05 11.01 201.07
t3:4 BMFC 1.82 32.11 2.05 11.01 201.11
t3:5 KOC 1.82 32.10 2.05 11.01 201.07
t3:6 BMFC+KOC 1.89 32.11 2.05 11.01 201.11
BMFC, concentrate of phospho- and sphingolipids of milk fat globule membrane from buttermilk; KOC, con-
centrate of omega-3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) enriched in
phospholipids from krill oil; BMFC+KOC, combination of both concentrates
Fig. 1 DeterminationQ5 of insulin, glucose, and insulin resistance index in
rat serum. BMFC concentrate of phospho- and sphingolipids of milk fat
globule membrane from buttermilk; KOC concentrate of omega-3 fatty
acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA))
enriched in phospholipids from krill oil; BMFC+KOC combination of
both concentrates. a Glucose levels expressed in mg/ml. b Insulin levels
expressed in mg/ml. c homeostasis model assessment ratio (HOMA-R),
which is an index of insulin resistance. Values are means ± SEM.
*Statistically significant difference regarding all study groups at p < 0.05
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366 insulin signaling. Moreover, cerebral cortex Akt is also acti-
367 vated (Fig. 2b), suggesting that this effect is not restricted to
368 one brain region.
369 Activation of insulin intracellular signaling stimulates the
370 translocation of the Glut4 transporter facilitating glucose up-
371 take [11]. Although we did not find significant differences in
372 Glut4 levels among any of the supplemented groups (Fig. 2a,
373 b), the implication of other glucose transporters cannot be
374 ruled out.
375 BMFC+KOC Ameliorate Cellular Energy States
376 and Increase Mitochondrial Biogenesis
377 in Hippocampus
378 The energetic state of the brain is influenced by mitochondrial
379 biogenesis, which can be dramatically damaged during aging.
380 Thus, we first evaluated the intracellular levels of adenosine
381 triphosphate (ATP) in hippocampal samples. We found that
382 all experimental groups showed an increase in ATP levels,
383 although statistical significance was only reached in BMFC-
384 supplemented animals (Fig. 3a). Interestingly, this improve-
385 ment was not detected in cerebral cortex samples (Fig. 3b),
386 suggesting that supplementation with bioactive phospholipids
387 differentially affects brain areas at this level. Consequently,
388we wanted to figure out whether this potentially increased
389hippocampal energetic state could be related to augmented
390mitochondrial biogenesis. To achieve this, we analyzed the
391expression of proteins from the five electron transport chain
392complexes (Fig. 3c). Animals fed with both BMFC and KOC
393supplement showed increased protein expression in all com-
394plexes studied, suggesting that amelioration of cell energy
395state could be mediated by an increase in hippocampal mito-
396chondrial biogenesis.
397We also evaluated the expression of 70 genes correspond-
398ing to the five mitochondrial complexes and seven associated
399with the respiratory chain (not included in any complex) in the
400hippocampus. An increase in the expression of key genes in-
401volved in the complexes I, IV, and V (Fig. 3d) was detected by
402qRT-PCR, confirming the observed changes in protein levels.
403Mitochondrial Biogenesis
404in BMFC+KOC-Supplemented Animals Is Mediated
405Through BDNF
406To determine whether the increased levels in mitochondrial
407complex proteins weremediated by the regulator of mitochon-
408drial biogenesis, i.e., the peroxisome proliferator-activated re-
409ceptor γ coactivator 1-α (PGC-1α), we explored the levels of
Fig. 2 Western blot of proteins involved in the insulin-signaling pathway.
aHippocampus and b temporal cortex. IRβ insulin receptor-beta subunit;
pIRS1 phosphorylated insulin receptor substrate 1; IRS1 insulin receptor
substrate 1; IRS2 insulin receptor substrate 2; p85 subunit of
phosphatidylinositol 3-kinase (PI3K); Akt serine/threonine protein
kinase; pAkt 308 phosphorylated Akt threonine 308; pAkt 473
phosphorylated Akt serine 473; GLUT4 glucose transporter 4; BMFC
concentrate of phospho- and sphingolipids of milk fat globule
membrane from buttermilk; KOC concentrate of omega-3 fatty acids
(eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA))
enriched in phospholipids from krill oil; BMFC+KOC combination of
both concentrates. Values are means ± SEM. Statistically significant
difference regarding all study groups at *p < 0.05–0.005; **p < 0.005–
0.0005; ***p < 0.0005
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410 this protein in hippocampal and cortical samples (Fig. 4a, b).
411 As seen in Fig. 4a, b, PGC1-αwas increased in BMFC+KOC-
412 supplemented rats in both brain areas. As this coactivator is
413 regulated by the master metabolic regulator 5’AMP-activated
414 protein kinase (AMPK), we further explored the levels of this
415 kinase along with the NAD+-dependent type III deacetylase
416 sirtuin 1 (SIRT1) [30]. Remarkably, although phosphorylated
417 levels of AMPK were only increased in the KOC group both
418 in hippocampus and cerebral cortex, SIRT1 levels were de-
419 creased in all experimental groups in the hippocampus and a
420 trend (not significant) was observed in the cortex. As it has
421 been described that PGC-1α activation requires both AMPK
422 and SIRT1 [30], results suggest that AMPK-SIRT1-mediated
423 PGC1-α regulation is not taking place in this model.
424Brain-derived neurotrophic factor (BDNF) has been impli-
425cated in neural ATP enhancement and in PGC-1α activation
426[31]. Thus, we next analyzed BDNF levels in hippocampal
427samples (Fig. 4a). Only BMFC+KOC-supplemented animals
428showed an increase in BDNF levels, in accordance with the
429results for PGC-1α. However, although cortical BDNF was
430increased in all supplemented groups, statistical significance
431was not reached, suggesting that the amelioration of the ener-
432gy state observed in the hippocampus of BMFC+KOC-sup-
433plemented rats could be mediated by BDNF. Some authors
434propose that BDNF acts through the mammalian target of
435rapamycin (mTOR), favoring local protein synthesis in den-
436drites [32]. Increased levels of mTOR activity were detected
437in rats supplemented with BMFC+KOC, suggesting a
Fig. 3 Evaluation of cellular energy status and mitochondrial biogenesis.
a, b ATP levels expressed in pmol/μl. cWestern blot analysis of proteins
involved in the hippocampal respiratory mitochondrial chain. d
Hippocampal gene expression regarding the mitochondrial respiratory
chain pathway. ATP adenosine triphosphate; Ndufab1 NADH
dehydrogenase (ubiquinone) 1, alpha/beta subcomplex 1; Slc25a10
solute carrier family 25 (mitochondrial carrier, dicarboxylate
transporter) member 10; Atp5h ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit D; Atp4a ATPase H+/K+
transporting alpha subunit; Cox8c cytochrome c oxidase subunit 8C;
Atp4b ATPase H+/K+ transporting beta subunit; Cox17 cytochrome c
oxidase copper chaperone; Uqcrb ubiquinol-cytochrome c reductase
binding protein; CI complex I; NC does not belong to any complex;
CIV complex IV; CV complex V; BMFC concentrate of phospho- and
sphingolipids of milk fat globule membrane from buttermilk; KOC
concentrate of omega-3 fatty acids (eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil;
BMFC+KOC combination of both concentrates. Values are means ±
SEM. Statistically significant difference regarding all study groups at
*p < 0.05–0.005; **p < 0.005–0.0005; ***p < 0.0005
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438 possible BDNF-associated role of mTOR in the improvement
439 of hippocampal energy state.
440 Synaptic Proteins Are Differentially Regulated
441 in Distinct Brain Areas
442 Considering that mitochondrial biogenesis is relevant for
443 BDNF to stimulate the formation of new synapses and to
444 maintain the existing ones [31], we wondered whether the
445 observed changes in energy status after supplementation
446 could be linked to synaptic signaling. Hence, we first ana-
447 lyzed the expression levels of genes encoding pre- and post-
448 synaptic proteins in hippocampal samples (Fig. 5a).
449 Interestingly, syntaxin 1A (Stx1A) gene levels were increased
450 in BMFC+KOC-supplemented animals, whereas synapsin I
451 (Syn1) and synaptotagmin 1 (Syt1) did not change. We further
452 examined postsynaptic structural proteins PDS95, PDS93,
453 and SAP-102 levels (Dlg4, Dlg2, and Dlg3, respectively),
454 and, surprisingly, while Dlg4 levels were increased in KOC
455 rats, the expression of all three genes was decreased in the
456 BMFC+KOC group. In order to confirm these results, we
457 applied Western blot techniques to the protein Stx1A and
458 two other presynaptic proteins associated with synaptic vesi-
459 cles, synaptobrevin 2 (Vamp2) and the chaperone α-
460 synuclein (α-Syn) (Fig. 5b). Even though Stx1A mRNA
461 levels were increased in the BMFC+KOC-supplemented an-
462 imals, protein levels were not changed in any of the experi-
463 mental groups. On the other hand, Vamp-2 levels were in-
464 creased in all supplemented animals.
465In the case of cerebral cortex, some of the pre- and post-
466synaptic proteins studied increased gene expression levels
467(Fig. 5c). Stx1A levels were significantly increased in
468BMFC+KOC-supplemented rats, whereas Syt1 mRNA was
469upregulated in all studied groups compared to that in control
470animals. At protein level (Fig. 5d), Stx1a and α-Syn were
471increased in the KOC group and α-Syn was augmented only
472in the BMFC group. These results highlight different synaptic
473regulations in distinct brain areas.
474Discussion
475There is growing evidence that age-associated cognitive de-
476cline can be partially prevented by an appropriate lifestyle
477that includes proper diet and regular exercise [33, 34]. One
478example is that of the Mediterranean diet, which has been
479correlated with lower incidence of age-related disorders, such
480as AD and cardiovascular disease [35, 36]. Dietary fats such
481as those of fish or olive oil could be responsible for such
482effects by ameliorating, for instance, insulin signaling in
483brain [14]. Dietary supplementation with PUFAs, such as
484DHA or the more bioavailable n-3 FAs associated to phos-
485pholipids, present in krill oil, could represent a good pharma-
486nutritional tool to partially prevent the noxious consequences
487of age [19, 22]. Indeed, milk phospholipid intake seems to
488have beneficial effects on stress-induced memory impairment
489in adults [37]. Although MFGM supplementation in infant
490and children appears to have some neurodevelopmental
Fig. 4 Western blot of proteins involved in mitochondrial biogenesis. a
Hippocampus and b temporal cortex. PGC1 peroxisome proliferative
act ivated receptor, gamma, coactivator 1 alpha; pAMPK
phosphorylated AMPK; AMPK AMP-activated protein kinase; SIRT1
sirtuin 1; BDNF brain-derived neurotrophic factor; pmTOR
phosphorylated mechanistic target of rapamycin kinase; mTOR
mechanistic target of rapamycin kinase; BMFC concentrate of phospho-
and sphingolipids of milk fat globule membrane from buttermilk; KOC
concentrate of omega-3 fatty acids (eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil;
BMFC+KOC combination of both concentrates. Values are means ±
SEM. Statistically significant difference regarding all study groups at
*p < 0.05–0.005; **p < 0.005–0.0005; ***p < 0.0005
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491 benefits [38], their effects on the elderly are insufficiently
492 investigated [39, 40].
493 As insulin resistance increases with age and its associated
494 diseases [5], we aimed at studying brain insulin signaling in
495 response to dietary supplementation with bioactive phospho-
496 lipid concentrates of krill oil and buttermilk in aged rats. After
497 3 months of supplementation, although all groups of animals
498 showed clear signs of peripheral insulin resistance, the combi-
499 nation of KOC and BMFC was able to improve peripheral
500 insulin sensitivity. In agreement, both krill oil and MFGM
501 have been previously shown to reduce insulin levels in type
502 2 diabetes and obese individuals, respectively [41, 42], sug-
503 gesting that dietary fatty acids/phospholipids could help in this
504 respect. In order to know whether this amelioration in periph-
505 eral insulin resistance could also be detected in the central
506 nervous system, we further explored insulin signaling in the
507 hippocampus and cerebral cortex, both implicated in cognitive
508processes. Interestingly, insulin signaling was improved in
509both structures, since the cascade of events was active when
510animals were supplemented with BMFC, KOC, or both. These
511results highlight the potential of dietary fats to compensate the
512disturbance in the insulin pathway observed with aging.
513Considering that the energetic state level in brain is influ-
514enced by its mitochondrial content, we further explored brain
515energy balance. Interestingly, the hippocampus of supple-
516mented rats—mainly with BMFC or the combination of
517KOC and BMFC—showed an increase in ATP levels, where-
518as no difference was observed in the cerebral cortex, suggest-
519ing that dietary fats induce different energy states in distinct
520brain areas, which is coherent with the observation that n-3
521fatty acids incorporate into the various brain structures in a
522non-random, selected fashion [43]. The increased energy sta-
523tus of the hippocampus might be due to an increase in mito-
524chondrial biogenesis, because both mitochondrial complex
Fig. 5 Synaptic protein expression in both tissues. a Hippocampal
expression analysis of genes encoding for proteins involved in the
nerve synapse. b Western blots of hippocampal proteins involved in
neurotransmission signaling. c Temporal cortex expression analysis of
genes encoding for proteins involved in the nerve synapse. d Western
blot of temporal cortex proteins involved in neurotransmission
signaling. STX1A syntaxin 1A; SYN synapsin I; SYT1 synaptotagmin
1; Dlg4 discs largeMAGUK scaffold protein 4 (PSD95); Dlg2 discs large
MAGUK scaffold protein 2 (PSD93); Dlg3 discs largeMAGUK scaffold
protein 3 (SAP-102); Vamp-2 vesicle-associated membrane protein 2; α-
Syn synuclein alpha; BMFC concentrate of phospho- and sphingolipids
of milk fat globule membrane from buttermilk; KOC concentrate of
omega-3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA)) enriched in phospholipids from krill oil; BMFC+KOC
combination of both concentrates. Values are means ± SEM.
Statistically significant difference regarding all study groups at
*p < 0.05–0.005; **p < 0.005–0.0005; ***p < 0.0005
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525 proteins and PGC-1α, the key regulator of mitochondrial bio-
526 genesis, were augmented in BMFC+KOC-supplemented ani-
527 mals. Remarkably, although we did not record higher ATP
528 levels in the cerebral cortex of supplemented animals,
529 BMFC+KOC rats presented increased levels of PGC-1α, sug-
530 gesting that the combination of the two types of fat favors the
531 increase of this transcription factor, in turn indicating an in-
532 crease in mitochondrial biogenesis signaling in this brain area.
533 Since all treated animals presented increased levels of the
534 neurotrophin BDNF, upregulation of PGC-1α appears to be
535 mediated through it rather than AMPK-SIRT1. However, we
536 only found a significant increase of BDNF in the hippocam-
537 pus of BMFC+KOC animals. It is noteworthy that cerebral
538 BDNF levels are quite low [31] and perhaps even a slight rise
539 in BDNF levels could promote the action of PGC-1α in the
540 cerebral cortex.
541 BDNF stimulates mitochondrial biogenesis to form new
542 synapses and to maintain the existing ones [31]. In fact, den-
543 dritic protein synthesis is indispensable to sustain synaptic
544 plasticity, where BDNF is the main modulator [32]. BDNF
545 facilitates synaptogenesis by inducing the mTOR pathway,
546 which mediates signals for local protein synthesis [32].
547 According to our results, combined supplementation with
548 both KOC and BMFC favored mTOR activation in the hip-
549 pocampus. Thus, animals fed with both fats exhibit all the
550 necessary steps for synapse formation [32, 44].
551 Although our results point to an improvement in synapto-
552 genesis in hippocampal samples of BMFC+KOC-supplement-
553 ed animals, when we explored synaptic genes and proteins, we
554 did not find significant increases in this brain area.
555 Surprisingly, cerebral cortices presented an induction of synap-
556 tic protein synthesis in all supplemented groups, although the
557 highest levels were detected in the BMFC+KOC-supplement-
558 ed group. As mentioned above, although BDNF and mTOR
559 levels increased, statistical significance was not seen regarding
560 controls, but it may be possible that such increase is enough to
561 improve synaptic protein synthesis at the dendrite level.
562 In summary, dietary supplementation with KOC and/or
563 BMFC improves peripheral and central insulin resistance
564 and suggests that it could help delay their onset. Moreover,
565 as described before [45], n-3 fatty acids ingested as phospho-
566 lipids increase BDNF brain levels, favoring an improvement
567 in energy state within neurons and facilitating both mitochon-
568 drial and protein synthesis, which are necessary for synaptic
569 plasticity. Thus, dietary supplementation with n-3 FAs could
570 protect local protein synthesis and energy balance within den-
571 drites, favoring neuronal health and delaying cognitive decline
572 associated to age-related disrepair.
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Supplementary Table 1. Sequence of synapto-proteins primers analyzed. 
Gene Primers sequences 
 
 
 
Presynaptic 
 
Stx1A 
 
F: 5′- GCCCTGTTTGATTACGACAA-3′ 
R: 5′- ACTCGGTTCTGAGCTATGAG  
 
Syn1 
 
F: 5′- TGTCCCGAAAGTTTGTG-3′ 
R: 5′- GCGTTCTCGGTAGTCT 
 
Syt1 
 
F: 5′- CTTCTCCAAGCACGACATCA-3′ 
R: 5′- CCACCCACATCCATCTTCTT -3′ 
 
 
 
Postsynaptic 
 
Dlg4 
 
F: 5′- TAGGGCCCTGTTTGATTACG-3′ 
R: 5′- TGGCCTTTAACCTTGACCAC -3′ 
 
Dlg3 
 
F: 5′- GAGTTCCCGCATAAGTTTGG-3 
R: 5′- CGGACACGTCTAAGATGCAG -3′ 
 
Dlg2 
 
F: 5′- GTCGGAGGTTTCCCACAGTA-3′   
R: 5′- CTGTGCAGCTCCACCATCTA -3′  
Stx1A: syntaxin 1A; Syn: synapsin I; Syt1: synaptotagmin 1; Dlg4: discs large MAGUK scaffold protein 
4; Dlg2: discs large MAGUK scaffold protein 2; Dlg3: discs large MAGUK scaffold protein 3; F: 
Forward; R: Reverse.  
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 2. List of the primary antibodies 664 used to analyze insulin 
signaling pathways, neurotransmission, and neurodegeneration. 
 
Antibodies Molecular 
Weight (kDa) 
Host Company 
p-thr308-
AKT 
60 Rabbit Cell Signaling * 
p-thr473-
AKT 
60 Rabbit Cell Signaling * 
AKT 60 Rabbit Cell Signaling * 
p-mTOR 289 Rabbit Cell Signaling * 
mTOR 289 Rabbit Cell Signaling * 
p-IRS1 90 Rabbit Santa Cruz Biotechnology ** 
IRS1 90 Rabbit Santa Cruz Biotechnology ** 
IRS2 185 Mouse Millipore * 
IRβ 75-100 Mouse Santa Cruz Biotechnology ** 
p85 PI3K 75-85 Mouse Santa Cruz Biotechnology ** 
p-AMPK 
α1/2 
60 Rabbit Santa Cruz Biotechnology ** 
AMPK α1/2 63 Mouse Santa Cruz Biotechnology ** 
SIRT1 120 Rabbit Santa Cruz Biotechnology ** 
PGC1 90 Rabbit Santa Cruz Biotechnology ** 
GLUT2 55-60 Rabbit AD Internacional *** 
GLUT4 50-63 Mouse Santa Cruz Biotechnology ** 
VAMP-2 18 Mouse Santa Cruz Biotechnology ** 
Syntaxin 1 35 Mouse Santa Cruz Biotechnology ** 
p-TAU 50-80 Mouse Cell Signaling * 
TAU-5 46-80 Mouse Santa Cruz Biotechnology ** 
α-synuclein  19 Mouse Santa Cruz Biotechnology ** 
BDNF 14 Mouse Novusbio **** 
UBB 9 Mouse Millipore * 
*(Madrid, Spain); **(Heidelberg, Germany); ***(San Antonio, USA); ****(Abingdon, 
667 United Kingdom); ***** (Cambridge, United Kingdom). 
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Abstract 24 
The increasing incidence of age-induced cognitive decline justifies the search for 25 
complementary ways of prevention or delay. We studied the effects of concentrates of 26 
phospholipids, sphingolipids, and/or 3-n fatty acids on the expression of genes or 27 
miRNAs related to synaptic activity and/or neurodegeneration, in the hippocampus of 28 
aged Wistar rats following a 3-month supplementation. The combination of two 29 
phospholipidic concentrates of krill oil (KOC) and buttermilk (BMFC) origin 30 
modulated the hippocampal expression of 119 miRNAs (11 were common to both 31 
BMFC and BMFC+KOC groups). miR-191a-5p and miR-29a-3p changed significantly 32 
only in the BMFC group, whereas miR-195-3p and miR-148a-5p did so only in the 33 
combined-supplemented group. Thirty-eight, 58, and 72 differentially expressed genes 34 
(DEG) were found in the groups supplemented with KOC, BMFC and BMFC + KOC, 35 
respectively. Interaction analysis unveiled networks of selected miRNAs with their 36 
potential target genes. DEG found in the KOC and BMFC groups were mainly involved 37 
in neuroactive processes, whereas they were associated with lysosomes and mRNA 38 
surveillance pathways in the BMFC + KOC group. We also report a significant 39 
reduction in hippocampal ceramide levels with BMFC + KOC. Our results encourage 40 
additional in-depth investigations regarding the potential beneficial effects of these 41 
compounds.42 
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Introduction 43 
According to the most recent Global Burden of Disease Study 2015 1, 44 
the burden of neurological disorders has increased substantially over the past 25 years 45 
because of expanding population numbers and ageing. Even though the prevalence of 46 
communicable neurological disorders decreases, the number of patients who will need 47 
care by neurologists will continue to grow in coming decades. Indeed, mostly because 48 
of the lack of suitable animal models, neurodegeneration – including cognitive decline - 49 
is currently difficult to treat and poses an economical and sociological burden on the 50 
national health care systems. Disease-unrelated memory decline increases with age in 51 
rodents and humans and appears to be associated with subtle changes in the 52 
connectional and functional integrity of key hippocampal circuits 2-4. Emphasizing the 53 
importance of this brain region, several gene transcriptional changes influence a wide 54 
range of learning and memory-related processes in the hippocampus of aged rats with 55 
memory impairment 5. Moreover, these processes - including neurogenesis, synaptic 56 
plasticity and neuronal connectivity - are affected by nutrition 6. In this respect, the 57 
Mediterranean diet has been suggested as being neuroprotective 7. Its effects are 58 
mediated by changes in the expression of multiple genes and associated regulatory 59 
networks; nutrition-gene interactions play important roles in optimal and sub-optimal 60 
cognitive function. Epigenetics is also emerging as an important mechanism through 61 
which nutrition can directly influence the genome 8. Numerous epigenetic processes are 62 
involved in complex mechanisms of gene regulation, as is the case of synaptic 63 
plasticity, learning, and memory. Among other players, these processes include changes 64 
in non-protein-coding RNAs (ncRNAs) 8,9. MicroRNAs (miRNAs), small ncRNAs, 65 
which post transcriptionally repress the expression of target genes, have the potential to 66 
be used as biomarkers of neurodegenerative disease 10.  67 
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Age-related loss of cerebral n-3 fatty acids (FAs) and polar lipids (PL) together 68 
with low intakes of these compounds (which are essential for the activity, functioning, 69 
and maintenance of the nervous system) is related to a greater risk of neurodegenerative 70 
diseases 11. The ISSFAL, the World Health Organization (WHO) and the Food and 71 
Agricultural Organization (FAO) recommend (for adults) a daily intake of at least 500 72 
mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 12. In this respect, 73 
krill oil is an attractive source of n-3 FAs incorporated into phosphatidylcholine (PC). 74 
In addition, buttermilk (BM), a by-product obtained from butter manufacturing with a 75 
high content of milk fat globule membrane (MFGM), is rich in polar lipids, particularly 76 
phosphatidylserine (PS) and sphingomyelin (SM), with potential positive effects in 77 
neurological pathologies 13 and is currently not employed in the supplement arena. The 78 
nutritional recommendations of physiological doses indicated for an adult of 79 
phosphatidylserine are 300-500 mg/d.  80 
In this study, we evaluated whether buttermilk and krill oil as sources of essential 81 
fatty acids modulate the expression of miRNAs and their target genes in the 82 
hippocampus, due to its importance in neurodegenerative processes, of aged rats. 83 
 84 
Results  85 
Supplementation with polar lipids does not affect body weight 86 
To determine whether the consumption of different supplements (Table 1) influences 87 
body weight, rats were weighted every week during the three months of 88 
supplementation. We did not find any significant difference in body weight throughout 89 
the study (Figure 1). The different diets contained similar caloric composition (Table 90 
2) but differ on the types of fatty acids (Table 3).   91 
Blood tests 92 
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We studied selected biological markers to see if supplements had effects on the lipid 93 
profile, namely on cholesterol, triglyceride, non-esterified fatty acid, and phospholipids 94 
concentrations. There were no significant differences between the groups in the 95 
lipoprotein profile as analyzed by FPLC (Figure 2A); significant differences were 96 
found in phospholipid levels, which were decreased in the BMFC and BMFC + KOC 97 
groups as compared with controls (Figure 2B).  These decreases could be due to a 98 
compensatory physiological mechanism in response to the extra supply of 99 
phospholipids. We did not find significant changes between groups in the other 100 
parameters analyzed.  101 
Ceramide levels are reduced by BMFC + krill oil supplementation  102 
Possible effects of dietetic supplementations on the composition of key lipids were 103 
assessed in the hippocampus. No major differences in lipids classes were observed 104 
(results not shown), except for ceramides, whose level was significantly reduced in the 105 
BMFC + KOC group (Figure 3).  106 
Supplementation with phospholipid concentrates modulates the expression of 107 
selected miRNAs 108 
As epigenetic regulation of gene expression is highly flexible in the brain 14 and 109 
miRNAs – considered epigenetic markers – are involved in brain development and 110 
cognition 10, we assessed the expression of miRNAs in the hippocampus. Whole 111 
transcriptome of small RNAs was performed by RNA-sequencing. We show that 112 
numerous miRNAs were induced or repressed in response to phospholipid concentrates 113 
supplementations (Supplementary Table S1). Compared to the control group, BMFC 114 
differentially modulated the expression of 23 miRNAs (Figure 4A), three up-regulated 115 
and 20 down-regulated, whereas krill oil did not exert any significant effects (Figure 116 
4B). Interestingly, the mixture of both lipids dramatically modulated the expression of 117 
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these and other novel miRNAs. Namely, 119 miRNAs were modulated: 55 of them 118 
overexpressed and 64 repressed (Figure 4C); 18 miRNAs are shared between BMFC 119 
and BMFC + KOC (Figure 4D). 120 
In order to confirm our results, we selected some miRNAs and validated them using 121 
RT-qPCR. Fifteen miRNAs were selected based on criteria such as the level of change 122 
in expression and their involvement in processes of the nervous system 123 
(Supplementary Table S2).  Validation of the selected miRNAs of both treatments 124 
indicated that BMFC and BMFC+KOC modulate the expression of miRNAs in the 125 
hippocampus (Figure 4E). 126 
Validation confirmed that both BMFC and BMFC+KOC supplementation modulated 127 
the expression of 11 miRNAs in the hippocampus: miR-99a-5p, -128-3p, -148a- 3p, -128 
379-5p, -381-3p, -146a-5p, -30e-3p, -370-3p, -106b-3p, -770-3p and let-7f-5p (Figure 129 
4E). On the other hand, miR-191a-5p and -29a-3p showed significant changes only in 130 
rats supplemented with BMFC; while miR-195-3p and -148a-5p were the only miRNAs 131 
significantly affected in the combined-supplement group. Moreover, miR-148a-3p, -132 
370-3p, -379-5p, -99a-5p and let-7f-5p showed a significant expression increase in 133 
KOC-consuming rats, although no significant changes had been found by mass 134 
sequencing. In addition, miR-128-3p and -30e-3p were up-regulated both in the BMFC 135 
group and in the combined-supplement fed group. 136 
With regards to the significant miRNAs validated by RT-qPCR, functional analysis of 137 
their predicted target genes showed an association with nervous system related 138 
processes, such as axon guidance, neurotrophin signaling, neuroactive ligand-receptor 139 
interaction, neuron differentiation and migration or neurological development, among 140 
others (Supplementary Table S3).  141 
 142 
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 143 
Supplementation with phospholipid concentrates modulates hippocampus gene 144 
expression 145 
To appraise the diet-modulated hippocampal transcriptome, we performed gene 146 
expression microarrays. The complete results are shown in Supplementary Table S4. 147 
The Heat Map representation of each of the three supplemented groups is shown in 148 
Figure 5A and dispersion representation in Figures 5B, C and D. 149 
Thirty-eight genes were found to be differentially expressed in the KOC supplemented 150 
group, 11 up-regulated and 27 down-regulated. In the group supplemented with BMFC, 151 
we found 58 differentially expressed genes (DEG), two of which with higher expression 152 
and 56 with lower expression than in the control group. Finally, the group that 153 
consumed the BMFC + KOC diet had the highest number (72) of DEG, of which 11 154 
were up-regulated and 61 down-regulated. Some DEG were shared by two or three 155 
groups (Figure 5E). 156 
Functional analysis of the differently expressed genes found in the microarray was 157 
based on different databases and displayed several neural system-related processes, 158 
among others (Supplementary Table S5). In all supplemented groups, we found 159 
processes related to lipid metabolism, like fatty acids synthesis and arachidonic acid 160 
metabolism, and neurotransmitter biosynthesis, such as serotonin, adrenaline and 161 
noradrenaline, transport and brain development.  162 
 163 
BMFC-modulated genes in the hippocampus are influenced by miRNA-gene 164 
interaction. 165 
Due to the post-transcriptional regulation by miRNAs, we performed an interaction 166 
analysis between DEG identified in the array and the miRNAs selected for validation 167 
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(Supplementary Table S6). This analysis related the modulated miRNAs and their 168 
targets, considering their regulatory function, i.e. up-regulated miRNAs with down-169 
regulated targets or vice versa. In the KOC group, five miRNAs formed a network of 170 
interaction with 11 DEG (Figure 6A). In the BMFC group, six miRNAs showed an 171 
interaction network with eight DEG (Figure 6B). Finally, in the BMFC + KOC group, 172 
32 genes were found to be potential targets of 10 miRNAs (Figure 6C). According to 173 
gene ontology analysis (Figure 6D), DEG found in the group consuming KOC are 174 
primarily involved in receptor-ligand neuroactive processes, although an involvement in 175 
transport processes such as secretion and absorption was also identified. Neuroactive 176 
receptor-ligand processes were also the main route found in the BMFC group, together 177 
with axonal orientation and Alzheimer's disease-related processes. As for the BMFC + 178 
KOC group, DEG were associated with lysosomes - cells’ digestive system, and mRNA 179 
surveillance pathways, a quality control mechanism to detect and degrade abnormal 180 
mRNAs. DEG found in this group were also involved in transport processes such as 181 
secretion and absorption. 182 
Ten DEG were then selected, based on their relation to cognitive function or 183 
neurodegenerative disease and that they were targets of miRNAs previously associated 184 
to some type of cognitive function, for validation by RT-qPCR (Figure 6E). In the 185 
group that consumed the KOC-supplemented diet, genes Arc, Mrps23 and Capn7 186 
showed a statistically significant increase in expression compared to the control group. 187 
In accordance with the microarray results, Capn7 and Cbr3 were found to be 188 
significantly up- and down-regulated, respectively, in the BMFC group, but in this case 189 
statistical significance was not reached. Three up-regulated genes - Tshz3, Satb2 and 190 
Capn7- were validated in the BMFC+KOC group with confirmation of statistically 191 
significant changes compared to the control group. 192 
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 193 
Discussion 194 
We supplemented aged rats with a MFGM-rich concentrate and/or a krill oil 195 
concentrate for three months and report the transcriptomic and miRNA expression in 196 
their hippocampus, in addition to changes in total ceramide concentrations.  197 
Previous works have shown that MFGM supplementation of human infants (6-198 
11 months of age) could reduce diarrhea episodes 15 or acute otitis media infections 16, 199 
which might be related to oral microbiome changes 17. MFGM have also shown to 200 
reduce differences in cognitive development 18 and serum lipid status 19 between 201 
formula- and breast-fed infants (from <2 until 6 months of age) when supplemented in 202 
fed-formula. Interestingly, young piglets supplemented with MFGM and other 203 
prebiotics seemed to be more advanced neurodevelopmentally 20. In adults (18-65 y of 204 
age), buttermilk supplementation reduced cholesterol concentrations 21 and blood 205 
pressure in normotensive individuals 22. Indeed, supplementation of overweight adults 206 
with milk fat enclosed in MFGM prevented the increase of plasma lipids compared to 207 
that of milk fat without MFGM 23. Regarding other physiological contexts, consumption 208 
of MFGM (1g/day during 10 weeks) plus exercise have been shown to improve physical 209 
performance 24 or skeletal muscle strength (1g/day during 4 weeks) 25 of healthy adults. 210 
In the elderly, dietary supplementation with MFGM (1g/day during 3 months) 211 
combined with exercise improved the frailty status as compared to the MFGM alone 26. 212 
Moreover, also in elderly (60-73 y), supplementation with MFGM (1g/day for 10 213 
weeks) was shown to increase physical performance and muscle function when coupled 214 
with a light exercise program 27.  However, very few studies focused on brain function 215 
18,20 and none on the aged brain.  216 
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We did not observe any appreciable adverse effect due to dietary 217 
supplementation. Although MFGM consumption by healthy adults has been shown to 218 
be safe at a doses of 6.5 g for 4 weeks 28, a higher rate of eczema was observed in 219 
infants administered MFGM-enriched infant formula supplementation (up to 4 months 220 
of age) as compared with standard infant formula 29.  221 
To the best of our knowledge, our study is the first to evaluate miRNA 222 
expression in response to BFMC supplementation. Dietary modulation of miRNAs, i.e. 223 
through food bioactive compounds 30 or dietary lipids 31,32, is feasible and might be an 224 
alternative to the pharmacological modulation of miRNAs. Through gene interaction 225 
analyses, we report that miRNAs might contribute to the regulation of the modulated 226 
hippocampal genes. Gene Ontology analysis suggests that modulated genes participate 227 
in pathways related to neuroactive receptor-ligand processes, axonal orientation, 228 
Alzheimer's disease-related processes, or lysosomes pathways, most of which are 229 
related to brain function. Some such modulated genes have been previously associated 230 
with synaptic activity. Arc protein have been related to synaptic plasticity and 231 
cognition, as its neuronal activity-induced expression is critical for long-term 232 
potentiation and depression of synaptic transmission, homeostatic synaptic scaling, and 233 
adaptive functions such as long-term memory formation 33. In this context, the 234 
significant increase of Arc observed in the KOC supplemented group could be 235 
beneficial. Although the physiological importance of Capn7, which encodes for calpain 236 
7, is not clear, calpains are ubiquitous calcium sensitive proteases involved in essential 237 
neuronal functions including maintaining synaptic plasticity, protein turnover and cell 238 
signaling 34. Here, the increase in the expression of this gene seen in both KOC and 239 
BMFC+KOC supplemented groups could be linked to improved synaptic plasticity. We 240 
also observed a rise in Tshz3 expression in the BMFC+KOC supplemented group. 241 
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Tshz3 deletion affects the cortical expression of a number of genes related to autism 242 
spectrum disorder (ASD) and induces ASD-relevant deficits that are associated with 243 
functional changes at synapses formed by deep-layer cerebral cortical projection 244 
neurons (CPN) 35. Finally, Satb2 is necessary for long-term memory formation and 245 
hippocampal late-long-term potentiation and determines the expression of protein-246 
coding genes and miRNAs linked to learning and memory in the hippocampus 36. In this 247 
context, the increased expression of this gene seen in the BMFC+KOC supplemented 248 
group could be beneficial for well-balanced neurocognitive processes. 249 
Even though whether the modulated genes are only a direct consequence of the 250 
modulated miRNAs it is still unclear, we show that BFMC + KOC supplementation 251 
influences the expression of several mRNAs and miRNAs in the hippocampus. In this 252 
sense, a general association with nervous system related processes, such as axon 253 
guidance, neurotrophin signaling, neuroactive ligand-receptor interaction, neuron 254 
differentiation and migration or neurological development, was found in the functional 255 
analysis of the RT-qPCR-validated miRNAs. Together with the above-mentioned genes, 256 
several miRNAs described herein have been previously related to neurodegenerative 257 
diseases. For example, it has been proposed that a loss of specific miRNAs, such as the 258 
cluster miR-29a/b-1, can contribute to increased BACE1 and Aβ levels in sporadic 259 
Alzheimer's disease 37. If this is the case, then the increase in miR-29a expression seen 260 
in the BFMC-supplemented group could be advantageous against AD, nonetheless 261 
additional investigation is required. On the other hand, Lukiw et al. suggested that 262 
miRNA-146a-mediated modulation of complement factor H (an important repressor of 263 
the inflammatory response of the brain) gene expression may in part regulate an 264 
inflammatory response in AD brain and in stressed HN cell models of AD 38. In this 265 
context, the rise in miR-146a expression seen in the BFMC group could be related to 266 
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changes in inflammatory processes; again, further ad-hoc research is needed. Also, Kim 267 
and colleagues identified miR-106b as a regulator of Aβ metabolism, increasing Aβ 268 
production and preventing its clearance. In this case, the rise in miR-106 observed for 269 
the BMFC+KOC supplemented group does not appear to be desirable, but literature is 270 
scant and additional studies are indispensable. We acknowledge that additional 271 
investigation is necessary. Moreover, despite the modulation of the aforementioned 272 
miRNAs, rises in expression levels could not be surely correlated with a decrease in 273 
their respective predicted target genes validated here and causality could not be 274 
established. In this context, gene expression analyses reveal changes in mRNA levels 275 
even though miRNAs can bind to mRNAs without necessarily inducing degradation but 276 
still being able to prevent protein synthesis, which could have an important impact on 277 
cell function. In fact, we cannot discard other interactions, i.e. the case of a miRNA that 278 
impacts on the protein expression levels without any apparent changes on its mRNA 279 
target, due to the solely evaluation of the transcriptome (and not protein levels). Overall, 280 
we believe that our results warrant further investigation to determine the impact of these 281 
supplements on cognitive symptoms associated with aging, that is to say more in-depth 282 
biological/molecular analysis and behavioral tests are justified.  283 
Consumption of omega-3 fatty acids from marine sources 39 or their derivatives 284 
40 decreases plasma triglyceride levels. Namely, krill oil consumption decreases 285 
triglyceride concentrations 41 both in healthy 42 and hypertrygliceridemic subjects 43. 286 
The bioavailability of n-3 FAs from krill has been shown to be similar to that of other 287 
long-chain n-3 polyunsaturated fatty acids 44; however, their specific effects in the 288 
elderly have not been studied thus far. A recent study suggested that dietary krill oil 289 
supplementation enhanced neurocognitive function in aging mice, by changing the 290 
expression of Celsr3 and Ppp1r1b 45, which are implicated in memory and learning 291 
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process. In this study, we did not observe any change in triglyceride concentrations in 292 
supplemented aged rats. Whether krill oil or other sources of omega-3 fatty acids also 293 
influence lipid levels in the elderly remains unresolved. Indeed, omega-3 fatty acid-rich 294 
oils (beginning at 12 months of age) apparently shorten the life span of long-lived F1 295 
mice and krill oil modestly increases bilirubin, triglyceride, and glucose levels 46. 296 
Whether the lowering effects of omega-3 fatty acid-rich oils on triglyceride levels are 297 
reduced by aging is unknown.    298 
We also report that dietary supplementation with different phospholipids did not 299 
remarkably influence the lipid profile of the hippocampus, with the exception for a 300 
significant reduction in ceramide levels in rats supplemented with a MFGM-rich 301 
concentrate in combination with a krill oil concentrate. Whether changes in ceramide 302 
levels can contribute to delaying mild-cognitive decline due to aging is not clear but 303 
further investigation is entitled. Ceramides play an important role in the neurons and its 304 
composition changes through the different stages of development 47. Indeed, ceramide 305 
accumulations in the brain results in a deregulation of energy balance and lead to 306 
different disorders as obesity, disturbance of glucose homeostasis 48, neurodegenerative 307 
diseases 49 and AD pathogenesis 50,51. Our data shows changes in the transcriptomic and 308 
miRNA expression profiling in response to dietary supplementation with a MFGM-rich 309 
concentrate in the hippocampus. Whether there is a direct causality between these 310 
changes and the reduction in ceramide levels is unknown, but, to the best of our 311 
knowledge, cannot be discarded. Ceramide deregulation has been shown to cause 312 
distinct global alterations of gene expression in hepatocyte cell lines 52 or changes in 313 
miRNA expression in multiple myeloma cells in vitro 53. However, the in vivo effects of 314 
these changes on the whole transcriptome or miRNome are understudied, especially in 315 
the hippocampus.  316 
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In summary, the experimental evidence presented here and elsewhere suggests 317 
that a buttermilk fat concentrate, rich in MFGM, alone or in combination with a krill oil 318 
concentrate, may influence cognitive development 18 or brain function 20 by targeting 319 
both genetic and epigenetic mechanisms through miRNA modulation. Whether these 320 
epigenomic and nutrigenomic changes can influence functional readouts is still 321 
unknown. As mentioned in the Introduction, the increasing incidence of age-induced 322 
cognitive declines calls for immediate action and the use of dietary supplements, e.g. 323 
BFMC + KOC and others warrants intense investigation.    324 
 325 
Material and methods 326 
Animals, diets and experimental design 327 
We followed the Guide to the Care and Use of Laboratory Animals, published by the 328 
US National Research Council (Eight Edition, 2010). The animal experimentation 329 
committee of the National University of Distance Education (UNED) approved these 330 
experiments.  Nine-month old Wistar rats (n=46) were purchased from Charles River 331 
Laboratories (Barcelona, Spain) and were housed for nine months. At 18 months of age 332 
(when rats begin to present a variety of cognitive symptoms associated with aging), the 333 
animals were randomly assigned to four experimental groups of diet supplementation 334 
with phospho- and sphingolipids concentrates from buttermilk (BM) and krill oil (KO), 335 
or a combination of both (Table 1). Concentrates were produced at the Institute of Food 336 
Science Research (CIAL, Madrid, Spain) and were given in the form of frozen 337 
strawberry jellies. Nutritional and methyl ester fatty acids composition of the 338 
concentrates are described in Table 2 and Table 3, respectively. The nutritional 339 
intervention lasted for three months. Briefly, rats were weighed every week during the 340 
supplementation period, after which they were sacrificed by decapitation. Blood 341 
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samples were centrifuged for plasma collection at 1500 xg for 15 minutes, RT. Tissues 342 
and organs were quickly extracted and frozen in liquid nitrogen. All samples were 343 
stored at -80 ˚C.  344 
Determination of plasma lipids and lipoproteins 345 
Plasma concentrations of cholesterol and triglycerides were analyzed enzymatically 346 
using commercial kits (Centronic, Germany & Bradford Diagnostics, Kemia Científica 347 
S.A., Spain). To determine the plasma lipoprotein profile, a pool of plasmas was 348 
subjected to fast protein liquid chromatography (FPLC) gel filtration through a 349 
Superose 6 HR 10/30 column (Pharmacia). Samples (220 μl) were eluted with 150 mM 350 
NaCl, 10 mM Tris–HCl, 2 mM Na2-EDTA and 0.02% NaN3, pH 7.4, at a flow rate of 351 
0.3 ml/min, and 0.4-ml fractions were collected.  352 
Cholesterol, triglyceride, non-esterified fatty acid (FAs) and phospholipid levels were 353 
determined in plasma samples using appropriate commercial assay kits, according to the 354 
instruction’s manual (Spinreact, Sant Esteve de Bas, Spain & Wako Chemicals GmbH, 355 
Neuss, Germany). 356 
 357 
Ceramide and lipid analysis 358 
Tissue lipids were extracted using the Folch method described by Löfgren et al. 54 with 359 
slight modifications. Briefly, tissues samples were dissolved in methanol in 50 mL glass 360 
tubes. The mix was sonicated in an ultrasonic processor (Dr. Hielscher, Teltow, 361 
Germany) during 15 second, two cycles. Then, dichloromethane (1:2 362 
methanol/dichloromethane) was added and mixed during 20 min. Acetic acid 20 mM 363 
(1:3 acetic acid/dichloromethane) was added and samples were again mixed for 20 min. 364 
Samples were centrifuged at 2100 rpm, 5 min, 4 ºC. Bottom organic phases were 365 
transferred to a new glass tube and the methanolic phase was washed with 366 
dichloromethane (1:1 dichloromethane/ methanol) and mixed for 10 min before 367 
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centrifugation with the same conditions as described above. The organic phases were 368 
collected and mixed and filtered through 0.45 µm, evaporated with nitrogen and 369 
weighted. Lipids extracts were maintained at -35 ºC. The separation of ceramides of 370 
lipid extracts from tissues samples were performed with a HPLC Agilent Technologies, 371 
model 1200 (Agilent Technologies, Palo Alto, CA, USA) coupled to an evaporative 372 
light scattering detector (ELSD) (SEDERE. SEDEX 85 model, Alfortville Cedex, 373 
France) using pre-filtered compressed air as the nebulizing gas at pressure of 350 KPa, 374 
temperature of 90ºC and the gain was set at 6. Two columns Zorvax Rx-SIL column 375 
(Agilent Technologies, Palo Alto, CA, USA) of 250 mm × 4.5 mm and 5 μm particle 376 
size, were coupled in series with a precolumn with the same refill. They were 377 
equilibrated at 40 ºC. The injection volume was 50 μL at concentration of 5 mg/mL in 378 
CH2Cl2 using chromatographic solvent gradient as we have previously described 
55. 379 
 380 
RNA isolation 381 
Total small and large RNA extraction from hippocampus samples were performed 382 
according to the manufacturer’s instructions (NucleoSpin® miRNA kit, Macherey 383 
Nagel, Düren, Germany). RNA quantity was determined by NanoDrop® ND-2000 384 
Spectrophotometer (Thermo Fisher Scientific Inc., Spain). 385 
 386 
Small RNA library construction and sequencing 387 
Purity and integrity of RNA extracted from hippocampal samples (n = 5 per group), 388 
were assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 389 
CA). A NEBNext® Small RNA Library Prep Set for Illumina (New England BioLabs, 390 
Ipswich, MA) was used to prepare the libraries according to the manufacturer’s 391 
protocol. The cDNA library was sequenced with NextSeq 500 from Illumina. To 392 
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facilitate the analysis a filter of sequences with a maximum length of 50NT was applied. 393 
Samples passed the quality controls performed through the FASTQC tool. Bowtie2 was 394 
used for sequence alignment with reference genomes, first against rat miRNA sequences 395 
downloaded from miRbase, and then against the rat genome Rnor_5.0 (Ensembl release 396 
79). The integrated Genome Viewer (IGV) software was used for alignment 397 
visualization. Finally, gene counting was carried out using HTSeq-count to allow 398 
differential expression analysis, mainly, of the miRNAs obtained from each 399 
experimental group versus the control group. 400 
 401 
Arrays 402 
Expression arrays were performed in hippocampal tissue of three samples per study 403 
group, using the 4x44K complete rat genome platform from Affymetrix (Clariom S 404 
Assays). Each microarray screens approximately 22,900 unique rat genes and 405 
transcripts. Briefly, double-stranded cDNA was synthesized from total RNA using One-406 
cycle cDNA Synthesis Kit (Affymetrix, Santa Clara, CA). cRNA was fragmented and 407 
hybridized to the Affymetrix matrix following the manufacturer's instructions. Finally, 408 
microarrays were washed and cartridges were scanned in a GeneChip® 3000 scanner 409 
for fluorescence signal acquisition.  410 
The generated output files in CEL format were used for downstream analysis. Data was 411 
normalized with the RMA method. Probes with lower variance were filtered out, 412 
resulting in approximately 12000 remaining probes. Differential gene expression was 413 
assessed with the Bioconductor Limma package. Genes with a FDR lower than 0.1 were 414 
considered as statistically significant. 415 
 416 
Interactions analysis 417 
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For interaction analysis, we screened miRNAs selected for validation. Prediction of 418 
miRNA targets was obtained using the Diana microT-CDS algorithm. Only the 419 
corresponding targets that showed statistically significant differential gene expression in 420 
microarrays were considered as valid interactions. Target point sizes are directly 421 
correlated with the number of interactions within the set of miRNAs. 422 
 423 
Functional analysis and miRNA target prediction  424 
Genecodis3 algorithm was used for functional analysis of the obtained gene lists, 425 
focusing on biological processes and pathways, using the Gene Ontology and KEGG 426 
pathway databases respectively. Predicted miRNA gene targets were obtained using the 427 
Diana microT-CDS algorithm. For each miRNA, the prediction score was set to a 428 
convenient value in order to obtain in the output a gene target list ranging from 200 to 429 
1500 items.  430 
Validation of miRNA and gene expression by RT-qPCR 431 
miScript®II reverse transcription kit (Qiagen, Germantown, MD) was used to converted 432 
total RNA into first strand cDNA for miRNA validations whereas iScript™ Advanced 433 
cDNA Synthesis Kit (BIO-RAD, Hercules, CA) was used for gene validations, both 434 
according to the manufacturer’s guidelines.  435 
Selected miRNAs were obtained from the miRBase database, and the genes for the 436 
validation were designed using Primer3 online program and amplify4 (Supplementary 437 
Tables S7 and S8). Designed primers were constructed by ISOGEN (Life Science, 438 
Belgium). Real time PCR was performed in a 384-plate format using a 7900HT system 439 
(Life Technologies, Alcobendas, Spain). Cycling conditions for both gene and miRNA 440 
amplification included a first step of activation at 95 °C 15 minutes. For gene 441 
amplification, 40 cycles at 94 °C for 15 seconds for the denaturation, annealing at 58 °C 442 
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for 30 seconds were applied subsequently. As for miRNA amplification, 40 cycles of 443 
denaturation at 94 °C for 15 seconds, annealing at 58 °C for 30 seconds and an 444 
extension at 70 °C for 15 seconds were applied. Finally, a dissociation curve step at 95 445 
°C for 15 seconds, followed by 15 seconds at 60 °C and 95 °C for 15 seconds was 446 
carried out for both amplification types. miScript SYBR Green qPCR Master Mix 447 
(Qiagen,Madrid, Spain) was used for both validations. GAPDH and RNU6 were used as 448 
reference genes for gene and miRNA data normalization, respectively. The ΔΔCt 449 
method was used for gene expression analysis and fold-change values were reported as 450 
2−(ΔΔCt). 451 
 452 
Statistical analysis 453 
Significance of the functional enrichment results was assessed using the hypergeometric 454 
test and items with corrected p < 0.05 were considered as statistically significant. 455 
Differences between groups were assessed by one-way ANOVA followed by Bonferroni 456 
test for post hoc comparisons. p < 0.05 was considered as statistically significant. 457 
Results are presented as means ± SEM. Statistical analyses were performed with 458 
GraphPad Prism 7.02 software (GraphPad Software, Inc., La Jolla, CA, USA).  459 
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Figure legends 486 
Figure 1. Variation of body mass. Values are expressed as mean ± SEM of the mean. 487 
BMFC: buttermilk fat concentrate rich in phospho- and sphingolipids; KOC: krill oil 488 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic 489 
acid) and phospholipids; BMFC+KOC: combination of BMFC and KOC. 490 
Figure 2. Lipid levels and lipoprotein profile of rat plasma. A) FPLC profile of plasma 491 
cholesterol and triglycerides. B) Cholesterol, triglycerides, non-esterified fatty acids, 492 
and phospholipid levels in plasma. Values are means ± SEM. Statistically significant 493 
difference from control at *p< 0.05-0.005; **p< 0.005-0.0005. BMFC: buttermilk fat 494 
concentrate rich in phospho- and sphingolipids; KOC: krill oil concentrate rich in 495 
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omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 496 
phospholipids; BMFC+KOC: combination of BMFC and KOC. 497 
Figure 3. Ceramide concentrations in the hippocampus. Values are the mean ± SEM, 498 
n≥10 per group. Different letters denote differences at p< 0.05. BMFC: buttermilk fat 499 
concentrate rich in phospho- and sphingolipids; KOC: krill oil concentrate rich in 500 
omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 501 
phospholipids; BMFC+KOC: combination of BMFC and KOC. 502 
Figure 4. sRNASeq results. Smear plots for control vs KOC (A), BMFC (C) and 503 
KOC+BMFC (B) groups. D) Venn diagram of differentially expressed miRNAs. E) 504 
Validation of selected miRNAs. Values are means ± SEM. Statistically significant 505 
difference vs control at *p< 0.05-0.005; **p< 0.005-0.0005; ***p< 0.0005. BMFC: 506 
buttermilk fat concentrate rich in phospho- and sphingolipids; KOC: krill oil 507 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic 508 
acid) and phospholipids; BMFC+KOC: combination of BMFC and KOC. 509 
Figure 5. Gene expression analysis.  A) Heatmap of microarray data. Scattered plots for 510 
KOC (B), BMFC (C) and KOC+BMFC (D) groups. E) Venn diagram of differently 511 
expressed genes. BMFC: buttermilk fat concentrate rich in phospho- and sphingolipids; 512 
KOC: krill oil concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and 513 
docosahexaenoic acid) and phospholipids; BMFC+KOC: combination of BMFC and 514 
KOC. 515 
Figure 6. Genetic interaction analysis between miRNAs and their possible mRNAs 516 
targets for KOC (A), BMFC (B) and BMFC+KOC (C) groups. D) Functional 517 
enrichment analysis of differentially expressed genes. E) Validation of potential target 518 
genes of previously validated miRNAs. Arc: activity-regulated cytoskeleton-associated 519 
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protein; Cbr3: carbonyl reductase 3; Tshz3: teashirt zinc finger homeobox 3; Pla2g5: 520 
phospholipase A2 group V; Htr2c: 5-hydroxytryptamine receptor 2C; Mrps23: 521 
mitochondrial ribosomal protein S23; Sst: somatostatin; Satb2: SATB homeobox 2; 522 
Ip6k1: inositol hexakisphosphate kinase 1; Capn7: calpain 7. BMFC: buttermilk fat 523 
concentrate rich in phospho- and sphingolipids; KOC: krill oil concentrate rich in 524 
omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 525 
phospholipids; BMFC+KOC: combination of BMFC and KOC. 526 
 527 
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Table 1. Experimental design and administered diets. 680 
 
Diets 
Experimental design 
Control BMFC KOC BMFC+KOC 
standard 
diet 
EURodent Diet 
22% 
EURodent Diet 
22% 
EURodent 
Diet 22% 
EURodent Diet 
22% 
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Daily 
jelly 
70 mg refined 
olive oil 
70 mg BMFC 70 mg KOC 70 mg BMFC+70 
mg KOC 
BMFC: buttermilk fat concentrate rich in phospho- and sphingolipids; KOC: krill oil 681 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic 682 
acid) and phospholipids; BMFC+KOC: combination of BMFC and KOC. EURodent 683 
Diet 22% (LabDiet, San Luis, Missouri). 684 
 685 
Table 2. Nutritional composition of the supplements. 686 
Dose 
contribution/ 
animal/Day 
 
Control 
 
BMFC 
 
KOC 
 
BMFC+KOC 
Energy (Kcal) 201,07 201,11 201,07 201,75 
Lipids (g) 1,82 1,82 1,82 1,89 
Carbohydrates (g) 32,10 32,11 32,10 32,11 
Fiber (g) 2,05 2,05 2,05 2,05 
Proteins (g) 11,01 11,01 11,01 11,01 
BMFC, buttermilk fat concentrate rich in phospho- and sphingolipids; KOC, krill oil 687 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic 688 
acid) and phospholipids; BMFC+KOC, combination of BMFC and KOC. 689 
 690 
Table 3. Fatty acids (as methyl esters) included in the nutritional supplements. 691 
MEFA g/100g 
supplement 
 
Control 
 
BMFC 
 
KOC 
 
BMFC+KOC 
Ʃ SFA 15,29 ± 0,11 47,77 ± 0,61 27,66 ± 0,27 32,90 ± 0,64 
Ʃ MFA 77,54 ± 0,55 40,20 ± 0,72 23,08 ± 0,15 34,18 ± 1,32  
Ʃ PUFA 6,66 ± 0,16 11,39 ± 0,42 44,73 ± 0,62  33,17 ± 0,83  
Ʃ n-6 6,26 ± 0,10 10,13 ± 0,37 2,09 ± 0,05  5,77 ± 0,50 
Ʃ n-3 0,41 ± 0,06 0.61 ± 0,04 43,06 ± 0,65  24,14 ± 1,07 
Ʃ mFA 0,50 ± 0,10 1,54 ± 0,09 2,22 ± 0,22 2,68 ± 0,07 
MEFA, methyl esters of fatty acids; SFA, saturated fatty acids; MFA, monounsaturated 692 
fatty acids; PUFA, polyunsaturated fatty acids; n-6, omega−6 fatty acids; n-3, omega−3 693 
fatty acids; mFa, other minor fatty acids; BMFC, buttermilk fat concentrate rich in 694 
phospho- and sphingolipids; KOC, krill oil concentrate rich in omega-3 fatty acids 695 
(eicosapentaenoic acid and docosahexaenoic acid) and phospholipids; BMFC+KOC, 696 
combination of BMFC and KOC. 697 
 698 
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Table S1. miRNA sequencing results 
 
 miRNA logFC PValue FDR 
 miR-146a-3p -3.674 0.000 0.013 
 miR-3552 -3.389 0.000 0.013 
 miR-181a-5p -2.760 0.001 0.039 
 miR-17-1-3p -2.168 0.001 0.032 
 miR-483-3p -2.083 0.001 0.032 
 miR-17-5p -1.756 0.001 0.033 
 miR-20a-5p -1.575 0.000 0.013 
 miR-339-5p -1.569 0.000 0.013 
 miR-99a-3p -1.501 0.001 0.032 
BMFC vs 
Control 
  miR-3102  -1.397  0.000  0.008  
  miR-31a-5p  -1.394  0.001  0.033  
miR-582-5p -1.376 0.001 0.032 
 miR-3065-3p -1.261 0.001 0.035 
 miR-369-3p -1.255 0.002 0.044 
 miR-872-3p -1.238 0.001 0.039 
 miR-219a-5p -1.147 0.001 0.032 
 miR-674-5p -1.004 0.002 0.041 
 miR-450a-5p -0.970 0.001 0.032 
 miR-15b-5p -0.956 0.002 0.044 
 miR-181b-5p -0.932 0.001 0.040 
 let-7f-5p 0.822 0.002 0.045 
 miR-148a-5p 0.918 0.002 0.047 
 miR-195-3p 1.023 0.002 0.042 
 
 
 miRNA logFC PValue FDR 
 miR-17-5p -2.747 0.001 0.008 
 miR-3583-3p -2.575 0.011 0.045 
 miR-362-3p -2.464 0.002 0.013 
 miR-17-1-3p -2.377 0.007 0.031 
 miR-20a-5p -2.305 0.000 0.000 
 miR-449a-5p -2.287 0.002 0.014 
 miR-369-3p -2.254 0.000 0.006 
 miR-362-5p -2.242 0.001 0.009 
 let-7f-2-3p -2.192 0.002 0.015 
 miR-339-5p -2.154 0.000 0.004 
 miR-764-3p -2.115 0.011 0.043 
 miR-107-3p -2.102 0.000 0.002 
 miR-194-5p -1.922 0.000 0.002 
 miR-770-5p -1.899 0.001 0.009 
 miR-144-5p -1.896 0.006 0.028 
 miR-93-3p -1.876 0.003 0.018 
 miR-374-5p -1.849 0.000 0.001 
 miR-582-5p -1.824 0.000 0.003 
 miR-3065-3p -1.797 0.000 0.002 
 miR-137-3p -1.771 0.000 0.002 
 miR-99a-3p -1.699 0.001 0.008 
 miR-106b-5p -1.696 0.000 0.001 
 miR-324-3p -1.689 0.000 0.005 
 miR-539-3p -1.671 0.000 0.006 
 miR-143-5p -1.592 0.001 0.008 
 miR-34c-3p -1.585 0.003 0.017 
 miR-30c-5p -1.546 0.001 0.007 
 miR-494-3p -1.543 0.000 0.006 
 miR-872-3p -1.522 0.001 0.009 
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 miR-98-3p -1.465 0.009 0.038 
 miR-31a-5p -1.457 0.000 0.004 
 miR-16-5p -1.453 0.000 0.002 
 miR-126a-5p -1.408 0.001 0.008 
 miR-708-5p -1.396 0.000 0.005 
 miR-410-3p -1.391 0.000 0.006 
BMFC+KOC 
vs Control 
  miR-1193-3p  -1.344  0.008  0.033  
  miR-425-3p  -1.326  0.002  0.015  
  miR-93-5p  -1.272  0.000  0.004  
 miR-674-5p -1.266 0.001 0.008 
 miR-376b-3p -1.238 0.004 0.022 
 miR-361-5p -1.225 0.001 0.009 
 miR-181b-5p -1.222 0.001 0.009 
 miR-221-3p -1.216 0.001 0.008 
 miR-219a-5p -1.200 0.007 0.033 
 miR-450a-5p -1.181 0.001 0.008 
 miR-186-5p -1.177 0.000 0.006 
 miR-138-5p -1.166 0.001 0.009 
 miR-497-5p -1.146 0.007 0.029 
 miR-3589 -1.126 0.003 0.019 
 let-7e-3p -1.079 0.001 0.009 
 miR-384-5p -1.073 0.004 0.022 
 miR-98-5p -1.071 0.001 0.009 
 miR-15b-5p -1.048 0.006 0.027 
 miR-384-3p -0.997 0.006 0.028 
 miR-874-3p -0.986 0.004 0.023 
 miR-379-3p -0.970 0.002 0.015 
 miR-23a-3p -0.892 0.006 0.028 
 miR-195-5p -0.891 0.006 0.028 
 miR-191a-5p -0.874 0.003 0.016 
 miR-140-5p -0.863 0.003 0.019 
 miR-421-3p -0.863 0.009 0.038 
 miR-26b-5p -0.848 0.004 0.022 
 miR-146a-5p -0.844 0.004 0.021 
 miR-29a-3p -0.835 0.007 0.033 
 miR-543-3p 0.690 0.012 0.047 
 miR-455-5p 0.763 0.012 0.047 
 miR-495 0.810 0.006 0.028 
 let-7i-5p 0.811 0.007 0.030 
 miR-541-5p 0.822 0.009 0.038 
 miR-134-5p 0.840 0.010 0.041 
 miR-143-3p 0.884 0.005 0.024 
 miR-135a-3p 0.899 0.008 0.033 
 miR-125-1-3p 0.899 0.009 0.038 
 let-7f-5p 0.905 0.005 0.027 
 miR-139-5p 0.923 0.001 0.009 
 miR-99a-5p 0.940 0.004 0.021 
 miR-361-3p 0.965 0.006 0.028 
 miR-185-3p 0.969 0.009 0.038 
 miR-99b-5p 0.973 0.010 0.038 
 miR-380-5p 0.975 0.005 0.023 
 miR-6331 0.976 0.004 0.021 
 miR-128-3p 0.981 0.003 0.018 
 miR-30c-2-3p 0.995 0.001 0.010 
 miR-1843-5p 1.008 0.005 0.023 
 miR-106b-3p 1.015 0.003 0.018 
 miR-192-5p 1.042 0.001 0.010 
 miR-3559-3p 1.060 0.009 0.038 
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 miR-1843-5p 1.092 0.004 0.022 
 miR-99b-3p 1.156 0.001 0.008 
 miR-184 1.180 0.003 0.019 
 miR-30e-3p 1.208 0.002 0.013 
 miR-676 1.227 0.000 0.003 
 miR-344-1-3p 1.236 0.000 0.001 
 miR-673-3p 1.264 0.000 0.004 
 miR-770-3p 1.302 0.000 0.005 
 miR-493-3p 1.320 0.002 0.015 
 miR-370-3p 1.367 0.001 0.009 
 miR-485-5p 1.383 0.001 0.010 
 miR-379-5p 1.393 0.000 0.002 
 miR-3557-5p 1.422 0.000 0.003 
 miR-127-3p 1.423 0.000 0.001 
 miR-129-5p 1.460 0.002 0.015 
 miR-219-1-3p 1.464 0.002 0.012 
 miR-150-3p 1.605 0.001 0.007 
 miR-671 1.615 0.000 0.004 
 miR-381-3p 1.639 0.000 0.002 
 miR-674-3p 1.665 0.000 0.001 
 miR-148a-5p 1.682 0.000 0.001 
 miR-6329 1.690 0.000 0.001 
 miR-10a-5p 1.697 0.002 0.012 
 miR-27a-5p 1.725 0.000 0.002 
 miR-409b 1.728 0.000 0.001 
 miR-10b-5p 1.748 0.002 0.012 
 miR-195-3p 1.829 0.000 0.001 
 miR-708-3p 1.935 0.000 0.000 
 miR-6315 1.984 0.000 0.003 
 miR-151-3p 2.087 0.000 0.004 
 miR-148a-3p 2.288 0.000 0.000 
 miR-124-5p 3.505 0.002 0.013 
BMFC: buttermilk fat concentrate rich in phospho- and sphingolipids; KOC: krill oil 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 
phospholipids; BMFC+KOC: combination of BMFC and KOC. 
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Table S2. Selected miRNAs for validation by RT-qPCR. 
 
 miRNA logFC PValue FDR Function 
 let-7f-5p 0.822 0.002 0.045 Down-regulation in AD 
BMFC 
miR- 
195-3p 
1.023 0.002 0.042 Role in determining 
dementia susceptibility 
 miR- 
148a-5p 
0.918 0.002 0.047 Inhibition induces 
hepatocellular 
tumorigenesis 
 miR- 
99a-5p 
0.940 0.004 0.021 Neuroprotective effect 
 miR- 
128-3p 
0.981 0.003 0.018 Critical for hippocampus- 
related contextual learning 
 miR- 
148a-3p 
2.288 0.000 0.000 Downregulation in AD 
 miR- 
29a-3p 
-0.835 0.007 0.033 Neuronal synapse formation 
and plasticity 
 miR- 
191a-5p 
-0.874 0.003 0.016 Target genes to apoptosis 
and cell death pathways 
 miR- 
381-3p 
1.639 0.000 0.002 Linked to insulin resistance 
or T2D 
BMFC+KOC 
miR- 
379-5p 
1.393 0.000 0.002 Predispose to neuropathic 
pain identified 
 miR- 
30e-3p 
1.208 0.002 0.013 Linked to insulin resistance 
 miR- 
146a-5p 
-0.844 0.004 0.021 Associated with AD. 
 miR- 
370-3p 
1.367 0.001 0.009 Downregulated by Mild 
Stress in Rat Hippocampal 
Tissues 
 let-7f-5p 0.905 0.005 0.027 Downregulation in AD 
 miR- 
770-3p 
1.302 0.000 0.005 Down-regulated in the 
hippocampus of Sprague- 
Dawley rats with temporal 
lobe epilepsy 
 miR- 
106b-3p 
1.015 0.003 0.018 Protect mitochondrial 
functions 
 miR- 
195-3p 
1.829 0.000 0.001 Downregulation in AD 
 miR- 
148a-5p 
1.682 0.000 0.001 Cancer 
BMFC: buttermilk fat concentrate rich in phospho- and sphingolipids; KOC: krill oil 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 
phospholipids; BMFC+KOC: combination of BMFC and KOC. 
 
 
 
Table S3 (see online file)  
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Table S4. Gene expression microarray results. 
 
 Gene logFC P.Value Adj.P.Val 
KOC Kcnj13 -3 0.0000 0.0315 
 Dpt -2.4 0.0000 0.0275 
 Tph1 -2.1 0.0000 0.0000 
 Slc35f4 -2 0.0001 0.0452 
 Exoc5 -1.8 0.0000 0.0315 
 Barx1 -1.7 0.0000 0.0005 
 Ippk -1.5 0.0000 0.0013 
 Lilrb3l -1.4 0.0000 0.0013 
 P4hb -1.3 0.0000 0.0008 
 Cenpn -1.3 0.0001 0.0438 
 --- -1.2 0.0000 0.0049 
 Enpp2 -1.2 0.0001 0.0380 
 Osr1 -1.1 0.0000 0.0275 
 Ptgds -1.1 0.0000 0.0315 
 LOC654482 -1.1 0.0001 0.0341 
 Slc6a20 -1.1 0.0001 0.0380 
 Bicd2 -1 0.0000 0.0226 
 Ch25h -1 0.0000 0.0293 
 Arhgef15 -1 0.0001 0.0371 
 Sox21 -1 0.0001 0.0452 
 Nutm2f -1 0.0001 0.0452 
 Rarres1 -0.9 0.0000 0.0315 
 Car13 -0.9 0.0001 0.0332 
 Id4 -0.9 0.0001 0.0438 
 Efhc1 -0.9 0.0002 0.0490 
 Ctsc -0.8 0.0001 0.0452 
 Aox4 -0.8 0.0001 0.0452 
 Gpr135 0.8 0.0001 0.0426 
 Pygo2 0.8 0.0001 0.0452 
 Fam163b 0.8 0.0001 0.0452 
 Ptpn4 0.8 0.0001 0.0452 
 St6gal2 0.8 0.0002 0.0495 
 Pak6 0.9 0.0000 0.0315 
 Arc 0.9 0.0000 0.0315 
 Ramp3 0.9 0.0001 0.0341 
 Cckbr 0.9 0.0001 0.0371 
 N4bp2 1 0.0000 0.0266 
 Yeats2 1 0.0001 0.0438 
BMFC Kcnj13 -2.8 2.53E-12 2.91E-08 
 Dpt -2.3 8.23E-11 4.74E-07 
 Zfp358 -2.1 4.15E-09 6.81E-06 
 Cbr3 -2 2.60E-09 4.99E-06 
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 Mfrp -2 1.51E-08 2.17E-05 
 Tmem72 -1.9 5.70E-08 7.29E-05 
 Sostdc1 -1.8 4.66E-10 1.34E-06 
 Barx1 -1.8 4.56E-10 1.34E-06 
 Ippk -1.6 2.29E-09 4.99E-06 
 Slco1a5 -1.6 1.05E-07 0.00011518 
 Tph1 -1.6 2.45E-06 0.0011723 
 Ahsg -1.5 3.48E-07 0.00026687 
 Slc35f4 -1.4 1.10E-07 0.00011518 
 Exoc5 -1.4 1.75E-07 0.00016792 
 Slc4a5 -1.4 2.40E-07 0.00020184 
 Slc13a4 -1.4 4.28E-07 0.00029527 
 Prlr -1.4 1.45E-05 0.00476127 
 Ict1 -1.3 2.46E-07 0.00020184 
 C7 -1.3 4.88E-07 0.00029527 
 Prr32 -1.3 6.79E-07 0.00039051 
 Zfp24 -1.3 6.74E-06 0.0025839 
 Ptgds -1.2 4.47E-07 0.00029527 
 --- -1.2 4.70E-07 0.00029527 
 Slc6a20 -1.2 7.25E-07 0.00039735 
 Aqp1 -1.2 7.68E-06 0.00276169 
 Cldn2 -1.2 5.98E-05 0.01465844 
 Myog -1.1 1.60E-06 0.00079918 
 Ctsc -1.1 3.03E-06 0.00134359 
 Enpp2 -1.1 3.04E-06 0.00134359 
 Ch25h -1.1 3.43E-06 0.00146244 
 Abca4 -1.1 4.89E-06 0.00200889 
 Folr1 -1.1 2.45E-05 0.00721838 
 Cbr1 -1.1 5.20E-05 0.01329863 
 Emp3 -1 6.23E-06 0.00247225 
 Bicd2 -1 1.24E-05 0.00430572 
 LOC654482 -1 1.31E-05 0.0044311 
 Mospd1 -1 1.67E-05 0.00533843 
 Lepr -1 1.77E-05 0.00551727 
 P4hb -1 2.09E-05 0.00632722 
 Atp11c -1 3.81E-05 0.01086025 
 Cenpn -1 4.38E-05 0.01184456 
 Igf2 -1 6.44E-05 0.01544012 
 Rpl9 -1 8.19E-05 0.01884002 
 Sst -1 8.66E-05 0.01952348 
 Tmem27 -1 0.000134 0.02854155 
 Elovl7 -0.9 3.87E-05 0.01086025 
 Pla2g5 -0.9 4.43E-05 0.01184456 
 Ranbp3l -0.9 4.77E-05 0.01247554 
 Hmgb2l1 -0.9 5.99E-05 0.01465844 
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 Trim34 -0.9 6.94E-05 0.01628543 
 Capn7 -0.9 0.00011415 0.02525007 
 Slc2a12 -0.9 0.00013173 0.02854155 
 C1qtnf3 -0.9 0.00014208 0.02971226 
 Mdk -0.9 0.00014941 0.03068729 
 Slc22a8 -0.8 0.00021362 0.04310616 
 Spata20 -0.8 0.00022686 0.04498921 
 Arc 1 7.18E-06 0.00266579 
 Adss 1.3 1.03E-06 0.00053942 
BMFC+KOC Zfp358 -3.6 0.0000 0.0000 
 Kcnj13 -3.9 0.0000 0.0000 
 Dpt -3.7 0.0000 0.0000 
 Zfp24 -3.5 0.0000 0.0000 
 Cbr3 -3.4 0.0000 0.0000 
 Mfrp -3.2 0.0000 0.0000 
 Sostdc1 -2.9 0.0000 0.0000 
 Tmem72 -2.9 0.0000 0.0000 
 Prlr -2.6 0.0000 0.0000 
 Ahsg -2.4 0.0000 0.0000 
 Exoc5 -2.4 0.0000 0.0000 
 Cldn2 -2.4 0.0000 0.0001 
 Slc35f4 -2.2 0.0000 0.0000 
 Slc4a5 -2.1 0.0000 0.0000 
 Folr1 -2 0.0000 0.0000 
 Prr32 -2 0.0000 0.0000 
 Slco1a5 -2 0.0000 0.0000 
 Ict1 -1.9 0.0000 0.0000 
 Tmem27 -1.8 0.0000 0.0010 
 Sst -1.6 0.0000 0.0011 
 Cenpn -1.5 0.0000 0.0002 
 Aqp1 -1.5 0.0000 0.0007 
 Abca4 -1.5 0.0000 0.0007 
 Cbr1 -1.5 0.0000 0.0022 
 Slc13a4 -1.5 0.0000 0.0117 
 Htr2c -1.4 0.0000 0.0008 
 Capn7 -1.3 0.0000 0.0014 
 Itpripl1 -1.2 0.0000 0.0015 
 Glycam1 -1.2 0.0000 0.0015 
 Pla2g5 -1.2 0.0000 0.0017 
 LOC654482 -1.2 0.0000 0.0022 
 Rpl9 -1.2 0.0000 0.0063 
 Enpp2 -1.1 0.0000 0.0021 
 Spata20 -1.1 0.0000 0.0044 
 Itgb6 -1.1 0.0000 0.0057 
 Atp11c -1.1 0.0000 0.0070 
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 Scgb1c1 -1.1 0.0000 0.0077 
 Aimp2 -1.1 0.0000 0.0098 
 Mdk -1.1 0.0001 0.0231 
 Slc2a12 -1.1 0.0003 0.0475 
 Efhc1 -1 0.0000 0.0075 
 Tbc1d10a -1 0.0000 0.0088 
 Creg1 -1 0.0001 0.0177 
 Diaph3 -1 0.0001 0.0239 
 Narfl -0.9 0.0000 0.0082 
 Wdr63 -0.9 0.0000 0.0100 
 RGD1564074 -0.9 0.0000 0.0111 
 Glipr2 -0.9 0.0000 0.0117 
 Fbxo45 -0.9 0.0000 0.0119 
 LOC100909960 -0.9 0.0001 0.0134 
 Lama2 -0.9 0.0001 0.0163 
 Cars2 -0.9 0.0001 0.0264 
 Olr109 -0.9 0.0001 0.0289 
 Slc4a2 -0.9 0.0002 0.0316 
 Wfs1 -0.9 0.0002 0.0365 
 Muc19l1 -0.8 0.0001 0.0239 
 Igfbpl1 -0.8 0.0002 0.0383 
 Mast3 -0.8 0.0002 0.0384 
 --- -0.8 0.0002 0.0415 
 Fam92b -0.8 0.0003 0.0473 
 Six3 -0.8 0.0003 0.0486 
 LOC100911887 0.8 0.0001 0.0276 
 Samd15 0.8 0.0002 0.0365 
 Tnks 0.8 0.0003 0.0465 
 Sptssb 0.8 0.0003 0.0469 
 Satb2 0.8 0.0003 0.0489 
 ATP6 0.8 0.0003 0.0489 
 MGC116197 0.9 0.0002 0.0342 
 LOC102550585 1 0.0000 0.0068 
 Cckbr 1 0.0000 0.0070 
 LOC102555217 1 0.0000 0.0082 
 Npas4 1 0.0002 0.0351 
BMFC: buttermilk fat concentrate rich in phospho- and sphingolipids; KOC: krill oil 
concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 
phospholipids; BMFC+KOC: combination of BMFC and KOC. 
 
 
 
Table S5 (see online file) 
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Table S6. Differently expressed genes from microarray results selected for validation 
by RT-qPCR. 
 
 
 
Gene miR 
Interaction 
Study group Gene Function miRNA 
Function 
Arc 7f-5p KOC Neuronal plasticity and memory Downregulation 
in AD 
Cbr3 191a-5p BMFC Parkinson's disease Target genes to 
apoptosis and 
cell death 
pathways 
 106b BMFC+KOC Parkinson's disease. Protect 
mitochondrial 
functions 
tshz3 148a-5p BMFC+KOC Reduced expression of this gene and 
consequent caspase upregulation 
may be correlated with progression 
of Alzheimer's disease 
Inhibition 
induces 
hepatocellular 
  tumorigenesis  
 195-3p   Downregulation 
  in AD  
 30e-3p   Linked to insulin 
  resistance  
 381-3p    
pla2g5 106b BMFC+KOC Increased in several neurological 
and neurodegenerative disorders 
Protect 
mitochondrial 
  functions  
 148a-3p   Downregulation 
  in AD  
 195-3p   Downregulation 
in AD 
htr2c 195-3p BMFC+KOC Signaling of neurotransmitters Downregulation 
  in AD  
 379-5p   Predispose to 
neuropathic pain 
identified 
Mrps23 379-5p KOC Mitochondrial ribosomal proteins Predispose to 
neuropathic pain 
identified 
Capn7 128-3p BMFC Calpains are ubiquitous, have been 
implicated in neurodegenerative 
processes, 
Critical for 
hippocampus- 
related 
contextual 
  learning  
 370-3p KOC  Downregulated 
by Mild Stress in 
Rat Hippocampal 
  Tissues  
 128-3p BMFC+KOC  Critical for 
hippocampus- 
related 
contextual 
  learning  
 370-3p   Downregulated 
by Mild Stress in 
Rat Hippocampal 
  Tissues  
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 381-3p   Linked to insulin 
resistance or T2D 
Sst 106b BMFC+KOC Neurotransmission Protect 
mitochondrial 
functions 
Satb2 128-3p BMFC+KOC Memory Critical for 
hippocampus- 
related 
contextual 
  learning  
 148a-5p   Inhibition 
induces 
hepatocellular 
  tumorigenesis  
 381-3p   Linked to insulin 
resistance or T2D 
Ip6k1 148a-5p BMFC+KOC Neurotransmission Inhibition 
induces 
hepatocellular 
  tumorigenesis  
 770-3p   Down-regulated 
in the 
hippocampus of 
Sprague-Dawley 
rats with 
temporal lobe 
epilepsy 
Tph1 379-5p BMFC & 
KOC 
biosynthesis of serotonin Identified in 
primary sensory 
neurons that are 
associated with 
neuropathic pain 
Arc: activity-regulated cytoskeleton-associated protein; Cbr3: carbonyl reductase 3; Tshz3: 
teashirt zinc finger homeobox 3; Pla2g5: phospholipase A2, group V; Htr2c: 5- 
hydroxytryptamine receptor 2C; Mrps23: mitochondrial ribosomal protein S23; Capn7: calpain 
7; Sst: somatostatin; Satb2: SATB homeobox 2; Ip6k1: inositol hexakisphosphate kinase 1; 
Tph1: tryptophan hydroxylase 1; BMFC: buttermilk fat concentrate rich in phospho- and 
sphingolipids; KOC: krill oil concentrate rich in omega-3 fatty acids (eicosapentaenoic acid and 
docosahexaenoic acid) and phospholipids; BMFC+KOC: combination of BMFC and KOC. 
242 
 
 
Table S7. Sequence of miRNAs primers selected for validation. 
 
 
miRNA sequence 
rno-let-7f-5p TGAGGTAGTAGATTGTATAGTT 
rno-miR-106b-3p CCGCACTGTGGGTACTTGCTGC 
rno-miR-128-3p TCACAGTGAACCGGTCTCTTT 
rno-miR-146a-5p TGAGAACTGAATTCCATGGGTT 
rno-miR-148a-3p TCAGTGCACTACAGAACTTTG 
rno-miR-148a-5p AAAGTTCTGAGACACTCTGACTC 
rno-miR-191a-5p CAACGGAATCCCAAAAGCAGCTG 
rno-miR-195-3p CCAATATTGGCTGTGCTGCTCCA 
rno-miR-29a-3p TAGCACCATCTGAAATCGGTTA 
rno-miR-30e-3p CTTTCAGTCGGATGTTTACAGC 
rno-miR-370-3p GCCTGCTGGGGTGGAACCTGGT 
rno-miR-381-3p TATACAAGGGCAAGCTCT 
rno-miR-770-3p GTGGGCCTGACGTGGAG 
rno-miR-99a-5p AACCCGTAGATCCGATCTTGTG 
rno-miR-379-5p TGGTAGACTATGGAACGTAGG 
243  
Table S8. Sequence of genes primers selected for validation. 
 
Gene Name Sequence 
Arc rno-Arc-FW AAAGCAGCAGCAAGATGGTT 
rno-Arc-REV GAGTCTTGCCTCCTGTCCTG 
Cbr3 rno-Cbr3-FW GCTGCCCATAATGAAACCACA 
rno-Cbr3-REV GTCTGGCCAACCTTCTCTCT 
Tshz3 rno-Tshz3-FW GCAGCACAGCCATTATCACG 
rno-Tshz3-REV GGCCAGACTGTTGCTCATCT 
Pla2g5 rno-Pla2g5-FW CTTGGGCTGCCAGCATAAAC 
rno-Pla2g5-REV GCAGCCGTAGAAGCCATAGT 
Htr2c rno-Htr2c-FW CGGACGGGGTACAAAACTGG 
rno-Htr2c-REV AATCCAGACGGGGCACAAAT 
Mrps23 rno-Mrps23-FW CACATGGTGTGGTTCCTCGG 
rno-Mrps23-REV CTTAGCCCAACCCGTGACAT 
Capn7 rno-Capn7-FW AGTTCTCCTCGCAGTGCCTC 
rno-Capn7-REV TTGGGCAGCTTCCTTGTAGTA 
Sst rno-Sst-FW ACCCCAGACTCCGTCAGTTT 
rno-Sst -REV CCAGGGCATCGTTCTCTGTC 
Satb2 rno-Satb2-FW AAAACCTCGACACCGACAAC 
rno-Satb2-REV CCAACGAAGCAGTTCACAGA 
Ip6k1 rno-Ip6k1-FW ACCAAGGCTGCATCATTTTGAC 
rno-Ip6k1-REV AAACACACATTGCGTTGGGG 
Arc: activity-regulated cytoskeleton-associated protein; Cbr3: carbonyl reductase 3; 
Tshz3: teashirt zinc finger homeobox 3; Pla2g5: phospholipase A2, group V; Htr2c: 5- 
hydroxytryptamine receptor 2C; Mrps23: mitochondrial ribosomal protein S23; Capn7: 
calpain 7; Sst: somatostatin; Satb2: SATB homeobox 2; Ip6k1: inositol 
hexakisphosphate kinase 1; Tph1: tryptophan hydroxylase 1; FW: Forward; REV: 
Reverse. 
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The investigations reported in this thesis contribute to elucidating the molecular 
and nutrigenomic actions of several minor components of the diet. 
In the first publication pertinent to this thesis, we performed the first 
nutrigenomic study, with soy isoflavones, i.e. genistein and daidzein, in adipose tissue. 
The results show that isoflavones, administered in nutritionally-relevant amounts, have 
diverse yet modest effects on adipose tissue (known to be prominently involved in 
cardiometabolism). The relevance of this study builds on the fact that isoflavones are 
the subject of active research and current recommendations on their consumption are 
under intense scrutiny. Some investigations contend that soy isoflavones might act as 
tumor-promoting or tumor-inhibiting agents, because of their phytoestrogenic activities. 
However, there is consensus that estrogens exert complicated and poorly understood 
effects on cardiovascular health. In our study, soy isoflavones increased total 
cholesterol, while lowering triacylglycerol concentrations. As soy consumption brings 
about hypolipidemic effects (possibly due to its proteins), the true significance of the 
observed cholesterol increase is equivocal and deserves further investigation. In 
summary, this work adds further evidence to the notion that soy isoflavones have 
assorted effects (both positive and negative) on CMD risk factors. Keeping into account 
the moderate average exposure to such molecules, their impact on cardiovascular health 
is likely negligible, and soy and its isoflavones can be consumed as part of a balanced 
diet. 
The second study included a human trial concerning hydroxytyrosol (HT, the 
foremost and most actively studied component of extra virgin olive oil) consumption, 
which aimed at verifying the current hypothesis that (poly) phenols are processed by the 
body as xenobiotics. If this was true, (poly) phenols such as HT stimulate stress- related 
cell signalling pathways that result in increased expression of genes encoding 
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cytoprotective proteins.  In particular, Nrf2 (NF-E2-related factor 2) is a transcription 
factor that binds to the Antioxidant Response Element (ARE) in cells and, thus, 
regulates enzymes involved in antioxidant functions or detoxification such as 
thioredoxin reductase-1 and glutathione peroxidases. According to the hormesis theory, 
(poly) phenols paradoxically act on the Keap1/Nrf2/ARE signaling axis to produce 
additive increases in electrophilic signaling that result in the induction of Phase II 
enzymes and increased nucleophilic substrates, such as glutathione, thioredoxin, and 
NADPH. In brief, (poly) phenols likely exert indirect rather than direct antioxidant 
actions. Even though the Nrf2 hypothesis is gaining traction, there are no solid human 
data to confirm it. 
In this study, we tested the activities of HT on Phase II enzymes expression in a 
double-blind, randomized, crossover, placebo-controlled trial. We reported that HT, 
administered at two different doses (in a Latin-square design) was well tolerated (as 
shown by the unaltered levels of hepatic enzymes), but did not significantly modify the 
expression of Phase II enzymes in peripheral blood mononuclear cells (chosen because 
they are easy to obtain and reflect many whole body genetic expressions). Careful 
literature analysis shows that, while biochemical, i.e. in vitro, verification of Nrf2- 
mediated hormesis is strong, human evidence is scant or non-existent. Of note, the 
activation of Phase II enzymes might be organ-specific, e.g. chiefly taking place in the 
liver. However, whether sustained hepatic Phase II enzymes activation occurs in 
humans would require biopsies and, therefore, is very difficult to ascertain for obvious 
ethical and practical reasons. In short, the “hormesis hypothesis” that (poly) phenol 
activate Phase II enzymes requires solid human confirmation that might be provided by 
future trials. 
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We also performed a study regarding the bioavailability of HT, i.e. urinary 
excretion. We used 24-h urine samples from the volunteers who participated in the 
Phase II enzymes study to assess the degree of HT absorption, metabolization, and 
excretion. Indeed, one important - yet often overlooked issue – in the nutraceutical field 
is that of absorption and/or bioavailability of the active principle(s). A notable example 
is that of resveratrol, which is not bioavailable even when ingested in large quantities. 
Our results show that HT is absorbed and excreted when given as an olive mill 
wastewater extract preparation. In particular, ~8 to 10% (as mole %) of the administered 
HT was recovered in urine, and we confirmed that most of it undergoes sulphation at 
the 3´ position (HT-S-3´). It is noteworthy that there is ample evidence of the absorption 
and excretion of HT via extra virgin olive oil use. Yet, because HT is employed as 
nutraceutical either alone or as part of a formulation, data on its bioavailability could 
greatly help the development of appropriate investigations. For example, our data 
accentuate how HT-S-3´ should be quantified in studies of HT as nutraceutical, to 
monitor compliance. 
As mentioned, a major goal of this thesis was the identification of cellular, 
genetic, and molecular targets of micronutrients, to elucidate their mechanisms of 
action. One relevant mechanism of molecular regulation involves microRNAs 
(miRNAs), which exert important regulatory actions on gene expression not only under 
physiological circumstances, but also in disease. Indeed, miRNAs often target multiple 
functionally related genes and extensively interfere with biological processes, rendering 
them good candidates for therapeutic and/or nutraceutical interventions. Two divergent 
approaches are currently being studied: (1) miRNAs inhibition via pharmaceutical 
formulations and (2) the use of miRNAs mimics in therapy. Within this context, the 
potential role of plant-derived phenolic molecules (e.g. polyphenols) in miRNAs 
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modulation is being very actively investigated, but no clear-cut result has been 
published. Therefore, phenolic modulation of miRNAs becomes an attractive strategy to 
target several biological processes. 
The study presented in this thesis comprises animal, cellular, and human data 
obtained by testing HT effects on miRNAs expression. We provide the first in vivo 
evidence that HT intake modulates specific miRNAs in the small intestine of mice. 
Some of these miRNAs are also modulated in other tissues, strengthening the causality 
of our findings. Notably, some of these data were confirmed in a human setting, 
showing (also for the first time) that, in humans, HT modulates the expression of certain 
miRNAs. Although the precise molecular mechanism underlying the changes in miRNA 
expression induced by HT remains to be elucidated, our data suggest that the use of 
small, low-molecular-weight molecules capable of modulating miRNAs´ functions 
might be a viable alternative or an adjuvant to the current pharmacologic arsenal 
targeting endogenous miRNAs. 
Giordano et al. (2014) were the first ones to investigate the nutrigenomic actions 
of HT. Their results showed that HT – in nutritionally relevant amounts - is able to 
positively modulate the glutathione-driven antioxidant enzymatic machinery in adipose 
tissue, speculatively via homeostatic feedback. To further investigate the precise 
molecular mechanisms that explain several of HT’s potentially healthful actions, we 
performed a proteomic study. Of note, we used stable isotope labeling with amino acids 
in cell culture (SILAC), which is being acknowledged as a robust tool in proteomic 
quantification. In particular, as data on the effects of HT on tissue proteome in vivo are 
limited, we employed MS-based quantitative proteomics, namely super-SILAC, to 
investigate differences in protein levels in adipose tissue and the liver, i.e. the most 
metabolically active tissues, of mice fed long-term with HT. We also analyzed 
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peripheral blood mononuclear cells (PBMCs) obtained from healthy volunteers 
supplemented with HT for one week. We show that long-term hydroxytyrosol 
supplementation has the potential to modulate protein expression in adipose tissue and 
the liver. These proteins include fatty acid binding protein, glutamate dehydrogenase, 
ornithine carbamoyltransferase, epoxide hydrolase, nucleoside diphosphate kinase, 
pyruvate carboxylase mitochondrial, aconitate hydratase, 4-hydroxyphenylpyruvate 
dioxygenase, carboxylesterase, catalase, fructose-biphosphate aldolase, superoxide 
dismutase [Cu-Zn], vinculin, myosin-9, cofilin-1, vimentin, and hemoglobin subunit 
beta-1, among others. In other words, we confirmed, at the proteome level, the 
homeostatic effects of HT suggested by the nutrigenomic study of Giordano et al. 
(2014). 
 
The cardiovascular activities of HT are being vigorously investigated worldwide 
and even led to an EFSA-endorsed health claim. Conversely, the potential 
neuroprotective actions of this molecule are largely unexplored. Recent epidemiological 
evidence demonstrated that diabetes is a risk factor for Alzheimer’s disease (AD) onset 
and development. Indeed, meta-analyses of longitudinal epidemiologic studies show 
that diabetes increases AD risk by 50% - 100%, being insulin resistance (IR) the main 
binding link between diabetes and AD. Recent prospective studies showed that the 
Mediterranean diet is associated with lower incidence of AD. We hypothesized that HT 
could exert beneficial effects on IR associated to AD and investigated its mechanisms of 
action in an astrocytic model of AD., i.e. the astrocytic cell line C6 challenged with 
Aβ(25-35). We reported that HT prevented the pronounced activation of mTOR (which 
mediates IR), thereby restoring proper insulin signaling. Our results also suggest that 
the preventive role of HT on Aβ(25-35)-induced cytotoxicity in astrocytes is moderated 
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by an increased HT-induced activation of Akt, which is mediated by the insulin 
signaling pathway. In short, we demonstrate that HT protects Aβ(25-35)-treated 
astrocytes by improving insulin sensitivity and restoring proper insulin-signaling. These 
data provide some mechanistic insight on the observed inverse association between 
olive oil consumption and prevalence of cognitive impairment. 
Finally, the last two publications included in this doctoral thesis report the effect 
of polar lipids dietary supplementation (KOC, BMFC and a combination of both) in 
aged rats, and how these compounds could improve or prevent age-associated cognitive 
decline. Krill oil is an attractive source of n-3 FAs (a large proportion are incorporated 
into PC), being responsible for the synthesis of the neurotransmitter acetylcholine and 
linked to memory. Beneficial effects of krill oil have been described on cognitive 
function in the elderly. BMFC, a by-product obtained from butter manufacturing with a 
high content of MFGM, contains high proportions of PS and SM, which play important 
roles in mitochondrial membrane integrity, activity of postsynaptic receptors, and 
activation of Protein Kinase C in memory formation. 
We studied insulin signaling, mitochondrial activity, and synaptic signaling 
because impaired glucose metabolism and mitochondrial decay greatly increase with 
age. We hypothesized that these compounds, due to their characteristics, could have 
beneficial effects on glucose metabolism and mitochondrial dysfunction. Our results 
showed that, even though all animal groups had signs of peripheral insulin resistance, 
improvement was clearer in the group supplemented with BMFC+KOC. These data are 
in agreement with other studies where KO and MFGM have been shown to reduce 
insulin levels in type 2 diabetes obese individuals. Insulin signaling improved both in 
the hippocampus and cerebral cortex, two brain regions known to be essential in 
cognitive processes. We also report an increase in ATP levels in hippocampus, whereas 
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no changes were observed in the cerebral cortex. This is coherent with the observation 
that n-3 fatty acids incorporate into the various brain structures in a non-random, but 
selected manner. The apparent increased energy status of the hippocampus might be due 
to an increase in mitochondrial biogenesis and, therefore, mitochondrial signaling 
markers were analyzed. Significant differences were found in genes and proteins 
involved in the electron transport chain of mitochondria. Morever, increased levels of 
PGC-1α and BDNF also confirm this hypothesis. BDNF facilitates synaptogenesis by 
inducing the mTOR pathway, and the combined supplementation favored mTOR 
activation in the hippocampus. 
To investigate the nutrigenomic actions of theses bioactive polar lipids, we 
analyzed the expression of genes and miRNAs related to synaptic activity and/or 
neurodegeneration in the hippocampus. Several hippocampal gene transcriptional 
changes influence a wide range of learning and memory processes and could be related 
to cognitive decline. Very few studies with MFGM supplemention focused on brain 
function and none on the brain of aged animals. 
We found 38, 58, and 72 differentially expressed genes in the groups 
supplemented with KOC, BMFC and BMFC + KOC, respectively. Our study is the first 
to evaluate miRNA expression in response to BFMC supplementation. The combination 
of KOC and BMFC modulated the hippocampal expression of 119 and 23 miRNAs. 
Functional analysis of differently expressed miRNAs and their potential target genes, 
suggest they play a role in important neuroactive processes. The modulation of some 
miRNAs could not be solidly correlated with a decrease in the expression of their 
respective predicted target genes validated here and, therefore, we could not prove 
causation. Finally, we also reported a significant reduction in hippocampal ceramide 
levels with BMFC + KOC supplementation. Ceramide accumulation in the brain results 
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in a deregulation of energy balance and leads to different disorders such as obesity, 
disturbance of glucose homeostasis, neurodegenerative diseases and AD. 
In summary, our results show that the bioactive polar lipids concentrates studied 
could represent a good pharma-nutritional tool to help prevent the noxious 
consequences of age-related cognitive impairment. Dietary supplementation with these 
concentrates could contribute to maintain proper neuroactive gene and protein 
expression, in part through the modulation of certain miRNAs, and to help sustain a 
balanced energetic status within the hippocampus, favoring neuronal health and 
delaying cognitive decline associated to age-related disrepair.  
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The structure of the conclusion section is organized in accordance with the 
chapter sequence presented throughout this Doctoral Thesis: 
 
 Chapter 1: Soy Isoflavones. 
 
I. The nutrigenomic study performed here with these compounds was the first 
focusing in adipose tissue.  The administration of nutritionally relevant amounts 
of soy isoflavones by young mice resulted in an overexpression of genes 
involved in the MAPK pathway, and of genes that regulate different aspects of 
lipid metabolism (Fabp9, NPY and Sphk1), as well as a repression of genes 
associated with the chemokine signaling pathway.  
II. The administration of nutritionally relevant amounts of soy isoflavones triggers 
contradictory effects on circulating biomarkers, contributing to increased 
cholesterol and leptin levels and to a decrease in triglyceride plasmatic levels. 
 
 Chapter 2: Hydroxytyrosol 
 
III. The daily supplementation of two different concentrations of hydroxytyrosol (5 
and 25 mg), during one week, to healthy volunteers did not produce significant 
changes in the expression of Phase II enzymes by PBMCs, showing that, in 
these cells, the beneficial effects described for this molecule do not occur 
through this signaling pathway. The few significant effects observed may be due 
to the short supplementation period of this pilot study and trials with longer 
supplementation times would be necessary to confirm these results. On the other 
hand, HT supplementation did not cause adverse effects, as no alterations were 
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found in several inflammation, lipid profile, hepatic enzymes and oxidation 
markers of CVD.  
IV. HT is bioavailable in the doses supplemented to human volunteers. ~ 8 to 10% 
of HT metabolites were recovered in urine and the majority undergoes sulfation 
at position 3 (HT-S-3), which could play a relevant role in the biological 
activities described. HT-S-3 could be used as a reliable biomarker to monitor 
compliance of olive oil intake. 
V. In mice, at a dose that closely approximates human intake, HT significantly 
changed the expression of several genes and proteins associated to oxidation-
reduction processes and to several lipid metabolism-associated pathways. In 
addition, HT modulates specific miRNAs in the small intestine and in other 
tissues (e.g. miR-483-3p). In humans, miR-193a-3p was modulated by HT. 
VI. With regards to neurodegenerative diseases, HT increased the viability of 
astrocytes simulating Alzheimer's disease, leading to improved insulin 
sensitivity and restoring insulin-signaling.  
 
 Chapter 3: Bioactive polar lipids 
 
VII. Dietary supplementation of aged rats - for three months - with bioactive polar 
lipids improves peripheral and central insulin resistance. 
VIII. BMFC and/or KOC increased hippocampal ATP concentrations and increased 
the expression of several genes involved in the electron transport chain, 
suggesting an amelioration of mitochondrial damage. The n-3 fatty acids 
ingested as phospholipids increase BDNF brain levels favoring a correct 
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energetic state within neurons and facilitating both mitochondrial and protein 
synthesis necessary for synaptic plasticity.  
IX. Supplementation with these compounds induced epigenomic and nutrigenomic 
changes, in part by targeting both genetic and epigenetic mechanisms through 
miRNA modulation, which may influence cognitive development or brain 
function. 
X. BMFC and KOC conjunct supplementation was necessary for a significant 
reduction in ceramide levels, which play an important role in neuronal 
composition changes through the different stages of development and whose 
enhanced levels are associated with age-related decay. 
 
General conclusion 
The micronutrients studied in this PhD thesis modulate important physiological 
pathways, which can partially explain the health benefits attributed to particular diets. 
As the effects of micronutrients are necessarily modest in amplitude, we need to exert 
caution when extrapolating these results to human therapy. However, the appropriate 
formulation of well-studied micronutrients and science-based dietary advice should be 
relevant parts of public health policies and further ad-hoc studies should be funded and 
pursued. 
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La estructura de la sección de conclusiones se organiza de acuerdo a la secuencia 
de capítulos presentada a lo largo de esta Tesis Doctoral: 
 
 Capítulo 1: Isoflavonas de soja. 
 
I. Este es el primer estudio nutrigenómico realizado con estos compuestos en el 
tejido adiposo. La administración de cantidades nutricionalmente relevantes de 
isoflavonas de soja en ratones jóvenes dio como resultado una sobreexpresión de 
genes implicados en la vía MAPK y de genes que regulan diferentes aspectos del 
metabolismo lipídico (Fabp9, NPY y Sphk1), así como una represión de genes 
asociados con la vía de señalización de la quimioquina. 
II. La administración de cantidades nutricionalmente relevantes de isoflavonas de 
soja conlleva efectos contradictorios sobre los biomarcadores circulantes, 
contribuyendo a un aumento en los niveles de colesterol y leptina y a una 
disminución en los niveles plasmáticos de triglicéridos. 
 
 Capítulo 2: Hidroxitirosol 
 
III. La suplementación diaria de dos concentraciones diferentes de hidroxitirosol (5 
y 25 mg), durante una semana, a voluntarios sanos no produjo cambios 
significativos en la expresión de enzimas de Fase II en PBMCs, lo que 
demuestra que, en estas células, los efectos beneficiosos descritos para esta 
molécula no ocurren a través de esta vía de señalización. Los pocos efectos 
significativos observados pueden deberse al corto período de suplementación de 
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este estudio piloto y serían necesarios ensayos con tiempos de suplementación 
más largos para confirmar estos resultados. Por otro lado, la suplementación con 
HT no causó efectos adversos, ya no se encontraron alteraciones relevantes en 
varios marcadores de CVD, inflamación, oxidación, perfil lipídico y enzimas 
hepáticas.  
IV. El HT es biodisponible en las dosis suplementadas a voluntarios sanos. Entre un 
8 y un 10% de los metabolitos de HT se recuperaron en la orina y la mayoría 
sufre sulfatación en la posición 3 (HT-S-3). Este metabolito podría desempeñar 
un papel relevante en las actividades biológicas descritas por el HT y, además, 
podría usarse como un biomarcador fiable para supervisar el cumplimiento de la 
ingesta de aceite de oliva. 
V. En ratones, la suplementación con HT, a una dosis aproximada a la ingesta 
humana, modificó significativamente la expresión de varios genes y proteínas 
asociados a procesos de oxidación-reducción y a varias vías asociadas al 
metabolismo de lípidos. Además, el HT moduló miRNAs específicos en el 
intestino delgado y en otros tejidos (por ejemplo, miR-483-3p). En humanos, el 
consumo de HT resultó en una modulacion del miR-193a-3p.  
VI. Con respecto a las enfermedades neurodegenerativas, el HT aumentó la 
viabilidad celular, mejoró la sensibilidad a la insulina y restauró la vía de 
señalización de la insulina, en un modelo de astrocitos simulando la enfermedad 
de Alzheimer. 
 
 Capitulo 3: Lipidos polares bioactivos. 
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VII. La suplementación dietética con lípidos polares bioactivos a ratas viejas, durante 
tres meses, contribuyó a una mejora en la resistencia periférica y central a la 
insulina.  
VIII. La suplementación con BMFC y/o KOC contribuyó a un aumento de la 
concentracion de ATP en el hipocampo y a un aumento en la expresión de varios 
genes implicados en la cadena de transporte de electrones, lo que sugiere una 
mejora del daño mitocondrial. Los ácidos grasos n-3 ingeridos como 
fosfolípidos potenciaron un aumento en los niveles de BDNF en el cerebro, 
contribuyendo a un estado energético adecuado dentro de las neuronas y 
facilitando la síntesis mitocondrial y de proteínas necesarias para la plasticidad 
sináptica.  
IX. La suplementación con estos compuestos indujo cambios epigenómicos y 
nutrigenómicos, en parte, a través de la modulación de miRNAs, que pueden 
influir en el desarrollo cognitivo o en la función cerebral.  
X. La suplementación conjunta de BMFC y KOC fue necesaria para una reducción 
significativa en los niveles de ceramidas. Las ceramidas juegan un papel 
importante en los cambios de composición neuronal a través de las diferentes 
etapas de desarrollo y sus niveles elevados están asociados con el deterioro 
relacionado con la edad. 
 
Conclusión general 
Los micronutrientes estudiados en esta tesis doctoral modulan vías fisiológicas 
importantes, que pueden explicar parcialmente los beneficios para la salud atribuidos a 
diferentes dietas. Como los efectos de los micronutrientes son necesariamente modestos 
en amplitud, debemos tener precaución al extrapolar estos resultados a la terapia 
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humana. Sin embargo, el estudio exhaustivo de los efectos de los micronutrientes para 
su inclusión en formulaciones apropiadas y el asesoramiento dietético basado en la 
evidencia cientifica deberían ser partes relevantes de las políticas de salud pública, por 
ejemplo a través de la financiacion de más estudios como los aquí expuestos. 
 
 
 
